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SUMMARY
Progressive familial heart block I (PFHBI) is an inherited autosomal dominant cardiac 
conduction disorder which segregates in a large South African (SA) pedigree, two 
smaller SA families and a Lebanese family. It specifically affects conduction in the 
ventricles and is of unknown cause. Clinically, PFHBI is detected on electrocardiogram 
(ECG) by evidence of bundle-branch disease, i.e., as right bundle branch block, left 
anterior or posterior hemiblock, or complete heart block with broad QRS complexes. The 
PFHBI-causative gene was mapped to a lOcM region on chromosome 19ql3.3 using 
linkage analysis, and the locus was subsequently reduced to 7cM by genetic fine 
mapping.
The present study involved a multi-strategy approach to search for the PFHBI gene. The 
objectives were the further reduction of the PFHBI locus by genetic fine mapping using 
published and novel markers, searching for short gene transcripts from publicly available 
databases and the generation of an integrated map of the locus to which genes were 
mapped. Prioritised genes were screened for PFHBI-causing mutations and, in addition, 
the PFHBI locus was searched for the presence of a G protein-encoding gene (P I 15- 
RhoGEF), a connexin (Cx) gene and any genes containing a CTG repeat expansion motif, 
since these genes are plausible PFHBI candidate genes.
Genotyping and fine genetic mapping using known and novel polymorphic dinucleotide 
(CA)n and novel tetranucleotide (A3G)n repeat markers across the PFHBI locus were 
performed. Publicly available databases, such as LLNL (Livermore, USA), and 
GENEMAP (NCBI) were searched for ESTs which, in turn, were extended using 
clustering programmes, such as UNIGENE (NCBI) and STACK (SANBI), and the 
resulting consensus sequences were subsequently BLAST-searched against the protein 
databases. Using the available data, an integrated physical and genetic map of the PFHBI 
locus was generated and, as the HGP progressed, a number of novel genes were placed 
thereon. Subsequently, genes were prioritised on the basis of position, function and
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expression  profile.
Genetic fine mapping reduced the PFHBI locus from 7cM to 4cM. The EST approach 
yielded 38 ESTs, of which 24 ESTs matched proteins, such as activating transcription 
factor 5 (ATF5), actin-binding protein (KPTN) and zinc finger protein 473 (ZFP473) 
(May 2003). All the map data generated experimentally and computationally were placed 
on the PFHBI map. The PI 15-RhoGEF was excluded as a PFHBI candidate gene and 
although homologous sequences to connexin 37 (Cx37) was located on both chromosome 
19 radiation hybrid clones (RHG12 and ORIM-7), it was not identified on the DNA 
clones spanning the PFHBI locus. No evidence of an expansion of a CTG repeat motif 
sequence in PFHBI-affected individuals was found. Five highly prioritised candidate 
genes, namely, 5CZ2-associated X protein (BAX), potassium voltage-gated channel 
Shaker-related subfamily member 7 (KCNA7’), potassium inwardly-rectifying channel, 
subfamily J, member 14 (KIR2.4), lin-7 homolog B {LIN-7B) and glycogen synthase 1 
(GSYI) were selected for mutation screening. No disease associated mutations were 
identified in the exonic and flanking intronic regions of these genes.
In summary, this study reduced the PFHBI locus substantially and generated a detailed 
map o f the region. A number of attractive candidate genes were excluded from causing 
PFHBI; however, several plausible candidate genes are still present at this gene-rich 
locus and remain to be screened. Identifying the PFHBI-causative gene and associated 
mutation will provide a platform for further studies to understand the pathophysiology, 
not only o f PFHBI, but also of other more commonly occurring conduction disturbances.
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OPSOMMING
Progressiewe familiele hartblok I (PFHBI) is ‘n autosomaal dominant oorerflike kardiale 
geleidingstoomis wat in ‘n groot Suid-Afrikaanse (SA) familie, twee kleiner SA families en ‘n 
Lebanese familie segregeer. Dit affekteer hoofsaaklik die geleiding in die ventrikels en die oorsaak 
daarvan is onbekend. Klinies word PFHBI op elektrokardiogram (EKG) geidentifiseer as a 
bondeltak-siekte, naamlik, as regter bondeltakblok, linker anterior of posterior hemiblok, of 
volledige hartblok met wye QRS komplekse. Die PFHBI-veroorsakende geen is voorheen deur 
koppelingsanalise tot ‘n lOcM gebied op chromosoom 19ql3.3 gekarteer, en daaropvolgens is die 
lokus verklein tot 7cM deur genetiese fyn kartering.
Die huidige studie behels ‘n veelvuldige-strategie benadering in die soektog na die PFHBI geen. 
Die doel van die studie was die verdere verkleining van die PFHBI lokus deur gebruik te maak van 
beide gepubliseerde en nuwe genetiese merkers, die identifisering van kort geentranskripte (ESTs) 
uit publieke databanke en die generasie van ‘n geintegreerde kaart van die lokus. Geprioritiseerde 
gene is geanaliseer vir die PFHBI-veroorsakende mutasie en, daarby, is die PFHBI lokus deursoek 
vir die teenwoordigheid van ‘n G proteien-enkodeeringsgeen (PIJ5-RhoGEF), ‘n konneksien (Kx) 
geen en enige gene wat ‘n uitgebreide CTG-herhalingsmotief bevat, aangesien hierdie gene as sterk 
PFHBI kandidaatgene geag is.
Genotipering en fynkartering deur die gebruik van bekende asook nuwe polimorfiese dinukleotied- 
[(CA)n] en nuwe tertranukleotied- [(A3G)n] herhalingsmerkers wat die PFHBI lokus oorbrug, is 
uitgevoer. Publieke databanke, soos LLNL (Livermore, USA), en GENEMAP (NCBI) is ondersoek 
vir ESTs wat vervolgens verleng is deur gebruik te maak van groeperende programme soos 
UNIGENE (NCBI) en STACK (SANBI) en die gevolglike konsensus volgordes is daama met 
behulp van BLAST geanaliseer teen die protei'endatabanke. Die bekomde data is vervolgens
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gebruik om ‘n geintegreerde fisiese en genetiese kaart van die PFHBI lokus te produseer en, soos 
die mens genoomprojek gevorder het, is nuwe gene daarop geplaas. Daarna is gene geprioritiseer 
vir mutasie analise gebaseer op posisie, funksie en uitdrukkingsprofiele.
Genetiese fynkartering het die PFHBI lokus van 7cM tot 4cM verklein. Die EST benadering het 38 
ESTs gei'dentifiseer, waarvan 24 ESTs proteien gelyke gehad het, bv aktiverende transkripsie faktor 
5 (ATF5), aktien-verbindingsprotei'en (KPTN) en sink-vingerproteien 473 (ZFP473) (Mei 2003). A1 
die karterings data wat eksperimenteel en rekenaar-gewys gegenereer is, is op die PFHBI kaart 
geposisioneer. Die P115-RhoGEF is uitgeskakel as ‘n PFHBI kandidaatgeen en alhoewel ’n 
volgorde met homologie aan konneksien37 (Kx37) gevind is op albei chromosoom 19 radiasie- 
hibried klone (RGH12 and ORIM-7), is dit nie gei'dentifiseer in die DNS klone wat die PFHBI 
lokus oorbrug nie. Geen bewyse van uitbreiding van CTG herhalingsmotiewe is gevind in PFHBI- 
aangetasde persone nie. Vyf hoogs-geprioritiseerde kandidaat gene, naamlik, BCL2-geassosieerde 
X proteien (BAX), kalium spanningsbeheerde kanaal, subfamilie J, lid 14 (KIR2.4), lin-7 homoloog 
B (LIN-7b) en glikogeen sintase 1 (GYS1), is geselekteer vir mutasie-analise. Geen siekte- 
veroorsakende mutasie is egter gei'dentifiseer in die eksoniese of die naasliggende introniese 
gebiede van hierdie gene nie.
Ter opsomming, hierdie studie het die PFHBI lokus verklein en het ‘n omvattende kaart van die 
gebied gegenereer. Verskillende kandidaat gene is uitgesluit as die oorsaak van PFHBI, alhoewel 
daar nog heelwat goeie kandidaat gene in hierdie geen-ryke lokus is wat geanaliseer behoort te 
word. Die identifiseering van die PFHBI-veroorsakende mutasie sal ‘n platform bied vir verdere 
studies om die patofisiologie van nie alleen PFHBI nie, maar ook meer algemene 
geleidingstoomisse, te verstaan.
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TEACHING
Then said a teacher, Speak to us of Teaching.
And he said:
No man can reveal to you aught, but that which already lies half asleep in the 
dawning o f your knowledge.
The teacher who walks in the shadow of the temple, among his followers, gives 
not of his wisdom but rather o f his faith and his lovingness.
If he is indeed wise he does not bid you enter the house of his wisdom, but rather 
leads you to the threshold of your own mind.
The astronomer may speak to you of his understanding of space, but he cannot 
give you his understanding o f space,
The musician may sing to you o f rhythm, which is in all space, but he cannot give 
you the ear, which arrests the rhythm, nor the voice that echoes it.
And he who is versed in the science of genetics can tell of the regions of the 
chromosomes, but he cannot cure diseases.
For the vision of one man lends not its wings to another.
And even as each one o f you stands alone in God’s knowledge, so must each of 
you be alone in his knowledge of God and in his understanding of the earth.
revised from “The Prophet” by Kahlil Gibran
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APOB apolipoprotein B
ATF5 activating transcription factor 5
BAX BCL2-associated X protein
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Cx46 connexin 46
Stellenbosch University http://scholar.sun.ac.za/
Cx50 connexin 50
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FCGRT  Fc fragment o f Ig G receptor transporter alpha.
FLT3LG  fms-related tyrosine kinase 3 ligand
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GSK3A glycogen kinase 3-alpha
G YSl glycogen synthase 1
HLA major histocompatibility complex
HRAS Harvey rat sarcoma viral oncogene homolog
HRC  histidine-rich calcium binding protein
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KDELR 1 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention 
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LHB luteinising hormone beta polypeptide
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MEF  myocyte enhancer factor
MSX2 Msh homeobox homolog 2
MTRNR1 ribosomal RNA, mitochondrial, 12S
MyBP myosin-binding protein
M YH  myosin heavy chain
MYLIA myosin light chain polypeptide 1A
NKX2-5 NK2 transcription factor related, locus 5
NOSIP nitric oxide synthase interacting protein
NTF5 neurotrophin 5 (neurotrophin 4/5)
NTT5 neurotransmitter transporter 5
NUCBl nucleobindin 1
PLA2G4C  phospholipase A2 group IVC (cytosolic calcium-independent)
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RPL18 ribosomal protein L 18
R P S ll ribosomal protein SI 1
RRAS related RAS viral oncogene homolog
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SLC8A2 solute carrier family 8  (sodium independent inorganic phosphate 
cotransporter), member 2
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cotransporter), member 7 
SNRP70 small nuclear ribonucleoprotein 70kDa polypeptide (RNP antigen) 
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preferring member 1 
SULT2B1 sulfotransferase family cytosolic 2B member 1 
SYNGR4 synaptogyrin 4 
TBC1D17 TBC1 domain family, member 17 
Tbx2 murine T-box 2
TEAD2 TEA domain family member 2 
TULP2 tubbylike protein 2 
VRK3 vaccinia related kinase 3
ZNFP9 zinc finger protein 9 
ZFP473 zinc finger protein 473 (alias ZFP100) 
(http://www.ncbi.nlm.nih.gov/UNIGENE)
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31.1 ORGANISATION OF CHAPTER 1
This review forms the basis of my doctoral studies that involved the search for a mutated 
gene which causes a disorder named progressive familial heart block I (PFHBI:OMIM 
113900) in a large South African family (Brink and Torrington, 1977). PFHBI is a 
cardiac disorder affecting the cardiac conduction system (CCS), specifically the bundle 
branches (BBs), and is detected by an electrocardiogram (ECG). To further an 
understanding o f the aetiology of the disease, the structure, the development, ageing and 
electrophysiology of the CCS will be reviewed in the following section (section 1.2).
A number of other familial cardiac conduction diseases and syndromes are prevalent 
worldwide, for which in some cases the causative genes have been identified, namely, 
isolated cardiac conduction disease (ICCD) (Tan et al., 2001), progressive cardiac 
conduction disease (PCCD) (Schott et al., 1999) and idiopathic ventricular fibrillation 
(IVF) (Chen et al., 1998). One could suggest that similar disease-causing mechanisms 
may be involved in the pathophysiology of PFHBI, it is therefore relevant to review the 
literature pertaining to some of these diseases. In addition, there are also syndromic 
diseases associated with cardiac conduction abnormalities; these include Holt-Oram 
syndrome (HOS) (Terret et al., 1994), atrial septal defect (ASD) (Kahler et al., 1966; 
Pease et al., 1976; Basson et al., 1995) and myotonic dystrophy (DM) (Harper, 1989) 
(section 1.3), which also render them important for discussion. Since PFHBI is the focus 
of this study, a detailed background and description o f this condition is given o f this 
disorder (section 1.3.2.3.4).
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There are many different strategies available to search for a disease-causing gene and in 
the case of PFHBI, a positional candidate gene approach was adopted because the disease 
had been mapped to a specific locus and candidates were therefore selected based on 
position and cardiac function. The background for the strategies used in this study is 
reviewed in section 1.4. Previous linkage studies mapped the PFHBI locus to 
chromosome 19ql 3.3 (Brink et al., 1994; Brink et al., 1995), therefore, as part of this 
study, genes mapping to this region were investigated according to expression profile and 
function (see section 1.4.5). A list o f candidate genes was prioritised for mutation 
screening in a PFHBI panel and the background and rationale for the selection of each 
candidate is discussed in section 1.5.
In most cases, the management of gene searches involves a group or a collaborative 
effort, as is the situation with PFHBI. Therefore, as examples o f successfully managed 
disease gene identification strategies, the approaches followed for the genes causing 
retinitis pigmentosa (RP13) and keratolytic winter erythema (KWE) are discussed and 
compared to the PFHBI gene search (section 1.6 ).
1.2 CARDIAC CONDUCTION SYSTEM (CCS)
This section deals with the historical developments, the structure, the development, the 
ageing and the electrophysiology of the CCS.
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51.2.1 Historical overview
Over the past number o f years, there has been a paradigm shift from the previous 
understanding of the structure, development and functioning of the CCS (Davies et al., 
1983; Opie, 1991), which is partly due to research on Mus (M) musculus, Gallus (G) 
gallus and other vertebrates (Moorman et al., 1998; Nguyen-Tran et al., 2000; Pennisi et 
al., 2002). The discovery of the CCS dates back to the mid-nineteeth century and 
investigations focused largely on the anatomy of the CCS (Davies, 1971; Luderitz, 1995). 
The evolutionary origin of the CCS has been a subject o f much controversy, particularly 
as to whether the CCS develops from nervous or muscle tissue (see a more detailed 
discussion in section 1.2.3). As reviewed by Davies (1971), the myogenic theory was 
initiated by Gaskell in 1883, which proposes that the CCS is composed of specialised 
cardiac muscle cells; whereas the neurogenic theory, championed by Glomset and 
Glomset in 1940, proposed that the CCS develops from nervous tissue. Despite the 
overwhelming scientific evidence presented by Kistin (1949), Lev (1960) and Hudson 
(1965) that the CCS is myogenic in origin, electron microscopy studies in animal tissues 
show a close association between nerves and conduction fibres throughout the heart 
(reviewed by Davies, 1971). However, studies done by classic anatomists such as 
Purkinje, His, Tawara and Kent supported the myogenic theory (Davies, 1971).
The conduction of an electrical impulse in the heart is spontaneously generated by the 
specialised sino-atrial (S-A) node in the atrium, passed to the atrio-ventricular (A-V) 
node after spreading through the atria and ultimately to the His bundle, which delivers the
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impulse to the BBs. It has been found that conduction through the His bundles and down 
the BBs to the ventricular endocardium is by Purkinje fibres (reviewed by Opie, 1991).
More recently, the different stages o f cardiac development and the control o f mRNA and 
protein expression profiles of the CCS have been investigated (Moorman et al., 1998; 
Franco et al., 1998; Gourdie et al., 1999; Brunskill et al., 2001). The data generated by 
these studies resulted in the construction of an integrated transcriptional and 
morphological model of the developing heart that will be discussed in section 1.2.3.
1.2.2 Structure of the adult ventricular cardiac conduction system
Since PFHBI is a disorder that affects the CCS, more specifically the conduction o f the 
electrical impulse in the ventricles, a focus on the structure of the different components of 
the CCS, especially the ventricular and BB systems, is warranted. It can be proposed that 
any structural fault in the tissues comprising these systems could result in delay o f the 
electrical impulse, thus causing PFHBI.
The conduction of the impulse, as described in section 1.2.1, results in the contraction of 
the heart. ECG studies of individuals suffering from PFHBI indicate a conduction block 
in the ventricular region, therefore, the anatomy of the A-V junctional and the A-V BB 
areas is discussed. These areas can be divided into five sections (Davies et al., 1983; 
Brink, 1997) (fig. 1.1). They are (i) a transitional area composed initially of atrial 
working myocardium and then changing to the more compact cells of the A-V node, (ii) a 
compact area consisting of spindle-shaped cells similar to cells found in the SA node,
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Figure 1.1 Different components of the cardiac conduction system
(http://faculty-web.at.northwestem.edu/at/beaman/ecg/primer.htinl).
(iii) a transitional area with a presence o f Purkinje type o f cells found predominantly in 
the ventricular CCS, (iv) a non-branching ventricular component and (v) a branching 
ventricular component.
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1.2.2.1 Atrioventricular junctional area and the atrioventricular bundle branch 
tissue
The transitional and the compact area in the atrial working myocardium, and the 
transition to the bundle o f His, form the A-V node. The penetrating part and the non­
branching ventricular part are referred to as the bundle of His (fig. 1.1) (Davies et al., 
1983). Like the S-A node, the A-V node depolarises spontaneously but is slow in its 
conduction properties, 5cm/sec, whereas the conduction velocity of the bundle of His 
bundle and its branches is 200cm/sec. The cells found in BB tissue are the Purkinje cells, 
which closely resemble embryonic muscle cells. The reason for the difference in the 
speed of the nodes and the BBs is possibly due to the difference in the anatomy between 
the nodes and the bundle o f His. One explanation offered is that the nodes lack gap 
junctions and the bundle of His contains numerous gap junctions, which are presumed to 
be responsible for its fast conduction characteristics (reviewed by Brink, 1997). One of 
the major components of a gap junction is the protein connexin (Cx). A more detailed 
discussion of Cxs will be presented in section 1.2.2.3.
Another important feature of the A-V junctional area is that it is closely associated with 
the fibrous cardiac skeleton and therefore disease of the fibrous skeleton may have an 
effect on this area and may lead to A-V block (Davies et al., 1983). On entering the 
ventricles and leaving behind the cardiac skeleton, the bundle of His branches into a left 
bundle (LBB) and a right bundle branch (RBB) system (Davies et al., 1983). There are 
differences between the LBB and the RBB, for example, the RBB is a direct continuation 
o f the main bundle of conduction tissue and can be seen by the naked eye as a single
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distinct thin yellow streak due to the adipose tissue around the conduction tissue. It runs 
downward and forward into the septum towards the base o f the ventricle. When it reaches 
the muscle, the right branch breaks up into a complex network of fibres, which run 
throughout the ventricle beneath the endocardium. In contrast, the LBB leaves the main 
BB as slender strands o f fibres to form a wide fan of cells (Davies, 1971). The precise 
morphology of the left bundle has been a subject o f considerable debate. For the purposes 
o f this study, the focus is specifically on the RBBs since the disorder is characterised by 
RBB (Davies et al., 1983). Histologically, the right bundle consists o f parallel fibres, 
each 7.5|a in diameter, with few myofibrils and containing cells with a vacuolated 
cytoplasm (Davies, 1971).
Another explanation for the accelerated conduction velocity o f the RBB is that it is due to 
conduction via the numerous end-to-end connections between Purkinje cells, rather than 
conduction via the side-to-side connections found in other myocardial cells (Opie, 1991). 
The cytoskeletal protein, desmin, has been found to be present in the Purkinje cells 
(Moorman et al., 1998) and may be an important candidate gene for PFHBI. One could 
speculate that the cardiac conduction block found in PFHBI is caused by the 
malfunctioning of a defective (mutated) cytoskeletal protein. For this reason, any 
cytoskeletal gene present at the PFHBI locus should be considered an important 
candidate.
UNIVERSITEIT STELLENBOSCH 
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1.2.2.2 Proteins and ion channels of the conduction system
Guanine nucleotide-binding proteins (called GTPases or G proteins) are examples o f a 
family o f cytoplasmic signal-transducing proteins that are coupled to receptors, which are 
modulated by guanosine triphosphate (GTP). The binding of GTP to such a cellular 
receptor alters its conformation and increases its affinity to bind G proteins (Pollard and 
Eamshaw, 2002).
Eukaryotic cells use G proteins to regulate a host o f functions ranging from transduction 
o f signals from plasma membrane to regulation o f the cytoskeleton, membrane 
trafficking, nuclear transport and protein synthesis (Pollard and Eamshaw, 2002). All 
these G proteins share a homologous core domain that binds a guanine nucleotide and use 
a common enzymatic cycle o f GTP-binding, hydrolysis, and the product dissociation to 
switch the protein on or off.
The conformation o f a G protein depends on whether GTP or GDP is bound. The GTP- 
bound conformation is the active form, as it interacts with, and stimulates, effector 
proteins and it is the y-phosphate o f the GTP, which turns the molecular switches on or 
off. The GDP-bound conformation is inactive because it does not bind the effectors. In 
many cases, binding to the effector proteins or regulatory proteins accelerates the 
activation step. Although there are five different families o f G proteins, for the purposes 
o f this review, only the trimeric G protein and the small G protein families will be 
discussed because o f their roles in cardiac function.
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Families of related genes in the mammalian cell encode the subunits o f G proteins 
(Simon et al., 1991).The number o f genes in each mammalian gene family varies, e.g., 
a  subunits are encoded by 16 genes, P subunits are encoded by five genes, and the y 
subunits are encoded by 12 genes (reviewed by Downes and Gautam, 1999). The trimeric 
G proteins are heterotrimers made up o f an a , P and y subunits (reviewed by Downes and 
Gautam, 1999) (fig. 1.2). The seven-helix receptors activate trimeric G proteins by 
promoting the dissociation of GDP bound to an inactive trimeric protein. The GTP- 
binding changes the conformation o f the Ga and dissociates the Gpr. This generates two 
signals, as both Ga and Gpy can engage downstream effector proteins (fig. 1.2). There is 
evidence o f at least 2 0  a , 6  P subunits and 1 2  y subunits that comprise from 1 - 1 0 % of the 
membrane protein o f a cell and different combinations o f these subunits can generate up 
to 1440 combinatorial signal transduction options (Zipes and Jalife, 2001).
In the heart, a G protein-based communication network is vital for relaying extracellular 
signals that mediate fundamental activities o f the cardiac cycle such as electrical 
excitability, excitation-contraction coupling, calcium (Ca2T) signaling, metabolic activity 
and phosphorylation events. The basic components o f this system are the G protein- 
coupled receptor (GPCR), G protein complex o f Ga and Grg subunits and an effector 
(Zipes and Jalife, 2001). The two cardiac inward rectifier ion channel subunits, Kir 3.1 
and Kir 3.4, and the voltage-gated fast acting sodium (Na+) channel are under the direct 
regulation o f G proteins (Zipes and Jalife, 2001).
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The six families o f small G proteins, such as the Rho and Ras families, consist o f a single 
domain o f 200 amino acid residues (fig. 1.2). Their functions include nuclear transport 
and regulation of the actin cytoskeleton. There are a number o f proteins involved in the 
activation of the G proteins, for example, guanine nucleotide exchange factor (GEF), 
which stimulates the GTP hydrolysis that turns these molecules on or off (Hart et al.,
Seven helix 
receptor
Lipid 
bilayer
Trimeric 
G protein
Figure 1.2 Atomic model and activation of a seven-helix receptor and trimeric G protein.
Subunits Ga, GP and Gy of the trimeric G protein are circled. A, resting state, which lacks the binding of a 
ligand and the trimeric G-protein is in an inactive GDP-Gapy state. Both Ga and Gy are anchored to the 
lipid bilayer. B, the binding of the ligand activates the receptor, which catalyses the exchange o f GDP for 
GTP on Ga. C, active Ga and GPy dissociate from each other and the receptor become available to interact 
with effector proteins (Pollard and Eamshaw, 2002).
1996). Alterations in G protein-coupled receptors, or in the a  subunits o f the G protein, 
may lead to different human diseases with different phenotypes, such as 
pseudohypoparathyroidism type I, that is a disease caused by a defective a  subunit o f a G 
protein which results in an individual having shortened fingers, toes and stature 
(reviewed by Spiegel, 1996). McCune-Albright syndrome is also caused by a mutation in 
the a  subunits o f the G protein and is characterised by a classic triad o f polyostotic 
fibrous dysplasia, cafe-au-lait skin hyperpigmentation and premature puberty (reviewed 
by Spiegel, 1996). For the most part, the diseases are confined to rare endocrine
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disorders. A recent study suggests that mutations in G proteins can also lead to 
hypertension (reviewed by Farfel et al., 1999). To date, a defective G protein has not 
been linked to any conduction, arrhythmia or primary cardiac disease.
In summary, G proteins are important in cardiac functions such as complex signaling 
pathways and ion channel function. One can, therefore, hypothesise that a mutation in 
any G protein or G-interacting protein encoding gene, could result in a cardiac 
conduction disorder such as PFHBI, and can be considered as plausible candidates for 
PFHBI.
Cardiac ion channels
A number of different cardiac ion channels controlling the flow of ions, such as the Na+, 
Ca2+, potassium (K+) and chloride (Cl*) ions, are present in the membrane o f the 
myocytes of the heart. The movement of ions through these channels generates action 
potentials that ultimately activate the heart (Katz, 1993); Consequently, any change in 
gene expression or channel structure can be expected to result in a disruption of ion flow, 
which could lead to a cardiac conduction defect. One can, therefore, suggest that any ion 
channel gene, or any gene encoding a protein involved in ion channel function, would be 
a good PFHBI candidate. Ion channel genes and genes involved with ion channel 
function present at the PFHBI locus are discussed in more detail in sections 1.5.2 and 
1.5.3.
13
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1.2.2.3 Gap junctions
Gap junctions are specialised membranous intercellular channels, which connect adjacent 
cells in many tissues and organs, thereby providing chemical and electrical 
communication. In the heart, gap junctions provide pathways for intercellular current 
flow, enabling a coordinated propagation of action potential (reviewed by Bruzzone et 
al., 1996; reviewed by Jalife, 1999; Jongsma and Wilders, 2000). Mammalian gap 
junction channels are built of Cxs encoded by a family of closely related genes.
Connexins (Cxs)
Four major Cxs have been shown to be associated with the myocytes, namely, Cx40 (as 
connexin), Cx43 (aj connexin), Cx45 (a 6 connexin) and Cx37 (014 connexin) (Vozzi et 
al., 1999; Zipes and Jalife, 2001). Different types of Cxs exhibit different channel 
properties and are regulated by specific gating mechanisms. The distribution and the 
relative abundance of Cxs in various tissues are different and studies with Cx37, Cx40, 
Cx43, Cx45 and Cx46 have shown that individual numbers and size of gap junctions 
differ in specific areas of the human heart and have characteristic conductive properties 
(reviewed by Bruzonne et al., 1996). Research by Oosthoek et al., (1993) revealed that 
Cx43 is not present in the myocytes o f the A-V node, whereas abundant expression of 
Cx43 was found in the Purkinje fibres o f the A-V bundle and the BBs. These differences 
are likely to play a role in regulating cardiac conduction properties and mutations in gap 
junction proteins may contribute to development of arrhythmias (reviewed by Jongsma 
and Wilders, 2000). It is hypothesised that this compartmentalised expression of Cxs is 
the way in which there is an orderly and sequential spread o f activation from the atria to 
the ventricular chamber (reviewed by Gros et al., 1996).
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Each Cx is encoded by a single gene (Cx), which is composed of two exons separated by 
a large intron (fig. 1.3a). A typical Cx protein has four membrane-spanning regions and 
two extracellular loops and three cytoplasmic regions (fig. 1.3b). The original model of a 
complete intercellular channel was developed by Makowski et al., (1977) and is still 
valid today. Six Cx proteins form a connexon, which spans the plasma membrane of two 
adjacent cells, so that each connexon contributes to one half of the channel. The two 
connexons interact in the extracellular space to form the complete gap junction channel, 
allowing direct communication between the cytoplasm of the participating cells 
(reviewed by Bruzzone et al., 1996). A schematic view of the molecular steps leading to 
formation of an intercellular channel is shown in fig. 1.4. In the case o f intercellular 
channels, there are no known substances that increase the open state, whereas closure of 
the channels can be observed in response to diverse treatment such as pH variation and 
changes in cytosolic Ca2+. Studies have shown that Ca2+ levels o f 400 to 500 nM can 
cause a channel to close. However, it is unlikely that there is a direct effect of Ca2+ on 
Cxs, since there are no Ca2+-binding sites on Cxs. A recent hypothesis is that a Ca2+- 
receptor protein, calmodulin, is the mediator of the Ca2+ effect. Another possibility is that 
the activation of specific kinases and subsequent phosphorylation of Cxs may mediate 
Ca2+-gating (reviewed by Bruzonne et al., 1996). It can be suggested that a defect in a 
Ca2+-receptor protein, or a defect in a related kinase, may lead to an imbalance in the 
normal Ca2+ concentration, which could lead to cardiac conduction defects.
The use o f transgenic knockout mice has advanced the understanding of the role of Cxs 
in cardiac development and function. A recently produced Cx40 knockout mouse model
Stellenbosch University http://scholar.sun.ac.za/
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Figure 1 3  Schematic representation of a Cx gene and protein.
(a) Structure of a mammalian Cx gene. Cx genes consist of 2 exons separated by a large intron. 5 -UTR. 5 - 
untranslated region; 3’-UTR, 3’-untranslated region; ITS, intronic region.(b) Structure of a Cx protein. M l- 
M4, membrane-spanning regions; El and E2, the extracellular loops with spaced cysteine residues (C); NT, 
amino terminal; PM, plasma membrane; N, asparagine; P, proline; S, serine; Y, tyrosine (reproduced with 
minor modifications from Bruzzone et al., 1996).
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Figure 1.4 Schematic views of the molecular steps leading to the formation of intercellular channels.
The protein subunits, the connexins (A), oligomerise in a hexameric structure, the connexons (B), that are 
transported to the plasma membrane. Connexons from adjacent cells interact to form complete intercellular 
channels (C) that become clustered in specialised membrane regions, the gap junctions (Bruzzone et al., 
1996).
Stellenbosch University http://scholar.sun.ac.za/
showed cardiac conduction abnormalities characteristic of first degree A-V block and 
BBB (Simon et al., 1998). Studies with a Cx43/Cx40 double-knockout mouse model 
showed that Cx43 and Cx40 have additive effects on ventricular conduction and are also 
involved in heart morphogenesis (Kirchoff et al., 2000). Electrocardiography revealed 
very small increases in the QRS and QT intervals recorded by ECG in the double 
heterozygous knockout mice (Cx43+I'/Cx40+I'), compared with the wild-type 
(Cx43+/+/Cx40+/+) or single heterozygous knockout animals (Cx43+/' 
/Cx40+/+;C.x43+/+/Cx40+/~). These changes were proposed to have arisen from the 
combined effects o f slowed conduction in the central CCS (where Cx40 is expressed) and 
in the working myocytes (where Cx43 is expressed). The functions of Cx45 were 
revealed by using Cx4 5 -deficient mouse embryos, which exhibited striking abnormalities 
in vascular development. The embryos died by embryonic day 10 and exhibited a 
complex cardiac phenotype. In addition, there was a conduction block through the A-V 
canal and the contractions in the outflow tract were not co-ordinated (Kruger et al., 
2000). Analyses of mice with deletions o f Cx genes have provided evidence that Cx43, 
Cx40 and Cx45, and, consequently, the gap junctional channels are involved in both heart 
function and development (Miquerol et al., 2003).
Mutational alterations of Cx genes have led to several quite different diseases, indicating 
that these proteins have diverse functions. Individual mutations of Cx40, Cx43, and Cx50 
in M. musculus have been found to result in heart malformations or cardiac conduction 
defects (Jalife et al., 1999; Kirchoff et al., 2000). However in man, mutations in Cx26, 
can give rise to recessive nonsyndromic deafness or, more rarely, dominantly transmitted
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deafness (Kelsell et al., 1997). Recently, it has been shown that mutations at this locus 
are one o f the most common causes of deafness. Mutations in Cx30, Cx31 (reviewed by 
Krutovskikh and Yamasaki, 2000) and Cx43 (Liu et al., 2000) also lead to deafness. To 
date, Cx mutations involving cardiac conduction abnormalities and severe heart 
malformations have only been observed in studies in mice lacking Cx40 and Cx43 genes. 
It is envisaged that findings and future studies will eventually lead to an understanding of 
the involvement of Cxs in heart morphogenesis and in cardiac conduction disorders of 
humans.
In summary, any mutation in proteins involved in the constitution of gap junctions, such 
as a Cx, which is responsible for the transfer o f depolarising action potentials in the 
myocardium, are plausible candidate genes, which may be involved in the pathogenesis 
of PFHBI.
1.2.3 Development of the conduction system
The development of the cardiac conduction tissue of the heart is one o f the most 
contentious topics that exists in the conduction field. The co-expression of neural and 
muscle genes has confounded the understanding of the origin o f the CCS. However, it is 
believed that there are two possible origins, myogenic (Patten, 1956) or neurogenic 
(Gorza et al., 1988; Vitadello et al., 1990). Gorza et al., (1988) presented evidence that 
the so-called “neural proteins” originated from a neural crest origin. Another school of 
thought strongly supports the development of the CCS, specifically the BBs and Purkinje 
fibres from a myogenic origin (Gourdie et al., 1995; Cheng et al., 1999). Present
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knowledge of the development of the CCS is gained mostly from the study of animal 
embryonic material. However, it has been shown that there are a number of differences in 
cardiac development in different species (Davies et al., 1983; Fishman and Chien, 1997).
For reasons discussed previously, the next section outlines the four stages of the 
development of the CCS, which are the foetal, the postnatal, the adult and the ageing, 
with more o f a focus on the A-V and the BB regions.
1.2.3.1 Foetal, postnatal and adult development of the conduction system
Since 1970, histological differences between the developmental stages of the CCS have 
been studied (James, 1970; Davies et al., 1983). It was shown that by the sixth to eighth 
week o f foetal development, the human heart has attained most of its adult characteristics 
(James, 1970). At the initial stages of development, the small dark cells of the sinus are 
all similar but at a later stage some of these cells change and develop into the S-A node 
(James, 1970). It has been suggested that the S-A and the AV nodes develop from paired 
primordial sites, since they lie on either end o f the atrium. These two nodes are the two 
most efficient pacemaking units for several reasons: firstly, an optimal route for the 
pacemaking signal to the two atria and ventricles is provided, secondly, an abundant 
adrenergic and cholinergic innervation is present and, thirdly, a large artery is organised 
around the sinus within a dense collagen framework (Davies, 1971). All the cells in the 
foetal S-A node are similar, while at birth two distinct types of cells are distinguishable, 
the P and T cells. The sinus nodal artery also appears during foetal development and 
eventually develops into the largest single artery. It is hypothesised that the pressure, due
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to the blood flow in the artery during the development of the heart, has a significant 
effect on the S-A node’s pacemaking rate (Davies, 1971). Recent studies using G. gallus 
have shown that coronary arterial beds are necessary for the recruiting of adjacent 
myocytes to differentiate into conduction cells (Pennisi et al., 2002). At this stage, the 
foetal A-V node contains very little collagen; however, after birth, the collagen content of 
the S-A node increases rapidly until adult life. The collagen within the S-A node is 
intricately woven among the P and T cells to form a regular pattern framework, whereas 
the intemodal and interatrial pathways consist of largely fat and collagen and become 
fully defined during the postnatal period (Davies, 1971).
One could hypothesise that any structural gene expressed in the CCS, such as collagen, 
would be a plausible PFHBI-causing gene, since the increase in the collagen content 
during development coincides with the progressive course of this disease. This theory 
was further supported when an earlier weakly positive linkage result suggested that the 
PFHBI locus might map to chromosome 4, to a locus which encompassed three plausible 
collagen genes, collagen type I, alpha 1 (COL1A1), collagen type I, alpha 2 (COL1A2) 
and collagen type III, alpha 1 (C O L 3A 1 ). Subsequently, these genes were excluded as 
part of the same study (Brink et al., 1994).
Moorman et al., (1998) described the structure of the CCS of the embryonic heart as a 
cardiac tube with polarity. The atrial end of the tube contains the fast-conducting cells 
and the other end, the ventricular end, contains the slower conducting cells, so that the 
tube has a slow and fast area. This would explain how the electrical architecture of the 
embryonic heart is the same as the adult heart (Moorman et al., 1998).
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In 1970, James presented two theories about the embryological origin of the His bundle 
with its proximal branches. One theory states that the His bundle grows forward from the 
original A-V node and the other suggests that the His bundle and its proximal branches 
originate in situ within a primitive ventricular tissue and simply join the A-V node. In 
support of these theories, it has been observed that shreds o f A-V nodal tissue are strewn 
along margins of the central fibrous body (including the crest of the ventricular septum) 
in the human infant heart. The tissue gradually becomes absorbed during postnatal 
development so that it is rarely present in the adult heart (Davies, 1971). Recently, it has 
been reported that the fast conducting tissue of the His-Purkinje system from human 
embryonic hearts of 4.5 to 10 weeks showed that the A-V node develops from the canal 
myocardium and retains its continuity with the ventricular myocardium (Kim et al., 
2001).
The His bundles are composed exclusively o f typical Purkinje cells, as are the BBs. 
Gourdie et al., (1995) provided evidence that the lineage o f the Purkinje fibres develop 
from a myogenic origin. One set o f experimental data suggests that the Purkinje fibres 
and working myocytes share a common myogenic precursor in the embryonic tubular 
heart (Gourdie et al., 1995). Another set o f data provides evidence that the differentiation 
of Purkinje fibres may occur before the differentiation of working myocytes. A third set 
of data suggests that the peripheral (i.e., the intramural Purkinje fibre network) and the 
central components of the CCS are derived from independent parental cells, and that two 
components are linked together to establish the sequentially integrated CCS (Gourdie et 
al., 1995).
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Other evidence suggests that the His bundle and its branches originate separately. If this 
is the case, then the joining of the His bundle and its branches occurs during early foetal 
development since they are united during the second month o f gestation (Davies, 1971). 
The mechanisms governing the differentiation of these cardiac tissues are still poorly 
understood (Gourdie et al., 1995). The cell types at the junctions are predominantly T 
cells at the A-V node and Purkinje cells in the His bundle. At the border region, a mixture 
of the two types of cells is found (Davies, 1971). More recently, it was suggested that the 
distal CCS, such as the A-V node, His bundle and BB, is derived from working mocytes 
(reviewed by Pennisi et al., 2002). This was demonstrated in a series of retroviral lineage 
studies in chick embryos (reviewed by Mikawa, 1999).
To achieve its adult form, the His bundle undergoes extensive postnatal remodeling, 
which includes apoptosis (programmed cell death), just as morphogenesis often does 
(Davies, 1971). Apoptosis is a tightly regulated series of energy-dependent molecular and 
biochemical events orchestrated by a genetic programme (Colucci, 1996). Alterations in 
the apoptotic pathways can result in a number of diseases in humans, for example, 
apoptosis occurs in the myocardium of patients with arrhythmogenic right ventricular 
dysplasia, indicating that apoptosis is found in diseased hearts (Narula et al., 1996).
The volume of collagen in the different tissues of the adult heart is so large that it is the 
most readily distinguished protein on staining. It has been found that diseases in which 
the collagen framework is damaged are associated with arrhythmia because the S-A node 
becomes unstable (James, 1971). In the adult CCS, three pathways connect the S-A node
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to the A-V node and a fourth one connects the S-A node to the left atrium (fig. 1.1). The 
pathways are not ensheathed but are distinguished anatomically by the presence of the 
myocardial cells, which consist o f a mixture of Purkinje and ordinary working 
myocardial cells. The conduction speed is more rapid than in the working myocardium, 
although not as rapid as in the His bundle and its branches (Pennisi et a l, 2002).
During the development of the CCS from the foetal to the adult form a number of 
processes, such as the differentiation of cells, an increase in collagen content o f the CCS 
and extensive remodeling, occur. It can be suggested that any imbalances in one o f these 
processes may lead to PFHBI.
Molecular and genetic developments
It was proposed by Moorman et al., (1998) that, if  the development of the CCS were to 
be described at the molecular level, the following events would be relevant: (i) the 
development o f the cardiac tube, (ii) the development o f the polarity of nodes, (iii) the 
chamber formation, (iv) the development o f an electric impulse and (v) the involvement 
of Cxs, such as Cx37, Cx40, Cx43, Cx45 and Cx46; contractile proteins, such as a  and p 
myosin light chain (MLC); cytoskeletal proteins, such as desmin, neurofilament proteins 
and other proteins such as, atrial natriuretic factor (ANF), acetylcholinesterase and 
creatine kinase.
In addition, a review by Franco et a l,  (1998) of recent studies that investigated the 
genetic mechanisms controlling cardiac development has given good insights into the
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development o f the CCS. This review covers the patterns o f expression of a number of 
proteins that have been studied previously at the three developmental stages (tubular, 
embryonic and foetal heart) in Homo (H) sapiens, M. musculus, Rattus norvegicus and G. 
gallus. The proteins investigated were (i) the contractile proteins, such as MLC, actins,
9+tropomodulin, tropomyosin, troponins, calponin and titin; (ii) Ca handling proteins, 
such as the sarcoplasmic reticulum Ca2+ ATPase, phospholamban, ryanodine receptor, 
Na+-Ca2+ exchanger and Na+ K+ ATPase; (iii) impulse conduction proteins, such as Cxs;
(iv) energy metabolism proteins, such as creatine kinase; (v) intermediate filament 
proteins, such as desmin; (vi) cell-cell and cell-matrix molecules, such as integrins and 
cadherins; (vii) cardiac specific transcription factors, such as the NK homeobox genes, 
GATA-binding proteins (GATA), myocyte enhancer factor genes (MEF) and basic helix- 
loop-helix genes (bHLH); (viii) non-cardiac specific transcription factors, such as serum 
response factor, caspase-recruiting domain-containing protein (CAR) and cardiac muscle 
factor (CMF) and (ix) other proteins, such as the ANF  and acetylcholine esterase (Franco 
et al., 1998).
Using all the data from these studies, a transcriptionally regulated model o f the 
developing heart was proposed. For example, the development of the straight cardiac tube 
involved the expression of transcription factors MEF-2, heart and neural crest derivatives 
expressed 2 (dHAND) and GATA 4 (GATA-4'), in opposite gradients to each other. In the 
case of the looped heart, five functionally different segments can be distinguished, i.e., 
the inflow tract, the atria, the A-V canal, the ventricles and the outflow tract. During this 
stage, the expression patterns of a number of genes are either changed, remain the same
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or are switched off which implies that a negative domain-specific transcription factor 
(repressor) is present. This hypothesis is supported by the change o f expression patterns 
of several transcription factors, such as eHAND and dHAND and GATA-5 (Franco et al., 
1998). Interestingly, on examination o f the heart o f a human embryo that had died of 
cardiac arrest, it was found to have no right ventricular chamber and it was also 
discovered that the transcription factor gene dHAND was deleted (Srivastava, 1997; 
Barinaga, 1998). In the third stage of development, the heart becomes septated and 
distinct right and left atrial and ventricular components are recognisable. A possible 
model of right-left transcriptional specification has been suggested, similar to the 
segmentation of the fruit fly, Drosophila (D) melanogaster, but the experimental 
evidence for this model has not been finalised (Franco et al., 1998).
Another study that attempted to unravel the cell fate, lineage and morphogenetic decision 
that configure the vertebrate heart form and function in D. melanogaster and 
Caenorhabditis (C) elegans came to the conclusion that genetic analysis of these two 
organisms does not give all the answers. In a review by Pennisi et al., (2002) it was 
suggested that further studies using M. musculus and Danio (D) rerio may provide more 
answers about cell fate, lineage and morphogenic processes.
Transcription factors have also been implicated in the regulation o f heart development 
and conduction defects, e.g., genetic studies have shown that cardiac conduction defects 
in mouse models are linked to a mutation in a homeoprotein, namely, NK2 transcription 
factor related, locus 5 (NKX2-5). Habets et al., (2002) found that ANF  is expressed in the
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developing chamber, but is absent in the nodal tissue from fish to humans. The repressor 
gene, Tbx2, is expressed in the embryonic heart in a mutually exclusive pattern to ANF 
which led to the proposal that Tbx2 protein could be halting the expression o f the ANF  
gene in certain tissues such that they acquire nodal characteristics, rather than developing 
into chambers. They also discovered that Tbx2 binds transcription factor NKX2-5 and 
that the complex blocks the expression of the promoter region of the ANF  gene in tissues 
flanking the chambers.
At the 2003 meeting of the Novartis Foundation Symposium, the traditional hypothesis of 
ion pumps, channels and Cxs (ICC)-centric model, which suggests that the abnormal 
functioning of ion pumps, channels and Cxs causes conduction defects, was discussed 
(Miquerol et al., 2003). It was concluded that the ICC model had shortcomings and 
therefore two additional hypotheses were presented for the pathogenesis of conduction 
defects and arrhythmias. The one hypothesis proposed that conduction defects may arise 
from anatomic underdevelopment of the CCS in utero and the other hypothesis proposed 
that cardiac arrhythmias associated with Nkx2-5 mutations may result from the non- 
uniform alteration of cardiac myocyte channel proteins, leading to increased electrical 
heterogeneity. In addition to the traditional ICC-centric model, these two alternative 
hypotheses are under investigation, which should lead to a richer understanding of 
cardiac conduction defects.
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It is proposed that an understanding of the role and interplay of transcription factors, ion
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channels and Cxs during the development of the CCS will give a clearer idea of how 
mutations in one of the genes encoding a cardiac conduction protein can lead to a cardiac 
conduction defect, such as PFHBI.
Animal studies
Studies of the CCS using D. rerio, M. musculus and C. elegans have yielded interesting 
findings and insights into possible causes o f conduction defects (Stainier et al., 1996; 
Gourdie et al., 1999). These organisms are useful models for this type o f study, because 
they reproduce and develop rapidly. A vascular cytokine, endothelin (ET), was shown to 
induce avian embryonic cardiomyocytes to differentiate into Purkinje fibres but as the 
embryo matured the ability to convert to Purkinje fibres decreased (Kanzawa et al., 
2002). Additional studies, using the avian system, showed that when muscle cells 
converted to Purkinje fibres, they expressed a unique myogenic transcription programme 
before and after the conversion (Takebayashi-Suzukie et al., 2001).
D. rerio is an excellent model system in which to study cardiovascular development 
because a beating heart, which is functional within one day o f fertilisation, is formed. The 
zebrafish embryo does not require blood flow for survival during the first two days of 
development (Dempsey et al., 2000). Embryo research on D. rerio has given insight into 
the functioning of the pacemaker and the conducting system, because the embryo is 
transparent, the detection o f rhythm is easily visible with the naked eye (reviewed by 
Chen and Fishman, 2000). A number of mutations in different genes, that have been 
imaginatively named, have caused a number of different cardiac conduction defects such
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as, a slow heart beat, slo mo mutant, interference with conduction between chambers, 
breakdance and hip hop mutants, or a disturbance of conduction between cells, island 
beat, polka  and the tremblor mutants (Stainier et al., 1996). The identification o f these 
novel mutants present in D. rerio may help to identify human gene homologs with similar 
functions that could possibly aid in the identification o f the PFHBI-causative gene.
1.2.3.2 Ageing of the conduction system
Except for histological studies described by Davies and Pomerance (1972), very little 
research has been done in the past on the ageing process of the CCS. Investigations have 
shown that, with ageing, the amount o f fibrous tissue in the CCS increases (Mandel, 
1980). Fibrous tissue becomes more evident as the content o f nodal tissue per unit area of 
node decreases with increasing age (Mandel, 1980). Additionally, in the ventricular CCS 
of healthy individuals, an increase in fibrosis present per unit area increases with age. 
Processes causing this increase are not fully understood. In conduction disease, a 
replacement fibrosis of the bundle of His and the BBs features prominently. This 
phenomenon is called “idiopathic BB fibrosis,”  as it appears that the BB tissue is dying 
off (Davies et al., 1983). In 1970, Lev described a condition where adjacent myocardium 
is normal, but “sclerosis of the left-sided CCS” was present. Lenegre (1964) described a 
similar condition, but in this case the RBB was affected. Davies et al., (1983) suggested 
that the conditions described by Lenegre and Lev were the same disease.
Recent progress in the understanding of the genetic controls involving ageing is driven 
largely by the use of model systems, ranging from yeast and nematodes to mice. It
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appears that maintaining the genome integrity is a major factor in reducing ageing (Hasty 
et al., 2003). If this is the case, one can also propose that an increase in the fibrosis of the 
conduction tissue in cardiac conduction disease is probably due an imbalance in a genetic 
pathway, which initially maintained the conduction tissue.
1.2.4 Electrophysiology
From the 1950s to the late 1970s, the explanation of the spread of currents in the cardiac 
muscle was based on the “continuous conduction theory”. Since the discovery of the 
presence of gap junctions between cardiac cells, more experiments were performed and 
electrophysiological data were re-analysed; thus the concept of discontinuous conduction 
has gained more agreement (Spach, 2003).
A number of electrophysiological events lead to the excitation-contraction coupling in 
myocardial cells. Figure 1.5 shows the pattern of conduction from the SA node to the 
ventricles. The SA node has three depolarising currents, o f which the slow upstroke is 
largely Ca2+-dependent. In other tissues, such as the atrial muscle, Purkinje fibres and the 
ventricular muscle, the impulse travels very rapidly because the initial phase of 
depolarisation is much faster and is Na -dependent. The Ca -dependent A-V node slows 
down conduction between the atria and ventricles.
1.2.4.1 Depolarisation
In the resting state, myocardial cells are polarised, meaning that they are carrying an
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Figure 1.5 Pattern of conduction from the SA node to the ventricles.
On the left is a schematic drawing o f  components o f the cardiac conduction system, indicating the 
depolarising ionic currents in the nodes. On the right are traces showing the action potential generated by 
the different ion changes in the conduction system and the ventricles (Opie, 1991).
electrical charge. These cells are positively charged on the outside and negatively 
charged on the inside and the potential difference across the membrane is approximately 
-90mV. When an electrical current is transmitted, or the cell is stimulated, it begins to 
depolarise at -65mV. At -40mV the activation threshold is reached. At this point the 
voltage dependent ion channels facilitate the movement o f Na+ and Ca2+ ions into the cell
I  ^j ^
(Davies et al., 1971). The inward flux of Na and Ca into the cytosol o f the cell 
generates an action potential, which results in the contraction o f the myocyte. The 
activation of Na+ channels is much faster than that o f the Ca2+ channels (Katz, 1993).
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Consequently, the conduction o f the electrical impulse in the rapidly conducting 
ventricular CCS is dependent on the Na+ channel-generated action potential, with the
Ca2+ channel generating secondary inward currents (Opie, 1991; Katz, 1993). In contrast,
• 2+  •  • the slow conducting nodes depend mostly on the slow Ca ion channel-generated action
potential. In the A-V node, the conduction delay is largely due to the slow conduction
9+ • • •rate mediated by the Ca channels. The same depolarising stimulus responsible for the 
activation of the ion channels effects their inactivation, thus closing the Na+ and the Ca2+ 
channels (Opie, 1991; Katz, 1993).
1.2.4.2 Repolarisation
The return of the cells to their resting state is affected by the outward movement of K+ 
through K+ channels, possibly supplemented by the inward movement of Cl". The two K+ 
ion currents involved in this process are the transient outward current (It0), which is 
responsible for the early repolarisation and the delayed rectifier (Ik), which is responsible 
for the delayed repolarisation and also for maintaining repolarisation (Katz, 1993).
The electrocardiogram
The ECG patterns of individuals suffering from PFHBI are distinguished by the presence 
of a broad QRS complex (Brink and Torrington, 1977), (fig. 1.8) which is caused by 
RBBB, and results in the late depolarisation of the ventricles (Hampton, 1997). The ECG 
is a non-invasive technique that records the cumulative currents produced by the heart 
muscles, thereby providing valuable information about the heart’s normal or abnormal 
function (Goldberger and Goldberger, 1990). The ECG records the effect o f the
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depolarising stimulus on the myocardium (i.e., the sequential contraction of the atria and 
then the ventricles) as deflections, the P wave and the QRS complexes. The return to the 
resting state, repolarisation, is represented by the ST-segment and the T wave (fig. 1.5). 
In a healthy heart, the P wave represents the contraction of both atria in response to the 
depolarising stimulus initiated at the S-A node. The P wave is followed by a flat baseline, 
and represents the delay of the electrical impulse at the A-V node. Contraction o f both 
ventricles is represented as a QRS complex. Following the QRS complex is a gently 
upsloping ST segment which precedes a T wave depicting ventricular re-polarisation. 
One cardiac cycle is represented by the P wave, QRS complex and a T wave.
1. 3 CARDIAC CONDUCTION DISEASES
The CCS is responsible for the conduction of electrical impulses in the heart and 
therefore the impairment of any one of the components o f the CCS can result in heart 
rhythm disturbances (arrhythmias). These arrhythmias may progress to heart block, 
which may be fatal if  not treated by timely implantation o f an artificial pacemaker (Van 
der Merwe et al., 1988). A number of cardiac conduction disorders have an inherited 
congenital basis implying that they include a genetic component and can be inherited in a 
family setting (Vallianos and Sideris, 1974; Esscher et al., 1975; James et al., 1975; 
Brink and Torrington, 1977; Brink et al., 1995; De Meeus et al., 1995). The generation of 
congenital cardiac defects is thought most likely to occur during the complex 
morphogenesis of the heart.
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1.3.1 Familial congenital cardiac diseases
Cardiac development is a complex biological process requiring the integration of a 
variety o f processes involving a number o f cell components, morphogenesis and 
excitation-contraction coupling (Olson and Srivastava, 1996). A number of postnatal 
morphogenetic events only occur several months after birth (James and Facc, 1985). An 
understanding o f these finely controlled molecular mechanisms has come from studies of 
D. melanogaster, G. gallus and M. musculus (Levin et al., 1995; Rossant, 1995; Park et 
al., 1996). Studies using M. musculus are laying the groundwork for a comprehensive 
understanding o f cardiac organogenesis. One study involving M. musculus illustrated that 
the two related transcription factors, dHAND and eHAND, are expressed in a 
complementary fashion in the development of the right and left ventricles, respectively. 
Targeted mutations of these transcription factors revealed novel pathways o f the 
development of the heart (Srivatava, 1997). The basis o f congenital heart defects is still 
obscure, but disorders such as Holt-Oram syndrome (HOS) and atrial septal defect (ASD) 
have implicated mutations in transcription factor genes as being involved in heart 
development (Basson et al., 1997; Schott et al., 1998).
1.3.1.1 Holt-Oram sydrome (HOS)
Holt-Oram syndrome (HOS:OMIM 142900) is an autosomal dominantly inherited 
disorder that is characterised by skeletal abnormalities and cardiac malformations, such 
as either ASD, muscular ventricular septal defects (VSD) or multiple complex 
malformations (Holt and Oram, 1960; Basson et al., 1994). From classical genetic 
linkage studies, the HOS gene was mapped to chromosome 12q21.3-q22 (Terret et al.,
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1994). Using exon trap analysis o f genomic clones from this interval, two 
developmentally expressed genes (T-box-3, TBX3, and T-box-5, TBX5) from the 
Brachyury (T) gene family were identified (Li et al., 1997). Basson et al., (1997) refined 
the mapping o f the HOS locus to chromosome 12q24.1 by fluorescence in situ 
hybridisation (FISH) using a cosmid containing D12S129, which was tightly linked to the 
HOS gene. From the critical region, Basson and colleagues (1999) isolated a gene with a 
high degree of homology to M. musculus Tbx5 and identified several mutations in TBX5 
in affected members of the HOS families. To date, ten different mutations have been 
found in TBX5 in different affected families. Members of the TBX gene family act as 
transcription factors and the conserved TBX domain serves as a DNA-binding domain 
(Basson et al., 1999). Hiroi et al., (2001) found that TBX5 associates with NKX2-5 and 
synergistically promotes cardiomyocyte differentiation. Additional TBX5 protein-binding 
site studies have shown that the presence o f TBX5-binding sites in the upstream regions 
of several cardiac-expressed genes, including cardiac a-actin, ANF, a-cardiac MYH, p- 
cardiac MYH, MYL1A, MYL1V and NKX2-5, suggests a role for TBX5 in their regulation 
(Ghosh et al., 2001).
1.3.1.2 Atrial septal defect (ASD)
Atrial septal defect (ASD:OMIM 108900) is an autosomal dominantly inherited disorder 
that is characterised by cardiac malformations and A-V conduction abnormalities. Kahler 
et al., (1966) reported three families with this combination and Pease et al., (1976) and 
Basson et al., (1995) identified four more families with ASD conduction defects only. 
Shiojima et al., (1995) mapped the cardiac specific homeobox gene (CSX) to
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chromosome 5q34, using FISH and systematic screening of a yeast artificial chromosome 
(YAC) library using polymerase chain reaction (PCR). CSX  is expressed in various 
tissues including the CCS of the developing heart. Schott et al., (1998) showed that ASD- 
affected individuals had mutations in the CSX  gene, which encodes the transcription 
factor NKX2-5. In addition, another homeobox-containing gene, Msh homeobox 
homolog 2 (MSX2), was also mapped to this region. Shiojima et al., (1995) suggested that 
localisation o f CSX and MSX2 to the same region of the genome may indicate that they 
are coordinately regulated during human heart formation.
In studies by Shiojima et al., (1995), three different NKX2-5 mutations were identified, of 
which two are predicted to impair binding o f NKX2-5 to target DNA, resulting in 
haploinsufficiency, and the third potentially aids target-DNA binding. These 
investigations indicate that NKX2-5 is important for regulation of septation during 
cardiac morphogenesis and for maturation and maintenance of A-V node function 
throughout life.
1.3.2 Familial cardiac conduction diseases
Various forms of familial conduction diseases have been reported throughout the world; 
pedigrees o f six South African families with hereditary A-V block have been reported 
(Myburgh and Steenkamp, 1973). In an investigation in the United States o f America 
(USA), 26 of 59 members in four generations o f a family showed abnormal ECGs. The 
affected members had conduction abnormalities as the only manifestation o f the disease, 
inherited in an autosomal dominant manner (Schaal et al., 1973). In another study, five
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out o f 14 family members presented with conduction defects, such as A-V block, RBBB, 
and LAHB. Another sibling died suddenly, six did not have conduction abnormalities and 
information was not available regarding the remaining two (Vallianos and Sideris, 1974).
There are also a number o f inherited neurological disorders associated with cardiac 
arrhythmias that occur with either a direct involvement of the heart or induced 
neurohormonal abnormalities that act on the heart (Zipes and Jalife, 2000). Myotonic 
dystrophy (DM) and limb-girdle muscular dystrophy type IB (LGMD1B) are examples 
of diseases that show both neurological symptoms and cardiac abnormalities, including 
A-V conduction disturbances, RBBB, LBBB and dysrhythmias, and in some individuals 
this necessitates pacemaker implantation.
1.3.2.1 Myotonic dystrophy (DM)
Myotonic muscular dystrophy 1, or Steinert’s disease (DMl:OMIM 160900), is a disease 
showing an autosomal dominant form of inheritance. It is characterised by weakness and 
atrophy of distal skeletal muscles, as well as systemic manifestations, such as early 
balding, gonadal atrophy, cataracts, mental retardation and cardiac involvement (Harper, 
1989; Perloff et al., 1984). The myotonic dystrophy kinase, DMK, encodes a protein 
homologous to a serine/threonine protein kinase (Aslanidis et al., 1992; Buxton et al., 
1992). DM1-affected families illustrate the phenomenon of anticipation (see section
1.3.2.3.4 for more detail on anticipation), which shows an increase in the number of CTG 
triplet repeats in the 3’-untranslated region (3’-UTR) of DMK  gene (Brook et al., 1992; 
Mahadevan et al., 1992). Studies using DM1-affected individuals have shown that the
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cardiac conduction abnormality increases both with age and with the extent o f CTG 
repeat expansion (Melacini et al., 1995; Wang et al., 1995; Clarke et al., 2001). Since the 
phenomenon o f anticipation has also been observed with PFHBI (Van der Merwe et al.,
1988), one can speculate that PFHBI might be caused by a similar mechanism to DM1, 
implying an expansion of a triplet repeat in the PFHBI disease-causing gene.
The mechanism by which the amplified CTG repeat expansion leads to DM1 is unclear, 
however, a number of theories have been suggested, for example, an alteration in tissue 
phosphorylation due to a decrease in DMK activity which, in turn, has been postulated to 
cause a change in ion channel structure or function (Rudel et al., 1989; Timchenko et al.,
1995). Mounsey et al., (2000) used M. musculus myocytes that were either heterozygous 
(+/-) or homozygous (-/-) for the mouse ortholog of the human DMK  gene, dmk, to 
implicate abnormal Na+ channel function in causing DMK deficiency in DM1. Saveliev 
et al., (2003) have shown, using DMK transgenic mice, that triplet repeat expansions may 
result in gene silencing which in turn, may play a role in gene regulation. Other possible 
mechanisms associated with decreased DMK activity include impaired glucose 
utilisation, possibly related to abnormal protein kinase function, a potential relationship 
between an expanded DMK and an adjacent gene and an abnormal coronary reserve 
(Annane et al., 1994; Annane et al., 1996). It has also been proposed that the triplet 
repeat expansion within the DMK gene affects and interferes with the chromosome 
structure and with the expression of multiple neighbouring genes, resulting in the 
multisystemic clinical phenotype of DM (Jansen et al., 1992; Mahadevan et al., 1993; 
Perryman et al., 1993).
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Additionally, a number of families were found with clinical features characteristic of 
DM1, but without the CTG repeat in the DMK  gene (Thornton et al., 1994).
Subsequently, a second locus for another DM-causing gene, DM2, was mapped to
chromosome 3q21 (Ranum et al., 1998). DM2 is caused by an expansion of a 
tetranucleotide (CCTG) repeat motif located in intron 1 of the zinc finger protein 9 gene 
(ZNFP9), which causes the same multisystemic features as DM1 (Liquori et al., 2001). 
Parallels between these two types of diseases indicate that the microsatellite expansions 
in the unspliced DMK mRNA may be pathogenic and cause the disease (Liquori et al.,
2001). Ranum and Day (2004) have shown that both DM1 and DM2 are caused by a 
gain-of-function RNA, in which the CUG and CCUG repeats alter cellular function, 
including alternative splicing of various genes.
Experimental work using murine mutants indicate that mutant RNA is retained in 
myonuclei where it aggregates and interferes with the export o f the wild type mRNA 
(Taneja et al., 1995; Davis et al., 1997). Another interesting finding was that a null 
murine mutant for the dmk gene (-/-) developed only cardiac conduction defects and did 
not show any other signs of DM, such as myotonia or cataract formation (Tappscott et al., 
2001; Burton and Davis, 2002). This study seems to imply that dmk is specifically 
involved in the cardiac conduction pathway and could possibly give indications about the 
mechanism involved in the development of PFHBI.
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1.3.2.2 Limb girdle muscular dystrophy (LGMD)
Limb girdle muscular dystrophy constitutes a heterogeneous group of disorders 
characterised by a general limb-girdle weakness. A recently recognised autosomal 
dominant limb girdle muscular dystrophy IB (LGMD1B:0MIM 159001), with a high 
degree of cardiac involvement, was mapped to chromosome lq l 1-21 (Kass et al., 1994). 
In affected individuals, symmetric weakness starts in the proximal lower-limb muscles 
before the age of 20 years, and in the third or fourth decade, the upper-limb muscles 
become affected. Van der Kooi et al., (1997) described three new families with 
LGMD IB with cardiac involvement. Cardiac abnormalities found in 62.5% of the 
patients, included A-V conduction disturbances similar to the family described by Kass et 
al., (1994). The disease-causing gene was found to be lamin A/C, LMNA, which encodes 
two proteins of the nuclear envelope. Muchir et al., (2000) identified three specific 
mutations in LMNA in all the affected members of each LGMD1 family. Since cardiac 
conduction abnormalities in LGMD IB are linked to mutations in LMNA, and PFHBI is a 
disease which affects the CCS, one can propose that a LMNA paralog on chromosome 19, 
if present, would be a good gene to screen for PFHBI-causative mutations.
1.3.2.3 Familial bundle branch block diseases
Morquio first reported familial BB heart diseases in 1901. At a later stage Combrink et 
al. (1962), described another family, which included five brothers with A-V conduction 
disturbances. Thirty years ago the pathological basis for BBB was poorly defined and the 
diagnosis was based solely on an ECG profile (Davies, 1971). In addition, the wide 
branching of the BBs over the septum has made adequate histological examination
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difficult (Davies, 1971). Graber et a l ,  (1986) concluded from a study of familial CCS 
and myocardial disease that extensive biochemical investigations would provide clues to 
the molecular aetiology of these diseases. BBB occurs when an interruption of 
conduction in one of the main BBs occurs and the presence of a prolonged QRS complex 
is observed on ECG. The normal width o f the QRS complex is 0.1 second, but, in the 
case o f BBB, it is greater than 0.1 second (Goldberger and Goldberger, 1990). CHB 
occurs when a total cessation of conduction o f the impulse through the A-V node and the 
bundle o f His occurs; that is, atrial and ventricular depolarisations are completely 
independent. Complete heart block (CHB) is potentially life-threatening and is treated by 
implantation of a ventricular pacemaker (Goldberger and Goldberger, 1990).
Globally, a number o f familial BB conduction diseases have been described which share 
similarities to PFHBI, although identified under different names (see table 1.1) (Brink et 
al., 1994), such as as progressive cardiac conduction disease (PCCD), isolated cardiac 
conduction disorder (ICCD) and PFHBII.
1.3.2.3.1 Progressive familial cardiac conduction disease (PCCD)
Progressive cardiac conduction disease (PCCD:OMIM 113900) segregates in an 
autosomal dominant manner in a French family who had originally been diagnosed with 
Lenegre-Lev disease (Lenegre, 1964; Lev, 1964). Long-term follow-ups o f several 
affected members demonstrated that their conduction defect increased in severity with 
increasing age. Schott et al., (1999) excluded linkage of PCCD to the PFHBI locus on 
chromosome 19, and other loci associated with inherited cardiac diseases with conduction
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Table 1.1 Summary of familial bundle branch disease with similarities to PFHBI.
Table I . Familial bundle branch disease. Summary of reports in the liter­
ature of disorders with similarities to PFHB.
No. individuals
Pedi- Total/
Source SB RBBB BFB CHB grecs study AFF
Moseui 1954 (9) - - -  1 11 4
Trivella el al. 1960 (10) - - -  1 7 5
Combrink et al. 1962* (11) - - + 1 6 4
Gazes el ft I. 1965 (12) + - + 1 21 9
Simonsen et al. 1970 (13) - - + 1 28 5
Steenkamp 1972* (14) - + + 1 17 6
Myburgh el al. 1973* (15) + - + 6 48 22
Schaal et al. 1973 (16) - + + 1 45 31
Vallianos et al. 1974 (17) - + + 1 14 8
Esscher et al. 1975 (18) - - -  2 69 20
Brink el al. 1977* (1) + + + 1 55 31
Stephan 1979 (19) - + + 3 505 128
v.d. Merwe 1988* (4) •+ + + many 181 84
*, South African families suffering from PFHBI; SB, sinus bradycardia; RBBB, right bundle 
branch block; BFB, bifascicular block; CHB, complete heart block; AFF, affected; +, ECG 
abnormality considered present; ECG abnormality not recorded (Brink et at., 1994).
defects, and the PCCD locus was eventually mapped to chromosome 3p21. It was found 
that the disease-causative mutation occurred in the cardiac-specific Na+ channel 5 A gene 
(SCN5A), namely, a T to C transition in the highly conserved donor splice site of intron 
22, resulting in the formation of an abnormal transcript with an in-frame skipping of exon 
22 (Schott et al., 1999). Thereafter, a second mutation was observed in a Dutch family, 
and in this case, the mutation was a lbp deletion (G) at nucleotide 5280 of SCN5A, 
resulting in a frameshift causing a premature stop codon (Schott et al., 1999). 
Interestingly, SCN5A has been implicated in three other cardiac conduction diseases, 
namely, Brugada syndrome, in which patients have marked abnormalities in ventricular
Stellenbosch University http://scholar.sun.ac.za/
conduction (Vatta et al., 2000), isolated cardiac conduction disease (ICCD)(section 
1.3.2.3.2), a sustained, isolated conduction defect which slows down the cardiac rhythm 
(Tan et al., 2001) and long QT syndrome-3 (LQT3) (Wang et al., 1995).
1.3.2.3.2 Isolated cardiac conduction disease (ICCD)
In 2001, Tan et al., found another mutation in SCN5A, which co-segregates with another 
conduction disorder called isolated cardiac conduction disease (ICCD). The ECG of a 3- 
year old patient with ICCD showed characteristics of slow conduction through the atria 
and ventricles, including a broad P wave, PR interval prolongation and a wide QRS 
complex. The described mutation in exon 12 of SCN5A results in a substitution of 
cysteine 514 for glycine (G514C) in the channel protein (Tan et al., 2001). Recent work 
by Tan et al., (2002) showed that a Ca2+ sensor in SCN5A-encoded channel modulates 
cardiac excitability and that a different mutation in the carboxy-terminal 'IQ' domain of 
the same protein causes ventricular arrhythmias. These findings support the notion that 
ion channels and or calcium homeostasis may play a role in the development of PFHBI.
1.3.2.3.3 Progressive familial heart block II (PFHBII)
Progressive familial heart block II (PFHBII :OMIM 140400) segregates in a South 
African family and is inherited in an autosomal dominant fashion (Brink and Torrington, 
1977). It is characterised by a sinus bradycardia with a left posterior hemiblock, and a 
narrow QRS complex on ECG. Clinically, PFHBII presents with syncopal episodes and 
Stoke-Adams seizures when CHB supervenes and the conduction abnormalities are 
accompanied by dilated cardiomyopathy (Fernandez et al., 2004). Recent linkage studies
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have placed the PFHBII locus on the long arm of chromosome lq32 (personal 
communication, Fernandez, 2004) although the disease-causing gene has not yet been 
identified.
1.3.2.3.4 Progressive familial heart block I (PFHBI) 
Background
Progressive familial heart block I (OMIM 113900) was first described by Brink and 
Torrington in 1977 in several branches of a large South African pedigree. The disease is 
an autosomal, dominantly inherited, progressive BB conduction disorder that may 
progress to complete heart block (Brink and Torrington, 1977; Van der Merwe et al., 
1986; Van der Merwe et al., 1988). In earlier studies, it had been estimated that there may 
be between 1000 and 9000 gene carriers among the descendants from a Portuguese 
ancestor (Brink and Torrington, 1977; Torrington et al., 1986; Van der Merwe et al.,
1994). To date, three apparently unrelated pedigrees designated 1, 2 and 5 have been 
established (fig. 1.6). Pedigree 2 consists o f nine generations, all descended from one 
ancestor who emigrated from Lisbon, Portugal in 1696 (Brink and Torrington, 1977). He 
married a woman of French origin in 1735 and they moved to the Eastern Cape near the 
Gouritz River. Pedigrees 1 and 5 are smaller pedigrees with the affected members 
displaying the same phenotype and disease-associated haplotype as individuals in 
pedigree 2. However, no family data linking pedigrees 1 and 5 to the same ancestor of 
pedigree 2 is available (Brink, 1997). Currently, a large branch of the family lives in the 
Free State Province, while others have moved to various places in South Africa (fig. 1.7).
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Figure 1.6 Family pedigrees 1 ,2  and 5 segregating for PFHBL
A, pedigree 2 is a nine generation pedigree traced back to a single male (1.01) and his wife (1.02). 
Individual 1.01, was one o f  10 siblings, all offspring o f  a Portuguese immigrant and his wife o f  French 
ancestry, who married in South Africa in 1735. B, pedigree 1 and 5, are two smaller pedigrees with affected 
members showing the same phenotype as individuals in pedigree 2 and were, therefore, regarded as 
segregating for PFHBI. N o genealogical links have been established with pedigree 2. Affected individuals 
had either right bundle branch block, complicated right bundle branch block, or complete heart block and 
the same haplotype (Brink et al., 1995).
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Figure 1.7 The distribution and movement o f the pedigree 2 PFHBI family in South Africa.
“ indicating the movement o f  the PFHBI families from Cape Town to the Gouritz river, spreading to the 
Eastern Cape and then finally moving to the Free State and onto Gauteng (modified map from Encarta 2001).
PFHBI is defined on ECG by evidence of BB disease, i.e., RBBB, LAHB or LPHB or 
CHB with broad QRS-complexes (fig. 1.8) (Brink and Torrington, 1977).
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Age of onset
There are four high-risk periods reported for the onset o f PFHBI, namely at birth, soon 
after birth, the early 20s, and again towards middle age (Brink and Torrington, 1977). It 
was also found that in familial cases an early normal ECG does not exclude the 
occurrence o f an underlying conduction disorder in later life (Brink and Torrington, 
1977).
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(a)
(b)
VI
V6
Figure 1.8 ECG tracings showing a typical pattern of right bundle branch block and a normal ECG. 
(a) A  typical ECG showing the deflections resulting from the electrical changes in the components o f  the 
conduction system resulting in the P, Q, R, S and T waves. In a normal individual, the QRS com plex is 120 
ms wide. 0>) An ECG obtained from an individual with right bundle branch block. The QRS complex is 
more than 120 ms wide with a delayed terminal wave attributable to late right ventricular depolarisation as 
shown by a terminal slurred R wave in standard VI and a slurred S wave in V6 
(http://www.lond.ambulance.freeuk.com/ecg/ECG2htm).
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These findings suggest that the PFHBI-causative gene might be involved in the 
developmental pathways o f the CCS, since the manifestation of the disease occurs at 
specific developmental stages.
Pathology of PFHBI
By way o f comparison, pathological studies o f the CCS, in DM1-affected individuals 
showed evidence o f non-specific conduction fibre loss throughout the system, with 
replacement by fat rather than fibrosis (Nguyen et al., 1988). The only autopsy from a 
PFHBI-affected individual was performed on a 2 year-old child, and showed fibrosis of 
the conduction tissue, namely, the main and the proximal part o f the BBs, in the presence 
o f dilated cardiomyopathy. However, the post mortem also revealed that the patient died 
of a cerebral embolus (Van der Merwe et al., 1991), which was considered atypical of 
PFHBI.
Replacement fibrosis is a common feature in general conduction disease (Davies et al.,
1983). The process involves a dying-off o f the BB tissue, with substitution o f fibrotic 
tissue. Post-mortem studies by Davies in 1971 showed that 46% of patients suffering 
from CHB had fibrosis of the bundle o f His and BBs in the absence of any other 
myocardial disease. The fibrosis o f the BBs might be caused by an underlying collagen 
defect termed “exaggerated ageing effects”, as suggested by Lev in 1964, or “primary 
degenerative Lenegre disease” as suggested by Lenegre (1964).
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Currently, the only treatment for PFHBI is the timely implantation of a pacemaker, which 
enables the affected individual to lead a normal and productive life (Torrington et al.,
1986).
Anticipation
The phenomenon o f anticipation was considered to be present within the PFHBI 
pedigrees, as it had been noted that successive generations required earlier implantation 
of pacemakers (Van der Merwe et al., 1988). The mean age of pacemaker implantation in 
PFHBI-affected individuals decreased with successive generations, namely, implantation 
was at 9,8 years in generation 8, 30,8 years in generation 7 and at 60,5 years in 
generation 6; suggesting that members of the younger generation are more severely 
affected than members of the older generation. Unusual triplet and tetranucleotide repeat 
expansion have been associated with a number o f diseases which show anticipation 
(Sheffield et al., 1995; Rosenberg, 1996; Liquori et al., 2001 (section 1.4.1.3). As part of 
this study, the search for expanded triplet repeats was pursued.
Linkage studies to identify the PFHBI locus
Brink et al., (1994) performed a linkage study using pedigrees 1 and 2 originally reported 
by Brink and Torrington (1977). O f 80 marker loci tested, 68 were excluded from linkage 
with the PFHBI locus. Additionally, large portions of chromosome 1 (72%), chromosome 
4 (70%) and chromosome 19 (55%) were excluded from linkage using multipoint 
mapping (Brink et al., 1994). Subsequent linkage studies mapped the PFHBI gene to a 
region of approximately lOcM on chromosome 19ql3.2-ql3.3 (Brink et al., 1995).
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A French group mapped a second conduction defect named ICCD by linkage analysis to 
the same region o f chromosome 19ql3.3 as PFHBI (De Meeus et al., 1995). Although 
ICCD has the same name as a disease identified by Schott et al., (1999) and Tan et al., 
(2001), it has different clinical features and is caused by different chromosome mutations 
in the SCN5A gene on a different chromosome too. To avoid confusion, it will be referred 
to as CCD in this thesis. Through collaborative studies conducted by the PFHBI group 
with the French group, it was confirmed that common clinical features are shared by both 
PFHBI and CCD. On this basis, it was decided that these two conduction disorders are 
likely to be the same disease (personal communication, Brink and Bouvagnet, 1998).
The PFHBI locus centered on the kallikrein (KLKl) locus, within a lOcM region and was 
flanked by the apolipoprotein C-II (APOC2) and related RAS viral (r-ras) oncogene 
(RRAS) genes (Brink et al., 1995), whereas the CCD gene was localised to a larger 13cM 
interval, between the flanking markers D19S606 and D19S571 (De Meeus et al., 1995) 
(fig. 1-9).
An integrated map combining the different markers used by the two groups showed that 
the two intervals overlapped. Using genetic fine mapping, the PFHBI locus was reduced 
to 7cM between markers D19S412 and D19S866 (fig. 1.9) (personal communication, De 
Jager, 1998). As part of the present study, fine genetic mapping was continued to further 
reduce the area in order to localise the disease-causing gene.
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D19S412, D19S606, D19S866 and D19S571 are genetic markers. APOC2, Apoliprotein C-H; RRAS, 
related RAS viral (r-ras) oncogene and KLKl, kallikrein 1 are genes flanking the PFHBI locus (Brink et 
al., 1995; de Meeus et al., 1995).
1.4 POSITIONAL CANDIDATE STRATEGIES
The Human Genome Project (HGP) has generated a number o f resources, such as 
genetic, physical and transcript maps, DNA clones, sequences, expression and phenotypic 
data, which have sped the identification o f novel disease-causing genes. As the HGP 
progressed, search strategies were modified so that available data from the publicly
CCD
locus
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accessible databases and bioinformatic tools could aid the search for the PFHBI gene. 
Some o f the strategies used to find the PFHBI gene are described in sections 1.4.1, 1.4.2 
and 1.4.3 o f this study, and include linkage analysis, genetic fine mapping, somatic cell 
hybrid mapping, bacterial artificial chromosome (BAC) and cosmid mapping, 
establishing o f clone contigs, and retrieving and clustering of expressed sequence tags 
(ESTs). An EST is a partial sequence o f a fragment o f a cDNA clone, generated from 5’- 
and 3’-ends o f the clone, that is between 150 to 200bp in length and represents an 
uncorrected single read sequence (Adams et al., 1991) (see section 1.4.3.1 for a more 
detailed discussion of ESTs).
1.4.1 Genetic map
The earliest classical human genetic maps consisted o f protein polymorphisms, notably 
blood groups and serum protein markers, which are both rare and not very informative 
(Gyapay et al., 1994). In 1987, the first complete genetic map of the human genome was 
published using restriction fragment length polymorphisms (RFLPs) (Donis-Keller et al.,
1987). The discovery of microsatellites allowed great advances in the development o f a 
human genetic map and aided its resolution (Weber and May, 1989). Subsequently, 
Weber et al., (1993) generated a higher resolution linkage map o f short tandem repeat 
(STR) markers.
Since the 1990’s, there have been rapid advances in developing genetic maps for humans, 
greatly advancing the ability o f researchers to localise and identify genes for inherited 
disorders. Through the efforts o f three large groups generating microsatellite markers,
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and the efforts of 110 collaborators o f the Centre d’Etudes du Polymorphisme Humain 
(CEPH), comprehensive linkage maps o f all the human chromosomes are now available 
(Cooperative Human Linkage Centre, CHLC, 1994). The Genethon group in France 
worked on maps based on markers that contained CA repeat motifs, which are the most 
common STR in the human genome (Weissenbach et al., 1992; Gyapay et al., 1994). The 
CHLC and the Utah marker development group (based in the state of Utah, USA) 
developed maps based on di-, tri-, and tetranucleotide repeats (CHLC, 1994). The maps 
were produced through the collaborative efforts of the different groups, which generated 
markers at an average density of 0.7cM (CHLC, 1994). Searches for disease-causing 
genes require the establishment of fine genetic maps and saturation fine mapping using of 
polymorphic markers, to detect recombination events (Keating, 1992), as in the case of 
the search for the PFHBI gene.
During the course of the PFHBI gene search, the available genetic markers o f the current 
STR map of chromosome 19ql 3.3 had been utilised and the development o f novel STRs 
was required for further fine mapping studies of the PFHBI locus. This involved the 
search for di-, tri- and tetranucleotide sequences in DNA clones spanning the PFHBI 
locus (Christoffels, 1997; Makubalo, 2000).
1.4.1.1 Dinucleotide markers
(CA)n repeat sequences are abundantly dispersed repetitive elements present in genomes 
of many eukaryotes, including humans (Hamada et al., 1984) and are the most frequently 
found repeat sequences in the human genome (Beckman et al., 1992). In 1989, Tautz
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demonstrated hypervariability in the length of the (CA)n repeat sequences o f two loci in a 
family, in addition, the repeats showed a Mendelian pattern o f inheritance. The 
polymorphic and Mendelian characteristics of these motifs were developed as a source of 
genetic markers (Gyapay et al., 1994).
There are three categories of (CA)n repeat sequences, namely, perfect repeats without 
interruptions in the runs of CA, imperfect repeats with one or more interruptions in the 
run of repeats and a compound o f repeat sequences with adjacent tandem simple repeats 
of a different sequence (Weber, 1990). Weber (1990) demonstrated that loci with 10 or 
fewer (CA)n repeats had little or no allelic variation, whereas loci with 11 to 15 repeats 
were more polymorphic and those with 16 or more repeats were highly polymorphic and 
therefore highly informative markers. The function of (CA)n repeats is unknown, but it 
has been proposed that they serve as hot spots for recombination (Slightom et al., 1980) 
or participate in gene regulation (Hamada et al., 1984).
1.4.1.2 Tri- and tetranucleotide markers
Human trimeric and tetrameric short tandem repeats (STRs) are highly polymorphic in 
humans, where they are distributed randomly within the intronic and sometimes in the 
exonic regions of the genome on an average of every 300kb (Edwards et al., 1992) and 
are generally inherited stably (Edwards et al., 1991). It was found that the 
informativeness of a STR was dependent on the repeat type and length e.g., STRs with 
eight or more triplet repeat motifs (Gastier et al., 1995) and tetranucleotide repeats of six 
or more are informative (Sheffield et al., 1995). The tetranucleotide STRs occurring most
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abundantly are AAAG (38%), AGAT (29%), AAGG (10%) and AAAT (5%) (Utah 
Marker Development Group, 1995).
However, a different class of trinucleotide and tetranucleotide repeats has been found 
which are distributed in both intronic and exonic regions, which may sometimes be 
pathogenic (section 1.3.2.1 and 1.4.1.3) and which are not stably inherited (Chakraborty 
eta l., 1997).
1.4.1.3 Pathogenic microsatellites
At least 13 inherited diseases are caused by mutations in triplet repeat sequences, 
characterised by the abnormal expansion of the mutated allele (Warren, 1996). For 
example, in the case of DM1, the normal allele is 5-30 CTG repeats in length and the 
mutated allele is expanded to 50-2000 in the affected individual (Groh et al., 2002).
A number of different mechanisms have been proposed to explain how the expansion of 
trinucleotide repeats may cause disease. Suggested mechanisms are interference with 
either transcription, a gain of function if exonic or a protein conformation change 
(Jennings, 1995). In the case of Friedreich’s ataxia (FRDA), the abnormally expanded 
GAA repeat adopts a triple helical conformation at the DNA level in vitro, which may be 
responsible for the suppression of gene expression (Ohshima et al., 1998). Interestingly, 
DM1 and DM2 are caused by a non-translated trinucleotide (CTG) (Brook et al., 1992; 
Mahadevan et al., 1992) and tetranucleotide (CCTG) expansion (Liquori et a l ,  2001), 
respectively. The mechanism by which these amplified repeat expansions lead to DM is 
discussed in section 1.3.2.1.
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Since anticipation was reported in PFHBI-affected families (Van der Merwe et al., 1986), 
the exonic sequences o f genes within the PFHBI locus containing triplet repeats were 
examined. In previous studies, possible pathological expansion of the GAT and the GAG 
triplet repeat in exon 1 of histidine-rich calcium binding protein (HRC) (Christoffels,
1997) and the expansion of a CAG triplet repeat in exon 13 of nucleobindin 1 (NUCB1) 
(*F. February, 2002) were investigated, but no expansion of the repeat motifs was found 
in these genes in PFHBI-affected individuals.
*
1.4.2 Chromosome 19
Human chromosome 19 is estimated to be 55.8 Megabases (Mb) in length (Grimwood et 
al., 2004) and constitutes slightly more than 2% of the human genome (Mayall et al.,
1984). Previously, the International Human Genome Sequencing Consortium (IHGSC), 
(2001) determined the chromosome size to be 72Mb, which included all gaps and 
duplications. Chromosome 19 is known to have a relatively high GC content (Larsden et 
al., 1992), estimated at an average of 48% (fig. 1.10) (Grimwood et al., 2004) compared 
to 41% for the whole human genome (IHGSC, 2001). Although chromosome 19 is 
relatively small compared to the other chromosomes, it has a very high density of genes, 
namely, 26 protein-encoding gene loci per Mb (Grimwood et al., 2004), making it the 
most gene-rich chromosome of all the chromosomes (Venter et al., 2001). In total, 1,461 
protein encoding genes and 321 pseudogenes have been placed on chromosome 19.
* Please note that when a reference is m ade to F. February in the text, it refers to an individual.
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Chromosome 19 is also unusual in its density o f repeat sequences, because nearly 55% of 
this chromosome consists of repetitive elements, whereas chromosomes 6, 7, 14, 20, 21 
and 22 all have repeat contents ranging from 40% to 46% (IHGSC, 2001). Alu repeats 
make up 25.8% of the chromosome compared to 13.8%, 13.3%, 9.5% and 16.8% on 
chromosomes 7, 14, 21 and 22, respectively (Grimwood et al., 2004). It has been 
estimated that 568 of the estimated 1,461 genes (39%) show evidence o f alternative 
splicing. In addition, 321 pseudogenes have been identified, of which 177 (55%) are 
classified as “processed” pseudogenes, that is, products of viral retrotransposition events 
involving spliced mRNA. It has also been found that chromosome 19 is notable for the 
prevalence of duplication, namely, tandemly clustered gene families and large segmental 
duplication with evidence of genomic duplication. Sequence homology of 7.35% of 
chromosome 19 sequences are shared with more than one location within the genome. 
Finally, comparative analyses revealed large blocks of genes with orthology to rodent 
genes and segments of coding and non-coding sequence conserved in the fish species 
Takifugu (fig. 1.10) (Grimwood et al., 2004).
As part o f the HGP, the sequencing of chromosome 19 was assigned to the sequencing 
group based at the Human Genome Centre at the Lawrence Livermore National 
Laboratories (LLNL), Livermore, California, which resulted in the generation o f the first 
published physical map of chromosome 19 (Ashworth et al., 1995) (see section 1.4.2.2). 
Subsequently, the final map containing the full chromosome 19 sequence was published 
in 2004 (Grimwood et al., 2004).
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Figure 1.10 Chromosome 19 landscape.
The following sections appear from top to bottom: (1) The human and mouse blocks o f  homology larger 
than lOOkb are shown. The grey triangles indicate regions where significant lineage-specific and orthology 
can be identified. Extensive intrachromosomal and interchromosomal rearrangement between human and 
mouse can be observed. (2) The duplicated gene families cover more than 25% o f  the chromosome. (3) The 
G+C content profile shows that the zinc finger and olfactory receptor gene families have a lower G+C 
content than the rest o f  the chromosome which has a very high G+C content. (4) The exon density 
correlates with the G+C content fluctuations. (5) The location o f  the CpG islands on chromosome 19. (6) 
The psuedogenes identified during the annotation o f  chromosome 19. (7) Human/mouse and 
human!Takifugu non-coding DNA element density. This density is unevenly distributed over the 
chromosome with a 5Mb region in the proximal region o f  the q arm containing the highest density o f  
human/mouse non-coding and the majority o f  the non-coding o f  human/Takifugu elements (Grimwood et 
al., 2004).
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1.4.2.1 Somatic cell hybrids
Somatic cell hybrids are produced by the fusion of human and rodent cell lines under 
specific experimental conditions. Several somatic cell hybrids for the physical mapping 
of chromosome 19 have been described (Brook et al., 1986; Hulsebos et al., 1986). 
Schonk et al., (1989) constructed and characterised a series of somatic cell hybrids of 
chromosome 19q, which allowed a finer physical subdivision of the region (fig. 1.11). 
Bachinski et al., (1993) constructed a panel of 22 somatic cell hybrids, which divided the 
chromosome 19q arm into 22 ordered subregions. The panel was characterised with 
respect to 41 genetic markers and it aided in the establishment of the order o f a number of 
genes that had already been placed in this region o f chromosome 19q.
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Figure 1.11 Diagram of chromosome 19 segments contained in somatic cell hybrids.
908K1, 908K1A1, 908K1B, 104016, Orim 7-l, 1219G2 and 1184C9, somatic cell hybrids; **, position of the 
PFHBI locus (Schonk et al., 1989).
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1.4.2.2 Metric FISH framework map of chromosome 19
Ashworth et al., (1995) published the first metric physical map of human chromosome 19 
(fig. 1.12) which was composed of overlapping cosmids contigs, generated by automated 
fingerprinting, spanning 50Mb. The distances between selected cosmid clones were 
estimated using FISH, which provided order and distance between contigs. FISH maps 
were constructed of the p-arm (Brandriff et al., 1994) and the q-arm (Gordon et al., 1995) 
with an average inter-marker distance of 230kb across the non-centromeric sections of 
the chromosome. An additional 57 cosmids were ordered relative to the known reference 
clones. The published map of chromosome 19 consisted of 51 ‘islands’ containing 
information from cosmid, YAC, BAC, and PI artificial chromosome (PAC) clones, 
whose size and order were known. Over 450 genes, genetic markers, sequence tagged 
sites (STSs), anonymous cDNAs and other markers were placed on the chromosome 19 
map. Figure 1.13 shows the DNA clones, genes, genetic markers, STSs and cDNAs at the 
PFHBI locus in February 2003.
In addition, a EcoRI restriction map was generated for 41Mb (-83%) of the chromosome 
which enabled the selection o f minimal overlapping clones for DNA sequencing. This 
map, however, contained a number of gaps between contigs, and consequently, mainly 
BACs and, in some instances, PACs were used to effect gap closure. The cosmid contigs 
were extended and merged by hybridisation screening of cosmid and BAC libraries using 
a number o f different probes, such as ^/w-polymerase chain reaction (PCR) products, 
sequence tagged site (STS) PCR products, oligonucleotides, and cDNAs (Ashworth et 
al., 1995). This resulted in an in depth coverage o f overlapping clone contigs, which
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Figure 1.12 Contig map of the C19ql3.3 region (Ashworth et al., 1995).
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facilitated the selection of a minimal number o f clones for sequencing, reducing the cost 
and time of the project. In 1997, the Joint Genome Institute (JGI) was established and 
continued the sequencing of chromosome 19, in addition to chromosome 5 and 
chromosome 16 (http://www.jgi.doe.gov). In 1999, a new Production Genomics Facility 
in Walnut Creek, California was established. The month of February 2001 heralded the 
publishing of a number of papers describing the initial sequencing and analysis o f the 
human genome, including chromosome 19, as discussed in section 1.4.2 (IHGSC, 2001; 
Venter et al., 2001). In 2002, the Stanford Human Genome Center based at Stanford 
University (http://www.shgc.stanford,edu/) continued the sequencing of chromosome 19 
and generated 300Mb of finished human sequence. By April 2004, 99.9% chromosome 
of 19 was sequenced and the analysis o f the most recent map was published (Grimwood 
et al., 2004). The entire sequence for chromosome 19 q l3.3 is available in Genbank under 
the accession number NT 011109, which was used in this study.
1.4.3 Transcript map
The metric map generated by Ashworth et al., (1995) was also used to refine placements 
of ESTs that had previously been assigned to somatic cell or radiation hybrid panels. At 
that stage of the project, very few ESTs had been placed on the map (fig. 1.12). The next 
transcript map of the region, spanning 10Mb on chromosome 19q 13.3 to 19q. 13.4, 
between markers D19S408 and D19S866 (Hamshere et al., 1999), was derived using 
exon trapping to identify coding regions (Duyk et al., 1990) and from genomic data 
deposited in the databases. Exon trapping was performed for this region of chromosome 
19q on pools of three cosmids from contigs that had been anchored to the physical map
62
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from LLNL (http://www-bio.llnl.gov/bbrp/bbrp.homepage.html), which aided the 
identification of 96 unique exonic sequences. Of these, 55 matched EST sequences, 
which had been deposited in the databases at the United Kingdom (UK) Human Genome 
Mapping Project (HGMP) and NCBI. The remaining 41 exonic sequences, which did not 
show a significant match to sequences in the databases, were deposited at the EMBO 
alerting page (http://www.bork.embl-heidelberg.de/Alerting/).
1.4.3.1 Identification and characterisation of ESTs
With the advent of high-throughput technology and the need to hasten the search for 
disease-causing genes, large-scale partial sequencing cDNA projects, which generated a 
vast number o f ESTs of all human chromosomes including chromosome 19, were 
undertaken. Hillier et al., (1996) from the Genome Sequencing Center, Washington, USA 
generated 280, 000 human ESTs obtained from 194,031 human cDNA clones and 17 
different tissues, representing three developmental states. The Integrated Molecular 
Analysis of Gene Expression (IMAGE) and the Institute of Genomic Research (TIGR) 
have also generated a large number of ESTs that have been deposited into the publicly 
available database, dbEST (Boguski and Schuler, 1995).
Cardiac ESTs
Clones from cardiac cDNA libraries at different developmental stages, namely, 
embryonic, foetal and adult, were partially sequenced to give an insight into gene 
involvement in cardiovascular disease. Liew et al., (1994) generated 3,500 human cardiac 
ESTs and by performing a sequence similarity search against the Genbank/EMBL
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databases, generated the following results: o f the ESTs, 44.1% matched known genes, 
47.4% had no match and the remaining 8.5% matched previously deposited human ESTs. 
Hwang et al., (1997) from the Centre o f Cardiovascular Research, Ontario, Canada, 
generated 43,285 ESTs from human heart cDNA libraries. This group retrieved an 
additional 41,619 ESTs from public databases. This total of 84,904 ESTs were obtained 
from 13 independent cardiovascular-based cDNA libraries, 55% of these ESTs matched 
known genes in Genbank/EMBL/DDBJ, 33% matched other ESTs, and 12% did not 
match any known sequence. ESTs matching known genes were classified according to 
function, transcription patterns of various tissue or developmental stage. In addition, over 
57,000 ESTs from nine cDNA libraries constructed from human heart tissue from various 
anatomical, developmental and pathological stages were generated. In a review by 
Dempsey et al., (2000), it was reported that the total number of ESTs deposited into 
Genbank from cardiovascular tissue represents less than 4%, of the total number from all 
tissues. This finding emphasises the need to increase the production of cardiovascular- 
based ESTs, which will improve the usefulness o f this resource and allow better 
exploitation by cardiovascular researchers.
In addition, a wealth o f information on the basic pathways o f heart development can also 
be obtained by comparison of EST profiles from model organisms such as D. 
melanogaster, X. laevis and D. rerio. However, EST resources currently available for 
these organisms are severely limited, which greatly reduces the effectiveness of the 
approach (only 63,659 cardiac ESTs from cDNA libraries of D. rerio libraries, 22,788 
ESTs from M. musculus-heart and 5,127 ESTs from R. norvegicus-heart) (reviewed by
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Dempsey et al., 2000). Subsequently, a vast number of additional ESTs from different 
organisms have been deposited into Genbank (Benson et al., 2003).
1.4.3.2 Bioinformatic tools for EST analysis
Usually an EST is only 150-200bp long, which is too short for a significant protein 
homology search. In order to work with a longer sequence length EST, clustering 
programmes such as STACK at SANBI (Miller et al., 1999; Christoffels et al., 2001), or 
UNIGENE at NCBI (http://www.ncbi.nlm.nih.gov/unigene), are used. Once the ESTs are 
submitted to the respective programme, a longer consensus sequence, or cluster, is 
generated, which when BLAST-searched against protein databases is likely to produce a 
more meaningful protein hit than a shorter sequence.
Although both UNIGENE and STACK are EST clustering programmes, they have 
different EST data sources and use different mathematical processing methods, i.e., 
algorithms, to group sequences. Thus, UNIGENE utilises ESTs and only properly 
annotated mRNA sequences derived from the dbEST and Genbank databases (Boguski et 
al., 1993; Benson et al., 1996). The EST sequences are compared with the respective 
mRNA and all the sequences that share sequence homology with the mRNA, either at the 
3’- or 5’-end, are grouped together. If the ESTs do not overlap with each other, they need 
to share homology to the template (mRNA) used and are placed into a single group, 
which represents a gene. In addition, sequences are also grouped if sequencing reads are 
performed from the same clone according to the template used. In some cases, no 
consensus sequence is found for a cluster (Bouck et al., 1999). Regarding the STACK
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dataset, EST data obtained from dbEST sequence data is classified according to the tissue 
from which it was derived. The clustering algorithm used identifies ESTs that are highly 
similar (>95% identical over 150 bases) and these sequences are aligned to provide a 
consensus sequence. At this point, the ESTs are grouped together if  they are derived from 
the same cDNA clone. The way in which the two clustering systems handle problems, 
such as chimeric clones and alternatively spliced transcripts, are different, as will be 
discussed in the following paragraph.
Chimeric clones contain sequences from two different cDNAs that can cause serious 
problems when the clustering analysis is performed. UNIGENE handles the problem by 
searching for a single clone that joins two otherwise unconnected groups. Since STACK 
uses alignment in its system, chimeras are more easily identified during the alignment 
process.
The second problem is the identification of alternatively spliced transcripts, because these 
sequences contain identical regions, as well as disparate ones. As different isoforms of a 
transcript are generally expressed in different tissues, or at different stages of 
development (Bouck et al., 1999), STACK separates transcripts by their origins; 
therefore, alternative transcripts should be significantly limited within a group. Whereas, 
with UNIGENE, fairly relaxed criteria are used for clustering; therefore groups 
containing transcripts with a small number of exons are common and, for this reason, the 
programme is not able to distinguish between chimeric clones and alternatively spliced 
transcripts (Bouck et al., 1999).
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ESTGENOM E is a programme used for the alignment o f spliced cDNA to unspliced 
genomic DNA (Mott, 1997). Other standard alignment tools are not able to correctly 
align a spliced product to genomic DNA, if large introns occur in the genomic sequence 
and conserved sequences found at intron/exon boundaries are ignored.
1.4.4 Morbid map of chromosome 19ql3.3
The development o f a more detailed map of chromosome 19ql3.3 was aided because a 
number of different disease loci were mapped in or near the PFHBI target, namely, limb- 
girdle muscular dystrophy (LGMD2), Camurati-Engelmann disease (CED), a 
nonsyndromic deafness disorder (DFNA4) and DM1 (fig. 1.14).
LGMD2 is an autosomal recessively inherited disorder and belongs to a genetically 
heterogeneous group of diseases characterised by progressive degeneration of pelvic and 
shoulder muscles. The LGMD2 locus maps to chromosome 19ql3.3 to a 9cM interval 
between genetic markers, D19S412 and D19S879, within the PFHBI locus (fig. 1.14) 
(Driss et al., 2000). Genomic screening identified an area o f interest on chromosome 19, 
as evidence o f linkage was observed with the microsatellite marker D19S606. In addition, 
genetic distances between microsatellite markers were given, namely, D19S412-6.3cM- 
D19S606-2.lcM -D19S879-2.3cM , which aided in mapping the PFHBI locus.
CED is an autosomal dominantly inherited disorder, which is characterised by the clinical 
features o f a waddling gait, muscle weakness and wasting, and generalised fatigue. The 
CED locus maps to a 15.1 cM region on chromosome 19ql3.1-ql3.3 and is
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Figure 3.15 An integrated physical map of the PFHBI locus on contig NT_011109.
The positions of the published genetic markers are shown using red arrows. The novel CA repeat markers are shown using small black arrows. Fully annotated genes in blue , selected predicted genes in green , ESTs, the BAC or cosmid clones and novel genetic markers are shown in black on contig NT_011109.
From top to bottom: The position of the database and novel markers on contig NT_011109 which spans the PFHBI locus are shown. The ESTs are linked to the respective gene which in turn is linked to the respective BAC and cosmid clones numbered 1 to 27 by dotted black lines. Genes screened in this and paralled studies are boxed in red. Predicted proteins are denoted 
by FU , MGC and KIAA. The genbank acc numbers of the BACs and cosmids are:l, AC010331; 2, AC008745; 3, AC024582; 4, AC010330; 5, AC010458; 6, AC011466; 7, AC008392; 8, AC020955; 9, AC011514; 10, AC011527; 11, AC008403; 12, AC009002; 13, AC026803; 14, AC008687; 15, AC008891; 16, AC011450; 17, AC010524; 18, AC010643; 19, 
AC010619; 20,AC011495; 21, AC006942; 22, AC018766; 23, AC024079; 24, AC011452; 25, AC010642; 26, AC008655; 27, AC020909. The gene abbreviations are; SLCXA2, solute carrier family 8 (sodium independent inorganic phosphate cotransporter), member 2; KPTN, actin binding protein,' CABP5, calcium binding protein 5; PLA2G4C, phospholipase A2, group 
IVC (cytosolic, calcium-independent); CARDS, caspase recruitment domain family member 8; EMPS epithelial membrane protein 3; KDELR, (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 1; GRWD, glutamate rich WD repeat protein; PSCD2, pleckstrin homology, sec 7 and coiled -coil domain 2; KIR2.4, potassium inwardly-rectifying channel, 
subfamily J, member \\SULT2B, sulfotransferase family, cytosolic, 2B, member 1; CA 1/ carbonic anhydrase XI; FGF2I, fibroblast growth factor 21; PLEKHA4, pleckstrin homology domain containing, family A (phosphoinositide binding specific) member 4; NUCB1, nucleobindin 1; BAX, BCL2-associated X protein; GYSl, glycogen synthase 1; RUVBL2 RuvB-like 2 
(E. coli); KCNA7, potassium voltage-gated channel, shaker-related subfamily, member 7; SNRP70, small nuclear ribonucleoprotein 70kDa polypeptide (RNP antigen); L1N-7B, lin-7 homolog B (C. elegans); HRC, histidine richcalcium binding protein ; CDJ7,
CD37 antigen; CGB7, chorionic gonadotrophin beta polypeptide 7; TEAD2, TEA domain family member 2; FCGRT, Fc fragment of IgG, receptor, transporter, alpha ; SLC17A7, solute carrier family 17 (sodium independent inorganic phosphate; RRAS, related RAS viral oncogene homolog; SR-A1, serine arginine-rich pre-mRNA splicing factor; ATF5, activating 
transcriptor factorS; VRK3, vaccinia related kinase 3; ZNF473, Zinc finger protein 473. *SUMO-l,small ubiquitin-related modifier-1 and *COX6C, cytochrome oxidase VIC, represent predicted genes identified from syntenic mouse ESTs.
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Figure 1.14 Schematic morbid map o f chromosome 19ql3.3.
Loci o f  different diseases mapping in the region o f the PFHBI locus are indicated with a solid black 
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flanked by genetic markers, D19S881 and D19S606 (fig. 1.14) (Ghadami et al., 2000). 
The CED and the PFHBI loci overlap in the following way: the distal CED marker, 
D19S606, lies within, and the proximal D19S881 marker lies centromeric to, the PFHBI 
locus (fig. 1.14). It was found that the transforming growth factor-beta-1 gene (TGFB1) 
maps to the same region o f chromosome 19 and is a potential candidate gene for CED. 
Kinoshita et al., (2000) screened TGFB1 for mutations in seven unrelated Japanese 
families and two families o f European descent and detected three different heterozygous 
missense mutations in exon 4, near the carboxy-terminus of the latency-associated 
peptide (LAP), in all nine families examined.
An autosomal dominant nonsyndromic deafness locus, DFNA4, was mapped to 
chromosome 19 q l3.3 by linkage studies and is flanked by genetic markers, D19S414 and 
D19S246 (fig. 1.14) (Chen et al., 1995). The PFHBI locus lies within the DFNA4 locus 
and two genes mapping to this locus have been suggested as candidates for DFNA4, 
namely, DMK, and a gene-encoding mitochondrial ribosomal protein S12 (MTRNR1) 
(Johnson et al., 1998; Shah et al., 1998). Myotonic dystrophy is characterised by 
myotonia, in conjunction with progressive weakening and wasting of skeletal muscles, 
although central nervous system, ocular, cardiovascular and auditory manifestations have 
also been observed. Recently, the examination of a four-generation German kindred led 
to the identification o f a 1.44Mb map segment in contig NT 011109 as being the most 
likely DFNA4 candidate region in chromosome 19q 13.33, and placed the DFNA4 locus 
between the markers D19S879 and D19S246. This region overlaps with the telomeric 
region o f the PFHBI locus. More than fifty annotated and predicted genes were found in
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the 1.44Mb region, of which several were promising DFNA4 candidates (Pusch et al., 
2004). To date, the disease-causing gene responsible for DFNA4 has not been identified.
1.4.5 Prioritisation of candidate genes for PFHBI
A number of genes have been characterised and placed at the PFHBI locus by LLNL, 
JGI, and NCBI mappers. These genes are all potential candidate genes for PFHBI by 
virtue o f position, and prioritisation was a difficult task. For some of these genes, 
published information exists in the UNIGENE (NCBI) and LOCUSLINK (NCBI) 
databases regarding their tissue expression, function, exon and intron size and 
chromosomal location. The analysis o f this information aids in prioritising genes for 
mutation screening, based on the appropriate function, tissue expression profile and 
developmental stage.
The HGP has produced hundreds o f megabases o f sequence; however, initially the 
sequence itself does not provide knowledge o f gene structure, such as the number of 
exons or the functionally important domains. The initiative to have a ‘rough draft’ 
produced by 2001, shifted the efforts o f the scientists involved to focus on the gene 
structure, regulatory regions and the translated products. A number of different gene 
prediction programmes, such as GeneScan (Burge and Karlin, 1997), the conserved 
domain database (CDD) (Marchler-Bauer et al., 2002) and Pfam (Bateman et al., 2002) 
were used to determine the structural organisation and the presence of important domains 
o f predicted genes. After analysis, the predicted genes and their respective data were
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submitted to Locuslink at NCBI databases and INFOGENE at Sanger Centre, UK 
(Solovyev and Salamov, 1999).
1.4.6 Mutation versus polymorphism
The human genome is not a static entity and is subject to a variety o f heritable changes 
(mutations), which can include small changes, the so-called point mutations. These 
changes involve a loss, duplication or alteration of a single nucleotide of DNA (Cooper et 
al., 1998). A DNA polymorphism is described as an allelic sequence variation where 
more than one allele occurs at a locus in a population with the frequency of the rarer 
allele being greater than 0.01 (Strachan and Read, 1996).
Cotton and Scriver (1998) examined the question ‘when does a mutation have a 
deleterious effect on an individual?’ A likely answer is that it might be dependent on the 
type and/or the position of the mutation. A base substitution at the DNA level, if 
synonymous, will not change the encoded protein, unless the base change is at an 
exon/intron junction, or in the regulatory region outside the exon, in which case, it may 
be pathogenic. These substitutions often occur at the third base pair position which often 
means that the altered codon specifies the same amino acid.
A nonsynonymous substitution can result in a nonsense mutation which is the 
replacement of a codon specifying an amino acid by a termination codon which is likely 
to result in a dramatic reduction in gene function. If, however, the nonsynonymous 
substitution is a missense mutation, one of two situations can arise, namely, a
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conservative substitution which will result in replacement of an amino acid that is 
chemically similar and which therefore may not have any deleterious effect on protein 
function. The alternative being a nonconservative substitution in which one amino acid is 
replaced by another amino acid with a dissimilar side chain, which may be pathogenic, as 
it is more likely to affect protein function.
Protein-encoding genes show an enormous variation in the rate of nonsynonymous 
substitutions. At one extreme are proteins whose sequences are highly conserved, such as 
ubiquitin and calmodulin. For example, the ubiquitin proteins of H. sapiens, M. musculus 
and D. melanogaster show 100% sequence identity. Genes falling into this category have 
an extremely low rate of nonsynonymous codon substitution compared with other genes. 
The reason being that these proteins play such a crucial role and are, therefore, under 
selective pressure to conserve their sequence. At the other extreme, the fibrinopeptides 
are proteins which are evolving extremely rapidly and therefore appear not to have been 
under selective constraint.
Both a polymorphism and a mutation can be detected using various mutation screening 
techniques, such as heteroduplex analysis (Grompe, 1993), single-strand conformational 
polymorphism (SSCP) analysis (Orita et al., 1989), denaturing gradient gel 
electrophoresis (Vijg and van Orsouw, 1999), the protein truncation test (Den Dunnen 
and Van Ommen, 1999) and direct sequencing o f PCR products. These changes in the 
nucleotide sequences may cause frameshifts, splice sites or nonsense mutations, which in 
turn cause truncation of a protein product. The different methods usually test for
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differences between a test and a standard sequence. These methods have shortcomings 
and have been critically analysed in reviews by Grompe (1993) and Prosser (1993). The 
final test to be performed is the functional analysis of the mutant gene, which will 
measure the biological activity of resultant protein confirming whether the mutation is 
phenotype-modifying.
Cotton and Scriver (1998) generated a list o f criteria for the designation of mutations, 
which may modify the phenotype. The criteria are based on the particular types of 
mutation discussed earlier. They state that it is important to analyse the complete gene 
sequence and not specific exons o f a gene because a “significant” mutation may be 
missed. In publications, it is therefore important to specify the regions analysed and the 
efficiency of the mutation detection method employed. Segregation analysis should be 
performed and reported. Reports should also mention whether or not a conserved amino 
acid is changed by the base substitution. A report on the prevalence of a mutation is 
important, because a mutation that occurs on less than 1% of the alleles in the population 
is, by definition, rare and may be disease-causing, whereas a variant that is found at 
higher frequency may be a “neutral” polymorphism. Reports o f changes resembling 
polymorphisms should include the analysis of 100 chromosomes from the same ethnic 
group.
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1.5 PFHBI CANDIDATE GENES
This section introduces each candidate gene selected by virtue o f its position at the 
PFHBI locus for further analysis, as the possible PFHBI disease-causative gene. The 
organisation of each gene and the possible role o f its protein product in cardiac function 
are discussed. The functional characteristics of each gene-encoding protein play a role in 
the selection of PFHBI candidate genes. In the present study, the genes selected for 
mutation screening were an apoptotic gene (BAX), two voltage gated K+ channel genes 
(KCNA7 and KIR2.4), a membrane-associated-guanylate kinase gene (LIN-7B) and a 
gene involved in glycogen metabolism (GSYI) and they are therefore described in more 
detail below.
1.5.1 BAX
BAX  maps to the PFHBI disease locus on chromosome 19ql 3.3 (fig. 1.13) (Apte et al.,
1995). The BAX protein is encoded by six exons and demonstrates a complex pattern of 
alternative splicing with six alternatively spliced transcript variants encoding different 
isoforms (Oltvai et al., 1993).
BAX induces cell death by acting on the mitochondrion, where it binds to the pore 
complex involved in the regulation of mitochondrial permeability (reviewed by Kroemer,
1998). Mitochondria play an important role in the signaling machinery of apoptotic cell 
death by releasing several apoptotic factors such as cytochrome c and procaspases. 
Furthermore, Ca2+ signals have been identified as one of the major signals to trigger the 
mitochondrion-dependent pathway of apoptotic cell death (Pacher et al., 1999). The 
importance of apoptosis in cell growth and differentiation was only realised in the last
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decade with the discovery of the cell death machinery in C. elegans and mammals. A 
delicate balance exists between cell proliferation and programmed cell death. Alterations 
in the apoptotic pathways can result in a number of diseases in humans. The activation o f 
apoptotic pathways have been implicated in neurodegenerative diseases, such as 
Huntington’s disease (Jellinger et al., 2001), Alzheimer’s disease (Sanchez et al., 2001) 
and heart disease (Kumar et al., 2002).
In the human heart, the morphogenesis of the CCS and the normal postnatal involution of 
the right ventricle are both mediated by apoptosis. However, the exact mechanisms by 
which these events are initiated or terminated remain poorly understood (James et al.,
1996). Although apoptosis is essential for normal development, excessive apoptosis may 
be triggered by pathological changes and result in the destruction o f tissues and the 
development of heart disease in which a fatal arrhythmic event may occur. James et al. 
(1996) concluded the latter from histological examinations o f the CCSs o f a young 
woman and two o f three brothers who had died of CHB. In two of the three hearts, the A- 
V node was absent, in the third heart, only fragments of the A-V node remained and in all 
three hearts, the sinus node was nearly destroyed by a non-inflammatory degeneration 
with no abnormal fibrosis or infiltrate. The histological abnormalities of the patients’ 
CCS are best interpreted as resulting from apoptosis (James et al., 1996). At present, the 
triggers for programmed cell death in disorders o f the cardiac rhythm are not well 
understood, but it may be that a mutation in BAX  makes it more effective to respond to 
inappropriate signals (Nerheim et al., 2001).
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1.5.2 Ion channels
Since a number o f ion channels have been implicated in cardiac function and disease, the 
investigation of the two K+ ion channel genes mapping to the PFHBI locus was vital. The 
one candidate was a voltage-gated shaker-related K+ ion channel gene (KCNA 7) (Chandy 
and Gutman, 1995; Kalman et al., 1998; Bardien-Kruger et al., 2002) and the other an 
internal K+ rectifier gene (K1R2.4) (Topert et al., 2000).
K+ ion channels belong to a family of voltage-gated membrane cation channels (Kv) that 
form aqueous pores through which K+ can flow, and which are found in virtually all 
organisms (reviewed by Miller, 2000). These channels are responsible for a number of 
diverse functions including maintaining membrane potential, regulating cell volume and 
modulating electrical excitability in specialised cells. There are two broad classes o f K+ 
ion channels, as reflected in their primary sequence: a six-transmembrane helix voltage- 
gated channel (Kv) and a two transmembrane helix inward rectifier channel (Kir). The 
six-transmembrane segment o f Kv, designated S 1-S6, forms a module that controls the 
opening and closing of the pore. The first three segments (S I-S3) are inferred to be 
helical along most of their length and are located on the lipid-exposed periphery o f the 
membrane-embedded complex. The fourth transmembrane segment (S4) is not lipid- 
exposed and is thought to form the voltage-sensing element of these channels. The P 
loop, the fifth and sixth transmembrane segments (S5 and S6) form the pore and 
selectivity filter (Pollard and Eamshaw, 2002). All Kv channels have a conserved 
domain, called T l, in the region near the amino-terminal side o f the first transmembrane
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helix (fig. 1.15). It has been shown that globular subunits o f unknown function bind to 
the lower part o f the T1 domain (reviewed by Miller, 2000).
A. Membrane topology B. Structure
C. Top view D. Pore structure
Figure 1.15 Voltage-gated potassium channels.
A, subunit transmembrane topology. Each o f the four subunits has six transmembrane a-helices with a P 
loop between S5 and S6. B, ribbon diagram (for S5, P, S6), T l, and the N-terminal inactivation peptide. SI 
to S4 are shown to be hypothetical helices lateral to the central pore-forming S5, P, S6. C, top view o f the 
hypothetical arrangement o f  the six helices in each o f the four subunits. D, side view o f two subunits 
showing the central pore. Positively charged segment S4 senses the membrane potential. The T l domain of 
K+ channels controls the assembly o f  four separate subunits into a functional channel (reproduced from 
Pollard and Eamshaw, 2002).
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1.5.2.1 KCNA7
Kv channels in mammalian cells are encoded by an extended family of at least 19 genes 
(Chandy and Gutman, 1995). In humans, seven members of the subfamily, Kvl ,  have 
been identified and are designated Kvl.  1-K vl.7 (Chandy and Gutman, 1995; Kalman et 
al., 1998). KCNA7, encoding the potassium channel K vl.7, was mapped to chromosome 
19ql3.3 (fig. 1.13) (Kalman et al., 1998) and at the initiation of this study, only the 
mouse homolog, kcna7, was characterised and had been mapped to mouse chromosome 7 
(Kalman et al., 1998). It was also shown that a region o f mouse chromosome 7 was 
syntenic to the human KCNA 7 region and, during the present study, this data was used to 
determine the organisation o f the human KCNA 7, namely, that it is encoded by two exons 
separated by a 1742bp long intron (Bardien-Kruger et al., 2002).
1.5.2.2 KIR2.4
There are seven subfamilies (K irl-K ir7) involved in diverse functions, such as K+ 
homeostasis, setting the membrane resting potential, modulating neural fusion rates, 
controlling pacemaker activity in the heart and, more recently, the Kir channels have 
been implicated in developmental processes (Doupnik et al., 1995; Plaster et al., 2001). 
Kir subfamilies have been found in the heart, skeletal muscle, endothelial cells and cells 
in the immune system (Kurachi et al., 1999). Topert et al., (2000) cloned, characterised 
and mapped K1R2.4 to chromosome 19ql3.3 (fig. 1.13).
Recent studies reveal that the function and localisation o f ion channels are regulated by 
interactions with members o f the membrane-associated guanylate kinase (MAGUK)
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protein family. It has been experimentally shown that there is a direct association of 
Kir2.1, Kir2.2 and Kir2.3 with the synapse-associated protein (SAP97), a MAGUK 
family member (Leonoudakis et al., 2000). It was also shown that SAP97 might play an 
important role in the modulation of K vl.5  (Murata et al., 2001). These findings suggest 
that Kir channels form part o f a macromolecular signaling complex in many different 
tissues. Recently, it has been shown that mutations in a Kir gene, i.e., Kir2.1, cause 
dysmorphic features and cardiac arrhythmias in an inherited disorder, named Andersen’s 
syndrome (Plaster et al., 2001). Figure 1.16 shows the positions of the seven missense 
mutations and the two in frame deletions found in the different exons of Kir2.1. Since a 
Kir gene has been implicated in playing an important function in controlling cell 
excitability in skeletal muscle and heart (Plaster et al., 2001), there is a strong possibility 
that mutations in other Kir genes may cause cardiac disturbances and are responsible for 
PFHBI.
1.5.3 LIN-7B
LIN-7B was mapped to the PFHBI locus between genetic markers D19S902 and D19S604 
(fig. 1.13) (Strausberg et al., 2002). It is encoded by five exons and is expressed in many 
tissues, including heart. The LIN/VELI/MALS family belongs to the MAGUK group of 
proteins, which contain multidomain modules, such as the PDZ domains (postsynaptic 
density-95, discs large, zonula occludens), which mediate protein-protein interactions. 
Using functional evidence, it has been shown that the PDZ domain of the MAGUK group 
interacts with the Shaker-subfamily K+ channel, resulting in the clustering of the channels 
at the cell surface. In the case of Kvl.5, the interaction involves the COOH-terminal tail
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Figure 1.16 Schematic drawing of Kir2.1, an inward rectifying K+ channel, outlining the position of 
the different disease-causing mutations in Andersen’s syndrome.
M l and M2, two transmembrane segments; D71V, S136F, G144S, R218W, R218Q, G300V and E303K, 
seven missense mutations; A95-98 and A314-15, in-frame deletions (Plaster et al., 2001).
end o f the K+ channel with the PSD-95 protein of the MAGUK protein (Eldstrom et al.,
2002). This type o f interaction was also shown to occur with Kir channels, where the 
PDZ domain of the human Lin7/CASK complex interacts with the COOH-terminal tail of 
Kir2.5 in renal epithelia (Olsen et al., 2002).
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A study using MALS-M2 double knockout mice demonstrated that the proteins containing 
the PDZ domains play a general role in recruiting receptors and enzymes at specific 
synaptic sites. A mechanism by which a PDZ interaction co-ordinates a one step 
basolateral membrane sorting programme was suggested (Misawa et al., 2001). The role 
o f LIN-7B in a signaling mechanism involving ion channels and its expression in the 
heart supports the hypothesis that LIN-7B interacts with Kir and, therefore, a mutation in 
one o f these genes may be disease-causing, which makes both of them attractive 
candidates to screen for PFHBI disease-causative mutations.
1.5.4 GSY1
GSY1 cDNA has been cloned from human and rabbit skeletal muscle (Browner et al.,
1989) and from rat and human liver (Bai et al., 1990). The muscle and liver isozymes are 
encoded by two different genes, muscle GSY1, which is located on chromosome 19 q l3.3 
(position is indicated on fig. 1.13) (Lehto et al., 1993) and GSY2 on chromosome 12pl2.2 
(Nuttall et al., 1994). GSY1 is composed of 16 exons, which span approximately 27kb of 
DNA (Orho et al., 1995) and specify a protein o f 737 amino acids of which the NH2- and 
COOH-termini contain nine phosphorylation sites, resulting in a very negatively charged 
molecule (Browner et al., 1989).
GSY catalyses the rate-limiting step in glycogen synthesis and although glycogen occurs 
in abundance in the CCS, its role is unclear (James, 1970; Davies, 1971). However, it is 
known that glycolytic flux maintains membrane activity, reduces arrhythmia and 
improves the functional recovery of the ischaemic heart (King and Opie, 1998). GSY1 has
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been implicated as an important candidate gene for the genetic defect causing insulin 
resistance and non-insulin-dependent diabetes mellitus (NIDDM) (Orho et al., 1995); 
therefore, a mutation in GSY1 may affect the glycolytic levels, which may in turn affect 
the functioning o f the heart and could possibly be PFHBI disease-causing.
Glycogen synthase kinase-3 p (GSK-3 P) has been shown to inhibit glycogen synthesis 
through phosphorylation of GSY1. GSK-3 (3 is involved in the regulation of heart 
development via the Wnt signaling pathway (Hardt and Sadoshima, 2002). This could 
indicate that GSY1 may play a role in the complex pathway of cardiac development. If 
this is so, it strengthens the case for GSYI as a candidate gene for PFHBI.
1.6 MANAGEMENT OF GENE SEARCHES
The search for the PFHBI gene is part o f a team effort, a common situation in disease 
gene searches, examples o f which include the identification of the genes causing FRDA 
(Campuzano et al., 1996), RP13 (McKie et al., 2001) and KWE (Findlay et al., 1977). In 
the FRDA and RP13 gene searches, the disease-causative gene was found, whereas, the 
search for the KWE and the PFHBI genes are still ongoing.
The diseases RP13, KWE and PFHBI share a number o f characteristics, for example, all 
three are autosomal dominantly inherited and affect South African families; many similar 
strategies are being used in the search for both the PFHBI and KWE genes. The strategies 
used and the results generated will be discussed below to give further insight into the
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approaches used, the time span of a gene search, the pitfalls, the contributions of different 
team members and ideas o f how to proceed with the search for the PFHBI gene.
1.6.1 Retinitis pigmentosa
Unlike KWE and PFHBI, RP13 is a genetically and clinically heterogeneous disorder 
characterised by progressive degeneration of the peripheral retina leading to night 
blindness and loss of visual field (Greenberg et al., 1994).
In the early 1990’s, the search for a gene causing autosomal dominant RP (adRP) was 
seriously pursued by a South African group under the supervision of Professor Jacquie 
Greenberg, based at the Human Genetics Department, University of Cape Town, South 
Africa. The RP13 locus for adRP was placed on chromosome 17pl 3.1 by linkage 
analysis (Greenberg et al., 1994) in a large South African family of British ancestry. 
Since the recoverin (RCV1) gene mapped to chromosome 17 p l3.1 and was assumed to be 
involved in the pathogenesis o f adRP, it was considered a prime candidate. However, 
mutational screening of all three exons of RCV1 failed to reveal any mutations 
(Greenberg et al., 1994) and at a later stage RCV1 was excluded because of 
recombination events (Goliath et al., 1995). Further studies, using the South African 
family, refined the RP13 locus to a region between markers D17S1529 and D17S831 
flanking a distance of 3cM (Goliath et al., 1995). A year later, an American group 
mapped the RP13 gene of another family o f British descent living in the USA to 
chromosome 17pl 3.3 (Kojis et al., 1996). At about the same time, an English group re­
analysed the South African family data and refined the RP13 locus of their three-
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generation family to chromosome 17 p l3.3 (Tarttelin et al., 1996). Collaborations 
between the South African and the English groups were established and physical fine 
mapping of the region was actively pursued. The combined efforts resulted in the 
establishment of a YAC and PAC clone contig across the area. To further aid the search 
for the RP13 gene, an expression map of the region was constructed (McHale et al., 
2000).
As part o f a doctoral study by Goliath (2000), a bioinformatic approach was used to 
establish the first sequence contig of the region. This study resulted in the reduction of 
the target region to lcM  and the identification of ten positional candidate genes, of which 
four were excluded from involvement in RP13 by mutation screening procedures. The 
fifth gene screened was a pre-mRNA splicing factor gene (PRPC8), which is composed 
of 42 exons and is ubiquitously expressed (McKie et al., 2001).
The first 41 exons were excluded from harbouring RP13 disease-causing mutations, 
however, the final exon contained seven different mutations clustered in a 14-codon 
stretch of PRPC8 in several unrelated RP families. It is therefore important to 
meticulously screen all the exons of PFHBI candidates as the disease-causing mutation 
may lie in the very last exon, as in the case of RP13 (McKie et al., 2001).
1.6.2 Keratolytic winter erythema
Findlay et al., (1977) first described KWE, which is also known as “Oudtshoom skin
i
disease”, as an inherited dermatosis, which is traceable to certain nineteenth-century 
inhabitants of Oudtshoom, Cape Province. Co-incidently, PFHBI (Brink and Torrington,
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1977) was also first described in 1977. KWE is an autosomal dominant skin disorder 
characterised by erythema, hyperkeratosis and peeling of the palms and soles, especially 
during winter. This disorder occurs at a frequency of 1 in 7000 in the South African 
Afrikaans-speaking Caucasoid population and has been attributed to a founder effect 
(Starfield et al., 1997). Interestingly, the belief about the frequency of PFHBI closely 
follows KWE, namely, 1 in 9000 in the same population group (Torrington et al., 1986; 
Van der Merwe et al., 1988).
KWE, like PFHBI, initially was thought to be unique to South Africa, but recently a 
single family in Germany was identified (Starfield et al., 1997). Using a genome wide 
linkage analysis, the KWE locus was linked to marker D8S550 on chromosome 8p22-23 
with a maximum LOD score o f 9.2 in a German family and 7.4 in five of the fourteen 
South African families (Starfield et al., 1997). Eleven of fourteen South African KWE 
families studied, had an “ancestral” haplotype (Starfield et al., 1997). New recombination 
events in the German family placed the KWE gene within a 1 OcM region, while analysis 
of recombination events in the South African families reduced the region to 6cM. An 
additional ancestral recombination event in the South African family further reduced the 
target region to a lcM region flanked by markers D8S550 and D8S265 (Starfield et al.,
1997).
To identify positional candidate genes for KWE, a BAC contig spanning the KWE 
region, between markers D8S550 and D8S1695, was constructed (fig. 1.17). The BAC 
clones spanning the KWE locus were identified by PCR, using primers o f markers,
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namely D8S550, D8S265 and D8S1695 at the KWE locus. All the BACs spanning the 
KWE locus were sequenced by Appel et al., (2002), which resulted in the construction of 
a 634,404bp contig. A detailed physical and transcript map was constructed of the KWE 
locus by using various techniques, such as exon trapping, cDNA selection and sequence 
analysis, and twelve gene transcripts were identified (fig. 1.17). These transcripts were 
further characterised by determining the exon/intron structure and the expression profiles 
using reverse transcriptase-PCR (RT-PCR) with cDNAs from different tissues. 
Mutational analyses of each of the exons of the twelve transcripts were performed, but no 
potentially pathogenic mutations were found (Appel et al., 2002). The search for the 
KWE gene is ongoing.
1.6.3 Progressive familial heart block I
The rationale for the PFHBI gene search and the earlier mapping data are discussed in 
detail in section 1.3.2.3.4. Saturation mapping by the group further narrowed the PFHBI 
locus to a 7cM region between markers D19S412 and D19S866 (fig. 1.9) (personal 
communication, de Jager, 1998). Due to a shortage of genetic markers within the PFHBI 
locus, the recombinant cosmid and BAC clones were probed for di- and tetranucleotide, 
such as (CA)n, (AaT)n and (A3G)n, repeat motifs for marker development. The novel 
markers, in turn, were used to further refine the map o f the PFHBI locus. Over a period of 
time, a number of attractive candidate genes were selected for mutation screening by 
different members of the PFHBI group. One of the first genes selected for mutation 
screening was HRC (Hofmann et al., 1991/ The HRC protein is found in lumen of the
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Figure 1.17 Physical and transcript map o f the KWE critical region on human chromosome 8p22- 
p34.
Genetic markers in bold have been previously identified. The new microsatellite markers are marked with 
an * in the top map. The transcript map is shown underneath. The transcripts are depicted as filled boxes. 
EST locus D8S1593 is part a novel myotubularin-related protein gene MTMR8. Partial overlap o f the genes 
are shown in hatched boxes. The arrows show the direction o f transcription. The G+C content o f  the 
genomic sequence is shown. The average G+C content is shown by the dotted line. The BAC clones, 
306G 11 to 148021 were identified by PCR screening o f a human BAC library. The BAC clones covering 
the region D8S550 and D8S1695 were completely sequenced. Within this sequence, markers D8S550, 
D8S1755, D8S265 and D8S1695 were identified. The contig was extended by partially sequenced BAC 
clone R P11-148021 (Appel et al., 2002).
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sarcoplasmic reticulum and it has been proposed that sarcoplasmic proteins may play a 
role in Ca2+-binding,therefore mutations in this gene could affect intracellular Ca2+ 
homeostasis.
As part of his study, Christoffels (1997) analysed the two triplet repeats, GAG and GAT, 
within exon 1 of HRC for abnormal expansions that might cause disease, since the 
phenomenon of anticipation was observed in the PFHBI family (Van der Merwe et al., 
1988). The (GAT)n repeat motif comprises 12 to 15 repeats and is tetra-allelic, whereas 
the (GAG)n repeat motif comprises 8  or 9 repeats and is biallelic in a normal Caucasion 
population. His investigation showed no expansions of either o f these triplets in PFHBI- 
affected individuals. De Meeus and colleagues (1995) also investigated the members of 
the Lebanese family for repeat expansions of the two triplet repeats in exon 1 o f HRC but 
no expansion was found. In addition, Christoffels (1997) developed a polymorphic (CA)n 
marker, D19S1172, which was genotyped in the PFHBI family and confirmed the 
telomeric limit of the PFHBI locus at D19S866.
In a more recent study, Makubalo (2000) screened the entire exon 1 sequence and the 
remaining exons of HRC (exons 2 to 6 ) using PCR-single-strand conformation 
polymorphism (PCR-SSCP) analysis. In addition, in 1998, a collaborative project with Dr 
Brian Black of the Cardiovascular Research Institute (University of California, San 
Francisco, USA) was formed which involved sequencing of the entire HRC, including the 
5’and 3’ UTR, exonic and intronic sequences o f two PFHBI-affected individuals from
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each o f the pedigrees 1, 2 and 5 and two unaffected close relatives. However, no disease- 
causing mutations were found (personal communications, Black, 2001).
GSY1 was the next gene selected by the PFHBI group for mutation screening, based on 
the reasoning that although glycogen occurs in abundance in the CCS, its role is unclear 
(James, 1970; Davies, 1971). Five (4, 5, 11, 12 and 16) out of sixteen exons of GSY1 
were selected for mutation screening for PFHBI mutation screening by Makubalo (2000), 
using PCR-SSCP. These particular exons were selected because they contained domains 
which are conserved across the species. The proposal was that any sequence variation 
occurring in these regions might have a deleterious effect on the function of the protein. 
However, no mobility shifts were observed in any o f the five exons examined. The 
remaining GSY1 exons and the UTR regions were screened as part o f the study described 
in this thesis.
In a more recent study by F. February (2002), all thirteen exons o f NUCBl were screened 
for PFHBI disease-causing mutations by direct sequencing. The rationale for the selection 
of the human NUCBl gene for PFHBI mutation screening was that studies showed that 
lupus-prone mice secreted a murine nucbl protein that promotes the production of DNA- 
specific antibodies (Kanai et al., 1993). These antibodies were also shown to be present 
in babies of mothers with systemic lupus erythromatosis (SLE) and one of the clinical 
symptoms of SLE is heart block in the absence o f muscle failure (Lanham et al., 1983). 
The screening of the exonic and flanking intronic sequences of all the exons of the 
NUCB1 in PFHBI-affected individuals revealed no disease-causing mutations (F. 
February, 2002).
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In 2002, another member o f the PFHBI group screened the small nuclear 
ribonucleoprotein 70kD polypeptide (SNRP70) and serine arginine-rich pre-mRNA 
splicing factor SR-A1 (SR-A1) encoding genes (Du Plessis, 2004). The rationale was that 
defective mRNA splicing might result in disease (Faustino and Cooper, 2003), which 
implicates the involvement o f splicing factor genes, since they are involved in the 
development of the CCS. Therefore, a mutation in genes involved in the splicing 
mechanism could possibly be PFHBI-causative. Although, at first sight, involvement of 
splicing factors would appear as an unlikely cause o f a specific CCS defect, previous 
studies showed that a mutation in the PRPC8 gene, which is a splicing factor pre-mRNA, 
cause RP13 (for more detail on RP13, see section 1.6.1). In the case o f SNRP70, no 
disease-causing mutations were found in PFHBI-affected individuals. In the case o f SR- 
A l,  both the SR (serine, arginine) and the DR (aspartic acid, arginine) domains in exon 6  
were screened, but again no disease-causing mutations were found.
As part of Christoffel’s (2001) doctoral studies, and as part of the PFHBI/SANBI 
collaboration, he identified 1184 fragment sequences o f DNA clones spanning the PFHBI 
locus, which he screened using in silico methods, for microsatellite identification. In 
addition, he produced an integrated map o f the PFHBI locus by assembling the 1184 
sequenced fragments, mostly in draft form. To this, he mapped 119 STACK transcripts, 
24 BodyMap transcripts, mouse ESTs and six RefSeq contigs. He identified seven 
cardiac positional candidates, which included actin-binding protein (KPTN), transcription 
factor (TEAD2) and a signal transduction protein, CD37, as possible disease-causative 
genes for PFHBI.
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1.7 THE PRESENT STUDY
The aim of this study was to find the PFHBI-causative gene. The first step involved the 
reduction of the PFHBI locus using published markers. Further refinement of the locus 
involved, initially, the development of tetranucleotide (A3G)n repeat motifs as markers, 
from cosmid clones obtained from LLNL, USA, and subsequently, the development of 
dinucleotide markers from publicly available chromosome 19 sequence data. The 
sequences from these clones were used to develop polymorphic markers, which were 
subsequently used in PCR-based genotyping analysis of the PFHBI families.
The second step used was the identification and prioritisation of the genes present at the 
PFHBI locus. The strategy involved searching the publicly available databases for ESTs, 
which were extended using two clustering programmes (STACK, SANBI and 
UNIGENE, NCBI). The significant clusters were retrieved and searched against protein 
databases with the aim of identifying novel candidate genes.
In order to accelerate the search for the PFHBI gene, an integrated map of the PFHBI 
locus was generated. All available information relevant to genetic and physical data, such 
as genetic markers, ESTs, clusters, genes, BAC cosmid clones and contigs spanning the 
region were integrated into a combined map of the target region using bioinformatic tools 
and wet-bench techniques. The map information was updated on a regular basis by 
performing BLAST homology searches using the physical data.
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Since chromosome 19 is one of the most gene-rich chromosomes, it was necessary to 
prioritise both predicted and annotated genes. Candidates were selected for mutation 
screening based on their function and expression profile. In addition, the PFHBI locus 
was searched for a Cx and a G protein-encoding gene following the rationale discussed in 
sections 1.2.2.2 and 1.2.2.3. The whole genome of selected affected individuals was 
scanned for pathogenic a CTG repeat expansion which were largely done by 
collaborators (section 1.4.1.3).
1.8 CONTRIBUTIONS FROM THE OTHER PFHBI TEAM MEMBERS
During the course of the present study, I supervised 4 B.Sc Honours and 2 M.Sc projects: 
“The retrieval, clustering and protein homology searches of ESTs at the PFHBI locus“ (F. 
February, B.Sc Hons 2000), “Development of (CA)n repeat markers in the region between 
genetic markers D19S604 and D19S866 at the PFHBI locus “ (M. Du Plessis, B.Sc Hons 
2001), “ The search for tetra and triplet repeats within the PFHBI locus with a view to 
screening a strong candidate gene for PFHBI-causative mutations" (M. McCabe, B.Sc 
Hons 2002), “Optimisation o f the PCR reactions using fluorescently labeled published 
genetic markers spanning the PFHBI locus“ (A. Cloete, B.Sc Hons 2002), “Identification 
and mapping of expressed sequence tags, ESTs, with a view to identifying and to 
screening an attractive candidate gene for PFHBI “ (F. February, 2002) and “The use of 
the mouse regions syntenic to the PFHBI region for identifying novel genes and the 
mutation screening of a candidate gene(s)“ (M. Du Plessis, 2004).
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In the present study, the Schalling group screened the whole genome of selected PFHBI 
individuals for a pathogenic CTG repeat expansion. Dr S. Bardien-Kruger was involved 
in the expression studies and the mouse/human homology sequence studies of KCNA7, 
together we designed primers which were used for mutation screening of affected and 
unaffected PFHBI individuals and I was principally responsible for the characterisation 
of the two SNPs of KCNA 7.
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2.1 SELECTION OF FAMILIES
Brink and Torrington (1977) first described a South African family, now designated 
pedigree 2, in which PFHBI segregates. Subsequently two smaller unrelated pedigrees, 
named pedigrees 1 and 5, were described. Pedigree 2 is the largest pedigree that can be 
traced back nine generations to a single male (1.01) and his wife (1.02). Individual 1.01 
was one of 10 siblings, the offspring of a Portuguese immigrant and his wife of French 
ancestory (see fig. 2.1 A) (Torrington et al., 1986; Brink et al., 1994; Van der Merwe et 
al., 1994). In this study, the different branches of pedigree 2 are referred to as kindreds 
(fig. 2.1). The smaller pedigrees (fig. 2 .IB) display the same phenotype and the same 
haplotype as pedigree 2 (Brink et al., 1995), and are therefore seen to represent a founder 
effect.
PFHBI-affected and unaffected family members were selected based on strict criteria 
with unequivocal clinical features described in section 2.2. In addition, affected 
individuals carried the disease-associated haplotype, except for individual 5.1.2 the 
disease was non-penetrant i.e., the disease-associated haplotype was present but the 
individual was not clinically affected (Brink, 1997). The control individuals were 
individuals that were married into the PFHBI pedigree, had a normal ECG and did not 
carry the disease-associated haplotype. Thus, for mutation screening studies, a panel 
comprising selected PFHBI-affected individuals from pedigrees 1, 2 and 5 and control 
individuals were used (fig. 2.1 A and B). PFHBI-affected individuals from pedigree 2 
were also investigated for the presence of a CTG repeat motif expansion (see the boxed 
samples in fig. 2.1 A). The reason for selecting the CTG repeat motif for expansion is
Stellenbosch University http://scholar.sun.ac.za/
2.III.9 (A) 
2.IV.1 (A) 
4.IV.2 (A) 
4.IV.4 (A) 
13.II.1 (A)
2. V III.10
Pedigree 2 (kindred 10)
2.IX .17 2 .IX .18 2 .IX .19  2 .IX .20
* *
Figure 2.1 PFHBI-affected family branches from pedrigrees 1 ,2  (kindreds 4, 7 , 9 and 10) and pedigree 5. Pedi ree 2 (kindred 4 )
The kindreds o f  pedigree 2 relevant to  this study are enlarged and the nomenclature was changed. Subsequent to the previous study, 6  v
newly affected individual 9.IV.5 was added to the study and changes to the clinical status o f  individuals were made, namely,
individual 7.IV.2 is now affected and individuals 9.III.1 and 9.III.9 is classified as normal and . * , the DNA samples analysed for
disease-causing mutations by PCR-SSCP analysis and direct sequencing. The boxed samples were investigated for CTG repeat
expansions. Samples from pedigrees 1, 5, kindreds 4, 7, 9 and 10 were used for m arker developm ent and genetic fine mapping. In
this study, the numbering system use for kindreds 4, 7, 9 and 10 o f  pedigree 2 is shown on the kindred drawing (Brink et at., 1995).
2.V III.87 2 .v i l l .s
Pedigree 2 (kindred 7)
2. V III.11 2 .V III.I3  2. VIII. 14 2.V III.16 2 .V IIII8  2 .V III.I9
2.IX .1 2.IX .2 2.IX .3 2.IX .4 2.IX .5
Pedigree 2 (kindred 9)
o n Clinically unaffected (U) 
Clinically affected (A)
;  PEOIC5REE 2
■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ ■ I
B
*5.111.1
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addressed in subsequent chapters. Finally, individuals were selected from pedigrees 1, 2 
and 5, which included siblings, children and married-in individuals, for genetic fine 
mapping studies (fig. 2.1 A and B).
Additional DNA samples were obtained from 52 unaffected South African individuals of 
Afrikaner descent, with their consent, who were unrelated to the PFHBI families used in 
this study. These samples were used to determine the allelic frequency o f the novel (CA)n 
markers and the frequency o f single nucleotide polymorphisms (SNPs) o f KCNA7.
2.2 CLINICAL EVALUATION
The clinical diagnosis of PFHBI was made by Dr P-L van der Merwe Department of 
Cardiology (Van der Merwe et al., 1986; Van der Merwe et al., 1988), Professor Brink, 
Department of Internal Medicine, Tygerberg Hospital (Brink et al., 1994; Brink et al.,
1995) and personal physicians of referred patients, following strict criteria based on 
ECG-defined right RBBB, RBBB complicated by LAHB/LPHB or posterior hemiblock 
(bifascicular block) or CHB with a broad QRS-complex, in the absence o f other cardiac 
conditions.
Patients with a pacemaker were accepted as o f PFHBI-affected status, as it was not 
always possible to obtain a record o f the cardiac rhythm that existed prior to 
implantation. Sinus bradycardia in isolation was considered normal and LAHB and 
LPHB in isolation were regarded as equivocal. Incomplete RBBB, indefinite
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intraventricular conduction defect and first-degree heart block were regarded as normal in 
the absence of BB disease. The Minnesota code was adhered to in making ECG diagnosis 
(Higgins et al., 1965).
2.3 BLOOD COLLECTION
This is a longstanding study, which involved the use o f samples that had been banked, 
prior to the present study. The University of Stellenbosch’s ethics committee approved 
the PFHBI project (Project 86/085). The blood samples were collected by Professors P-L 
Van der Merwe and P. Brink, the referred patient’s physicians or Genetics Service nurses. 
All participants in the initial part of the study gave informed verbal consent and, in the 
case o f minors, the consent of the parents was required. Written informed consent was 
required from new members participating in the study before any testing was done.
2.4 HUMAN GENOMIC DNA EXTRACTION FROM CELLS
DNA was extracted from either the nuclei of lymphocytes harvested from freshly 
collected blood samples or from Epstein-Barr virus transformed lymphocytes (modified 
Neitzel (1986) method), as described by Corfield et al., (1993). The extracted DNA was 
air-dried and resuspended in lml of lx TE (Appendix 1), mixed gently on a rotator (Voss 
of Maldon, Protea Dento-Medical Services, Cape Town) and quantitated using a 
spectrophotometer (Specronic 1201, Milton Roy). The concentration was adjusted to 
0,2fig/ p.1 by dilution with lx TE and was stored at 4°C.
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2.5 PRIMER AND OLIGONUCLEOTIDE PROBE DESIGN AND SYNTHESIS
Oligonucleotide primers were designed for known STRs, for novel (CA)„ STRs and 
(A3G)n STRs from BACs and cosmid clones spanning the PFHBI region, for use in 
genotyping. Primers were also designed for mutation screening of exons and exon/intron 
boundaries of plausible candidate genes. Where possible, published primer sequences or 
database primers were used, but, when necessary, primer sequences were designed from 
published gene sequences with the assistance of the primer programme PRIMERFINDER 
(http://eatworms.swmed.edu/~tim/primerfmder). Primer sequences used in genotyping 
are given in table 2 .1 , those used for development of (CA)„ dinucleotide and 
tetranucleotide STRs are given in table 2.2 and those used for the amplification of exons 
o f candidate genes are given in table 2.3. All primers and the (A3G)io oligonucleotide 
were synthesised at the DNA Laboratory based at the University o f Cape Town (UCT), 
SA.
2.5.1 Primer design for known and novel STRs
The sequences of published primers of known STRs were retrieved from the Genbank 
database using Genbank accession numbers. Primers designed for novel (A3 G)„ STRs 
from recombinant cosmid DNA are described in section 2.9. Primers designed for novel 
(CA)n STRs from sequenced BAC and cosmid clones are described in section 2.10.
2.5.2 Primer design for candidate genes
Primers for the amplification of exons of candidate genes were designed in such a way 
that approximately 30 nucleotides preceding and following the exon of interest were
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included. This allowed examination o f the intron/exon boundaries for the presence of 
disease-causing mutations. There were a number of large exons, for which primers were 
designed to amplify the exons in a series o f overlapping products, such as both exons of 
KCNA7 and exons 2 and 3 of KIR2.4. The design of KCNA7 and KIR2.4 primers is 
discussed in more detail in sections 2.14.4 and 2.14.5, respectively.
The sequence of each exon was retrieved from the Ensembl database 
(http://www.ensembl.org) and each exonic sequence was BLAST-searched 
(http://www.ncbi.nlm.nih.gov/BLAST) against the nonredundant database 
(http://www.ncbi.nlm.nih.gov/nr) to find its position on a BAC clone (Altschul et al., 
1990). Using the BAC clone sequence information, the flanking intronic sequences were 
retrieved. To confirm that the exonic sequence and the flanking intronic sequence were 
unique and on chromosome 19ql3.3, a BLAST search was performed against the human 
genome database (http://www.ncbi.nlm.nih.gov/human genome) and the nucleic acid 
databases (http://www.ncbi.nlm.nih.gov/nr; http://www.ncbi.nlm.nih.gov/htgs).
2.6 PCR AMPLIFICATION AND SEQUENCING
2.6.1 Non-radioactive PCR
Non-radioactive PCR amplification was used in STR development which involved the 
amplification of cosmid inserts harbouring (A3G)n repeat motifs and of database sequence 
o f BACs and cosmids harbouring (CA)n repeat motifs. PCR amplification was also used 
to search DNA clones spanning the PFHBI locus for the presence o f a Cx (see fig. 2.2)
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Table 2.1 Database sequences of primers used to amplify published (CA)„ repeat 
markers used in genotyping family members.
GENETIC MARKER GENBANK 
Acc No
PRIMER
5’— 3’
T.
°C
PRODUCT
SIZE
bp
D19S412 Z24042 F: tgagcgacagaatgagact 
R: acatcttactgaatgcttgc
55 89-113
D19S606 Z53152 F: agggctgggacctcac 
R: ccaacacactgtctgcctt
55 190-211
D19S902 Z53165 F: ccatcctaatgagggcaa 
R: gcaccagtgactgcctgt
55 199-217
D19S596 Z52219 F: gaatccgagaggtggg 
R: gccagagccactgtgt
55 213-221
D19S604 Z53032 F: tgtatgnaaagcacacgc 
R: atgtcatggagcatttgttg
55 135-159
D19S879 Z52767 F: ctgagtgtgaatgaggcaac 
R aggccagagggggggactgattg
55 251-278
D19S866 Z52072 F: catgagtttgactatgaagacg 
R: cactccagcctgggtaa
55 183-217
The Genbank accession number (Acc No) for each genetic marker, the forward and reverse primer 
sequences (F and R), optimum annealing temperatures (Ta) and the expected amplicon size (bp) are 
indicated.
and a G protein-encoding gene. Finally, PCR amplification was used for mutation 
screening of the exons and exon/intron regions of the candidate genes, GSYI, KCNA7, 
BAX, KIR2.4 and LIN-7B.
Stellenbosch University http://scholar.sun.ac.za/
104
Table 2.2 Primer sequences for novel (CA)„ markers generated during this study 
from recombinant BAC and cosmid sequences which were used in genotyping 
family members.
BAC/cosmid 
Acc No
Primer sequence 
5’ 3 ’
Ta
°C
Product size 
bp
*AC008392 F: taggttggtcaggcttcgtg 
R: ctctgctttctgggttcaag
56 248
AC008888 F: gtggatcacctgaggtcagg 
R: agctcctgttgcccaggctg
59 226
*AC008403 F; gtgttgggattgcaggtgtg 
R: aggcaaaggatgcagcgaac
59 249
AC010619 F: taacataaagggctgtcttc 
R: gtgaaaatagaacagcta
50 169
*AC011495 F: ttgcagtgagctgagatcac 
R: tcgcatctagaacctattgc
55 2 0 2
*AC018766 F: ctaatccactatggctggtg 
R: gaaatcttacaggggaaggg
55 171
ACO10624 F: gggtaaatgcttgactctcc 
R: agccagttcctgtccttatg
58 225
The clone accession numbers (Acc No); the forward and reverse primer sequences (F and R); optimum 
annealing temperatures (Ta) and expected amplicon size (bp) are indicated; *, deposited in Genbank as 
(CA)n markers during this study (section 3.1.5 and table 3.1).
The general method for PCR amplification involved the preparation of a reaction mixture 
in a sterile 0.5ml microfuge tube which contained 150ng o f each primer, 75pM each of 
dATP, dGTP, dTTP and dCTP (Promega Corp, Madison, Wisconsin, USA), 1.5mM 
MgCh, 0.5U of BIOTAQim DNA polymerase (Bioline, UK Ltd, UK) and lOx NH4 
reaction buffer (as supplied by manufacturer) (containing 160mM (N H ^SC^,
Stellenbosch University http://scholar.sun.ac.za/
105
Table 2.3 Primer sequences used to PCR amplify exons and flanking intronic 
sequence of exons of candidate genes for mutation screening.
GENE EXON FORWARD PRIMER REVERSE PRIMER T] SIZE
5’— 3 ’ 5’— 3’ °C bp
*KCNA T
exon 1
1A acacgtcggttcgcgggtcg agtagagcacggcgtcgaag 55 200
IB ccgcgagtatttcttcgacc tctcgggaaactcgaaaagc 55 200
exon 2
2C tggcacgcctgcgcgaggac cgcccatctcctcccaaacc 55 200
2D atgtgtaaagaggagctggg aagtagggaaggatagccac 55 200
2E gtccaagcaaggctatcttc agaggaccacaccgatgaag 55 200
2F aatcttgggccagacgcttc aattggagacaatgacgggc 55 200
2G aagatagtgggctctctgtg tctagggaggtgtgaggtcc 55 200
U B A J ?
1 cgttcagcggggctctca caggccggtaggaaggat 54 207
2-3 cccctagaacccaagagtc ggctgagagtcctgtgtcc 58 400
4 tctcctgcaggatgattgc tccccaggtcctcacagat 58 209
5 caggcagtggggacaaggtt gcggtggtgggggtgaggag 62 192
6 cccctggccgagtcactgaa aatgcccatgtcccccaatg 60 237
*KIR2.4C
1 cactggactctctcagac ccctgtatctcctttatatg 52 400
2A ctacatctcccacaatccc gccttctggctcattgcctc 62 430
2B agctggccacgtgtgagaag tgttgcccctgacgtttctg 62 450
3A gtgtagggttccagagcat tggttccagaaagctcat 52 680
3B gcttgcctctgtggtcaacc gtccccttccccgtgtatg 58 500
3C tccctgctgtctttggctcc tacacggggaaggggacatc 62 691
KLIN-7Ba
1 caggtggtcggagcagtc gggggctgggtatgtagg 60 220
2 cgctctccttgcttctctgc gacaagcaggaggaggagga 60 240
3 gggagttgtagttttctcggcc agggaggaaacagaaatgactgg 60 280
4 gtaacccaggctaaatcgctgtc ttgagtgaatgtcaaaagcaggg 60 340
5 ggcaccaggctcactagcag tggaagatccaggaagcactg 60 320
continued  overleaf
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Table 2.3 cont.
G ENE EXON FORWARD PRIMER
5’—  3 ’
REVERSE PRIMER 
5’—  3’
T.
°C
SIZE
bp
HGSY1*
5’UTRA ccgcctcagatccagaagtc gagccagaagatctcgctcc 58 280
5’UTRB gatctcgatggttcctcata ggccttcagctctgtcaatc 59 302
5’UTRC tttgaggcctccagctccag agtagctggtgccgacgggaag 68 360
1 gtcttgcaataggaagccgagcgt catccactactgtccttctc 60 310
2 cccagaactatggacctcg gcaggctgtccacccgcttc 60 279
3 gagcctccctatggtgcctc gtcatgtagtttcaggtatgg 58 273
6 accacaacattgatotgaatg cctcctctcttaagacctag 57 213
7 ggctttaccgtgccttgtg ttgcttgccctccctgtcc 60 189
8 ccacatgatcctggcctcc ccggagcgagggctgctaac 61 167
9 gcagctggtgtgtatgtgac gagaacggagtaatgagagg 58 170
10 cctctcattactccgttctc ggctgccaggaactgctatc 58 172
13 ttaagacggtaggcgatgag aggagtcactgttctcaagc 58 207
14 ctggagaccatgaagatctc aggagctgctgatttgccag 57 270
15 tggctctcacatcctctgcc cctttagctcctggctaagc 60 163
16B ctgggcgaggagcgtaactaag acttgatcgccccattcgcagg 68 438
16C ccaccaagttctggaaaccacgtg gttgggaataagccaggttagggg 64 427
16D gatttagactctagagggaggag catctcatctccggacacactc 64 378
Ta =  annealing temperature; * = primer sequences generated during this study from database gene 
sequences; # = primer sequences obtained from literature; 5UTR = 5’-untranslated region; candidate genes: 
KCNA7, Potassium voltage-gated channel shaker related, member 7; BAX, BCL2-associated X protein; 
KIR2.4, Potassium inwardly-rectifying channel, sub-family J; LIN-7B, mammalian LIN-7 protein 2; GSY1, 
Glycogen synthase I; a = Bardien-Kruger et al., 2002; b = Chou et al., 1996; c = Genbank accession 
number NM_013348; d = Genbank accession number AF 311862; e = Ohro et al., 1995.
670mM Tris-HCl, pH8 . 8  at 25°C, 0.1% Tween-20) and 5%  formamide (Sigma Chemical 
Company, St Louis, Missouri, USA). To this, 200ng of human genomic 
/BAC/cosmid/radiation hybrid DNA was added and ddH20  to a final volume of 50p.l. A 
negative control was also prepared which contained all the components of the PCR 
reaction mix, except that the DNA was replaced by ddH2 0 .
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The reaction mixture was subsequently overlaid with 30pl mineral oil to prevent 
evaporation during amplification using the Gene-E-Thermal Cycler (Techne Ltd., 
Cambridge, UK). Each cycle typically comprised a 30 seconds (sec) denaturation at 
94°C, incubation at the appropriate annealing temperature (Ta) for 30 sec and a 45 sec 
extension at 72°C. The annealing temperature selected was usually 3-5°C below the 
lowest melting temperature (Tm) of the primer set. The Tm for both the forward and the 
reverse primers were calculated as follows:
Tm = 4(G+C) + 2(A+T) (Innis and Gelfand, 1990)
Tables 2.1 and 2.2 list the specific amplification parameters for all markers and table 2.3 
lists the parameters used for the amplifications o f exonic sequences of selected candidate 
genes used in this study. In the case of the Cx gene search, Cx degenerate primers were 
used (see fig. 2.2) (Coucke et al., 2000) under the following PCR conditions: 1 min 
denaturation at 95°C, 1 min annealing at 55°C and 1 min extension at 72°C for 35 cycles.
2.6.2 Radioactive PCR
Radioactive PCR was used to genotype individuals from all three PFHBI pedigrees (see 
fig. 2.1) using published genetic markers, novel (CA)n repeat and tetranucleotide repeat 
markers. Radioactive PCR amplification involved the preparation o f a mixture containing 
60ng o f each primer, lpCi [a-32P]dCTP (Amersham International, UK), 5|iM unlabeled 
dCTP, 200pM of each of dATP, dTTP and dGTP, 1.5mM MgCl2, 0.5U of BIOTAQ™ 
DNA polymerase (Bioline, UK Ltd, UK), lOx NH4  reaction buffer (supplied by
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manufacturer) and 5% formamide (Sigma Chemical Company, St Louis, Missouri, USA), 
which were added to lOOng o f genomic DNA template in a 0.5ml microfuge tube and 
was made up to a final volume o f lOjil using ddH2 0 . The reaction mixture was 
subsequently overlaid with 1 5jj.1 mineral oil to prevent evaporation during amplification.
(b) Primer CxDEG-F 5’-GGNAAGRTCTGGCTSACNGTNCTBTTCATHTTCCG-3’ 
Primer CxDEG-R 3 ’-CGDT AGAGGGTRY ANGCGRWGACCCASGACGTC-5 ’
Figure 2.2 Generation of Cx degenerate primers (Coucke et a l 2000).
(a) Schematic representation of the general structure of a connexin protein. The arrows indicate the location 
of the degenerate primers on a protein, (b) The nucleotide sequence of the forward (CxDEG-F) primer and 
the reverse (CxDEG-R) primer which was obtained from the alignment of six human connexins. The 
degenerate primers were designed and given as a gift by Coucke. The symbols in the degenerate primers 
represent: N = A/C/G/T, R = A/G, S = G/C, B = C/G/T, H = A/C/T, Y = C/T, W = A/T. A, adenine; C, 
cytosine; G, guanine; T, thymine.
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After amplification, the samples were stored at room temperature in a perspex box until 
required for further analysis. In most cases, samples were stored for not longer than a 
month.
2.6.3 Direct Sequencing
2.6.3.1 Preparation of template
Direct sequencing o f cosmids containing (A3G)n, which were identified by Southern 
blotting (Southern, 1975) described in section 2.9.1.3, was performed on both DNA 
strands. Firstly, 30pl of PCR amplification product was electrophoresed on an agarose 
gel and the DNA product was extracted using a GFX PCR DNA gel extraction kit 
(Amersham, UK) according to the manufacturer’s protocol. The extraction of the DNA 
from the gel was performed as follows: After electrophoresis of the DNA on the agarose 
gel, the correctly sized DNA fragment was excised from the gel, by using a sterile razor 
blade for each sample to prevent contamination. After excision, the agarose band 
containing the DNA was weighed in a sterile microfuge tube. To the gel slice, 300pl 
capture buffer was added and the contents were mixed by vigorous vortexing, followed 
by incubation at 60°C in a waterbath until the agarose was completely dissolved. A new 
GFX column was washed with 250pl o f capture buffer (buffered solution containing 
acetate and chaotrope) and left to stand for 1 min. A collection tube containing a GFX 
column was placed in a microfuge tube and was spun at 13,000rpm for 30 sec in a 
benchtop centrifuge (model Microfuge* Lite, Beckmann Instruments, California, USA). 
The flow-through in the collection tube was discarded and capture buffer containing the 
dissolved agarose band was added to the column and spun at 13,000rpm for 30 sec in a
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benchtop centrifuge (model MicrofugeR Lite, Beckmann Instruments, California, USA). 
The DNA was retained on a glass fibre matrix on the GFX column. The GFX column 
containing the DNA was washed with 500^1 o f wash buffer and was centrifuged at 
13,000rpm for 30 sec in a centrifuge (model MicrofugeR Lite, Beckmann instruments, 
California, USA). Thereafter, the GFX column was placed in a sterile 1.5ml microfuge 
tube and to the column was added 50(j.l distilled sterile water, which was left to stand for
1 min at room temperature. In order to elute the DNA from the GFX column, it was spun 
at 13,000rpm for 1 min in a benchtop centrifuge (model Microfuge* Lite, Beckmann 
Instruments, California, USA). The eluted DNA was used as a template for the 
sequencing reactions. The DNA was quantified spectrophotometrically.
2.6.3.2 Sequencing
In the initial part o f the project, the inserts containing (A3G)n repeat markers were 
sequenced using manual sequencing. Sequencing was performed using the fmol™ 
sequencing kit (Promega, USA) according to the manufacturer’s specifications. The 
sequencing reaction mixture contained 5|al DNA template, 5|al 5x sequencing buffer, 5% 
DMSO (2:3 dilution in ddH20 ) (Sigma, USA), lOpmol of primer, 0.5|il [ a - 3 2P]dCTP 
(3000Ci/mmol) (Amersham International, UK), ddH20  to 16|il and 5U of sequencing 
grade Taq polymerase (Promega, USA). Four microliters o f the above cocktail mixture 
was added to four pre-chilled 0.5ml microfuge tubes, each containing 2(il aliquots of a 
cocktail composed of all four deoxynucleotides, as well as one specific 
dideoxynucleotide, namely, ddATP, ddTTP, ddGTP or ddCTP. Twenty microliters of 
mineral oil was carefully layered on top of the reaction mixture. Samples were then
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placed into a pre-heated GeneE Thermal Cycler (Techne Ltd., Cambridge, UK) and kept 
at 95°C for 2 min before cycling was commenced. The same thermal cycling profile was 
used as that of the original PCR amplification. When the sequencing cycle was 
completed, 4|fl sequencing stop solution (Promega, USA) was added to each tube. These 
samples were either stored at -20°C until required or denatured at 95°C in a heating block 
for 2  min and a 4fil aliquot immediately loaded on a pre-electrophoresed denaturing 
polyacrylamide gel (section 2.7.3).
2.6.3.3 Automated sequencing
In addition to manual sequencing, at a later stage o f the project, PCR products of 
amplified exons of candidate genes were screened for mutations by direct sequencing, on 
an ABI Prism 3100 Genetic Analyser at the Core DNA Sequencing Facility, US. The 
templates used for sequencing were prepared as described in section 2.6.3.1 and the 
primers used for sequencing are described in section 2.6.1 (table 2.3).
2.7 GEL ELECTROPHORESIS
2.7.1 Agarose gel electrophoresis
Agarose gels were used for verification o f the success of non-radioactive PCR 
amplifications, for preparative gels for sequencing template and for analysis of the 
purified BAC, cosmid and plasmid DNA. Five microlitres o f either a PCR product or 
BAC/cosmid/plasmid DNA (0.1jag/|il) were mixed with l(il of bromophenol blue loading 
dye (Appendix I). The samples were subsequently loaded and electrophoresed in 1.5% to
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2% (depending on the size of the amplified PCR product) or 0.7% to 1% (depending on 
the size o f cosmid and plasmid DNA) horizontal agarose gels (12cm x 5cm x 1cm), 
containing lpg/ml EtBr and lxTBE electrophoresis buffer (Appendix I). The samples 
were co-electrophoresed with a sample o f bacteriophage lambda DNA digested with 
restriction enzyme Pst\ (X P s tl) (Promega, USA) that was used as molecular size 
marker (Appendix I) or with a lOObp marker (Promega, USA). The gel was subsequently 
visualised on a longwave ultraviolet transilluminator (3UVtm Transilluminator model 
LMS-26E) and a photograph was taken using an ITC camera (Berkenhoff and Drebes, 
Germany) and a Sony video graphic printer (UP-860CE).
2.7.2 Non-denaturing polyacrylamide gel electrophoresis
In order to screen exons of candidate genes for sequence variations, non-denaturing 
polyacrylamide gels were used for PCR single strand conformation polymorphism 
(SSCP) analysis according to methods modified from Orita et al., (1989). For each panel 
o f samples (fig. 2 .1 ) analysed, four different non-denaturing polyacrylamide gel 
conditions were used, namely, 8 % or 1 0 % non-denaturing polyacrylamide gel, either with 
or without 1 0 % glycerol, in order to maximise the likelihood of detecting sequence 
changes. In addition, a 0.35x MDE™ (FMC Bioproducts, USA) gel was used for further 
analysis of samples where no SSCP mobility shifts were observed. Electrophoresis was 
performed at 4°C, since this prevented Ohmic heating (Liu and Sommer, 1994).
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The casting of the gel
The gel was cast between 390mm x 290mm x 1mm glass plates and covalently bound 
onto Gelbond™ PAG polyester film (FMC Bioproducts, Maine, USA) during the gel 
polymerisation process (Appendix I). The fixing o f the gel facilitated its subsequent 
handling during the staining procedure. The details o f the casting o f the gels and 
solutions are given in Appendix I. Once the gel was polymerised, the apparatus was 
dismantled in the following order, the casting boot, the sealing tape at the bottom of the
plates and lastly the comb were removed. The glass plate assembly was mounted 
vertically on the electrophoresis apparatus (Omeg Scientific, SA.), moved to the cold 
room (4°C) and 0.5xTBE buffer (Appendix I) was added to the reservoir tanks. The wells 
were washed with buffer to remove any gel residues, and the denatured PCR samples 
(section 2.6.1) were immediately loaded. Electrophoresis was carried out in 0.5xTBE 
buffer, at a constant power of 50W for 2-7 hours (hrs) at 4°C. For the separation o f 100 to 
2 0 0 bp fragments, the fragments were electrophoresed until the bromophenol blue o f the 
loading dye had migrated to the bottom of the gel. The separation o f larger fragments 
(>2 0 0 bp) was achieved by electrophoresing the xylene cyanol two-thirds o f the gel 
length. Subsequently, the glass assembly was dismantled and the gel silver stained.
Silver staining
In order to visualise unlabeled amplified DNA fragments, silver staining was used. 
Following electrophoresis, the glass assembly was dismantled and the gel, still attached 
to the Gelbond™, was silver stained by immersion in solution B (Appendix I), on a
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Labcon shaking platform (Labdesign Engineering, SA) for 10 min at room temperature, 
followed by a brief ddKhO rinse and incubation in the solution C (Appendix I) on a 
Labcon shaking platform, for a minimum of 20 min or until the bands became visible. 
Thereafter, gels were again rinsed in ddthO  and air-dried, photographed as a record and 
stored in a sealed plastic bag.
2.7.3 Denaturing gel electrophoresis
Following radioactive PCR amplification of STRs, or following manual sequencing 
reactions, samples were electrophoresed on denaturing polyacrylamide gels to separate 
alleles containing different numbers o f repeat sequences or labeled fragments, 
respectively. The 0.5mm 5%  polyacrylamide denaturing sequencing gel (Appendix I) was 
cast as described in section 2.7.2, but without the use of Gelbond™ film and using 
0.5mm thin spacers and a sharks-tooth comb. Pre-electrophoresis was carried out in 0.5x 
TBE buffer at 1800V for 30 min prior to loading. The samples that needed to be 
electrophoresed were prepared in the following way: 6 fj.l o f sequencing stop solution 
(Appendix I) was added to each sample, which were then heat-denatured at 95°C for 5 
min. Before loading, the wells o f the gels were first washed out to remove any gel debris 
or air bubbles trapped in the wells. Thereafter, a sample volume o f 3-5|nl was loaded into 
the wells. The electrophoresis at 1800V continued for 2 hrs for genotyping STRs, 
however, for longer DNA sequencing reads, electrophoresis proceeded until the 
bromophenol blue dye had migrated more than two third of the way down the gel. At this 
point, the power was switched off and an additional 4jj.1 aliquot of the same sample, heat- 
denatured, was loaded in a different lane for short sequence reads. Electrophoresis was
Stellenbosch University http://scholar.sun.ac.za/
115
resumed at 1800V and allowed to proceed until the second bromophenol blue front had 
migrated more than two thirds of the way down the gel.
After electrophoretic separation was completed, the plates were dismantled, the gel was 
carefully lifted off the glass plates using 3MM Whatman paper (Whatman International 
Ltd, Madstone, England) cut to the same size as the gel plates, and thereafter covered 
with cling-film (GLADwrap™). Subsequently, the gel was dried for 1 hr on a Drygel 
Slabgel Dryer (model 1160, Hoeffer Scientific Instruments, San Francisco, USA), placed 
in a cassette and exposed to an X-ray film (Cronex-4, Protea Medical) overnight at room 
temperature.
2.7.4 X-ray development
The X-ray film (Cronex-4, Protea Medical) was developed, in the dark, by immersion in 
developing solution (Appendix I) for 4 min, stop solution (Appendix I) for 0.5 min and 
fixing solution (Appendix I) for 2 min. The X-ray film (Cronex-4, Protea Medical) was 
then rinsed off with running water and dried at room temperature.
2.7.5 Genotype analysis
The genotype scores were only assigned after agreement was reached between two 
independent individuals, blinded to the phenotypic status o f the subject.
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2.8 MUTATION SCREENING ANALYSIS
2.8.1 DNA sequence analysis
Each sample was sequenced in both the forward and reverse direction. The reverse 
complement o f the reverse sequence o f each sample was obtained using the BCM 
searchlauncher tool (http://www.hgsc.bcm.tcm.edu). Thereafter, the reverse complement 
o f the forward sequence and the database sequence o f each exon with flanking intronic 
sequences of each candidate gene were aligned using the CLUSTALW 1.81 programme 
(http://www.ebi.ac.uk/clustalw). All eight sequences were aligned against the database 
sequence retrieved from the NCBI database (http://www.ncbi.nlm.nih/nucleotide).
2.8.2 ClustalW 1.81 alignment of exons
The sequences obtained were aligned in the following order:-
1 = sequence of the exon from the database (http://www.ncbi.nlm.nih/nucleotide)
2  = forward sequence
3 = reverse complement sequence o f the reverse sequence r  Unaffected individual
4 = forward sequence
5 = reverse complement sequence of the reverse sequence
6  = forward sequence
7= reverse complement sequence of the reverse sequence
8  = forward sequence
9 = reverse complement of the reverse sequence
Affected individual from Pedigree 1
Affected individual from Pedigree 5
Affected individual from Pedigree 2
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2.8.3 Submission of SNP to SNP database
A single nucleotide polymorphism (SNP) is defined as any polymorphic single nucleotide 
variation, which may or may not alter a restriction site (Vogel and Motulsky, 1986). In 
this project the PCR-SSCP technique and sequencing were used to detect SNPs. In 
addition, the frequencies of the polymorphic alleles of the SNP were analysed in 50 
unaffected South African Afrikaner individuals. All the SNPs detected in this project 
were submitted to the SNP database (http://www.ncbi.nih.gov/SNP) (Wang et al., 1998).
2.9 (A3G)„ MARKER DEVELOPMENT
As part o f this study, the development o f (A3G)n repeat markers was initially pursued and 
subsequently (CA)„ repeat markers were developed from available chromosome 19 
sequences from public databases.
Twenty five Lawrist-16 cosmids containing fragments of human chromosome 19ql3.3 
(De Jong et al., 1989), spaced at 500Kb intervals across the chromosome 19ql3.3 region, 
were obtained from LLNL, California, USA. These cosmids were propagated in the 
D H 5a strain of E. coli. In order to develop the (A3G)n repeat markers, the approach 
outlined in fig. 2.3 was followed.
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2.9.1 The identification of (AjG),, repeat-containing recombinant cosmids (fig. 2.3A)
2.9.1.1 Cosmid culture preparation, isolation and purification of cosmid DNA
The recombinant Lawrist-16 cosmid cultures were prepared using the detailed method 
described in appendix I. The QIAGEN™ commercial DNA purification kit (QIAGEN, 
Germany) was used to isolate cosmid DNA from bacterial genomic DNA. Absorbance 
was read on a spectrophotometer at 260nm to determine the DNA concentration (pg/ml) 
using the formula: OD260 x 50 x Dilution factor (10D 26o= 50pg). The DNA was analysed 
on a 0.7% agarose gel containing 0.01% EtBr and lxTBE to check its integrity (section 
2.7.1). The cosmid DNA could now be utilised for the preparation of dot blots (section 
2.9.1.2), Southern blots (section 2.9.1.3) or sub-cloning (section 2.9.4).
2.9.1.2 Preparation of dot blots
Dot blots were used for the initial screening of cosmids to identify those cosmids 
containing (A3G)n repeats and again later to verify the presence of (A3G)n repeats in the 
inserts. The denaturation of the cosmid DNA was performed in the following steps: to 
each 200ng o f cosmid DNA an equal volume of 0.4N NaOH was added and the mixture 
was incubated at room temperature for 5 min. The mixture was snap-cooled on ice for 2 
min and spotted onto the previously marked positions on a Hybond™ N+ filter 
(Amersham, UK), which had been placed on 3MM-chromatography paper (Whatman, 
International Ltd, Madstone, England). Fifty nanograms of human genomic DNA were 
spotted onto the filter as a positive control and ddF^O as a negative control. The filter 
was air-dried for 15 min and thereafter baked for 2 hrs at 80°C in a vacuum oven 
(Towson and Mecer Ltd, England). Subsequently, the filter was either re-hydrated in 2x
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Figure 23 Schematic representation of the development of (A3G),, markers
A. describes the steps taken to identify (AjG)n repeats in recombinant cosmid clones. B, describes the steps involved in the preparation of 
the insert from (A3G)n -containing clones. C, describes the preparation of the pBuescript vector. D, steps involved in the subcloning of 
vector and (A3G)n-containing insert, sequencing of the insert and the determination of the polymorphic nature of the insert.
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SSC (Appendix I) prior to the pre-hybridisation step o f the screening process (Appendix 
I) or covered with clingfilm (GLADwrap™) and stored at 4°C until required.
In order to identify the (A3G)n repeat containing cosmids to be used for subcloning, the 
Hybond™ N+ membrane was probed with an end labeled y - 32P[dATP]-(A3G)io 
oligonucleotide. A detailed description of the probe preparation, pre-hybridisation and 
post-hybridistion protocols are presented in Appendix I.
2.9.1.3 Cosmid DNA digestion and Southern blot preparation
The digestion reaction, which contained 30pg cosmid DNA, 90U Sau3A\ (Promega, 
USA), 15 pi lOx buffer as specified by the manufacturer (Promega,US A), and ddH20  to 
150pl, was incubated at 37°C for 3 hrs, gel electrophoresed and Southern blotted (see fig. 
2.3A) (Appendix I). Thereafter, the Hybond™ N+ membrane was either re-hydrated in 2x 
SSC (Appendix I) in preparation for probing with a radioactively labeled oligonucleotide 
(Appendix I) or stored at 4°C.
In order to identify the (A3G)n repeat containing fragments to be used for subcloning, the 
Hybond™ N+ membrane was probed with an end labeled y - 3 2P[dATP]-(A3G)io 
oligonucleotide (Appendix I).
2.9.2 Insert preparation (fig. 2.3B)
For the purposes of subcloning, 30pg of cosmid DNA containing the (A3G)„ repeat were 
digested with 90U of Saw3Al (Amersham, UK) according to the manufacturer’s protocol
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for 3 hrs and electrophoresed on 0.7% agarose gel (20cm x 20cm x 3cm) (Appendix I) at 
30V overnight alongside X Pstl (Promega, USA). The Sau3A\ fragments were excised 
from the gel using a sterile blade and then the DNA was extracted from the gel slice 
using a GFX kit (Amersham, UK) according to the manufacturer’s protocol (as described 
in section 2.6.3.1) and resuspended in 40jj.1 ddH2 0 .
2.9.3 Vector preparation (fig. 2.3C)
Plasmid vector pBluescript SK (Stratagene, USA) (fig. 2.4) cultures were prepared in a 
similar manner to the cosmid, as described in Appendix I except LB/ampicillin (Amp) 
(50fig/ml) selective medium was used (fig. 2.3B). The plasmid vector, pBluescript SK, 
molecular weight 2.9kb, was linearised by digesting with Sail restriction enzyme 
(Promega, USA). The digestion reaction mixture contained lOjag vector DNA, 4pl 
(lOOmM) spermidine, 200U Sail (Promega, USA), lOpl lOx buffer as specified by the 
manufacturer (Promega, USA) and ddH2 0  to a final volume of lOOjil. The reaction was 
incubated at 37°C for 3 hrs. Thereafter, linearised vector DNA was ethanol precipitated 
(Appendix I).
Partial fill-in reactions for insert and vector
In order to prevent self-ligation o f the insert molecules and to render the ends compatible 
in the vector, dGTP and dATP were added to the insert in the presence of the Klenow 
fragment o f DNA polymerase (Promega, USA). The fill-in reaction mixture consisted of 
40|ol (lOng) of insert DNA, 0.5pl dGTP (lOmM), 0.5pl dATP (lOmM), 2pl (10U) 
Klenow fragment o f DNA polymerase (Promega, USA), 5 pi lOx Klenow buffer
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(Promega, USA) and ddthO made up to a final volume of 50j_tl. Incubation was carried 
out at 37°C for 2 hrs, after which lp.1 (0.5M) EDTA was added to terminate each reaction 
and the reaction tube stored at 4°C.
(b)
pBluescript SK (+/-) Multiple Cloning Site Region 
(sequence shown 601—826)
Apo I Hinc II
I_________T7 hwiHtf l___________^  Kpn I pro II * Xho I S SV
TTQTAAAACOACOQCCAOTQAATTQTAATACGACTCACTATAOGGCQAATTQQQTACCGGOCCCCCCCTCGAOQTCQACQQT. . .
Ml  3 —20 primar binding s T 7  prfmor binding erto ^  KS prtmar binding ilt«...
Bsp 1 06 I Not |
<pia I Hind III ^coR V |coR I P»t I Smo I ^omH I Sp. I Xba I J log I ^,iX I Sac II Sac I
• • • ATCQATAAQCTTQATATCQAATTCCTOCAQCCCQQGQQATCCACTAQTTCTAQAQCQQCCOCCACciaCQQTQQAQCTCCA. . .
...ICS primer binding site SK prlm»r binding >H«
—_______T3 IVwnot»r_____________ ^B-nol a-fragrm nl
. . . QCTTTTOTTCCCTTTAGTQAGQ<3TTAAT'fTCQAQCTTa<3CQTAATCATQOTCATAGCTQTTTCC
Figure 2.4 Diagram and restriction map o f pBluescript SK vector.
(a) fl (+) ori, fl origin; lacZ, lactose Z gene ; MCS, multiple cloning site found within the lac Z gene 
showing enzyme restriction sites, Kpn I and Sad; P lac, promoter of the lactose operon; pUC ori, pUC 
origin (b) The sequence of MCS showing the position of the different primer binding sites of M13, T3, KS 
and T7 and the different enzyme restriction sites found in MCS. (http://www.stratagene.com/vectors).
2.9.4 Subcloning of (A3G)n repeat fragments (fig. 2.3D)
For subcloning, the partially filled insert and vector were purified using the organic 
extraction (Appendix I). The ligation o f the vector and the insert, the transformation of
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the E. coli XL 1-blue competent using the ligation mixture and colony lifts o f the 
recombinant clones are described in detail in Appendix I.
2.9.5 Identification and characterisation of (AjG),, repeat motif (fig. 2.3D)
Recombinant plasmid DNA was extracted (section 2.9.4) and digested with Kpnl and 
Sacl at the vector restriction enzyme sites on either side o f the multiple cloning site 
(MCS) (fig. 2.4), to verify that the positive colonies picked from the plates contained 
cloned insert (Appendix I). Following the verification o f the presence of the insert, the 
corresponding recombinant plasmid clone were sequenced (section 2.6.3) using vector 
primers T3 and T7 (fig. 2.4).
2.9.6 Determination of the polymorphic nature of marker
The polymorphic nature o f each marker was determined by PCR amplification (as 
described in section 2.6.2) using DNA o f 20-25 unrelated individuals of South African 
Afrikaner population. The PCR products were electrophoresed on a 6 % denaturing gel as 
described in section 2.7.3 and the gel was exposed to X-ray film (section 2.7.4). 
Generally two alleles, one inherited from each parent per individual were observed on the 
autoradiograph. The alleles were numbered in order o f decreasing molecular weight and 
the frequency of each allele was calculated as a fraction for a South African Afrikaner 
population group. DNA samples from selected individuals from kindreds 4 and 9 from 
pedigree 2 were also genotyped simultaneously, in order to fine map the PFHBI locus.
Stellenbosch University http://scholar.sun.ac.za/
124
2.10 (CA)n MARKER DEVELOPMENT
2.10.1 Sequence acquisition
The availability o f draft and final sequence from the Human Genome Project (HGP) has 
prompted the use o f in-silico methods for the identification o f STRs (Benson, 1999). 
During the course of the study, (CA)n genetic markers from the PFHBI locus on 
chromosome 19ql3.3 had been utilised and the necessity arose to identify novel markers 
to refine the existing breakpoints in the critical area.
In-silico identification of tandem repeats became feasible with the release o f the complete 
draft and final sequence for chromosome 19 in June 2000 (http://www.jgi.doe.gov) in the 
form o f sequenced recombinant BACs and cosmids in the Joint Genome Institute (JGI) 
(fig. 2.5). Using both an in-silico approach and experimental techniques a number o f 
CA/GT repeat markers were developed (fig. 2.6) using these sequences. A total o f 1184 
sequences spanning a 4Mb region o f the PFHBI locus on chromosome 19ql3.3 were 
downloaded from the JGI ftp site (ftp://sawdoff.llnl.gov/pub/JGI_data/Human/Chl9) as 
part o f the PFHBI/SANBI collaboration (Christoffels, 2001). Sequences deposited into 
the publicly available databases are contaminated with E. coli sequences (Hillier et al.,
1996) and these contaminating sequences were removed by masking the E. coli 
sequences by using the programme Repeatmasker (http://ftp.genome.washington.edu/cgi- 
bin/RepeatMasker) prior to screening for tandem repeats (Christoffels, 2001).
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•D19S412
•D19S606
'D19S902
'D19S596
•D19S604
I
3 cM
1 cM
1 cM
2 cM
LLNL UNIVERSAL GENBAIN
Clone ID Clone name Acc No.
BC821616 CITB-E1_3001H11 AC010331
F24003 LLNL-FJ98H7 AC008985
R30005 LLNL-R_261D9 AC010519
BC782556 CITB-E1 257L23 AC008745
BC858854 CITB-E1_3098H1 AC024582
BC815354 CITB-E1_2657C13 ACO10330
BC694629 CITB-H_2265M8 AC010458
BC324323 CIT-HSPC 453G23 AC011466
BC242886 CIT-HSPC_241 F20 AC008392
R33773 LLNL-R 300F9 AC020955
F16353 LLNL-F119C1 AC011514
R26730 LLNL-R 227C10 AC0I1527
BC255070 CIT-HSPC_273B12 AC008403
R29279 LLNL-R 253H3
BC677569 CITB-H1_2221F12 AC008888
R31763 LLNL-R_279G3 AC009002
BC808483 CITB-E1_2639E6 AC026803
BC52309 CIT978SKB 60B18 AC008687
BC679592 CITB-H1 2226J19 AC008891
BC266129 CIT-HSPC_30107 AC011450
R31681 LLNL-R_278H5 ACO10524
R29295 LLNL-R_254A7 ACO10643
BC878087 CITB-E 3148110 AC010619
BC42053 C1TB78SKB_33G10 AC011495
R31181 LLNL-R_273F9 AC006942
F23669 LLNL-FJ95D9 ACO18766
R28785 LLNL-R 248GI AC024079
BC275645 CIT-HSPC 326K19 AC011452
BC641056 CITB-H1_2126E3 AC010624
BC61330 CIT978SKB_191K22 AC008655
R28901 CITB-E_254M3 AC020909
—D19S866
Figure 2.5 Genetic map o f the PFHBI locus showing the positions o f  recom binant cosmid and BAC  
clones ( February 5 ,2003).
From left to right: the genetic map o f the PFHBI locus, LLNL clone ID, Universal clone ID and the 
Genbank accession number for each cosmid and BAC clones present at the PFHBI locus is shown. The 
cosmid clones are indicated in green and the BAC clones are indicated in blue.
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2.10.2 Screening cosmid and BAC sequences for tandem repeats
Tandem Repeatfinder (http://c3biomath.mssm.edu/trf.basic.submit.html) (Benson et al., 
1999) is a programme designed to detect long stretches o f twelve or more tandem repeats. 
Each o f the 32 cosmid and BAC sequences spanning the PFHBI locus were first masked 
for contaminating vector, simple repeats, mitochondrial and ribosomal regions and E. coli 
sequences after which it was subjected to Tandem Repeatfinder in order to detect all 
(CA)n repeats (fig. 2.6) (Christoffels, 2001). All the (CA)„ repeat-containing cosmid and 
BAC sequences were downloaded and placed at
http://ziggy.sanbi.ac.za/alan/TandemRepeats.html. (personal communication, 
Christoffels, 2001). As part o f the present study, 27 BAC and cosmid sequences 
containing (CA)n repeats spanning the PFHBI locus were retrieved and investigated for 
marker development.
2.10.3 Protocol for marker development
2.10.3.1 Primer generation
Using the programme Primerfinder (http://eatworms.swmed.edu/~tim/primerfinder), 
primers flanking the (CA)n repeats were designed from sequence data from the identified 
clones (fig. 2.6a). The sequence containing the primer, flanking sequence and entire 
repeat (400-500bp in length) (fig. 2.6b) was BLAST-searched against the complete, 
incomplete and the nonredundant nucleotide databases
(http://www.ncbi.nlm.nih.gov/BLAST) to confirm the degree o f homology to other 
sequences in the database. The set o f sequences from the BAC or cosmid clones were
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4 Mb mmm
spanning
PFHBI
target
region
CA
ICA
Chromosome 19ql3.3 Fragments o f
Chromosomal DNA
BACs and cosmids containing 
CA/GT repeat motifs
Software programme 
(Tandem Repeatfinder) 
Identifies repeats
(a)
CTCCCAAAGTGTTGGGATTGCAGGTGTGAGCCACTGCACCTGGCCCCAAAGATGCT
TTTTGATATATGTCACACACACACACACACACACACGCCCAGCAAAAGATGTGCA
AGGATAGTATAGTAATGAAACTCGGGGTGCACATGAAATGTGAGGTCTGTATCACT
CAATATTTTTGTTGTTTGAGATGGAGTCTCTCTCTGTCACCCAGGCTGGAGTGCAGT
GGCATGATCTCAGTTCGCTGCATCCTTTGCCTCCCAGGTTCAGGTGATTCTCCTGCCT
C AGCCTCCTGAGT AGCT
Primer design (Primerfinder)
W  PCR-ampIify repeat motifs
Forw ard prim er
CCCAAAGTGTTGGGATTGCAGGTGTGAGCCACTGCACCTGGCCCCAAAGATGCT 
TTTTGATATATGTCACACACACACACACACACACACGCCCAGCAAAAGATGTGCA
(b) AGGATAGTATAGTAATGAAACTCGGGGTGCACATGAAATGTGAGGTCTGTATCACT 
CAATATTTTTGTTGTTTGAGATGGAGTCTCTCTCTGTCACCCAGGCTGGAGTGCA
5’-TG CACTCCAGCCTGGGTGAC-3’ 
Reverse complement 
reverse prim er
PCR-amplify in panel of 
unrelated individuals
Figure 2.6 Diagram m atic representation illustrating the generation o f (CA)n markers from  
recom binant cosm ids and BACs.
(a) Sequence containing a (CA)n repeat from the PFHBI locus, cloned into a BAC/cosmid (b) (CA)n repeat 
containing sequence flanked by the forward and the reverse primers.
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only selected for marker development if it had a 1 0 0 % homology to the clone from which 
it originated.
The selected 400-5OObp sequence was copied from the clone sequence and using the 
“paste” option the sequence was placed into the PRIMERFINDER window. Using the 
“next” option, a new window was activated which allowed the parameters for the primer 
design to be set, namely, primer length, GC content, Ta, and MgCl2 concentration. Using 
the same window, the forward or the reverse complement primer of the marker could be 
generated. Once the appropriate button was selected the “submit” option was activated. A 
separate web page containing all the possible primers, their sequence, Ta, and hairpin 
looping and self complimentarity was given. The same procedure was performed for the 
reverse primer (reverse complement). In addition, another two windows could be 
activated, one in which the forward primer and a second window in which the reverse 
was pasted. Using the “submit” option, the complimentarity between the two primers was 
determined.
2 .10 .3 .2  C hrom osom e 19 som atic cell hybrids and D N A  isolation  from  recom binant clones  
Chromosome 19 somatic cell hybrids
The two somatic cell hybrids, ORIM7-1 and 1219G2, as described in section 1.4.2.1, 
were obtained from the Dept o f Human Genetics, University o f Amsterdam, The 
Netherlands (Schonk et al., 1989). Somatic cell hybrid ORIM-7 consisted o f a human 
t(X;19) (Xqter- Xp21;19ql3.1-qter) chromosome and a few additional human 
chromosomes in a hamster Wg3-h background. Hybrid 1219G2 was obtained from the
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fusion o f hamster A3 cells and parental lymphoblastoid cells carrying a reciprocal 
t(12;19) translocation. Hybridisation and cytogenetic studies revealed that that 1219G2 
carries human 19ql3.1-qter::12pter-ql5 segment (Schonk et al., 1989).
The somatic hybrids cell lines were maintained in Dulbeco’s modified Eagle’s medium 
supplemented with 15% fetal calf serum, 100|o.g/ml penicillin G, and 100|ig/ml 
streptomycin. The hypoxanthine-guanine phosphoribosyl transferase (HPRT)-positive or 
the HPRT-negative somatic cell hybrids were selected in DMEM containing either 
13.6(j.g/ml hypoxanthine, 0.22^g/ml aminopterine and 9.7|ag/ml thymidine (HAT) or 
12)j.g/ml thioguanine, respectively (Schonk et al., 1989). The DNA was extracted as 
described by Corfield et al., (1993)
BAC and cosmid DNA isolation (Mini prep)
BAC and cosmid clones were cultured and plated as described in section 2.9.1.1 
(Appendix I). In the case o f BAC clones, the antibiotic chloramphenicol (50mg/ml) was 
used and in the case of the cosmid clones, the antibiotic kanamycin (Kn) (50mg/ml) was 
used. Single colonies were selected and grown overnight in 10ml LB with the appropriate 
antibiotic. The DNA was extracted as follows: Each tube was spun at 3500rpm at room 
temperature in a Sorvall centrifuge (Du Pont Instruments, model RC-5B) for 10 min 
(Bimboim, 1983). The resulting pellet containing bacterial cells was gently resuspended 
in 200(j.l of chilled solution I (GTE) (Appendix I). The next step was the addition of 
400(il o f freshly prepared solution II (0.2M NaOH; 1% SDS) (Appendix I) to the 
suspension. To this 300(il o f solution III (3M KAc, 11.5% CH3COOH) (Appendix I)
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were added and the tube was centrifuged for 6  min at 13000rpm in a benchtop centrifuge 
(model MicrofugeR Lite, Beckmann Instruments, California, USA) at room temperature. 
Four hundred microlitres of supernatant were mixed with 200^1 phenol and 200jj.1 of 
chloroform-isoamyl alcohol, the mixture was centrifuged at 13000rpm for 5 min in a 
benchtop centrifuge (model Microfuge* Lite, Beckmann Instruments, California, USA) 
and the aqueous top phase was removed. The phenol/isoamyl chloroform step was 
repeated until the aqueous phase was clear. The final aqueous phase was mixed with 
800jj.1 o f 100% ethanol and the mixture was incubated at -20°C for 1 hr. The tubes were 
centrifuged at 13000rpm for 10 min in a benchtop centrifuge (model Microfuge* Lite, 
Beckmann Instruments, California, USA) and the DNA pellets were washed with 70% 
ethanol and air-dried. Forty five microlitres o f lx  TE and 5^1 (lOmg/ml) of RNAse 
solution (Sigma Chemical Company, St Louis, Missouri, USA) were added to the dried 
pellet and this was incubated at 37°C for 1 hr. The DNA was stored at 4°C until required.
2.10.3.3 PCR optimisation
The primers from the novel (CA)„ STRs generated from the BAC clone sequence (fig. 
2.6) were used in the PCR amplifications using the conditions shown in table 2.2 in 
section 2.6. Each PCR reaction was optimised with respect to the varying conditions and 
parameters such as Ta, extension time and MgCh concentration (table 2.2). In addition, a 
set o f cosmid and BAC clones were PCR amplified using different primer sets in order to 
verify that the primer set matched the purchased DNA clone from Research Genetics, 
USA. The following five control reactions were set up: PCR amplifications were 
prepared using each set of new primers with the isolated DNA from recombinant BAC or
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cosmid DNA clones from which the primers were generated; another control was set up, 
which used DNA isolated from recombinant cosmids or BACs from other DNA clones at 
the PFHBI locus. To verify that the primers came from a recombinant DNA clone from 
the chromosome 19q region, the chromosome 19q radiation hybrids were amplified. 
Genomic DNA was amplified with the novel primer sets as a positive control and as a 
negative control the DNA was replaced by water. The PCR protocol detailed in section
2.6.1 was used and 2|j.l of the PCR products mixed with 1 )0.1 bromophenol loading buffer 
were electrophoresed on a vertical (200mm x 150mm x 0.4mm) 12% non-denaturing 
polyacrylamide gel (Appendix I), with a sample of 1 (j.1 X Pst 1 used as a molecular size 
marker (Appendix I). The gel was silver stained as described in section 2.7.2 (Appendix
I).
2.10.3.4 Determination of polymorphic nature of marker
The polymorphic nature of the (CA)n repeat markers were determined in the same 
manner as the (A3G)n repeat marker (section 2.9.6).
2.10.3.5 Genotyping
Once the PCR conditions were optimised, as judged by the generation o f the expected 
size product seen after silver staining, a radioactive PCR was performed using the 
conditions described in section 2.6.2. A volume of 3-5|ol of the PCR products were 
electrophoresed on a 6 % denaturing polyacrylamide gel (390mm x 290mm x 1mm) as 
described in section 2.7.3 and Appendix I. After this, genotyping of the novel markers
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was performed in the PFHBI families, in an attempt to refine the existing recombination 
breakpoints.
2.10.4 Submission of novel genetic markers to STS database
Novel (CA)n repeat genetic markers developed during this study were submitted to the 
STS (sequence tag site) database (http://www.ncbi.nih.nlm.gov/STS). There are two sets 
o f file types for STS submissions; one is for the sequence data and one for any mapping 
data. The former was used for the submissions for this study (batch- 
sub@ncbi.nlm.nih.gov). After submission, there are validation checks performed by 
dbSTS curators. If the validation checks are successful, the dbSTS curator sends a list of 
dbST IDs and Genbank accession numbers to the submitter.
2.11 DATABASE SEARCHES FOR GENE TRANSCRIPTS
2.11.1 Transcript Searches
At the start o f this study, very few genes at the PFHBI locus had been annotated and 
deposited into the publicly available databases but a number o f ESTs had already been 
placed by other researchers (fig. 2.7). In the search for the PFHBI gene, it was important 
to find as many genes as possible in the region, in order to prioritise them as potential 
candidate genes.
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2.11.1.1 Retrieval of ESTs
During the course o f the study, the dbEST (http://www.ncbi.nlm.nih.gov/dbEST) was 
established and the data made publicly available. In addition, ESTs from the EST 
database for each chromosome were also being assembled and deposited into the 
Genemap99 database (http://www.ncbi.nlm.nih.gov/Genemap99). Concurrently, the 
group at LLNL, Livermore, USA involved in sequencing chromosome 19, was depositing 
ESTs at their site (http://www.bio-llnl.gov/genome). As part o f the project, all the ESTs 
mapping to the PFHBI critical region were retrieved from the available public databases 
and integrated into one map (fig 2.7a).
2.11.1.2 Clustering of ESTs
Since these retrieved ESTs were typically only 200-300 base pairs in length, a BLAST- 
search o f their translations against the protein database might not result in significant 
protein matches. Therefore, to obtain longer sequences, these ESTs were extended using 
STACKpack from the STACK database (http://www.sanbi.ac.za/STACK) and 
UNIGENE (http://www.ncbi.nlm.nih.gov/UNIGENE). The procedure for the STACK 
analysis is as follows: the STACK web page has one sequence input window. The 
accession number o f the EST from a database was retrieved, using the “copy” option, and 
inserted, using the “paste” option, into the “subject” window in the STACK web page. 
The information was then submitted and the STACK results containing all the cluster 
homologies with their scoring values were returned in a separate web page.
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The procedure for the UNIGENE database was as follows: The accession number o f an 
EST from a database was retrieved, using the “copy” option, and inserted, using the 
“paste” option, into the “subject” window in the UNIGENE sequence web page. The 
information was then submitted and the output was returned in a separate web page 
which contained protein homology, tissue expression profiles, homologene, all the ESTs 
with their orientation and also access to a number o f different databases.
The clustering programme generated a number o f STACK clusters and the STACK 
cluster with the highest scoring cluster value was selected for the BLAST search against 
the SWISS-PROT database (fig. 2.7b); whereas a search of the UNIGENE database using 
the retrieved ESTs produced direct protein homologies to proteins in the SWISS-PROT 
database (fig. 2.7e).
2.11.1.3 Positioning of ESTs on contig NT 011109
In silico  (computer-based) mapping was performed via the Internet (US/University of 
Western Cape (UWC) internet service provider), which involved finding the position of 
each EST on the chromosome 19 contig NT_011109 using the BLAST search tool. A 
BLAST search is performed when the electronic version o f a sequence is pasted into the 
window of the database o f interest and the “submit” button is activated. For example, in 
this case an EST, the sequence is pasted into the window o f the Human Genome 
database, after which a BLAST search against this database was performed in order to 
verify the bp positions o f the EST on chromosome 19 contig NT_011109 within the 
PFHBI locus (http://www.ncbi.nlm.nih.gov/human genome) (fig. 2.7d).
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GENEMAP 99 and LLNL
(a)
http://www.nchi.nih.n1m.gov/genemap99
http://www.bio-llnl.gov/genome
ESTs
(b)
HUMAN GENOME 
DATABASE
\
POSITION ON CONTIG
STACK CLUSTERS
1
Retrieve significant STACK clusters
\
STACK URL: http://www.sanbi.ac.za/STACK 
Unigene URL:http://www.ncbijiih.nhn.gov/Unigene 
Protein URL: http://www.hgsc.bcm.tmc.edu/
(c) PROTEIN
Figure 2.7 Illustration of the steps involved in the search for gene transcripts with the view to finding novel genes, 
(a) The retrieval of ESTs from the EST databases (b) A BLAST search of the retrieved ESTs against the STACK 
database (c) the STACK cluster matches against the protein databases, (d) A BLAST search of against the Human 
Genome database (e) A BLAST search of the ESTs against the UNIGENE database.
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2.11.2 Protein homology searches
The retrieved STACK clusters were BLAST-searched against the SWISS-PROT protein 
database using BCM Searchlauncher (http://www.hgsc.bcm.tmc.edu/) for possible 
protein homologies. Both STACK and UNIGENE databases contained tissue expression 
profiles for the different ESTs and this information was used to detect the tissue profile 
expression for each EST and gene placed at the PFHBI locus.
2.113 Interpretation of BLAST data
Expectation values (E values) are the scores reported by a similarity programme such as 
BLAST on their output file. The E-values should be treated like P values from traditional 
types o f statistical tests and represent the number o f times that a match with observed 
similarity score would occur by chance if  the database actually contained no sequences 
that were truly similar to the query sequence. Generally, E values o f zero or less than 
lO' 100 are assumed to be significant matches (Brown, 2000) and E values in this range 
was used in this study.
2.12 INTEGRATING OF PHYSICAL MAP
To facilitate the search for the PFHBI-causative gene, a high resolution, integrated 
physical o f the PFHBI target region was required. Two approaches were used in this 
study: the first was a bioinformatic approach, which involved the retrieval o f all available 
information from publicly available databases and then applying bioinformatic tools to
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the retrieved data. The second approach was the use o f laboratory based experimental 
techniques aimed at physical mapping o f loci (fig. 2 .8 ).
2.12.1 Data-mining
The sequence data and Genbank accession number of the BAC and cosmid clones 
spanning the 4Mb target region were retrieved from the LLNL database and the JGI site 
(http//:www-bio.llnl.gov/genomes/; http://www.jgi.doe). This step was followed by the 
retrieval o f ESTs from the EST databases, as described in section 2.10.
Information about the STSs, published/database genetic markers and the annotated genes 
were retrieved from the NCBI database (http://www.ncbi.nlm.nih.gov/nucleotide). The 
positions o f the BAC clones, cosmid clones, genetic markers and genes on the contig 
NT_011109 were found by performing BLAST searches (Altschul et al., 1990) against 
the human genome database using the Genbank accession numbers or the FASTA 
formatted sequences of the clones. ESTs corresponding to the respective genes and the 
expression profiles o f each gene were obtained by searching the UNIGENE database (fig. 
2 .8).
Since a number o f annotated genes were being deposited into the database, BLAST 
searches o f the Human Genome Database were performed to find the position o f these 
genes on the PFHBI contig. In order to find a gene contained in a BAC clone, the 
Genbank accession number or the FASTA formatted sequence o f the gene, was submitted
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Figure 2.8 Schematic diagram illustrating the two approaches used to produce an integrated physical 
map.
(a) Linking o f the ESTs to genes and the determination o f the expression profiles each gene, (b) Determination 
o f the physical position o f the ESTs on the recombinant BAC/cosmid clones, (c) Placement o f the sequences o f 
ESTs, published genetic markers, annotated genes and recombinant BACs and cosmids clones on the PFHB 
contig/s (d) PCR amplification o f published primers with recombinant BACs, cosmids and radiation hybrids 
clones.
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to the high throughput database (htgs) (http://www.ncbi.nlm.nih.gov/htgs). Additional 
information regarding annotated genes was also obtained from ENTREZ at NCBI 
(http://www.ncbi.nih.nlm.gov), Ensembl, (http://www.ensembl.org), Genbank 
(http://www.gdb.org) and LOCUSLINK (http://ncbi.nih.nlm.gov/LOCUSLINK).
2.12.2 Experimental approach
PCR amplification was used to verify the position o f the genetic markers on the BAC and 
cosmid clones, chromosome 19 radiation hybrids and genomic DNA. The selected DNA 
clones spanning the target region were firstly extracted using the protocol outlined in 
section 2.9.1.1 (Appendix I). Thereafter, amplification using the genetic marker primer 
sets from tables 2.1 and 2.2 on the various DNA sources were used as described in 
section 2.6.1. The PCR products were electrophoresed on a 1-2% agarose gel as 
described in section 2.7.1. The data obtained from the data-mining and the experimental 
approaches (sections 2 .1 2 . 1  and 2 . 1 2 .2 ) were collated and used to construct the integrated 
physical map. The subsequent step involved the analysis and prioritisation of the 
available annotated and predicted genes, present at the PFHBI locus, for mutation 
screening.
2.13 ANALYSIS OF PREDICTED AND ANNOTATED GENES
2.13.1 Criteria for prioritisation of PFHBI candidates
All the genes mapped to the PFHBI locus are candidates by virtue o f their position. 
However, some genes are functionally more attractive candidates because of additional
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features, such as expression in cardiac tissue, association with cardiac function and 
cardiac physiology, implication in cardiac disease, involvement with development, 
involvement in the apoptotic pathway, and presence o f triplet repeat motifs present either 
in the exonic, intronic or promoter regions.
2.13.2 Position, function and expression profile
Information regarding the position, function and expression profile o f both annotated and 
predicted genes present at the PFHBI locus was retrieved from the various databases at 
NCBI, such as UNIGENE (http://www.ncbi.nlm.nih.gov/UNIGENE) and Locuslink 
(http://www.ncbi.nlm.nih.gov/Locuslink) was obtained.
Known genes are defined as transcripts identified by experimental analysis, which are 
expressed in vivo (Stein, 2001). In addition, computer predicted genes for which there is 
experimental data to support that it has an in vivo biological function are also catalogued 
in HGP as a gene (Burge and Karlin, 1997).
Predicted genes which had been identified using bioinformatics similarity searches, 
namely, BLASTN (http://www.ncbi.nlm.nih/BLAST) and Genomescan 
(http://www.genomescan.gov) were retrieved as part of this study and prioritized, based 
on their putative functions.
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2.14 GENE SEARCHING AND MUTATION SCREENING
A number o f genes were prioritised based on the criteria described in section 2.13.1, as 
excellent candidate genes for PFHBI. In this study, using specific and significant criteria 
from section 2.13.1, five genes namely, KCNA7, K1R2.4, BAX, LIN-7B and GSY1 were 
selected for screening for disease-causing mutations in PFHBI.
The presence o f a CTG repeat expansion in the PFHBI families was investigated by 
Schalling o f the Karolinska Institute, Sweden using the repeat expansion detection (RED) 
method (Schalling et al., 1993) (section 2.14.1).
Professor C.T. Basson from the Department of Medicine (Cornell University Medical 
School, New York, USA) contacted the PFHBI group because he had isolated the cDNA 
of a G protein, which he had mapped to chromosome 19ql3.3. In a collaborative 
agreement, the PFHBI group used the Basson’s clone to probe the DNA clones spanning 
the PFHBI locus for the presence of the gene (section 2.14.2).
Dr P. Coucke from the University o f Antwerp, Belgium contacted the PFHBI group 
because he suggested an investigation of the PFHBI locus for a Cx, since Cxs were 
thought to be strong candidate genes for PFHBI (section 1.2.2.3). PCR amplification 
using a set o f degenerate primers (fig. 2.2), designed and synthesised by Coucke’s group, 
DNA from clones spanning the PFHBI locus and a selected panel o f PFHBI individuals 
(see fig. 2.1) to search for the presence o f a Cx (section 2.14.3).
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In the case of KCNA7, the PFHBI group contacted Professor G. Chandy from the 
Physiology and Biochemistry Department (University of California, Irvine, USA) 
because his group had localised, characterised and sequenced K cnal of M. musculus 
(Kalman et al., 1998) and, in addition, had placed the human orthologue, KCNA7, at the 
PFHBI locus. A collaboration with this group resulted in the characterisation of the 
human KCNA7 (Bardien-Kruger et al., 2002) (section 2.14.4).
In the case of HRC, Professor Brian Black from the Cardiovascular Institute (University 
of California, San Francisco, USA) contacted the PFHBI group in 1999 and offered to 
sequence the HRC gene, including the 5’ and 3’ UTRs, as well as the complete intronic 
sequences o f one affected and one unaffected first degree relative of PFHBI individuals 
from each o f the three pedigrees.
2.14.1 Search for CTG repeat expansion
The RED technique can identify potentially pathogenic repeat expansions without prior 
knowledge of chromosomal location. Genomic DNA is used as a template for a two step 
cycling process that generates oligonucleotide multimers when expanded trinucleotide 
sequences are present, as in the case o f DM and Huntington’s disease (fig. 2.9) (Schalling 
et al., 1993). Five DNA samples from affected PFHBI individuals were analysed by the 
Schalling group for possible CTG repeat expansions.
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Figure 2.9 Principle of repeat expansion detection (RED) technique.
The diagram illustrates the different steps of the RED technique which detects expanded 
trinucleotide (CAG)n repeats in genomic DNA. (a) Single-stranded genomic DNA containing a CAG 
repeat and a (CTG)I7 oligonucleotide is hybridised at a temperature near its melting point, (b) 
Thermostable ligase binds covalently adjacent oligonucleotides, producing multimers of the 
oligonucleotide (CTG)I7. The ligation step is then repeated several hundred times, (c) A mixed 
population of single-stranded multimers are produced. The detection of single-stranded multimers is 
achieved by size separation on a denaturing polyacrylamide gel, which is subsequently 
electrotransferred, hybridised and then probed with a 32P-labeled complementary oligonucleotide 
(Schalling et al., 1993).
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2.14.2 G protein-encoding gene
A human guanine nucleotide exchange factor p i  15-RhoGEF cDNA clone (Genbank Acc 
No. U64105) was obtained from C.T. Basson and was used to probe a dot blot of 
cosmids, BACs, YACs, DNA clones and chromosome 19 radiation hybrids (section
2.10.1.3) spanning the PFHBI locus for the presence o f G protein gene. The pi 15- 
GEFcDNA insert, 800 to 900bp in size, cloned in vector pCR2.1 (Stratagene, USA) (fig. 
2.10), was labeled (Appendix I). This was followed by hybridisation with the labeled 
probe and subsequent washing (Appendix I). The hybridised dot blot was exposed to an 
X-ray film (Cronex-4, Protea Medical) overnight at room temperature. The X-ray film 
was developed as described in 2.7.4.
2.14.3 Cx 
PCR using degenerate Cx primers
The presence o f a Cx at the PFHBI locus was investigated by the amplification of all the 
cosmids, BACs and the chromosome 19q radiation hybrids with the degenerate primers, 
using the protocol described in section 2.6.1 (fig. 2.2). The set of Cx degenerate primers, 
were obtained from P. Coucke, University of Antwerp, Belgium, which were designed by 
the alignment o f six Cxs, namely, Cx26 (M8849), Cx37 (M96789), Cx40 (U03486), Cx43 
(X52947), Cx45 (U03493), and Cx50 (U34802), using the CLUSTALW alignment 
programme (fig. 2.2) (personal communication, Coucke).
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The PCR products were electrophoresed on a 1% agarose gel, the expected 200bp 
product was cut out of the gel as described in section 2.7.1 and extracted using a GFX 
PCR DNA extraction kit (Amersham, UK) according to the manufacturer’s protocol 
(section 2.6.3.1). Automated sequencing of all the PCR products was performed at the 
DNA Sequencing Core Facility, University of Stellenbosch (US).
lacZu ATG 
M l 3 Reverse Primer
Hind III I Kpn I
Sac I SaotHII I Spe II
CAG (WA ACA GCT ATG AC C ATG ATT ACG CCA AGC TTG GTA CCG AGC TCG GAT CCA CTA 
GTC CTT TGT CCtt TAC TGjGTAC TAA TGC GGT TCG AAC CAT GGC TCG AGC CTA GGT GAT
DoCK I CcoT\ I E ee* 1
GTA ACG GCC GCC AGT GTg ' c TG GAA TTC GGC GCC GAA TTC TGC
CAT TGC CGG CGG TCA CAC GAC CTT AAG CCG 'C b S B I M M M M I  T T CGG CTT AAG ACG
Ava I 
PaeR7 I
EcoR V SsfX I Noll Xho I Ate I Xba I Apa I
AGA TAT CCA TCA CAC TGG CGG CCG d rC  GAG CAT CJCA 101 AGA GGG CCC AAT TCG 
TCT ATA GGT AGT GTG ACC GCC GGC GAG CTC GTA CGT AGA TCT CCC GGG TTA AGC
CCC TAT 
GGG ATA
T7 Promoter M l3 Forward (-20) Primer M13 Forward (-40) Pnmer - j
AGT GAG TCG TAT Ta| C AAT TCA |CTG GCC GTC GTT TTA C AA C 3T CGT GAC TOG GAA AAC 
TCA CTC AGC. ATA ATI GTTA AGT IGAC CGG CAG CAA AAT GjTT GtSA OCA CTG ACC CTT TTG
Figure 2.10 Map of vector pCR2.1 (Stratagene, USA) containing the p i  15-GEF cDNA insert.
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Analysis of sequence of PCR products
A protein homology search was done against the non-redundant protein database 
(http://www.ncbi.nih.nlm/BLAST/nr) using the Cx-amplifled sequences obtained, to 
identify significant protein matches.
A BLAST2 (http://www.ncbi.nih.nlm/BLAST2/) homology search was performed which 
involved the comparison of the Gr-amplified sequences with BAC or cosmid sequence 
spanning the PFHBI locus. The electronic versions o f the genomic clone-insert sequences 
and Cx-amplified sequences were aligned to each other using the “Blast 2 sequences” 
option of the BLAST algorithm. The procedure for the alignment analysis is as follows: 
the BLAST2 sequence web page has two sequence input windows. The accession number 
of a genomic clone-insert was retrieved, using the “copy” option, from a database and 
inserted, using the “paste” option, into the “subject” window in the BLAST2 sequence 
web page. The sequence o f the Cx-PCR product was inserted into the “query” window 
using the “copy and paste” options described previously. The information was then 
submitted and the alignment results were returned in a separate web page.
2.14.4 KCNA7 
The characterisation of the coding sequences of genomic DNA sequences
The sequence o f the human KCNA 7 was obtained by performing a BLAST search using 
the mouse Kcna7 cDNA (AF032099) against the Genoscope database 
(http//www.genoscope.org) and in addition a search against Genbank was carried out 
with the inferred human KCNA7 sequence /Bardien-Kruger et al., 2002). The coding
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sequence o f KCNA7 was deduced by aligning the mouse cDNA sequence (AF032099) 
with the programme EST2GENOME (http://ftp.sanger.ac.uk/pub/EMBOSS).
Mutation screening
As art o f this study, two sets o f overlapping of primers were designed from KCNA7 
sequence for exon 1 and five sets for the larger exon 2 (table 2.3) (fig. 2.11). Using the 
primer sets for exon 1 and exon 2 , the coding and flanking intronic regions o f affected 
individuals from pedigrees 1 (1.V.10), 2 (6.IV.12 and 9.IV.5) and 5 (5.III.1), unaffected 
individuals from pedigrees 1 (1.V.6) and 2 (9.III.6) and a married-in (13.II.8) were 
screened for pathogenic mutations using PCR-SSCP analysis and direct sequencing as 
described in sections 2.7.2 and 2.6.3, respectively.
Gf Gr
F *  Fr
Figure 2.11 Schematic representation of the overlapping primers designed for the screening of
KCNA7.
The filled black boxes correspond to the exonic sequences, and the black lines correspond to the 
intronic sequences. The overlapping primer sets A and B designed for the amplification of exonl and 
its flanking intronic sequences are shown. The overlapping primer sets C, D, , F and G designed for 
the amplification of exon 2 and its flanking intronic sequences are shown (Bardien-Kruger et al., 2002).
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The design of KCNA7 primers, the mutation screening of the exonic sequences of the 
KCNA7 and the investigation o f the two SNPs in exon 2 of KCNA 7 were investigated as 
part o f this study.
2.14.5 BAX, KIR2.4, LIN-7B and GSY1
The published or web based primer sequences o f BAX, KIR2.4 (fig. 2.12/ LIN-7B and 
GSY1, as shown in table 2.2, were used to amplify the exonic and flanking sequence of 
genes, analysed using the PCR-SSCP. Automated sequencing of all the PCR products 
was performed at the DNA Sequencing Core Facility, US and the sequence analysis and 
the CLUSTALW alignment were performed as described in sections 2.8.1 and 2.8.2.
2Bf 2Br 3Cf 3Cr
Figure 2.12 Schematic presentation of the positions of overlapping primers for the screening of 
KIR2.4.
The shaded black boxes correspond to the exonic sequences, and the black lines correspond to the 
intronic sequences. The two overlapping primer sets 2A and 2 B were designed to screen exon 2 and its 
flanking intronic sequences. The three overlapping primer sets 3A, 3B and 3C were designed to screen 
exon 3 and its flanking intronic sequences.
Stellenbosch University http://scholar.sun.ac.za/
149
Figure 2.13 Schematic diagram of the structure of the GSYI gene.
Each exon is represented by a box and is numbered. The filled boxes correspond to translated sequences, 
and the open segments of a box correspond to untranslated sequences (Ohro et al., 1995).
As part of this study the 5’UTR, the exonic and the flanking regions o f exons 1-3, 6-10, 
13-16 o f GSYI (fig. 2.12) were screened for mutations by direct sequencing of the PCR 
products obtained using the PFHBI panel ( fig. 2.1).
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3.1 REDUCTION OF THE PFHBI LOCUS BY GENETIC FINE MAPPING 
USING POLYMORPHIC MARKERS
3.1.1 PFHBI disease-associated haplotype
Previous studies conducted by other researchers fine mapped the PFHBI locus to a 7cM 
region on chromosome 19 q l3.3 between genetic markers D19S412, at the centromeric 
limit, and D19S866, at the telomeric limit, thereby establishing the disease-associated 
haplotype in PFHBI-affected individuals in pedigrees 1, 2 and 5 (fig. 3.1) (personal 
communication, De Jager, 1998).
As part o f a previous study, and continued as part of this study, genotyping with genetic 
markers D19S412-D19S596-D19S604-D19S866 generated a disease-associated haplotype 
of 8-6-8-10 for the PFHBI-affected individuals shown in pedigrees 1, 2 (kindreds 7, 9 and 
10) and 5 (fig. 3.1), or 8-6-(/)-10, as despite many efforts to overcome difficulties, 
D19S604 was refractory to amplification in some individuals. The possibility of a 
mutation at the primer binding site might be the reason for the problems experienced with 
this particular marker in both affected and unaffected in pedigree 1 and 5 and should be 
investigated using the allele-specific oligonucleotide hybridisation method. The 
genotyping o f PFHBI-affected individuals in kindred 4 o f pedigree 2 with these markers 
produced a disease-associated haplotype o f 7-6-8-10 or 7-6-(/)-l0 (fig. 3.1). The 
inheritance of allele 7 of marker D19S412 for PFHBI-affected individuals in kindred 4 of 
pedigree 2 , in the disease-associated haplotype, indicated that a recombination event had 
occurred in the region between D19S412 and D19S596 in affected individuals o f these
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Figure 3.1 Schem atic representation  of the genetic m ap of the PFH BI locus and the disease-associated haplotype in pedigrees 1, 2 (k indreds 4, 7, 9 and 10) and 5.
Pedigrees I, 2 and 5 are shown with the disease-associated haplotype at markers DI9S4I2, D19S596, D19S604 andDI9S866. Alleles which have been inferred are indicated 
with brackets. The disease-associated haplotype in each kindred is boxed. The pedigree generations are indicated by roman numerals. *, Indicates the pedigree and the kindred 
in which the locus-defining recombination event has occurred.
CJll-o
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families but not in the remaining families. Therefore, as part of this study, kindred 4 of 
pedigree 2  was genotyped with known and novel genetic markers, lying between 
D19S412 and D19S596, (as described in sections 3.1.3 and 3.1.5) in order to refine the 
PFHBI locus. DNA samples of individuals from kindred 9 were also genotyped and used 
as the reference kindred.
3.1.2 Genotyping with D19S606
Since the database genetic marker D19S606 was placed centromeric to D19S596 and a 
recombinant event was present between D19S412 and D19S596 in kindred 4, as shown in 
fig. 3.1, DJ9S606 was genotyped in the PFHBI families, as part o f this study. Kindred 9 
was used as the reference kindred. As presented in section 1.4.6 (fig. 1.9), D19S606 was 
also the most centromeric marker of the CCD locus (de Meeus et al., 1995).
From the comparison of the genotyping results with D19S606 in kindreds 4 and 9 of 
pedigree 2 , it was confirmed that a recombination event had occurred between markers 
D19S412 and D19S596 in kindred 4 (fig. 3.2). For example, four PFHBI-affected 
individuals from kindred 4 (4.III.2, 4.IV.1, 4.IV.2, 4.IV.4 and 4.V.2) carried allele 9, for 
marker D19S606, whereas the three PFHBI-affected individuals from kindred 9 (9.III.3,
9.III.4 and 9.III.8 and 9.IV.5) carried allele 6  for marker D19S606. This recombination 
event reduced the PFHBI locus to 4cM and reset the centromeric limit at D19S606 (fig.
3.3). In addition, marker D19S606 mapped to the same position as D19S902 on the 
genetic map o f chromosome 19 (fig. 3.1) (Makubalo, 2000). Genotyping o f D19S902 in
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Figure 3.2 Genotyping with genetic m arker D19S606 in kindreds 4 and 9 of pedigree 2.
Kindreds 4 and 9 are shown with the disease-associated haplotype at markers D19S412, D19S606, DI9S596, 
D19S604 and D19S866. Haplotypes which have been inferred are indicated with brackets. The disease-associated 
haplotype in each kindred is boxed. The pedigree generations are indicated by roman numerals.
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kindreds 4 and 9 confirmed the recombinant event at D19S606 (section 3.1.4, fig. 3.9).
3.1.3 Development of (A3G)n polymorphic markers
As part of an integrated approach to reduce the size of the PFHBI locus, different 
members o f the PFHBI group were involved in developing either polymorphic di- or 
tetranucleotide STR markers from the available recombinant cosmid clones spanning the 
PFHBI locus (fig. 3.3). As part of this study, the development o f (A3 G)n repeat markers 
was pursued.
To this end, a Southern blot containing 11 Sau3Al-digested chromosome 19 cosmid 
clones (18618, 15217, 24493, 29395, 27268, 8946, 20381, 19161, 24596, 25235, 23078 
(see section 2.9) was probed with a radioactively-labeled (A3 G)io oligonucleotide probe 
to identify the (A3 G)n STRs (fig. 3.4).
The chromosome 19 recombinant cosmid clones will be referred to as chromosome 19 
cosmids in the text. Three chromosome 19 cosmids 18618, 29395 and 20381 produced 
strong signals, chromosome 19 cosmids 20381, 19161 and 23078 gave fainter signals 
(fig. 3.4). The cosmids were prioritised for STR development based on the intensity of 
the signal, assuming that there is direct relationship between the number of (A3 G)n 
repeats and intensity. In addition, the position of the cosmids relative to the genetic map 
was also taken into account, thus cosmids 18618 and 29395 were selected and used for 
the development of (A3 G)„ markers. The (A3 G)„-containing fragments of these cosmids
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Figure 3.3 Schematic map of cosmid clones spanning the “start of study” 7cM PFHBI locus screened 
for (A3G)„ repeats.
Cosmids clones which gave a positive signal on probing with a (A3G)i0 are in bold. *, The clones which 
were pursued for development as markers in this study (see fig. 3.4).
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Figure 3.4 Identification of digested cosmid insert fragments harbouring (A3G)„ repeat motifs.
A Southern blot filter with Sa«3Al-digested cosmid DNA probed with the [y-32P]dATP labeled (A3G)i0 
oligonucleotide.
Lane: M: XPstl marker 6. 8946
1.18618 7.20381
2.15217 8.19161
3. 24493 9. 24596
4.29395 10.25235
5.27268 11.23078
The cosmids in lanes 1 and 4 were selected for development as (A3G)„ markers
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were subcloned into the plasmid vector pBluescript SK and used to transform E. coli 
strain XLl-blue as described in section 2.9. Colony blots, performed in duplicate, of the 
resulting recombinant plasmid transformants revealed several positive signals, indicating 
successful sub-cloning of the target fragment (fig. 3.5).
Cosmids 18618 and 29395
To confirm the subcloning of the (A3 G)n repeat motifs, recombinant plasmid DNA 
minipreps from positively hybridising colonies were digested with Kpnl and Sacl 
restriction endonucleases, located on either side o f the multiple cloning site (fig. 2.4), to 
release the insert from clones 18618 and 29395, which were then sequenced. However, 
sequencing o f the insert fragment released from cosmid 18618 did not reveal any (A3 G)„ 
repeat motifs.
Sequencing of the insert fragment released from cosmid 29395 revealed an (A3 G)n repeat 
m otif which comprised a string of 9 Gs, followed by 6  (A3 G) repeat motifs, 1 A2 G, 1 A3G 
2 Gs and 18 As (figs. 3.6 and 3.7). A BLAST homology search of the sequence 
containing the (A3 G) repeat motif and the flanking sequences revealed the presence of 
Alu sequences in the flanking sequences. The development of this marker was not 
pursued, since another member of the PFHBI project group was developing an (A3 T)n 
repeat marker from the insert of cosmid 29395 (Makubalo, 2000). In that study, an 
interrupted (A3 T) STR was
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Figure 3.5 Autoradiograph of duplicate colony blot hybridisation of sub-cloned cosmid fragment 29395.
The cosmid 29395 positively hybridising fragment was subcloned in Bluescript SK vector and the transformed 
colonies bound to the nylon membrane were probed with a labeled (A3G)I0. The duplicate colonies giving 
strong signals were numbered as indicated by arrows 1 to 5. The orientation of the duplicate filters are shown 
as crosses on the autoradiographs.
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Figure 3.6 Autoradiograph of the partial sequence of the sub-cloned cosmid fragment 29395 
sequences using pBluescript prim er T7.
The sequence of the (AAAG) repeat motif is shown on the right with the dashed line indicating the position 
within the flanking sequences on the left. The sequence is interrupted by an AAG which shown in black. 
The start and end of the flanking sequence is indicated by the solid arrows on the autoradiograph. The 
sequence read is given in fig. 3.7.
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AGACTC'TGT* AAAAAAAAAAAAAAAAAAGGGAAAGAAGAAAGAAAGAAA
GAAAGAAAGAAAGGGGGGGGGAGTAGGGAGGGAGGGAGAGAAGGAAG 
GAGGAGGAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGAAGGA 
AGGAAGGAAGGAAGC - 3 ’
Figure 3.7 A portion of the sequence of the cloned cosmid insert 29395 harbouring the (A3G)7 repeat 
motif.
The is shown in . Part of the Alu sequence is underlined in red. The (A3G)7
repeat motif is interrupted by a GAA.
identified which comprised four runs o f (A3T) repeat motifs, followed by the sequence 
AATAAATAAT, which was followed by another run of (A3 T) repeat motifs. The (A3 T),, 
repeat marker was tested in a panel o f control individuals but no polymorphic size 
variation was obtained (Makubalo, 2000).
3.1.4 Separation of D19S606 and D19S902
As the refinement o f the physical map o f chromosome 19 proceeded, D19S606 and 
D19S902 were separated in May 2003 (fig. 3.8), placing D19S902 telomeric to D19S606. 
BLAST homology searches against the human genome database allowed the physical 
distance between D19S606 and D19S902 to be determined. These searches places 
D19S606 at 20,241,753bp and D19S902 at 20,600,218bp on contig NT_011109 and 
therefore separated these two markers by a physical distance o f 358,465bp (fig. 3.8). The 
genotyping results generated with D19S902 for kindred 4 o f pedigree 2 for the four
5 ’-
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(a) Genetic Map
(b) Physical map
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/
D19S866
Figure 3.8 Maps showing the separation of genetic markers D19S606 and D19S902 (May 5,2003).
(a) A genetic map o f the PFHBI locus showing the position o f the genetic markers D19S412, D19S606, 
D19S902, D19S596, D19S604 and D19S866 in centimorgans (cM). In this map, D19S606 and D19S902 
are extremely tightly linked, (b) A physical map o f the region showing the separation o f markers D19S606 
and D19S902 by sequencing and the distances between them in bp.
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PFHBI-affected individuals 4.III.2, 4.IV.1, 4.IV.2 and 4.V.2 showed that they carried 
allele 3 o f marker D19S902, whereas, the three PFHBI-affected individuals from kindred 
9 o f pedigree 2 (9.III.3, 9.III.4 and 9.III.8) carried allele 5 of marker D19S902 (fig. 3.9). 
These data refined the recombination breakpoint, resetting the centromeric limit at 
D19S902, and further reducing the PFHBI locus in physical terms by 358,465bp. The 
length o f the physical distance of the PFHBI locus between genetic markers D19S902 
and D19S866 was calculated to be 2,422,562bp (fig. 3.8).
3.1.5 Development of novel (CA)„ repeat markers from database sequence
As the HGP progressed and published sequence data generated from cosmid and BACs 
became available, the natural progression was to develop STRs from sequence data rather 
than using cloning methods, for fine mapping of the PFHBI locus. In this study, selected 
(CA)n markers were developed from sequences deposited in publicly available databases 
in a further attempt to determine the breakpoint between markers D19S902 and D19S596. 
Twenty seven BAC and cosmid sequences containing (CA)n repeat motifs (fig. 3.10) 
spanned the 2.42Mb of the PFHBI locus, between markers D19S902 and D19S866. Of 
these, seven clone sequences (AC008392, AC008403, AC008888, AC010619, 
ACO11495, ACO18766 and ACO10624) were selected for development as potential 
genetic markers (fig. 3.10). Clones AC008392, AC008403 and AC008888 were selected 
because they physically mapped to a region centromeric to D19S596 and telomeric to 
D19S902, whilst the remaining four clones physically mapped to a region telomeric to 
marker D19S604 and centromeric to D19S866 (fig. 3.10).
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F igure 3.9 G enotyping with m arker D19S902 in kindreds 4 and 9 o f  pedigree 2.
Kindreds 4 and 9 are shown with the disease-associated haplotype at markers D19S412, D19S606, D19S902, 
D19S596, D19S604 and D19S866. Haplotypes which have been inferred are indicated with brackets. The common 
disease-associated haplotype in each kindred is boxed. The pedigree generations are indicated by roman numerals.
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Four clones (AC008392, AC008403, AC011495 and AC018766), out of the selected 
seven, were successfully developed as markers, which were subsequently submitted to 
Genbank and given the accession numbers G68141, G68142, G68143 and G68144, 
respectively (table 3.1). The markers G68141 and G68142 were genotyped in PFHBI 
families and demonstrated a Mendelian pattern o f inheritance, as shown (fig. 3.1 la). The 
genotyping results obtained with marker G68144 are not shown, since only one band was 
generated in all the samples.
The remaining three clones (AC00888, AC010619 and AC010624) were not used for 
marker development, for the following reasons. Firstly, the primers generated from the 
deposited sequence o f clone AC008888 did not yield a PCR product with the clone 
AC00888, which suggests that the sequence in the database for AC00888 was incorrect. 
Secondly, the BLAST results o f the sequence used for marker development did not 
correspond to clone ACO 10624 in the nucleic acid database, thus indicating that 
homology was not shared with the specified clone. This marker was not genotyped in the 
PFHBI families. Thirdly, 500bp o f clone ACO 10619 mapped to two places on contig 
NT 011109, namely, to a position inside the PFHBI locus and to another telomeric to the 
PFHBI locus. Genotyping with this marker in the PFHBI families showed that it was 
unlinked, because the allele typing was different in each family (data not shown), 
suggesting that this clone might have been incorrectly placed and belonged elsewhere or 
that the 500bp sequence of this clone was duplicated on contig NT_011109.
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Figure 3.10 Schematic drawing of the PFHBI locus showing the relative positions of the BAC and 
cosmid clones containing (CA). repeat motifs, identified by database searches.
Clones selected for the development o f (CA)n repeat markers, as detected by database searches, are shown 
in red. The number of (CA)„ repeat motifs contained in the selected clones according to database sequence 
are shown in blue. The positions of the available database genetic markers on the DNA clones are indicated 
by dotted lines.
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Table 3.1 Primer sequences of novel (CA)n markers generated from recombinant BAC 
and cosmid sequences. __________________________________________________
BAC/cosmid 
Clone Acc No
STS
Acc
No
Prim er sequence Ta *Size of 
product
AC008392 G68141 F 5 ’TAGGTTGGTCAGGCTTCGTG3 ’ 
R 5’-CTCTGCTTTCTGGGTTCAAG-3’
56UC 248bp
AC008888 F 5’-GTGGATCACCTGAGGTCAGG-3’ 
R 5’-AGCTCCTGTTGCCCAGGCTG-3’
59°C 226bp
AC008403 G68142 F 5’-GTGTTGGGATTGCAGGTGTG-3’
R 5’-AGGCAAAGGATGCAGCGAAC-3’
59UC 249bp
AC010619 F 5 ’-TAACATAAAGGGCTGTCTTC-3 ’ 
R 5 ’-GTG AAAATAG AACAGCT A-3 ’
50UC 169bp
ACO 11495 G68143 F 5 ’-TTGCAGTG AGCTGAGATCAC-3 ’ 
R 5’-TCGCATCTAGAACCTATTGC-3’
55°C 2 0 2 bp
AC018766 G68144 F 5’-CTAATCCACTATGGCTGGTG-3’
R 5’-GAAATCTTACAGGGGAAGGG-3’
55°C 171bp
ACO 10624 F 5 ’-GGGT A A ATGCTTG ACTCTCC-3 ’ 
R 5’-AGCCAGTTCCTGTCCTTATG-3’
58UC 225bp
The clone accession numbers, the STS accession number, the primer sequences, optimum annealing 
temperatures and the expected amplicon size, estimated size from database sequence, for each marker are 
indicated. *, the Genbank accession numbers of the submitted STSs.
The allelic frequency of the three markers (G68141, G68142 and G68143) was estimated 
by genotyping in an unrelated South African Afrikaner panel. The novel marker G68141 
was more polymorphic than markers G68142 and G68143 since the number of alleles for 
each marker was found to be 16, 4 and 2, respectively. Allele 12 o f marker G6841
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F igure 3.11 A utoradiographs of alleles of th ree polym orphic CA repeat m arkers developed from 
sequenced BAC and cosmid clones.
(a) A kindred consisting o f parents (1 and 2) and children (3 and 4) o f kindred 10 o f pedigree 2 genotyped with
(b) marker G68141. The allelic typing is shown in (b) and illustrates a Mendelian pattern o f  inheritance for marker 
G68141. The different alleles o f markers typed with markers G68142, G68143 and G68141 in DNA from PFHBI 
individuals correspond to (c), (d) and (e), respectively.
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Table 3.2 Allele frequencies for the marker G68141 in the South African Afrikaner 
population group
Allele number Allelic frequencies
1 0 . 0 2
2 0.06
3 0.04
4 0.06
5 0 . 1 0
6 0 . 1 0
7 0.06
8 0 . 1 2
9 0.04
1 0 0 . 1 2
1 1 0.04
1 2 0.14
13 0 . 0 2
14 0 . 0 2
15 0 . 0 2
16 0.04
Number of individuals genotyped = 25
Table 3.3 Allele frequencies for the marker G68142 in the South African Afrikaner
population group
Allele number Allelic frequencies
1 0.925
2 0.025
3 0.025
4 0.025
Number of individuals genotyped = 2 0
Table 3.4 Allele frequencies for the marker G68143 in the South African Afrikaner
population group
Allele number Allelic frequencies
1 0.35
2 0.65
Number of individuals genotyped = 20
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occurred most frequently with an allelic frequency of 0.14 (table 3.2), allele 1 of marker 
G68142 with an allelic frequency of 0.925 (table 3.3) and marker G68143 has two alleles 
with at an allelic frequency o f 0.35 and 0.65 (table 3.4). Marker G68144 was not 
polymorphic when typed in the unrelated South African Afrikaner population (results not 
shown). All four markers were submitted to the STS database. Genotyping results with 
markers G68141, G68142 and G68143 are shown in fig. 3.11 (c), (d) and (e).
Genotyping the PFHBI families with G68141 and G68142
Since markers G68141 and G68142 lie centromeric to D19S596 (fig. 3.10) and novel 
markers were required from this region in order to further refine the breakpoint in kindred 
4 o f pedigree 2, both G68141 and G68142 were used to genotype individuals from 
kindred 4 of pedigree 2. Individuals from kindred 9 o f pedigree 2 were also genotyped 
with both markers as a reference (fig. 3.12). The genotype for the disease-associated 
haplotype (D 19S902-G6S741-G68142-D19S596-D19S604-D19S866) was 5-10-1-6-8-10 
in kindred 4 (4.III.2, 4.IV.1, 4.IV.2, 4.IV.4 and 4.V.2) and 3-10-1-6-8-10 in kindred 9 
(9.III.3, 9.III.4 and 9.III. 8  and 9.IV.5), which showed that the centromeric breakpoint lies 
between D19S902 and G68141. This result suggests that more markers should be 
developed from sequence between D19S902 and G68141, in order to see how close the 
breakpoint lies to D19S902. The physical distance between G68141 and D19S902 was 
estimated to be 447kb.
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Figure 3.12 Genotyping kindreds 4 and 9 of pedigree 2 with novel (CA)n markers, G68141 and G68142.
Kindreds 4 and 9 are shown with the disease-associated haplotype at markers D19S412, D19S606, D19S596, D19S604, D19S866 and novel markers G68141 and G68142 .
The disease-associated haplotype in each kindred is boxed. Haplotypes, which have been inferred, are indicated with brackets. The pedigree generations are indicated by Zj
roman numerals. S am ples in which m arkers did not g enera te  any products and  could therefore not be genotyped.
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3.2 DATABASE SEARCHES TO IDENTIFY GENE TRANSCRIPTS
In June 1999, a search of the EST databases Genemap99 and the LLNL site was 
undertaken to find ESTs which mapped within the PFHBI locus, 38 transcripts were 
identified (table 3.5). Each EST was extended using STACKpack from the STACK 
database resulting in the generation of a number of STACK clusters, e.g., EST M78727 
yielded one STACK cluster, while EST M85740 yielded 85 STACK clusters (see table 
3.5). Two ESTs (G13834 and G17554) had no cluster hits. However, protein homology 
searches using all these clusters yielded only six proteins, namely, CA11, two zinc finger 
proteins, a hypothetical protein, collagen related KIAA089 and a myc protein, which 
corresponded to ESTs AF067662, M85740, G26380, T97152, AA031950 and F02213, 
respectively (table 3.5) (only protein homologies with the highest scoring BLAST values 
were selected) (June 1999). At this stage, very little information was available about 
these proteins and other gene identification and selection strategies were followed.
However, in May 2003, the same 38 ESTs were clustered using the UNIGENE database 
(NCBI) and the protein homology searches were repeated (table 3.6). Fifteen ESTs 
matched proteins in the nonredundant (nr) databases shown in red (table 3.6), of
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Table 3.5 STACK clusters and protein homologies of ESTs retrieved from Genemap99 and 
the LLNL site (June 1999).
EST Number of 
STACK clusters
Protein homology
M78727 1
AF067662 1 0 Carbonic anhydrase
Ml 4269 2
*M85740 85 Zinc finger protein
T 17236 4
T47573 6
T77818 1
H48539 1
R11661 2
*T74222 76
N25336 5
R09427 2
R26303 6
R46185 2
AA057647 7
R61534 2
G13826 2
Z39055 7
T90778 6
G13834 no cluster hits
*R11034 1 2
G15328 2
T87340 6
T02911 1
*T66137 17
G26380 14 Hypothetical protein
*T85363 9
Z41308 4
R37469 2
R49148 9
G22461 6
H50984 2
*R79413 6
♦T97152 82 Zinc finger protein
G17554 no cluster hits
AA031950 15 Collagen related KIAA089
Z39409 6
F02213 15 Myc protein
EST, expressed sequence tag. * Indicates EST expression in heart. The number of STACK clusters was 
obtained by doing a BLAST search against the STACK database.
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which six were expressed in cardiac tissue namely, KPTN, CA11, CRD8 , PLEKHA4 
ZNF473 (alias ZFP100) and ATF5, indicated by an asterisk (*). An example of 
redundancy of the EST databases was observed since three different ESTs (M78727, 
T17236 and Z41308) had homology to the same protein KPTN.
Nine ESTs (T77818, R26303, R61534, R11043, T87340, T66137, G26380, R37469 and 
F02213) had homology to a number of different predicted proteins, of which three 
proteins (FLJ2040, FLJ25129fis and FLJ33742fis) were expressed in heart (indicated by 
a cross (+) in table 3.6). Six ESTs (M14269, R11661, G13826, G13834, G15328 and 
G 17554) had homology to regions outside the PFHBI locus or to another chromosome, 
(shown in blue in table 3.6).
Two ESTs (T47573 and R11661) had homology to Alu sequences, one within and one 
outside the PFHBI locus, respectively. Twelve ESTs (M14269, H48539, R09427, 
AA057647, G13826, G13834, G15328, T02911, G22461, H50984, R79413 and G17554) 
had no homology to any protein.
The retrieved ESTs were mapped to three contigs, NT_011190, NT 011140 and 
N T011157, spanning the PFHBI locus (fig. 3.13) using their physical (base pair) 
position (table 3.6) and later to the merged contig NT_011109 (fig. 3.15). Annotated 
genes KPTN, ZNF473 and ATF5 from table 3.6 were identified as the most important
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Table 3.6 Protein homologies and the base pair positions of ESTs on the contig NT_011109 
(May 2003).
EST Acc No. Protein homology Position on contig 
NT_011109 (bp)
M78727 M78727 *KPTN 20,248,249bp
AF067662 XM 055856 *CA11/CARP2 20,246,994bp
M14269 Ml 4269 none chromosome 7
M85740 XM 009313 ZNF264 20,695,400bp
T17236 XM 055856 KPTN 20,248,249bp
T47573 T47573 Alu sequence 20 118,554bp
T77818 XM 091974 LOC147891 20,292,145bp
H48539 H48539 none 19,699, 700bp
R11661 R11661 Alu 5 sequence NT 011255 on chromosome 19
T74222 NM 005500 SAE1 19,980,632bp
N25336 XM 085943 GRLF1 19,772,900bp
R09427 none 19,855,157bp
R26303 NM 017805 +FLJ20401 21,493,023bp
R46185 XM 038970 SLC8A2 20,200,108bp
AA057647 AA057647 none 19,792,906bp
R61534 AK057858 +FLJ25129 fis 20,267,776bp
G13826 none chromosome 11
Z39055 NM 031485 GRWD 21,225,353bp
T90778 XM 049938 *CRD8 /TUCAN 20,974,604bp
G13834 none chromosome 6
R11034 XM 055859 MGC45806 20,514,581 bp
G15328 NM_017805 none chromosome 2
T87340 FLJ20401 21,492,032bp
T02911 none 20,241,639bp
T66137 XM 058466 FU20643 22,217,746bp
G26380 +FLJ33742fis 21,787,341bp
T85363 *PLEKHA4 21,608,544bp
Z41308 XM 055856 KPTN 20,246,598bp
R37469 NM 020309 cDNAFLJ33742fis 22,200,853bp
R49148 XM 097340 VRK3 22,747,915bp
G22461 none 21,983,283bp
H50984 138022 none 22,077,971 bp
R79413 none
T97152 *ZNF473 22,818,615bp
G17554 none chromosome 1 0
AA031950 AP2A1 22,578,558bp
Z39409 NM 012068 *ATF5 22,705,264bp
F02213 NM 032712 Hypothetical protein 
MGC13170
23,569,152bp
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Legend o f table 3.6
*/+, Indicates expression in heart tissue. *, annotated gene; +, predicted gene. ESTs matching proteins in 
the nonredundant database are shown in red. The ESTs M14269, M85740, R11661, G13826, G13834, 
G 15328 and G 17554, shown in blue, map outside the PFHBI locus. The proteins underlined in red are most 
highly prioritised ones.
KPTN, actin-binding protein; CA11/CARP2, carbonic anhydrase XI; ZNF264, zinc finger 264; 
LOC147891\ hypothetical protein LOCI4789\;SAE1, sumo activating enzyme subunit 1; GRLFI, 
glucocorticoid receptor DNA binding factor 1; FU20401, hypothetical protein FLJ20401; SLC8A2, Homo 
sapiens solute carrier family 8 (sodium-dependent inorganic phosphate cotransporter), member 8; 
FLJ25129, hypothetical protein FLJ25129; GRWD, Homo sapiens glutamate rich WD repeat protein; 
CRD8/TUCAN, tumor up-regulated CARD-containing antagonist of caspase nine; FU20643, hypothetical 
protein FLJ20643; SLC17A7, Homo sapiens solute carrier family 17 (sodium-dependent inorganic 
phosphate cotransporter), member 17; VRK3, vaccinia-related kinase 3; 138022, hypothetical protein 
1138022; ZNF473, zinc finger protein 473; ATF5, activating transcription factor 5; MGCI3170, 
hypothetical protein MGC13170.
candidate genes, based on their position, expression in cardiac tissue and their 
involvement in cardiac function, as plausible PFHBI candidate genes. The genes obtained 
from this search were also mapped to the integrated map (section 3.3, fig. 3.15) and were 
included in the evaluation process as potential PFHBI candidates (section 3.4).
3.3 A HIGH RESOLUTION MAP
In order to facilitate the search for the PFHBI gene, a high resolution map of the PFHBI 
locus, using the methods described in section 2.12, was generated. In February 2002, 
three contigs NT 011190, NT 011140 and NT 011157 spanned the PFHBI locus (fig. 
3.13). In May 2003, the three contigs were merged into one contig, NT 011109. An
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Figure 3.13 An early map of the three contigs spanning the PFHBI locus (February 5, 2002).
From left to right: Diagrammatic representation of chromosome 19 showing the position of the PFHBI locus, genetic map, 3 contigs 
N T 011190, NT 011140 and NT 011157 and the merged contig NT 011109, the positions of retrieved ESTs, EST clusters and some of 
the genes att the PFHBI locus *, genes showing expression in heart and other tissues. The genes in bold were genes selected for PFHBI 
mutation screening for this study. The gene abbreviations are:
DKFZp434II930, predicted gene; PLA2G4C, phospholipase A2, group IVC (cytosolic, calcium-independent); LIG1, ligase I DNA. ATP- 
dependent, KIAA0955, predicted gene; EMP3 epithelial membrane protein 3; KDELR, (Lys-Asp-Glu-Leu) endoplasmic reticulum protein 
retention receptor 1; KIR2.4, potassium inwardly-rectifying channel, subfamily J, member I; PSCD2, pleckstrin homology, sec7 and 
coiled-coil domain 2; CA11 carbonic anhydrase XI; PLEKHA4, pleckstrin homology domain containing, family A (phosphoinositide 
binding specific) member 4; NUCB1, nucleobindin 1; BAX, 5CZ,2-associated X protein; GYSl, glycogen synthase I; RUVBL2 RuvB-like 
2 (E. coli); CGB2, chorionic gonadotrophin beta polypeptide 2; KCNA7, potassium voltage-gated channel, shaker-related subfamily, 
member 7; SNRP70, small nuclear ribonucleoprotein 70kDa polypeptide (RNP antigen); L1N-7B, lin-7 homolog B (C. elegans); HRC, 
histidine rich calcium binding protein ; CD37, CD37 antigen; LOC95515, predicted gene; FU20643, hypothetical gene: RPSII, 
ribosomal protein SI 1. FCGRT, Fc fragment of IgG, receptor, transporter, alpha; ZNF473, zinc finger protein 473.
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updated map of the PFHBI locus was generated using the sequence data from contig 
NT 011109 (fig. 3.15).
3.3.1 Experimental data
PCR amplification using primers sets o f genetic markers D19S902, D19S606, D19S596, 
D19S604, D19S879 and D19S866 with BAC and cosmid DNA clones spanning the 
PFHBI area were performed (section 2.12.2). A representative data set of the PCR 
amplification results is shown (fig. 3.14). PCR products were obtained with markers 
D19S596, D19S879 and D19S866 using BAC clones AC009002, AC008687 and 
AC020906, respectively (fig. 3.14 and table 3.7).
Subsequent computational searches, which involved a BLAST search of both published 
and novel genetic markers (section 2 .1 2 .1 ) against the human genome database, was 
performed.
3.3.2 Bioinformatic data 
NT_011109 contig
Homology search results positioning the database genetic markers on the corresponding 
BAC clones and the NT 011109 contig are shown in table 3.8, while table 3.9 contains 
the BLAST results of the novel (CA)n repeat markers from section 3.1.5. BLAST results 
generated for the retrieved 38 ESTs (section 3.2) are shown in table 3.6, indicating the 
position of the 38 ESTS on contig NT_011109 spanning the PFHBI locus. In table 3.10,
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L a n e s
Marker
200bp
lOObp
Lanes:
1. AC008745
2. AC024582
3. AC010330
4. ACO 10458
5. AC011466
6. AC008392
7. AC020955
8. AC011514
9. AC009002
10. ACO 115727
11. AC008687
12. AC020906
13. AC008403
14. AC008888
15. AC026803
(a) D19S596 +
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
(b) D19S879 i
1 2  3 4 5 6 7 8 9 10 II 12 13 14
200bp
lOObp
(c) D19S866 T
1 2  3 4 5 6 7 8 9 10 11 12 13 14 15
Figure 3.14 PCR amplification products obtained using primers of genetic markers D19S596, 
D19S879 and D19S866 and DNA clones spanning the PFHBI locus as templates.
(a) PCR product obtained with genetic marker DI9S596 observed in lane 9. (b) PCR product obtained with 
genetic marker D19S879 observed in lane 11. (c) PCR product obtained with genetic marker D19S866 
observed in lane 12. The position of the various lOObp marker bands is shown on the left hand side of the 
gels. shows the lane in which the PCR product occurs (see table 3.7).
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(a) Table 3.7 Position of genetic markers on DNA BAC clones using PCR amplification
Genetic Markers
(b)
BAC or
cosmid
clones
D19S902 D19SS96 D19S879 D19S604 DI9S866
Genbank 
Acc No
LLNL ID
AC008745 BC782556 ++ - - - -
AC024582 BC858854 - - - -
ACO 10330 - - - -
ACO 10458 BC694129 - - - -
ACO 11466 BC324323 - - - -
AC008392 BC242886 - - - -
AC020955 R33773 - - - -
AC011514 F16353 - - - -
AC009002 R31763 ++ - - -
ACO 11527 - - - -
AC008687 BC52309 - ++ - -
ACO 10643 R29295 - - ++
AC008403 BC255070 - - - -
AC008888 BC008888 - - - -
AC026803 BC808483 - - - -
AC020906 BC61330 - - ++
(b)
Chromosome 19
Genetic
markers
BAC/Cosmid clones
■•AC008745
AC009002
..AC008687
-ACO 10643
AC020906
V  PFHBI locus
J
(a) PCR amplification results obtained with D19S902, DI9S596, D19S879, D19S604 and D19S866 primer 
sets using template DNA clones spanning the PFHBI locus, (b) Schematic representation of the results 
from (a). LLNL ID, Lawrence Livermore National Laboratories identity number for the chromosome 19 
BAC and cosmid clones; Genbank Acc No., accession number for each DNA clone; ++, PCR product 
present; -, no PCR product. Horizontal dotted line indicates marker identified with the corresponding clone.
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Table 3.8 Position of genetic markers on contig N T011109 (May 5, 2003)
Genetic Markers Genbank 
Acc No
BAC clone 
Acc No
BLAST results 
bp
D19S902 Z53165 AC008745 20600218-20600469
D19S596 Z52219 AC009002 21519195-21519452
D19S879 Z52767 AC008687 21784108-21784383
D19S604 Z53032 AC010643 22165196-22164953
D19S866 Z52072 AC008655 23022780-23022989
AC020909
The base pair position of the genetic marker on contig N T 0 1 1109 and the DNA clone to which the genetic 
marker has homology, is shown. Genbank Acc No., genbank accession number for each genetic marker; 
bp, base position.
Table 3.9 Position of novel (CA)„ markers on contig NT_011109 (May 5, 2003)
New (CA)„ Markers 
Genbank Acc No
BAC clone
Acc No
BLAST results 
bp
G68141 AC008392 21046497-21046744
G68142 AC008403 21292264-21292512
G68143 AC011495 22406103-22406304
G68144 AC018766 22598888-22599058
The base pair position of the genetic marker on contig N T 0 1 1109 and the DNA clone, to which the 
genetic marker has homology is shown. Genbank Acc No., genbank accession number for each novel 
genetic marker; bp, base position
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Table 3.10 The position o f annotated genes on contig N T 0 1 1 1 0 9  at the PFHBI locus (order from centrom ere to telomere -D19S902  to D19S866)
Gene Acc No BAC 
Acc No
Bit
score
E
value
Position of gene on 
contig NT 011109 (bp)
Size of BAC/cosmid 
bp
Position of BAC/cosmid 
on contig NT 011109
Gap size betweer 
overlapping BAC
KPTN NM_007059 ACO 10331 754 0 20246994-20248249 80240 20293689-20373929 117443
D19S902 Z53165 AC008745 20600218-20600469 180531 20491372-20671903 30369
CABP5 NM_019855 ACO 10458 1215 0 20802037-20815494 105788 20702272-20809060 44797
PLA2G4C NM_003706 ACO 10458 7031 0 20819836-20881933
LIGl NM_000234 ACO 11466 558 e.*56 20887182-20928591 167272 20853857-21021129 3881
CARD8 NM_014959 ACO 11466 512 e '142 20983157-21005925
EMP3 NM_001425 AC008392 469 0 21101748-21098336 91842 21025010-21116852
AC020955 41589 21085318-21126907
KDELR1 XM_006801 AC011514 635 e’179 21154441-21162949 39379 21124301-21163680
GRWD NM 031485 ACO 11527 560 e '157 21217453-21224472 35438 21159820-21195258
PSCD2 NM_004228 AC008403 314 e'82 2120797-21245464 190076 21187945-21378021 131354
K1R2.4 NM_170720 AC008403 3728 0 21235619-21233885
SULT2B NM_004605 AC008403 1037 0 21346987-21370872.
C A ll NM_0021217 1488 0 21417443-21411540
FGF21 NM019113 AC009002 562 e 157 21527684-21528476 37402 21509375-21546777
PLEKHA4 NM_020904 AC026803 998 0 21640048-21609461 224271 21534113-21758384 1755
NUCB1 NM_006184 AC026803 1834 0 21693762-21672231
BAX NM_004324 AC026803 875 0 21732255-21726410
GYS1 NM_002103 AC026803 2805 0 21764721-21739625
RUVBL2 NM 006666 AC008687 281 e-73 21775721-21786050 157633 21760139-21917772 95623
KCNA7 NM 031886 AC008687 6657 0 21844328-21838865
SNRP70 NM_003089 AC008687 1252 0 21857860-21879890
L1N-7B NM_022165 AC008687 410 e-112 21887708-21889907
HRC NM_002152 AC008891 3846 0 21926854-21922648 117628 22013395-22131023
CGB7 NM_001774 AC011450 569 e-160 22111696-22106925 106168 22101102-22207270
CD 3 7 NM 001774 AC011450 242 e-ia 22106988-22111775
TEAD2 NM 003598 AC011450 1627 0 22112042-22133904
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Table 3.10 cont
SLC17A7 AB032436 AC011450 
AC 10524
500 e -,38 22212766-22202002
D19S604 Z53032 AC010643 22165196-22164953
FCGRT NM 004107 AC010619 629 e-177 22297454-22284728
RRAS NM 006270 AC011495 706 0 22407108-22411393
SRA-1 AF254411 AC011495 685 e - 150 22416474-22434609
BCL2L12 NM 052842 AC011495 569 e->49 22437271-22440555
AP2A1 NM_014203 AC006942
AC018766
429 e 159 22553392-22577700
AKT1S1 NM_032375 AC024079 446 e '122 22644742-22641364
TBC1D17 NM_024682 AC024079 404 e '109 22649171-22660071
ATF5 NM_012068 AC011452 2909 0 22700650-22705381
VRK3 NM_016440 AC011452 589 e-.65 22748236-2277901
ZNF473 XM 046390 AC011452 
AC 10624 
AC008655
7891 0 22816116-30224513
D19S866 Z52072 AC020909
AC010515
23022780-23022989
37349
38902
179394
209844
42710
41624
146741
167787
123149
100826
41518
22110286-22147635
22145764-22184666
22184276-22363670
22345634-22555478
22555829-22598539
22595942-22637566 27738
22665304-22812045
22763297-22931084
23052178-23175327
23173141-23273967
23019563-23061081
121094
Acc No is the genbank accession number. The bit score means the number o f the bases matching the query sequence with the nucleic acid sequence in the atabase. E value is the expectation value and is treated like probability values. E values o f  smaller than 0.05 or 0.02 are 
considered as significant. Genetic markers D19S902, D19S604 and D19S866 o f the PFHBI locus are shown in underlined.
Gene abbreviations are: KPTN, actin binding protein; CABP5, calcium binding protein 5; PLA2G4C, phospholipase A2, group IVC (cytosolic, calcium-inde] ndent); CARD8, caspase recruitment domain family member 8,EMP3 epithelial membrane protein 3; KDELR, (Lys-Asp- 
Glu-Leu) endoplasmic reticulum protein retention receptor 1; GRWD, glutamate rich WD repeat protein; PSCD2, pleckstrin homology, sec 7 and coiled-oil domain 2; K1R2.4, potassium inwardly-rectifying channel, subfamily J, member 1; SULT2B, sulfotransferase family, 
cytosolic, 2B, member 1; CA11 carbonic anhydrase X I ; FGF21, fibroblast growth factor 21; PLEKHA4, pleckstrin homology domain containing, family A (j losphoinositide binding specific) member 4; NUCB1, nucleobindin 1; BAX, BCL2-associated X protein, GYSl, glycogen 
synthase 1; RUVBL2 RuvB-like 2 (E. coli); KCNA7, potassium voltage-gated channel, shaker-related subfamily, member 7; SNRP70, small nuclear ribonuc' oprotein 70kDa polypeptide (RNP antigen); LIN-7B, lin-7 homolog B (C. elegans); HRC, histidine rich calcium binding 
protein ; CD37, CD37 antigen; CGB7, chorionic gonadotrophin beta polypeptide 7; TEAD2, TEA domain family member 2; FCGR, Fc fragment o f IgG, iceptor, transporter, alpha ; SLC17A7, solute carrier family 17 (sodium independent inorganic phosphate cotransporter, 
member 7; RRAS, related RAS viral oncogene homolog BCL2L12. BCL2-like 12 (proline rich); AP2A1, adaptor-related protein complex 2, alpha 1 subunit AKT1S1, AK.T1 substrate 1 (proline-rich); TBC1D17, TBC1 domain family, member 17; A 7/■ 5, activating transcription 
factor 5; VRK3, vaccinia related kinase 3; ZNF473, Zinc finger protein 473.
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the homology search results generated for annotated genes have been placed at the 
PFHBI locus with their corresponding BAC clones.
Using the updated bioinformatics data (May 2003), an integrated map of the PFHBI locus 
was generated (fig. 3.15). However, there were some discrepancies with map data from 
table 3.10. Retrieved clone sequence ACO 18766 could not be positioned on the contig 
NT 011109 because there was not enough overlap. The gene density per clone differed, 
e.g., only HRC was present on BAC clone AC008891, whereas AC026803 contained four 
genes, PLEKHA4, NUCB1, BAX and GSYI and, in another case, CA11 which had not 
been assigned to a BAC but placed directly onto contig NT 011109 (table 3.10).
In all cases, the bioinformatic results supported the experimental results, with the 
exception o f genetic marker D19S866, which has BLAST homology to clones AC008655 
and AC020906, whereas the experimental data placed this marker only on DNA clone 
AC020906. Some possible explanations could be that part o f the sequence or the total 
insert containing the marker was lost during isolation of the BAC DNA clone or that the 
PCR was not successful.
3.4 EVALUATION OF GENES AS POTENTIAL CANDIDATES
An investigation of the merged contig, NT 011109 (fig. 3.15), showed that 82 genes 
were present at the PFHBI locus and therefore several criteria were used to prioritise the
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annotated and predicted genes, as described in section 2.13. The results of the analyses 
are shown in tables 3.11, 3.12 and 3.13.
3.4.1 Annotated and predicted genes on contig NT_011109
O f the total of 82 genes placed at the PFHBI locus, 35 annotated genes were present on 
contig NT 011109 (table 3.11, fig. 3.15). Twenty six genes are expressed in heart tissue, 
indicated, in turn, in bold in table 3.11, making them plausible candidates for PFHBI and 
they should, in turn, be further investigated by mutation screening. Genes that did not 
show cardiac expression was most probably due to the absence of data rather than the 
absence o f expression. Predicted proteins were analysed by the identification of protein 
domains, which have specific functions that are similar to known proteins. These proteins 
were therefore prioritised based, mainly, on the importance o f the predicted function of 
their identified domains in cardiac physiology. Forty-seven predicted genes were present 
on contig NT 011109, of which only six genes, indicated by an asterisk (*) in table 3.12, 
have predicted functional domains, which it could be speculated, may, if  mutated, affect 
cardiac function and therefore cause PFHBI.
3.4.2 Prioritised candidate genes
A list o f plausible candidate genes was generated (table 3.13) using the criteria for 
prioritisation described in section 2.13.1. The reason for prioritising genes were that a 
large number of plausible PFHBI candidate genes were present at the locus therefore, 
genes were prioritised ranging from A, the most highly prioritised, to D, the least
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Table 3.11 Annotated genes at the PFHBI locus on contig NT_011109
GENES EXPRESSION FUNCTION
D19S902
CABP5 retina belongs to subfamily of calcium binding proteins EF- 
hand-signaling proteins and buffering/transport 
proteins
eg calmodulin calcium-binding motif
PLA2G4C multiple+ heart cytosolic calcium independent phospholipase A2
LIGl multiple+ heart functions in DNA replication and the base excision 
repair process
CARDS multiple+ heart Cancer associated gene. Inhibits NF-kappa-B 
activation
EMP3 multiple+ heart involved in cell proliferation and cell-cell interactions
KDELR1 multiple+ heart endoplasmic reticulum protein receptor, protein has 
been isolated from the golgi apparatusglutamate 
receptor, receptor family-ligand binding region, 
ligand-gated ion channel region
GRWD multiple WD domain, WD40 repeat domain
PSCD2 multiple+ heart cytosolic guanine nucleotide-exchange factor for 
ADP-ribosylation factor ARF6
KIR2.4 multiple potassium inward-rectifying channel
SULT2B1 multiple+ heart sulfotransferase domain
CA11 multiple+ heart belongs to a large metallo enzymes. Plays a general 
role in the central nervous system.
FGF21 multiple + heart Branched chain aminotransferase 2, mitochondrial
PLEKHA4
multiple+ heart fibroblast growth factor 2 1
NUCB1 multiple+ heart
secreted protein with DNA binding activity, has signal 
peptide
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Table 3.11 Continued
GENES EXPRESSION FUNCTION
BAX multiple involved with the regulation of apoptosis
GYS1 muscle+heart glycogen metabolism, transfers glycosyl residue from 
UDP-glucose to glycogen
RUVBL2 multiple + heart DNAB-like helicase domain, similar to bacterial 
recombination factor E. coli RuvB, ATP dependent 
DNA helicase, chaperone, protein complex assembly, 
multi-chaperone pathway, DNA repair
KCNA7 amnionnormal,
muscle+heart
potassium channel protein
SNRP70 multiple+ heart pre-mRNA splicing factor, RNA binding mRNA 
processing
LIN-7B multiple+ heart PSD-95 domain, PDZ domain (also known as DHR or 
GLGF, a possible role is the anchoring of ion channels at 
specific subcellular sites
HRC ear, kidney, muscle 
+ heart
histidine-rich calcium-binding protein
CD 37 multiple+ heart cell surface glycoprotein, transmembrane 4 family, 
predicted to have 4 transmembrane spanning domain
CG7 multiple function unknown
TEAD2 multiple + heart Transcription factor. Expressed during early embryonic 
development
FCGRT
D19S604
multiple+ heart Fc fragment of IgG, receptor transporter, alpha 
__________________________________________________
188
GENES EXPRESSION FUNCTION
SLC17A7 multiple Transports glutamate into synaptic vesicles.
RRAS multiple + heart R-Ras promotes tumor growth of cervical epithelial cells 
and increases their migration potential over collagen 
through a pathway that involves PI 3-K.
SR-A1 multiple + heart predicted splicing factors
BCL2L12 multiple involved in the regulation of apoptosis
AP2A1 multiple + heart involved in golgi to endosome transport, protein transporter 
activity
AKT1S1 multiple function unknown
TBC1D17 multiple involved in the signal transduction mechanism
ATF5 multiple + heart Basic-leucine zipper (bZIP) transcription factor. 
Binds the camp response element (ere) (consensus
VRK3 multiple + heart Regulation of transcription
ZNF473
D19S866
multiple + heart Regulation of transcription
Published genetic markers D19S902, D19S604 and D19S866 are in bold and underlined. Gene 
abbreviations are: CABP5, calcium binding protein 5; PLA2G4C, phospholipase A2, group IVC 
(cytosolic, calcium-independent); CARD8, caspase recruitment domain family member 8; EMP3 
epithelial membrane protein 3; KDELR. (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention 
receptor 1; GRWD, glutamate rich WD repeat protein; PSCD2, pleckstrin homology, sec 7 and coiled- 
coil domain; K1R2.4, potassium inwardly-rectifying channel, subfamily J, member 1; SULT2B, 
sulfotransferase family, cytosolic, 2B, member I, CA 11 carbonic anhydrase XI; FGF21, fibroblast 
growth factor 21; PLEKHA4, pleckstrin homology domain containing, family A (phosphomositide 
binding specific) member 4; NUCB1, nucleobindin 1; BAX, BCL2-associated X protein; GYS1, 
glycogen synthase 1; RUVBL2. RuvB-like 2 (E. coli); KCNA7, potassium voltage-gated channel, 
shaker-related subfamily, member 7; SNRP70, small nuclear ribonucleoprotein 70kDa polypeptide 
(RNP antigen); LIN-7B, lin-7 homolog B (C. elegans); HRC, histidine rich calcium binding protein ; 
CD37, CD37 antigen; CGB7, chorionic gonadotrophin beta polypeptide 7; TEAD2, TEA domain family 
member 2; FCGR, Fc fragment of IgG, receptor, transporter, alpha ; SLC17A7, solute carrier family 17 
(sodium independent inorganic phosphate cotransporter, member 7; RRAS, related RAS viral oncogene 
homolog: SRA-1, serine arginine-rich pre-mRNA splicing factor; BCL2L12, BCL2-like 12 (proline 
rich); AP2A1, adaptor-related protein complex 2, alpha 1 subunit; AKTIS1, AKT1 substrate 1 (proline-
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Table 3.12 Predicted genes on contig N T 0 1 1 1 0 9
PREDICTED GENE ACC NO. FUNCTIONAL DOMAIN
LOC 147892 XP_097342 No function assigned
LOC147891 XP 091074 Myb-like DNA-binding receptor binding N-coR and 
TFIIIB DNA-binding CpG island domain
LOC126155 XP_064953 periplasmic substrate binding
LOC126152 XP064952 FAR1 FAMILY
WC163071 XP091973 krueppel associated box 
similar to HSPC059
WC147890 XP085954 No function assigned
LOC93233 XP049939 No function assigned
* FLJ10922 XP_012808 61% protein similarity to alpa -1C- andrenergic 
receptor splice form 2, 40% protein similarity to 
Caenorhabditis elegans collagen 2, tyrosine kinase 
catalytic domain
KIAA 1883 XP 055866 No function assigned
LOC147888 XP 085935 No function assigned
LOC147887 XP_055867 similar to ribosomal protein L I8
*LOC126147 XP 058987 laminin EGF-like domain netrin C-terminal domain 
glycosyl transferase domain
LOC93236 Not found No function assigned
LOC147886 Not found No function assigned
LOC93237 XP 049980 glycosyl transferase family 
similar to FUT2 in function
LOC126145 Not found No function assigned
LOC147885 XP085938 ras association domain
*F U 10922 Not found 402 aa similar to collagen alpha 2(1) domain
*FU20200 Not found apoptosis protein-caspase recruitment
protein, has a DIL domain, may be a myosin heavy
chain
K1AA0955 Not found No function assigned
FU20401 Not found No function assigned
LOC, Locuslink sequences; *, genes shown in the prioritised list in table 3.13 (section 3.4) 
FLJ, from the NEDO human cDNA sequencing project of the Kazusa DNA Research Institute; 
KIAA, from the Kazusa cDNA sequencing project of the Kazusa DNA Research Institute);
XP, Genbank protein sequences
PREDICTED GENE ACC NO. FUNCTIONAL DOMAIN
LOC163070 XP091972 ER lumen protein retaining receptor
LOC147886 XP009103 glycosyl transferase family
LOC147884 XP009100 fibroblast growth factor region
LOC51171 Not found retinal short chain dehydrogenase
LOC147883 XP_097346 No function assigned
LOC93314 XP050460 No function assigned
LOC147882 X PJ0323 No function assigned
LOC147881 XP085957 No function assigned
LOC147880 XP 097328 No function assigned
LOC147879 XP097345 No function assigned
LOC147875 X P097331 No function assigned
LOC147874 Not found No function assigned
F U 10490 Not found No function assigned
LOC163067 XP 103238 No function assigned
LOC147873 XP 097341 No function assigned
*LOC147872 XP 085941 myosin tail ezrin/radixin/moesin 
family
LOCI 13091 XP 053723 similar to tuberofimdibular 39
LOC57333 NP_065701 No function assigned
LOC147871 XP 085948 No function assigned
LOC126133 XP 058991 similar to aldehyde dehydrogenase
LOC51171/ Not found No function assigned
F U 10490 Not found No function assigned
*LOC95515 XP027924 similar to TEA domain family 
member 2.
FU20643 XP027903 No function assigned
K1AAA1205 XP-046305 structural constituent of cell wall
FU226888 NP_079405 function unknown
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prioritised based on their role in cardiac function. The most highly prioritised three genes 
select d to be screened in category A were genes which are involved in ion channel 
function and recruitment, namely, KCNA7, KIR2.4 and LIN-7B, since mutations in the 
ion channel gene SCN5A and Kir2.1 cause several cardiac disorders accompanying 
conduction disturbance, such as PCCD (Schott et al., 1999) and Andersons syndrome 
(Plaster et al., 2001), respectively (sections 1.3.2 and 1.5.2.2).
Category B lists two calcium binding genes, HRC and CAPB5, the rationale for selection
9+o f these two genes being that a mutation in a Ca -binding protein would result in an ion 
imbalance, possibly resulting in an electrophysiological disturbance causing arrhythmia 
(section 1.6.3) (Katz, 1993).
Category C lists NUCB1 as a plausible candidate gene for a number o f reasons. The 
rationale for the selection of the human NUCB1 gene for PFHBI mutation screening was 
that studies showed that lupus-prone mice secrete a murine Nucbl protein that promotes 
the production o f DNA-specific antibodies (Kanai et al., 1993). The human homolog of 
these antibodies were also shown to be present in babies o f mothers with systemic lupus 
erythromatosis (SLE) and one of the clinical symptoms o f SLE is heart block in the 
absence of muscle failure (Lanham et al., 1983). In addition, a previous study using 
PFHBI-affected individuals was undertaken to investigate the involvement o f specific 
circulating autoantibodies in the pathology of the disease (Moolman, 1992). Additional
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Table 3.13 Prioritised list of PFHBI candidates genes
CATEGORY GENE EXPRESSION FUNCTION
A
Ion channel genes *KCNA7 m+heart ion channel function
*KIR2.4 m ion channel function
B
Calcium-binding
* LIN-7B m+heart recruitment of ion channel
+HRC m+heart calcium-binding protein
genes CAPB5 m calcium-binding 
calcium binding motif & 
transporting o f proteins
Regulatory genes +NUCB1 m+heart signal peptide,
+SNRP70 m+heart mRNA processing
*/+GSYl m+heart glycogen metabolism
*BAX m regulation o f apoptosis
EMP3 m+heart cell proliferation control 
differentiation and death
TEAD2 m transcriptional activity
ZNF473 m+heart transcriptional activity
D
Predicted genes
CD 3 7 m+heart transport and development
FLJ10922 - tyrosine kinase domain
LOCI 26147 - lamin EGF-like domain
FLJ10922 - collagen domain
FLJ20200 - apoptotic, myosin domain
LOCI 47872 - myosin tail
LOC95515 - transcription activity
*, genes selected for mutation screening and screened in this study. +, genes selected for mutation 
screening in previous studies. */+, partial screening in a previous study and the remaining screening were 
performed in this study, m, expression in multiple tissues excluding heart. Categories of priority ranges 
from A to D, where A is the most, and D is the least, prioritised for mutation screening.
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reasons for selecting NUCB1 were that it has triplet repeat in exon 13 and has 
transcriptional factor activity (F. February, 2002).
A gene involved in development, namely, a splicing factor gene, SNRP70, was listed in 
category C. The rationale followed was that defective splicing of mRNA can be disease- 
causative (Faustino and Cooper, 2003), thus implicating splicing factor genes which, in 
turn, are involved in the development of organs and systems, possibly the cardiac 
conduction system. Therefore, a mutation in any gene involved in the splicing mechanism 
could be PFHBI-causative. Previous studies have shown that a mutation in the PRPCS 
gene, which is a splicing factor pre-mRNA, caused RP13 in affected families (sections
1.6.1 and 1.6.3) (McKie et al., 2001).
GSYI, in category C, was listed as a plausible candidate gene to screen because it has 
been shown experimentally that glycolytic flux maintains membrane activity, reduces 
arrhythmia and improves the functional recovery of the ischaemic heart (King and Opie, 
1998). Therefore, a mutation in GSYI may affect the glycolytic levels, which may, in 
turn, affect the functioning of the heart and could possibly be PFHBI disease-causing. 
Recent findings have shown that GSK-3 p inhibits glycogen synthesis through 
phosphorylation of GSYI. GSK-3 (i is involved in the regulation of heart development 
via the Wnt signaling pathway (Hardt and Sadoshima, 2002), which may also link GSYI 
as a role player in the complex pathway of cardiac development (section 1.5.4), thus 
further supporting its candidature as a PFHBI-causative gene.
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Two genes involved in apoptosis, cell differentiation and proliferation namely, BAX and 
EMP3, were also listed in category C, because, in the human heart, the morphogenesis of 
the CCS and the normal postnatal involution o f the right ventricle are both mediated by 
apoptosis. The exact mechanisms by which these events are initiated or terminated 
remain poorly understood (James et al., 1996). Apoptosis is essential for normal 
development, excessive apoptosis may be triggered by pathological changes and results 
in the destruction o f tissues and the development of heart disease in which a fatal 
arrhythmic event may occur (section 1.5.1) The reason for selecting genes with 
transcriptional activity, namely, ZNF473 and TEAD2, as possible PFHBI candidates is 
that it has been shown that faulty transcription factors can cause congenital cardiac 
disorders, for example mutations in TBX5 and NKX2-5 can cause HOS and ASD, 
respectively (section 1.3.1) (Basson et al., 1997; Schott et al., 1998). Another plausible 
PFHBI candidate gene is CD37, which encodes a cell surface glycoprotein, predicted to 
have four transmembrane spanning domains, which appears to play a role in the 
development, regulation and proliferation of cell tissues. The expression of this gene in 
heart strengthens its PFHBI candidacy.
Category D lists genes of lowest priority, as it contains only predicted genes which have 
signature domains of genes which have been implicated as possible PFHBI candidates. 
For example, F U 10922 has a tyrosine kinase-like domain (table 3.13), since a mutation 
encoding a serine threonine kinase causes DM, which manifests cardiac conduction
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abnormalities as one of its features (section 1.3.2.1) (Harper, 1989; Perloff et al., 1984), it 
is plausible that a mutation in a DMK homolog may cause PFHBI.
Another predicted gene, LOC126147, has a signature with a lamin-like domain, and since 
mutation in a LMNA gene causes cardiac abnormalities, including A-V conduction 
disturbances in LGMD1B (section 1.3.2.2)( (Kass et al., 1994), one can propose that a 
LMNA paralog would be a plausible gene to screen for PFHBI-causative mutations. The 
three predicted genes, FU10922, FU20200 and LOC147872, are plausible candidates as 
they have either a collagen or myosin signature, or both, respectively (table 3.13), since a 
defect in a structural gene expressed in the CCS, such as collagen or myosin, may be 
pathogenic. In addition, the increase in the collagen content during development 
coincides with the progressive course of PFHBI (section 1.2.3.1) (Brink et al., 1994).
Predicted gene, FL20200, also has an apoptotic signature domain (table 3.13). While 
apoptosis is essential for normal development, if  a gene involved in the apoptotic 
pathway is mutated, it can result in the triggering of excessive apoptosis and result in the 
destruction of tissues and the development of heart disease, such as, PFHBI in which a 
complete heart block may occur (section 1.5.1) (James et al., 1996). Finally, predicted 
gene LOC95515 has a signature domain which possesses transcriptional activity, since 
faulty transcription factors cause congenital cardiac disorders, such as, HOS and ASD 
(Basson et al., 1997; Schott et al., 1998), a mutation in this gene may possibly be PFHBI- 
causative.
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3.5 FURTHER GENE SEARCHES AT THE PFHBI LOCUS
A search of the PFHBI locus for three candidate genes, namely, a Cx gene, a G-protein- 
encoding gene and a gene with a CTG repeat motif, none of which were known to map 
there, but which were strong functional candidates, was undertaken (sections 2.14.1 and 
2.14.2). The results of these investigations are shown in sections 3.5.1, 3.5.2 and 3.5.3.
3.5.1 Connexin
The PCR amplification using the Cx degenerate primers (described in section 2.14.3) did
not generate any products from the BAC and cosmid clones spanning the PFHBI locus;
however, a product of approximate 176bp in size was obtained from two radiation
hybrids, namely, RHG12 and ORIM-7, and from genomic DNA (fig. 3.16). The
nucleotide sequence of this product is shown in fig. 3.17(a). In addition, a BLAST search
o f this sequence against the nr database showed that it had homology to a Cx37 gene-
encoding a Homo(H) sapiens gap junction protein, alpha 4, GJA4 (Acc no. NM 002060)
1 ^(January 2004), with an E value of 4e.‘ The Cx PCR product sequence was matched to 
the partial sequence o f Cx37 mRNA (Acc. no. BC027889), from base pair position 139 to 
position 318 (fig. 3.17c). The BLAST2 alignment results o f the sequence of the amplified 
product with each BAC or cosmid clone sequence spanning the PFHBI locus showed no 
homology with the 176bp Cx PCR product. A BLAST search of the sequence of the Cx 
PCR product against the contig NT 011109 and the clones spanning the PFHBI locus did 
not yield any homologies. At time of this analysis, the sequencing of chromosome 19 was 
still incomplete and a gap were still present in the contig spanning the PFHBI area
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Figure 3.16 PCR  amplified products obtained using Cx degenerate prim ers and DNA 
clones spanning the PFHBI locus.
1. 100 bp marker 13. BC694629 25. BC679592
2. genomic DNA 14. BC324323 26. BC266129
3. RHG12 15. BC242886 27. R31681
4. RH Orim-7 16. R33773 28. R29295
5. water control 17. F16353 29. BC878087
6 BC894691 18. R26730 30. BC42053
7. BC821616 19. BC255070 31. R31181
8. F24003 20. R29279 32. F23669
9. R30005 21. BC677569 33. R28785
10. BC782556 22. R31763 34. R28785
11. BC858854 23. BC808483 35. BC275645
12. BC815354 24. BC52309 36. BC61330
The samples from which a PCR product was genetated (lanes 2,3 and 4) are shown in bold. The position of 
the Cx PCR-amplified product is indicated by an arrow, lane 1, positive control; lane 5, negative control; RH, 
radiation hybrid; BC, bacterial artificial chromosome; R and F, cosmids.
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GNNTNNNTTTNNNTTTCCTTTGGGCCANNNCATNNTGNCTGNACCTAGCT 5 0
GC T GANTNAGTGTGGGGCNGANGAGCAGTCTGATTTNGANTGNAACACTCT 1 0 0
CCAGCCAGGCTGCACACAACGTGTTGCTACGACCAGGCNTTCZCTATCTC 1 5 0
CCATATNCGCTACTGGGTGCTGCAGA 1 7 6
(b)
Score = 110 bits (57), Expect = 9e-22 
Identities = 103/123 (83%), Gaps = 3/123 (2%) 
Strand = Plus / Plus
Querv: 54 qantnaqtgtgqqgcngangagcagtctgatttngantgnaacactctccagccaggctg 113
II I lllllllll II llllllll Mill II II Mill II I M II111II 
Sbjct: 199 gagtcagtgtgggg-tgacgagcagtcagatttcgagtgtaacacggcccagccaggctg 257
GJA4 protein 42 E S V W G  D E Q S D F E C N T A Q P G C
Query: 114 cacacaacgtgttgctacgaccaggcnttccctatctcccatatncgctactgggtgctg 173
III llllll I INI llllllll Mill 11IIIIII II 1111111IIIIIIII 
Sbjct: 258 cac-caacgtct-gctatgaccaggccttccccatctcccacatccgctactgggtgctg 315
GJA4 protein 62 T N V C Y D Q A F P I S H I R Y W V L
Query: 174 cag 176
III
Sbjct: 316 cag 318
GJA4 protein 81 Q
(c)
1 gcgggcgtca ctccggccat cgtccccacc tccacctggg ccgcccggca ggcaggcgac 
61 ggaggcccgg gagccatggg tgactggggc ttcctggaga agttgctgga ccaggtccag 
121 gagcactcga ccgtggtggg taagatctgg ctgacggtgc tcttcatctt ccgcatcctc 
181 atcctgggcc tggccggcga gtcagtgtgg ggtgacgagc agtcagattt cgagtgtaac 
241 acggcccagc caggctgcac caacgtctgc tatgaccagg ccttccccat ctcccacatc 
301 cgctactggg tgctgcagtt cctcttcgtc agcacaccca ccctggtcta cctgggccat 
361 gtcatttacc tgtctcggcg agaagagcgg ctgcggcaga aggaggggga gctgcgggca 
421 ctgccggcca aggacccaca ggtggagcgg gcgctggcgg ccgtagagcg tcagatggcc
Figure 3.17 Analysis of PCR amplified product obtained with Cx degenerate prim ers.
(a ) T h e  sequence o f the Cx PCR product obtained with the radiation hybrid RG 12 DNA sample. The 
sequence o f the Cx PCR underlined in black matches the Cx37 sequence encoding the GJA4 protein (b) 
BLAST 2 search o f the sequence o f the Cx PCR product (query) against Cx37 (subject) ( c) Partial 
sequence o f  Cx37 mRNA (accession no. BC027889). The sequences matching the Cx degenerate 
forw ard prim er are indicated in blue and are underlined and the sequences matching the Cx degenerate 
reverse p rim er are indicated in red and is underlined. Sequence o f the Cx PCR amplified product 
matching Cx37 mRNA is shown in bold.
E, glu; S, ser; V, val; W, Trp; G, gly ;D, asp; E, glu; Q, gin; F, phe; N, asn;T, thr; A, ala; P, pro; C, cys;
T, thr; Y, tyr; I, ile; H, his; R, arg; L, leu.
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(IHGSC, 2001), thus, there is still a possibility that a Cx might map to a gap at the PFHBI 
locus or to an area on chromosome 19ql 3.1 to 13.3. The sequence of the Cx PCR product 
also had homology to a rat connexin (results not shown) also with an E value of 4e,'13 
which suggests that the connexin detected may have been from the hamster DNA of the 
chromosome 19 radiation hybrid. Unfortunately, rodent DNA was not included as a 
control in the PCR amplification so as to verify the BLAST result.
3.5.2 G protein
A dot blot of cosmids and chromosome 19 radiation hybrids spanning the PFHBI region 
was probed with radioactively labeled G-protein (p i 15-RhoGEF cDNA) (2.14.2) and the 
hybridisation results are shown in fig. 3.18. After stringent washing of the labeled dot 
blot, only the chromosome 19 radiation hybrids and the genomic DNA control gave 
positive signals. In addition, a BLAST2 search o f RhoGEF cDNA sequence with each of 
the DNA clones spanning the PFHBI locus found no homologous sequence present on 
the clones. Since the chromosome 19 radiation hybrids spanned a region from 
chromosome 19ql3.1 to 19 q l3.3 (fig. 1.10), the dot blot results suggest that this gene is 
present in this greater region. A subsequent bioinformatic search for this gene revealed 
that it mapped to contig NT_011109 in a region centromeric to the PFHBI locus within 
chromosome 19q 13.1 to 19 q l3.1 region (fig. 3.19).
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1 2 3 4 5 6
7 8 9 10 11 12
13 14 15 16 17 m
19 20 21 22 23 24
25 26 27 28 29 30
31 32 33 34 35 36
Figure 3.18 Autoradiograph of a dot blot probed radioactively with a-32P[dCTP] 
G-protein cDNA probe.
Lanes: 1.C14187 11. C24680 21. C23078 31. water control
2. C l8073 12. C29025 22. C34759 32. genomic DNA
3.C18618 13. C27268 23. C30460 33. C19 RHG12
4. C222363 14. C8946 24. C32617 34. C19 RHOrim-7
5.C15217 15. C15743 25. C32617 35. Probe DNA
6. C22135 16. C20381 26. C24833 36. no sample
7. C l4690 17. C27993 27. C28410
8. C33205 18. C19161 28. no sample
9. C24493 19. C24596 29. no sample
10.C34439 20. C l0501 30. no sample
C, cosmid; C19RH, chromosome 19 radiation hybrid . Position o f clones at the 
PFHBI locus see figs. 1.11 and 1.12. Positively-hybridising DNA samples are 
shown in bold.
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centromeric
(a)
q
13.3
Chromosome 19
(b)
• G protein gene (14,679.473bp) 
(pllS-RhoGEF  cDNA)
' D19S606 (20,241,753bp)
• D19S902(20>600>2 18bP)
► PFHBI locus
D19S866 (23,022,780bp) 
telomeric
Figure 3.19 Schematic map showing the position of the G protein gene, pllS-RhoGEF  cDNA, relative to the 
PFHBI locus.
(a) Schematic drawing o f chromosome 19 showing the location o f the PFHBI locus at C19ql3.3. (b) Integrated 
physical and genetic map showing the positions o f  the PFHBI locus and the G protein gene. Base pair positions (bp) 
of p i  15-RhoGEF cDNA and genetic markers D19S606, D19S902 and D19S866 were obtained from BLAST 
searches o f  the human genome database.
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3.5.3 CTG repeat expansion
The results generated from employing the RED technique to analyse five PFHBI-affected 
samples, as described in section 2.14.1, performed in the Schalling laboratory, Karolinska 
Institute, Sweden, are shown in fig 3.20. Eleven controls were used, namely, three mildly 
affected DM patients, three DM patients and the genomic DNA from five unrelated 
healthy individuals (data not shown). A 120bp RED product is usually present in the 
general population and is considered normal. However, with sample 2 (2.III.9) larger 
products ranging from 150bp to 270bp and with sample 4 (2.IV.1) a 150bp product, were 
observed. The additional products were found to be due to expansion of a non-pathogenic 
polymorphic CTG repeat (AF020274) which maps to chromosome 18 (personal 
communication, Quiping [Schalling group]).
3.6 MUTATION SCREENING OF PFHBI CANDIDATES
The candidate genes selected for mutation screening, discussed in section 2.14, were 
KCNA7, GSYI, BAX, K1R2.4 and LIN-7B (sections 3.6.1 and 3.6.2).
3.6.1 KCNA7
In this study, both, exons and the flanking intronic junctions o f KCNA 7 were screened for 
disease-causing mutations (section 2.14.4), using the primer sets shown in table 2.3 
(section 2.5).
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Figure 3.20 Autoradioagraph of DNA samples from PFHBI-affected individuals 
using the RED technique.
RED products, separated by gel electrophoresis, for each of the five PFHBI-affected 
individuals analysed were transferred to a membrane and probed with a labeled 
(CTG)i7 oligonucleotide. Lanes 1-5, DNA samples from PFHBI-affected individuals. 
Product sizes in bp are shown on the right of the autoradiograph. All the samples 
have a strong 120bp product. Sample 2 has five fainter products, ranging from 150bp 
to 270bp. Sample 4 has a strong 150bp product. Samples are from pedigree 2: 1, 
13.11.1; 2, 2.III.9; 3, 4.IV.4; 4, 2.IV.1; 5, 4.IV.4 (personal communications, Quiping 
[Schalling group]).
— 270bp
—  210bp 
— 180bp
—  150bp 
— 120bp
—  90bp
M arker
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3.6.1.1 Characterisation of the coding sequences and the genomic organisation
A BLAST search o f the Genoscope database (http://www.genoscope.org) revealed that 
human genomic sequences (R0AA003ZF08G1) had homology to the mouse kcna7 cDNA 
(AF032099). Another BLAST search against Genbank using the inferred human KCNA 7 
sequence identified significant matches with human BAC clone BC52309 (AC0008687), 
mouse genomic contig (AC073711) and three placental expressed sequence tags (ESTs) 
AA021711, AI322534, AI324179) (Bardien-Kruger et al., 2002). Using the program 
EST2GENOME (http://fltp.sanger.ac.uk/pub/EMBOSS), the coding sequence of KCNA7 
was deduced by aligning the mouse cDNA sequence (AF032099) with the human BAC 
clone BC52309 (AC0008687), retrieved from the databases, and the KCNA7 sequence 
was deposited into the Genbank database (accession number AF315818). Concomitantly 
mouse kcna7 sequence was corrected at several positions based on the alignments 
between published cDNA sequence (AF032099), the mouse genomic sequence 
(AC073711) and mouse EST sequences (fig. 3.21) (Bardien-Kruger et al., 2002).
3.6.1.2 SSCP-PCR analysis
Two sets o f overlapping primers spanning exon 1 and five sets spanning the larger exon 2 
(table 2.3 and fig. 2.13) were used to screen the coding regions of KCNA7 for pathogenic 
mutations using both SSCP-PCR analysis and direct sequencing, as described in sections
2.6.3 and 2.7.2, respectively. The SSCP-PCR results for exons 1 and 2 are shown in
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- S I AC AC CTC  CCTTCCCOOG TCCCCCGGGC TOCOCGCOOC A T S OAG CCG COC TOC c o o CCG CCG TOC OOC TCC TGC a *
M et 6 1 a P r o A r g C y * P r o P r o P c ©  C y * O l y C ya C y a Bm
M et G lu P r o A r g C ya r r o n o r r o C Y » O l y c y a C y i BA
- r > AC AC CTC  C C T T O C C O S  T O TCTBCCCCCC fcTO OAG C CA OOC TOC CCC CCC C X TOC « r TCC TOC
3 ”? 5»A** ecu ; e r a o r e CTC AAC m e o c r CGC C T S COC TT C OAC ACC COO GCG COC ACC CTC s e e CCC T T C CCC OAC AC T C TC B *
M u A r g U *u V# i L e a K m V a l A U C l y <^nt k , 9 G lu T b t A r g A l a A r g T h r L e a S l y  A x g P h e P r o A a p TT.X L e u Ha
U a U w V e l L « s A n a v a l . A l a C l y L e o A r g » h * G lt> T h r A r g A l a A r g T h r L e e S l y A x g PtM* P r o A a p T h r L e u M e
3 ' SAG c o o C TC CTC C TC AAC CTC CCC OOC TTO c c c TT C CAC AOC o o c OCO COC ACO CTC s a c COC T T C c o c OAC A T fi r w * * *
I I S ztta «C G < u c o c a CCC 3CC o o c c c c CCC r r c T A C CAC CIVC OCO OOC OCC O AC T A 1 TTC TTC OAC C5G CAC COC OCC ACC Ms
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113 CTO OfiC OAC ccc CTC c o c COC AOC COC T TC T A C OAC OOC •CO COC COC OJU3 T A T TTC TTC OAC C 3A CAC COO CCC AOC ►*■
1 *3 TTC SAC a c c CTG CTC TAC TAC T A C CAC TCC C C T OOC o o c CTO COG COO COG o c u CAC 5TO CCG o r e OAC CTC TT C C TC tt .
PftB A * p A l a v a i L e u T y r T jrx T y x G in S c : O l y  O l y A x ^ u « a * 9 A x g F r o A l a A l * t r * l P « o U ru A a p V *1 P h * L e u Ks
P fte A » p A ^ a v a l p y x T y * T y x C l a 5 «? O l y O l y A T ? Lew A « « A »J P r o A l a K la v a l P r o L e u A a p T e l r t e L * U H e
193 TTC SJtT C CS CTC CTC TA C TAC T A C CAS TOC OOC OOC COO CTO AUA CCC CCG OCO CAC STG COC C TC OAC CTC f r c c r o * *
'J SA A SAC C TC (A T TTC T * L W A CTO OOC OCO OCO OCC CTO OCA COC C TO OCC OAC OAC SAO o o c TOC CCC O TS CCC c c c
3 1 J 31 u 9 * 1 A l a P h e T y r G l y u u o l y A l a A l a A l a L a c A l a A * f L ew O lu A ap S lt t c - y C y a r r o T e l P r o P r o MS
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human KCNA7
exon 1
Ala Ala Ala Oly Pro 
GCC GCA GCC GGC CCG pgagaggcgg..
1153 bp iniron exon 2
Phe Pro Alt Pro Leu Asr 
........ ....... //............. ...............cclccctgcagTDCCCCGCTCCOrrrG AAT
mouse kcna7 GCT GCT ACT GGC CCG ttgaezgg..
Ala All Thr Gly Pro
1929 bp intron
........... II......... cccttctgcjj TTC CTC GCC CGA CTG AAT 
Phe Leu Ala Arg Leu Ain
Figure 3.21 Comparison of human KCNA7 with mouse kcna7.
(a) Comparison o f the nucleotide and deduced amino acid sequences o f human KCNA7 and mouse kcna7. 
The six membrane-spanning domains (SI through S6) and the pore-forming regions (P-region) are 
indicated. The arrowhead (^) indicates the location o f the single intron that lies between SI and S2. 
Differences between the human and mouse amino acids are in bold and underlined. The two 
polymorphisms in the human gene are indicated (*) at nucleotide position 566 C:G and 1253 T:C o f  
KCNA7. The mouse kcna7 sequence has been corrected at several postions based on the alignment between 
the published cDNA sequence (AF032099), the mouse genomic sequence (AC073711) and mouse EST 
sequences. The missing ‘G’ at position 29 in AF032099 is indicated in bold and underlined.
(b) Exon-intron junctions of human KCNA7 and mouse kcna7. The human 1153bp intron and the mouse 
1929bp intron are shown (Bardien-Kruger et al., 2002).
figs 3.22 and 3.23, respectively. No disease-causing mobility shifts were found between 
affected (1.V.10, 6.IV.12, 9.IV.5 and 5.III.1) and unaffected PFHBI (1.V.6 and 9.III.6) 
family members. However, two changes in banding pattern were observed in an 
unaffected PFHBI individual (9.III.6) with primer sets D and G. This was further 
investigated in kindred 9 of pedigree 2.
3.6.1.3 Sequencing data
The PCR products A, B, C, D, E, F and G of affected (1.V.10, 9.IV.5 and 5.III.1) and 
unaffected PFHBI (1.V.6 and 9.III.6) individuals were sequenced using the ABI310 
system. The DNA sequencing data did not reveal any pathogenic mutations.
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Denatured samples of individuals: l.l.V .lO (A ) 5. l.V .6(U )
2. 6.IV.12 (A) 6. 9.III.6 (U)
3. 9.IV.5 (A) 7. 13.II.8 (S)
4. 5.III.1 (A)
Figure 3.22 PCR-SSCP mutation screening of exon 1 and 5’-end of exon 2 of KCNA7.
PCR products A and B were obtained by PCR amplification o f exon I using primer sets A and B (table 2) 
and DNA from individuals 1 to 7. PCR products C were obtained by amplification o f 5 ’-end o f exon 2 
using primer set C (table 2.3) and DNA from individuals 1 to 7. PCR-SSCP samples were run on a 8% 
polyacrylamide with glycerol: Lanes 1 to 7 contain heat denatured samples from part A o f exon 1, lanes 8 
to 14 contain heat-denatured samples from part B o f exon 1 and lanes 15 to 21 contain heat-denatured 
samples from part C of the 5’-end o f exon 2. A = PFHBI-affected. U = unaffected first-degree relative. S = 
unrelated spouse.
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Exon 2
Denatured samples of individuals: l .l .V .1 0 (A )  5. l.V .6(U )
2. 6.1V. 12 (A) 6. 9.III.6 (U)
3. 9.IV.5 (A) 7. 13.II.8 (S)
4. 5.III.1 (A)
Fig 3.23 PCR-SSCP mutation screening of exon 2 o f KCNA7.
PCR products were obtained by PCR amplification o f exon 2 using primer sets D, E, F and G 
(table 2.3) and DNA from individuals 1 to 7. PCR-SSCP samples were run on a 8% 
polyacrylamide with glycerol. Lanes 1 to 7 contain the heat-denatured samples o f part D o f exon 
2, lanes 8 to 14 contain the heat-denatured products o f  part E o f exon 2, lanes 15 to 21 contain the 
heat-denatured products of part F of exon 2 and lanes 22 to 28 contain the heat denatured samples 
o f part G of exon 2. The bold arrows on the left and the right show the single strand conformers 
for each part o f exon 2. The fine arrows indicates the D polymorphism in sample 6 and the G 
polymorphism in sample 27. A = PFHBI-affected. U = unaffected first-degree relative. S = 
unrelated spouse.
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3.6.1.4 Polymorphism analysis
Primer sets D and G were used to screen all the members o f kindred 9 of pedigree 2. The 
PCR-SSCP results using primer set D are shown in fig. 3.24. In both cases, using primer 
sets D and G, mobility shifts were observed in only two unaffected individuals (9.II. 1 and
9.III.1), namely, “a married in” and her son. The PCR products of both individuals were 
sequenced and are shown in fig. 3.25. In case of the D polymorphism, a C to G 
nucleotide change was observed at position 566, which caused an amino acid change 
from proline to arginine (fig. 3.25a). In case of the G polymorphism, a T to C nucleotide 
change was observed at position 1253, but no amino change occurred (fig. 3.25b). The 
allelic frequencies of the two exon 2 SNPs determined in a general South African 
Afrikaner population were 0.62:0.38 for nucleotide 566 C:G polymorphism, respectively, 
and 0.7:0.3 for the nucleotide 1253 T:C polymorphism, respectively. The two novel SNPs 
were submitted to the SNP database, NCBI and were designated AF315818-566 and 
A F315818-1253 (table 3.14).
3.6.2 KIR2.4, LIN-7B, BAX and GSY1
A summary of the mutation screening results generated for the exons and flanking 
intronic junctions of KIR2.4, LIN-7B, BAX and GSY1 are presented in tables 3.14 and 
3.15. The details of the exonic organisation of the candidate genes are shown in section 
2.14 and the clustal alignment results of each exon for each gene are shown in appendix 
III. A previously reported SNP in exon 7 (rs5464) (Genbank Acc no. Z33610) of GSY1 
was found in the DNA of an unaffected and an affected individual from pedigree 1
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III O
9.III.2 9.III.1 9.III.3 9.III.4
IV
9.111.5 9.III.9 9.III.8 * 9.III.6
9.IV.1 9.IV2 9.IV.3 9.IV.4 9.IV.5
Kindred 9 o f pedigree 2 
1 2 *3 4 5 6 7 8 9 10 11 12 13 *14
mm wS
I * * f
a l i A i M s s i M K a
Lanes:
1 =9.111.3
2 = 9.111.1 
*3 = 9.11.1
4 = 9.IV..1
5 = 9.IV.2
6 = 9.IV..3
7 = 9.III.3
8 =9.111.4
9 =9.111.5
10 = 9.IV.4
11 = 9.IV.5
12 =9.111.9
13 =9.111.8 
*14 = 9.III..6
on
* ;
Clinically unaffected 
Clinically affected (A)
Deceased affected
Figure 3.24 PCR-SSCP analysis of kindred 9 of pedigree 2 with primer set D.
The lane numbering (1-14) on the gel corresponds to heat-denatured PCR amplified products using 
primer set D (table 2.3, fig. 2.13). The PCR-SSCP produects were run on 8% polyacrylamide gel. *, 
Mobility shifts are visible in samples 3 (9.II.1) and 14 (9.III.1). The position o f  the shifts are indicated 
by the arrows.
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2 1 0
505 CCC GCT CCG CTG AAT GGC TCC 
Pro Ala Pro Leu Asn Gly Ser 
CCC GCT CGG CTG AAT GGC TCC 
Pro Ala Arg Leu Asn Gly Ser
1207 AGC CAT GTG GAC A JG  CAG CCT 
Ser His Val Asp Met Gin Pro 
AGC CAT GTG GAC ACG CAG CCT 
Ser His Val Asp Met Gin Pro
(b) Polymorphism in G
Figure 3.25 Sequencing traces showing the D and G polymorphisms o f exon 2 o f  K C N A 7 .
(a) A trace showing the polymorphism with primer set D, a nucleotide change o f  C to G. (b) A trace showing 
the polymorphism using primer set G, a nucleotide change o f  T to C. The changes are shown in bold and the 
polymorphism is indicated by a vertical arrow. The nucleotide sequence with the corresponding amino acids 
are also shown. The afffected amino acid is shown in red in both cases.
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(table 24 in Appendix III). The alleles observed were C/T in nucleotide position 1186 of 
the Genbank nucleotide sequence accession number J04501. In addition, a number of 
errors were found in previously submitted sequence data. A previously identified SNP 
(rs 1057369) was found in the submitted database sequence of exon 6 (L22473) of BAX at 
base pair position 552 (tables 3.14 and 3.15). The BLAST search results of this sequence 
against the human genome database indicated that the G at base pair position 1756471 on 
the N T 011109  contig should be replaced by an A (table 16 in Appendix III). This 
change may very well represent a SNP and the allelic frequency in different unaffected 
ethnic populations should have been determined. However, no disease-causing mutations 
were found in any of the exons o f BAX screened.
Table 3.14 Summary of mutation screening data
Gene Exon SNP/Polymorphisms/ Reference
No errors detected
KCNA7
1 none fig. 3.22
2 2 submitted SNPs,
AF315818-566 figs. 3.23
and AF315818-1253 and 3.25
KIR2.4
1 none table 1
2 none tables 2 & 3
3 none tables 4 ,5  & 6
LIN-7B
1 none table 7
2 none table 8
3 none table 9
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table 3.14 cont
4
5
none
none
table 10
table 11
BAX
GSYI
1
2
3
4
5
6
UTR5A
UTR5B
UTR5C
1
2
3
6
7
8
9
10
13
14
15
16
none
none
none
none
none
SNP in exon6 (rs l057369) 
(already described)
an error in the submitted 
sequence, S79190, CC 
none 
none 
none 
none 
none 
none
SNP in exon 7 (rs5464)
(already described)
none
none
none
none
none
none
none
table 12 
table 13 
table 13 
table 14 
table 15 
table 16
table 17 
table 18 
table 19 
table 20 
table 21 
table 22 
table 23 
table 24
table 25 
table 26 
table 27 
table 28 
table 29 
table 30 
tables 31, 
32 and 33
Tables 1 to 33 are found in appendix III.
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Table 3.15 Sum m ary and com parison of subm itted sequence variations identified in the present study and other 
studies.
Candidate
gene
SNP/
error
Amino acid 
substitution
Allelic
frequency
South
African
Afrikaaner
population
Present
study (Acc No.) 
date of 
submission
Other NCBI 
submissions 
date of 
submission
KCNA7 C>G
SNP
Pro566Arg 0.620.38 Brincor | 
KCNA7- 
5666
ss2419735
Yusuke IM | IMS 
JST16932 
ss4996592 
12/8/02
31/10/00
CSHL-HAPMAP | CSHL- 
HuAA-200402 ssl6790996 
17/2/04
SSAHASNP | WGSA-200403
ss21550400
20/3/04
T>C
SNP
synonomous 0.7:0.3 Brincor |
KCNA7
1253
31/10/00
TSC-CSHL| TSC0220257 
ss 1481085 ss2419736 
7/9/00
Yusuke IIMS-JST169930 
ss49965920 
12/8/02
WISSAHASNP ss6628714 
12/2/03
CSHL-HAPMAP ss 17613181 
19/2/04
SSAHASNP ss21521607 
20/3/04
BAX G>A synonomous not -not
determined submitted
LEE | 718434 ssl537999 
13/9/00
GSY1 CC>GG UTR5A in -not
error S79190 submitted
C>T exon 7 not not rs5464
SNP 1186 in 
J04501
determined submitted
Aravinda/00543 ss6929 
29/6/99
WIAF-CSNP/W1AF-12181 
Ss3173163
______________________________________________________________________________________ 19/6/01__________________
Acc, accession number; C, cytosine; G, guanine; T, thymine; Pro, proline; Arg, arginine; KCNA7, 
potassium voltage-gated channel shaker-related subfamily member 7; BAX, BCL2-associated X protein; 
GSY1, glycogen synthase 1
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The database sequence of UTR5A of GSY1 (acc no. S79190) 
(http://www.ncbi.nlm.nih.gov/nucleotide) at positions 139 and 140 were incorrect (table 
3.14). It was found that the nucleotides CC at these two positions should be replaced with 
nucleotides GG (table 17 in Appendix III). This result was verified by a BLAST 
homology search of the UTR5A database sequence against the Human genome database 
(http://www.ncbi.nlm.nih.gov/human genome). It is also possible that the sequence 
changes may represent SNPs and the allelic frequencies should have been determined in 
different ethnic population groups.
From the alignment results o f K1R2.4, LIN-7B, BAX and GSY1, no sequence changes 
were found when comparing the coding sequences, and the exon/intron boundary 
sequences o f affected to unaffected DNA samples from the PFHBI panel therefore, these 
regions were excluded as disease-causing.
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4.1 THE STUDY DESIGN
Previous studies in the search for the PFHBI gene involved the use of linkage analysis 
and genetic fine mapping, resulting in the placement of the PFHBI locus on chromosome 
19q 13.3 in a lOcM interval (Brink et al., 1994; Brink et al., 1995). Subsequent fine 
mapping further reduced the PFHBI locus to a 7cM interval (fig. 3.1) (personal 
communication, De Jager, 1998).
In this study, a multi-step strategy was used to continue the search for the PFHBI disease- 
causing gene, which involved further fine mapping and reduction of the PFHBI locus 
using published and novel polymorphic markers (section 3.1). In the early stages of this 
project (June 1999), very few annotated genes had been deposited into the publicly 
available databases; therefore, EST databases were scanned with a view to identifying as 
many expressed genes at the PFHBI locus as possible (section 3.2). An integrated 
physical map of the PFHBI locus was generated in order to facilitate the search for the 
PFHBI gene and the map was updated periodically, as new information was deposited 
into the databases (section 3.3).
Affected members of the PFHBI family were screened for the presence o f any unusually 
expanded triplet repeat (CTG)-containing genes, while the PFHBI locus was screened for 
the presence o f a G protein-encoding gene and a Cx gene, as they were considered 
plausible functional PFHBI candidate genes (section 3.5). As the HGP progressed (May
5, 2003), many more genes were identified and deposited into the databases and, as part
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of the present study, genes at the PFHBI locus were characterised and prioritised as 
PFHBI candidates. A priority list for the mutation screening o f PFHBI candidate genes 
was drawn up (section 3.4) and selected genes were screened for the disease-causative 
mutation, as part of the present study, in a panel of selected subjects (section 3.6).
The panel of PFHBI-affected and unaffected family members was selected based on strict 
criteria with unequivocal clinical features as described in section 2.2. In addition, the 
clinically affected individuals chosen carried the disease-associated haplotype, whereas 
the controls were unaffected first degree relatives and “married-in” individuals, who had 
a normal ECG and did not carry the disease-associated haplotype. Although sequence 
variants occurred in the candidate genes screened in this study, they were present in 
PFHBI-affected individuals, in unaffected family members and in the general population 
(tables 3.14 and 3.15); thus no disease-causing mutation was found.
During the course of the study, the associated region was reduced to 4cM. In addition, 
novel genetic markers and single SNPs were deposited in databases (NCBI). All the 
BLAST searches used in the generation o f the integrated physical map were performed 
against the final chromosome 19 contig NT 011109. This contig sequence data, which 
existed in May 2003, forms part of the final chromosome 19 sequence published in April 
2004 by Grimwood et al.
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4.2 REDUCTION OF THE PFHBI LOCUS
Finding a disease-causing gene in a 4cM target region is a challenging task, success more 
often follows when the region has been refined to a more manageable distance of 
approximately l-2cM. For example, RP13- and the Pendred syndrome-associated genes 
were identified when the relevant loci were reduced from 3 to lcM (McKie et al., 2001) 
and 2.5 to 1.7cM (Coucke et al., 1997), respectively.
Furthermore, limiting the size o f the locus was especially relevant, as chromosome 19 is 
particularly gene-rich and harbours an average o f 26 genes per Mb (Grimwood et al., 
2004), compared, for example, to 6.5 genes per Mb on chromosome 13 (Dunham et al., 
2004). During the present study, the estimated number of genes at the PFHBI locus was 
reduced by 34%, i.e., from a predicted 96 to a predicted 63 genes.
Further reduction of the region requires the investigation of more family members, or 
new families o f either South African origin or from other countries. During the present 
study, new family members of pedigree 2 were genotyped but they did not yield any new 
recombination events. In addition, a collaboration was established with a French group 
working on a Lebanese family with a conduction disease designated CCD (De Meeus et 
al., 1995), which was subsequently considered to be the same disease as PFHBI (personal 
communication, Brink, 2000) (section 1.3.2.3.4). An integrated map generated from the 
different markers used by the two groups (Brink et al., 1995; De Meeus et al., 1995) 
showed that the two intervals overlapped (fig. 1.9) (personal communication, Corfield,
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2000). Using genetic fine mapping, the PFHBI locus was reduced to 7cM between 
markers D19S412 and D19S866 (personal communication, De Jager, 1998). 
Unfortunately, the collaboration between the French and Brink/Corfield groups has 
lapsed.
Tetranucleotide m arkers
At the start of the present study, other PFHBI team members were developing 
dinucleotide markers from cosmid clones spanning the PFHBI locus, whereas part of this 
study focused on the development of tetranucleotide STRs from cosmid clones. The 
tetranucleotide STRs reported to occur most abundantly in the human genome are A3 G 
(38%), AGAT (29%), AAGG (10%) and AAAT (5%) (Utah Marker Development 
Group, 1995). Based on these findings, (A3 G)n STRs were selected for marker 
development as part of this study. Since the sequence of the PFHBI region is now readily 
available, a more feasible approach would be screen the region for commonly occurring 
repeat motifs for marker development using a bioinformatics tool such as Repeatfinder 
(Benson, 1999) or to scan for new polymorphic markers which may have recently been 
deposited into the public database.
Selection of the cosmids for (A3 G)n STR development was based on their position 
relative to the genetic map of the locus (fig. 3.3). It was hoped that the ones selected were 
close to recombination breakpoints detected during fine mapping and thus might serve to 
refine the search interval. On sequencing, it was found that cosmid insert 29395
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contained an (A3 G)n tetranucleotide repeat, however, further development of the marker 
was problematic because the repeat motif was embedded in a region containing Alu 
repeat sequences (figs. 3.6 and 3.7). This finding was not unexpected, since it is reported 
that Alu repeats occur at an average frequency of one copy per 4kb, in genomic sequence 
(Strachan and Read, 2000). It has also recently been reported that for chromosome 19 Alu 
repeats make up 25.8% of the total sequence, compared to 13.8%, 13.3%, 9.5% and 
16.8% on chromosomes 7, 14, 21, and 22, respectively (Grimwood et al., 2004). The 
disadvantage o f designing a primer from within an Alu repeat sequence is the generation 
o f a high background due to non-specific priming from the other similar sequences within 
the human genome (Beckman and Weber, 1992). For this reason, the marker within 
cosmid insert 29395 was not developed further.
Nucleotide sequencing of cosmid insert 18618, which had been given a positive signal on 
hybridisation to an (A3 G)„ probe, failed to reveal any (A3 G)n repeat motifs. The probable 
explanation is that the motif was lying within the un-sequenced region of the insert, since 
only about 500bp, adjacent to the forward and reverse Bluescript primers, of the 1.7kb 
insert (fig. 3.4) was sequenced. Assuming this to be the case, finding the (A3 G)n repeat 
motif would have involved the design of new primers from the sequences obtained with 
the vector-specific primers. However, the development of this marker was not pursued at 
this time as other strategies were being followed by the PFHBI team. At a later stage, 
when draft sequence became available, a bioinformatics approach was used and
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dinucleotide repeat sequences from BAC and cosmid clones spanning the PFHBI locus 
were developed as (CA)n markers (section 3.1.5).
Dinucleotide markers
In the present study, the draft sequences of 27 BAC and cosmid clones spanning the 
PFHBI locus were searched for the presence of (CA)n repeat motifs using Tandem 
Repeatfinder (fig. 3.10) (Benson, 1999). The strategy was to develop markers from BAC 
and cosmid clones centromeric to D19S596, and telomeric to D19S604 (fig. 3.10), in 
order to refine the PFHBI locus. Four markers were successfully developed, and showed 
a Mendelian pattern of inheritance (fig. 3.11). The deposited database sequences from 
which markers G68141, G68142, G68143 and G68144 were developed contained runs of 
CA repeat motifs of 20, 12, 11 and 6, respectively, which, in turn, when genotyped in a 
general population, generated 16, 4 ,2  and 1 alleles, respectively (Tables 3.2, 3.3 and 3.4). 
This was in agreement with the findings o f Weber (1990) that the length of the (CA)n 
repeat motif is an indicator of the extent o f polymorphism (see section 1.4.1.1).
Genotyping with G68141, G68142 and G68143
Genotyping with two of the novel markers developed, G68141 and G68142, in PFHBI- 
affected individuals in kindred 4 of pedigree 2 (section 3.1.5, fig. 3.12) showed that the 
centromeric breakpoint of the disease-associated haplotype lies between D19S902 and 
G68141. The disease-associated haplotype (G68141-G68142-D19S596-D19S604- 
D19S866) is thus maintained at 4cM or at the equivalent physical distance o f 2.42Mb
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(section 3.1.4 and fig. 3.8). In order to precisely delineate the recombination breakpoint, a 
search for STR markers lying between D19S902 and G68141 could be undertaken. This 
region represents a physical distance of only 447kb, but refining the interval could 
exclude up to five genes in this gene-rich location, namely, CABP5, PLA2G4C, LIG1, 
CARD8 and EMP3 (fig. 3.15), depending on exactly where the breakpoint lies.
As part of another study by a member of the PFHBI team, a recombination breakpoint 
occurring at the telomeric end of the PFHBI locus in kindred 13 of pedigree 2, i.e., 
between D19S604 and D19S866 (fig 3.1), was investigated (Du Plessis, 2000) (data not 
shown). The marker was used, G68143, in an attempt to narrow the locus was typed in 
the individuals from kindred 9 and 13 of pedigree 2, the former kindred serving as the 
“control”. However, no allelic differences were found between individuals o f kindred 9 
and 13 of pedigree 2, suggesting that the breakpoint was nearer the telomeric limit
Identification of new recombination events
As mentioned earlier, the acquisition of new PFHBI family members in pedigrees 1, 2 
and 5 may identify new recombination events, which may lead to further reduction of the 
disease region, thereby reducing the number of PFHBI candidate genes to be screened. 
Since the genetic distance o f the PFHBI locus is 4cM, the possibility of finding more 
recombination events is possible. It is, therefore, important to continue to trace new 
PFHBI individuals from pedigrees 1, 2 and 5 and to genotype them across the critical 
interval. For this purpose, a relationship between the research clinician, the genetic sister
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(Sr Althea Goosen) and the PFHBI families has been maintained to keep track o f new 
births. It would also be useful to re-establish links with the French (CCD) group, or any 
group from other countries that have mapped inherited cardiac conduction diseases to 
chromosome 19ql 3.3.
4.3 SEQUENCING OF CHROMOSOME 19
The sequencing of chromosome 19 lagged in comparison with the sequencing o f the 
other chromosomes (IHGSC, 2001). The first physical map of chromosome 19 was 
published in 1995 (Ashworth et al., 1995) and, at that stage, sequencing of chromosome 
19 was in the initial stages. In February 2002, 50% of the region containing the PFHBI 
locus was still in draft form and was composed of three smaller contigs, NT 011190, 
NT 011140 and N T011157 (fig. 3.13). In 2002, the Stanford Human Genome Center 
took over the sequencing of chromosome 19 and in April 2004, 99.9% of chromosome 19 
was sequenced and the analysis o f the most recent map was published (Grimwood et al., 
2004). By then, the nucleotide sequence data across the PFHBI locus had been merged 
into one contig designated NT 011109 (May 2003) (fig. 3.15).
Limitations of draft sequence
While developing STRs from draft sequence, a number of discrepancies in both the 
reported coverage and the accuracy of mapping of genomic clones were found, this 
suggested some limitations in the use o f the draft genome sequence to provide accurate
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positional information and detail o f chromosomal regions. For example, in the present 
study, it was found from BLAST searches o f a 500bp sequence of clone ACO 10619 that it 
mapped to two places on contig NT_011109, namely, within the PFHBI locus, as well as 
outside the telomeric limit o f the PFHBI locus (see section 3.1.5) (fig. 4.1). Katsanis and 
colleagues (2001) reported similar problems when they evaluated the quality o f the draft 
human genome sequence o f a representative region using experimental and 
computational methods.
PFHBI locus
cen D19S902 D19S866 tel
| — - ^ |  “ cont i g N T _ 011109
I AC010619 AC010619
Figure 4.1 Positions of BAC clone sequences mapping within and outside the telomeric end of the 
PFHBI locus.
Black line shows contig N T 011109. Solid black box show the position o f BAC clone AC010619 
sequences on the contig NT 011109. Centromeric genetic marker D19S902 and telomeric genetic marker 
D19S866 delineate the PFHBI locus, cen, centromeric end; tel, telomeric end.
This was possibly due to a duplication of this portion o f the ACO 10619 clone sequence 
on the chromosome, which would explain why the same sequence would map to two 
different positions on contig NT 011109 (IHGSC, 2001) (see section 3.1.5). This notion 
is supported by the finding that chromosome 19 sequence shows duplication, with 7.53% 
of the sequence sharing sequence homology with more than one location in the genome 
(Grimwood et al., 2004). Another problem experienced during this study was that
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primers generated from the insert o f BAC clone AC008888 draft sequence for potential 
(CA)n STRs development, when tested experimentally using PCR amplification, did not 
generate the expected product but did amplify genomic DNA. One possible explanation 
is that LLNL had assigned the incorrect sequence to the clone, or that a clone switch had 
occurred (section 3.1.5). Consequently, the draft sequence of this clone was not used 
further for marker development.
The four successfully developed (CA)n markers were submitted to Genbank (see table
3.1). These novel markers may serve as a useful resource for other researchers searching 
for disease-causing genes in the neighborhood of the PFHBI locus, such as LGMD2 
(Driss et al., 2000) and DFNA4 (Chen et al., 1995), since their loci encompass these 
markers (section 1.4.4 and figs. 1.14 and 3.15). To date, the responsible disease-causative 
genes have not been identified.
4.4 GENE TRANSCRIPT SEARCHES
In the early stages of the project (June 1999), consensus sequences derived from the 38 
STACK-clustered ESTs mapped to the PFHBI locus corresponded to only six proteins. 
Furthermore, not enough information regarding gene structure and tissue expression 
profiles o f the corresponding genes was available and the few protein hits obtained at this
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stage o f the study gave an indication of the paucity of annotated proteins in the protein 
databases (section 3.2, table 3.5).
By May 2003, the GENEMAP99 and the LLNL site had still not updated their EST 
database, probably because in 2002 Stanford University had taken over the sequencing of 
chromosome 19. However, the same 38 ESTs identified in mid-1999 now yielded 23 
protein matches, which is an indication o f the increase in annotation of the proteins in 
protein databases. O f the 23 proteins, seven (CA11, ZNF473, KPTN, FU25129, 
CRD8/TUCAN, EHD2 and ATF5) were listed as being expressed in heart.
Transcription factor mapping to the PFHBI locus
Application of gene prediction programmes showed that ZNF473 has a transcriptional 
factor signature domain and on this basis is a plausible PFHBI candidate gene. A number 
of transcription factors, namely, MEF-2 and GATA-4, have been implicated in cardiac 
development (Franco et al., 1998; Moorman et al., 1998) (section 1.2.3) and NK2-5 and 
TBX5 have been associated with the cardiac diseases, HOS (Basson et al., 1999) and 
ASD (Schott et al., 1998), respectively. The position of ZNF473 changed several times 
on the physical map during the course o f this study and homology searches would 
sometimes place this gene close to the telomeric limit o f the PFHBI locus (June 2000) 
and at other times outside the PFHBI locus (fig. 3.13) (February 10, 2002). In April 2004, 
a BLAST search showed that ZNF473 maps across the most telomeric marker D19S866 
o f the PFHBI locus (fig. 4.2). Unfortunately, insufficient time was available to screen
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ZNF473, but it should be investigated at a later stage, specifically the part of the gene 
which lies within the PFHBI locus.
PFHBI locus 
4
D19S866
■4-----------►
ZNF473
Figure 4.2 Position of the ZNF473 relative to genetic marker D19S866 (May 2004).
cen, centromeric; tel, telomeric. The PFHBI locus lies centromeric to D19S866.
Earlier gene searches using ESTs
In the earlier part of this study, plausible PFHBI candidate genes were identified using 
EST searches as discussed in sections 4.4 and 4.6 respectively. The retrieval o f ESTs 
from Genemap99 and LLNL was necessary at the start o f this study, since the dbEST 
database was in its infancy and very few genes had been placed at the PFHBI locus. In 
the later stages of the study (May 5, 2003), finished sequence covering the PFHBI locus, 
namely, contig NT 011109, became available and the updated sequence was used to 
generate an integrated physical and genetic map. The EST approach was a reasonable 
strategy during the earlier part of the study. If more sequence data had been available at 
that stage an alternative approach would have been to download this sequence and to 
perform a BLAST homology search of this data against the dbEST database. This would
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have resulted in obtaining most of the then available ESTs mapping to the PFHBI locus. 
The next steps would have been to use clustering programmes (such as STACK and 
UNIGENE) and protein homology searches to find as many of the encoding genes all the 
proteins mapping to the PFHBI locus as possible and then to prioritise them for mutation 
screening in a PFHBI panel.
S trengths and weakness
Some of the problems experienced when using ESTs were that they are single reads and 
therefore the probability of sequencing errors are high. It has also been found that ESTs 
are contaminated with intronic sequences (Wolfsberg and Landsman, 1997). The problem 
with the EST databases, LLNL site and GENEMAP99 used in this study, was the lack of 
updating of ESTs mapping to the PFHBI locus, during 1999 to 2003. Another 
shortcoming of EST databases is that some genes will not be well represented because 
they are poorly expressed in some tissues, and, of course the contrary is true for highly 
expressed genes.
Both STACK and UNIGENE incorporate alternatively spliced transcripts into their 
clustering algorithm (Bouck et al., 1999) and since it has been hypothesised that the 
cause o f PFHBI might be at the developmental level, and alternatively spliced transcripts 
have been implicated in the regulatory mechanisms of development (Faustino and 
Cooper, 2003), it was important to include alternatively spliced transcripts in the PFHBI-
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causative gene search. A shortcoming of both STACK and UNIGENE is that ESTs which 
are poorly expressed will be missed and thus not incorporated into their databases.
As mentioned later, gene prediction programmes have their strengths and weaknesses 
too, it is therefore important to use as many programmes as possible when identifying 
genes computationally.
4.5 AN INTEGRATED MAP OF THE PFHBI LOCUS
Since the information relevant to the PFHBI locus is scattered over a number of 
databases, namely, Ensembl, LLNL, NCBI, it was important to integrate all the physical 
and genetic data into a composite map (fig. 3.15). It facilitated navigation around the 
physical landscape o f the PFHBI locus. In addition, the map had to be updated regularly 
as the sequencing data of chromosome 19 was constantly changing.
When integrating the physical map, a number of discrepancies were found; these 
included, wrongly assigned ESTs. For example, a number of ESTs were assigned to the 
wrong chromosome (table 3.6) and a LLNL clone assigned to the PFHBI locus mapped 
to two different positions on contig NT 011109 (fig. 4.1). The latter discrepancy may be 
due to gene duplication at this position of chromosome 19. Katsanis et al., (2001) 
encountered similar problems during his study of the evaluation o f the quality of the draft 
human genome sequence using experimental and computational methods.
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In this study, the bioinformatic findings supported the experimental results, except in the 
case o f D19S866. It was found that the sequence of the genetic marker D19S866 has 
BLAST homology to clones AC008655 and AC020906 (fig. 4.3), whereas on 
amplification o f these clones a product was only obtained with clone AC020906. Possible 
explanations for the discrepancy between the BLAST and the experimental data are that 
the insert may have been lost during the isolation procedure, or a PCR amplification 
problem was encountered or the wrong clone was used. Subsequently, D19S866 was
NT-011109
contig
D19S866
BAC clones
AC020906
AC010515
Figure 4.3 Alignment of BAC clones AC020906 and AC010515 with marker D19S866 on contig 
NT 011109 using a bioinformatic approach.
mapped bioinformatically to the contig NT 011109 and could be positioned on the 
integrated map of the PFHBI locus (fig. 3.15).
Gaps in contig N T011109
In May 2003, using “old” contig data, nine gaps were found on the map generated, (table 
3.10). Gaps can arise when overlaps between end clones are too small to be detected by
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“fingerprints” (and therefore will only be detected once the end clones are sequenced), or 
where duplicated segments are wrongly assigned, or in GC-rich regions of the genome, 
which are difficult to sequence (IHGSC, 2001) or when no overlapping fragments exist. 
The nine gaps found in May 2003 when aligning the “old” BAC contig against the most 
recent contig NT 011109 (table 3.10) have subsequently been filled, except for two clone 
gaps; however, the position of these two gaps have not been published (Grimwood et al., 
2004) and they may lie in the PFHBI area. It was not possible to detect these gaps in the 
current study.
An earlier map of the PFHBI locus
In 2001, Christoffels also generated a map of the PFHBI locus using a bioinformatics 
approach, as part of his doctoral thesis (Christoffels, 2001). He used draft sequence, 
generated from the three earlier contigs NT_011190, NT 011140 and NT 011157 (fig. 
3.13), which was released in June 1999 by JGI. In his study, he identified seven 
positional PFHBI candidate genes, namely, KPTN, GLTSRC2, NUCB1, TEAD2, CD37, 
DKF2P761A179 and CGI-123, all shown to be expressed in heart tissue. The major 
difference between the maps of Christoffels and the current study are that Christoffels
(2001) used earlier draft sequence from the three contigs detailed above, whereas in the 
present study, sequence data from the newly merged contig NT 011109 was used. In 
addition, the order of genes and markers has also changed on the map generated in this 
study (fig. 3.15) (May 5, 2003).
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Genes at the PFHBI locus 
Predicted genes
As an outcome o f the HGP, a total o f 82 genes were placed at the PFHBI locus, o f which 
35 are annotated and 47 are predicted genes (tables 3.11 and 3.12). Included in the list of 
47 predicted genes are three genes, namely, LOC147891, FU20401 and FU20643, 
which were generated from the earlier EST searches (table 3.5) (section 3.2).
Only a limited amount of information was present in publicly available databases 
concerning the functional domains o f any o f the predicted proteins encoded by the 47 
predicted genes. Based on the available information summarised in table 3.12 (section
3.4.1), predicted genes generally received a lower priority rating as possible candidate 
genes for PFHBI. O f these, four predicted genes, namely, LOC147891, LOC16307, 
LOCI47872 and LOC95515 (fig. 3.15), were considered candidates which might be 
worthwhile pursuing, based on their signature domains. The predicted gene LOC95515 is 
of particular interest, since its predicted sequence places it in a family of developmentally 
regulated mammalian transcription factors and it has often been suggested that a mutation 
occurring in a gene involved in cardiac development (see section 1.2.3) (Basson et al.,
1999) may cause PFHBI. The reasons for not screening predicted genes in this study are 
discussed in more detail below. Nonetheless, one cannot exclude the remaining predicted 
genes from being plausible PFHBI disease-causative candidate genes.
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However, there are number of pitfalls and problems associated with gene prediction 
programmes (Mathe et al., 2002), which are related to the complexity o f eukaryotic 
genes, which must be taken into account when interpreting gene prediction data. One of 
the problems encountered is that of very long genes, for example, DMK is composed of 
79 exons spanning 2.3Mb (Nobile et al., 1997). The exons are interspersed with 
extremely long introns, some greater in length than lOOkb, which make up more than 
99% of the gene. Yet in some other genes, although these are rare causes, exons span 
only 3bp, and are easily missed if they are bordered by long introns (Nobile et al., 1997). 
Database sequences often contain errors, although in this study sequences of predicted 
genes were not analysed, sequence errors were noted within annotated genes, namely, 
BAX and GSY1 (section 3.6.2, tables 3.14 and 3.15) (Katsanis et al., 2001). Thus, 
predicted genes resulting from gene prediction programmes should be regarded with 
caution, until the “virtual” proteins are verified biologically, as an active protein (Mathe 
et al., 2002). However, gene prediction algorithms are improving constantly and more 
reliable data are generated at a rapid rate.
Annotated genes
During this study, 35 annotated genes were placed on contig NT 011109 at the PFHBI 
locus (section 3.4.1), of which 26 genes were reported to be expressed in cardiac tissue 
(table 3.11), thereby strengthening their candidacy for involvement in a cardiac disorder. 
However, there are also a number of other genes which, although not reported to be 
expressed in heart, based on their functions cannot be excluded from the list o f candidates
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to be screened, namely, BAX, KIR2.4 and CAPB5. The expression profiles o f a number of 
annotated genes are incomplete, since the UNIGENE database only contains expression 
data of cDNA sequences of tissues from which cDNA libraries have been constructed, 
though now there is more information on tissue and developmental stage expression 
obtained from microarray data but the data are yet to be integrated into annotated genome 
sequence sites like ENSEMBL and UCSC. Based on this, one cannot exclude non-cardiac 
expressed genes as plausible candidates and therefore BAX and KIR2.4 were screened in 
the present study. During this study, TEAD2 was not screened for PFHBI mutations 
because its exonic and intronic organisation was not characterised. Subsequently, new 
information on its genetic structure has been deposited into the Ensembl database, 
making it an attractive candidate gene for future mutation screening.
Previously, ESTs were randomly sequenced and deposited into the databases. However, 
attempts have been made to overcome this limitation, for example, a cardiovascular 
expression database has been established which gives information about the expression 
profile of genes during different stages of heart development (Liew et al., 1994; Hwang 
et al., 1997). This resource may prove useful in the PFHBI gene search, as expression of 
the causative gene may be developmentally regulated. There is an urgent need to increase 
the cardiovascular expression data in the EST database because Dempsey et al., (2000) 
reported that the cardiac ESTs comprises of less than 4% of the total number o f ESTs in 
Genbank (section 1.4.3.1). If this situation continues, it may hamper the chances of 
finding the PFHBI gene using EST data.
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4.6 PFHBI CANDIDATE GENES
Genes provisionally excluded in the present study
Position-independent genes
pll5-RhoGEF
In this grouping of genes, using a labeled p i  15-RhoGEF cDNA probe, the cognate gene 
was shown to map to two chromosome 19 radiation hybrids but not to any of the DNA 
clones spanning the PFHBI locus (fig. 3.18). In addition, no RhoGEF sequence was 
found at the PFHBI locus when a BLAST2 search o f p i  15-RhoGEF sequence with each 
DNA clone was performed. As both chromosome 19 radiation hybrids spanned 
chromosome 19 q l3.1 to q l3.3, it appeared, at the time, that the gene either lay outside 
the PFHBI locus or in a gap within the contig spanning the locus. The former assumption 
was confirmed when further sequencing data became available, and a bioinformatic 
search placed the gene centromeric to the PFHBI locus (fig. 3.19), thus excluding the 
p i  15-RhoGEF gene as a PFHBI-causative gene.
Cx
Although a Cx PCR product was not generated from PFHBI-spanning clones, using Cx 
degenerate primers, a product was obtained with chromosome 19 radiation hybrids which 
encompass the PFHBI locus and the flanking regions o f chromosome 19ql3.1 to 13.3 
(section 1.4.2.1, fig. 1.11). This data suggested that a Cx might be present, either in a gap 
within the contig spanning the PFHBI locus (Grimwood et al., 2004), or outside the 
PFHBI locus. A recent bioinformatic search found no Cx-like gene when the sequence 
was BLAST-searched against the finished chromosome 19 contig (2nd Sept, 2004).
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However, a homology search of the translated PCR product against the protein database 
revealed an 83% homology to the protein GJA4 on chromosome lp35.1, which is 
encoded by Cx37 (figs. 3.16 and 3.17). If a duplicate Cx37 was present in the region, then 
the homology search against contig NT_011109 should show it, thus it appears that a Cx 
is not present at the PFHBI locus. An explanation might be that the product generated 
from the radiation hybrid may very well be a hamster Cx, since the two somatic cell 
hybrids, ORIM7-1 and 1219G2, were produced from the fusion o f hamster A3 cells and 
parental lymphoblastoid cells carrying containing chromosome 19q 13.1 to ql3.3 (Schonk 
et al., 1989). Alternatively, a Cx may lie in one o f the remaining unsequenced gaps o f 
chromosome 19 as discussed earlier (Grimwood et al., 2004).
CTG repeat expansions
Van der Merwe et al., (1988) and de Meeus et al., (1995) observed anticipation in 
PFHBI-affected and CCD-affected individuals, respectively, (section 1.3.2.3.4) and since 
unusual triplet repeat expansions have been associated with a number o f diseases 
showing anticipation (see section 1.4.1.3) (Sheffield et al., 1995; Rosenberg, 1996; 
Liquori et al., 2001), the search for an expanded triplet repeat was undertaken.
The reasons for investigating the possibility o f a CTG expansion in particular as causing 
PFHBI, rather than any o f the other pathological triplet repeats, was that DM1, a 
multisystemic disease often associated cardiac conduction abnormalities, is caused by an 
expansion of a CTG repeat within a gene-encoding a serine/threonine protein kinase
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(Aslanidis et al., 1992; Buxton et al., 1992). Since DMK also maps to chromosome 19, 
within 2.1Mb of the PFHBI centromeric marker D19S902, it was reasoned that genes 
with a CTG repeat expansion might be involved in the pathology of both diseases. The 
rationale was that because chromosome 19 shows evidence of genomic duplication with 
7.35% o f its sequence sharing sequence homology to more than one location in the 
genome (Grimwood et al., 2004), a duplicate DMK might cause PFHBI. Furthermore, 
within the human genome paralogous genes occurring within 50kb or greater o f DNA are 
not uncommon (Strachan and Read, 2000).
However, screening o f the entire genome of selected PFHBI-affected individuals (fig. 
2.1) by the Schalling group revealed no disease-causing CTG repeat expansions (fig. 
3.20) (personal communication, Schalling). Since no CTG expansions were found, a 
search for other triplet or tetranucleotide repeat sequences should be investigated. Given 
that the entire sequence o f the PFHBI locus is available in public databases, a modem 
alternative to the RED technique could be to download and to scan the PFHBI target 
sequence for repeat sequences using a repeat finder programme. Identified repeat 
sequences could then be tested experimentally for pathological expansions in PFHBI- 
affected individuals. This would accelerate the search for possible pathological 
expansions and would target only specific repeat motifs found at the PFHBI locus.
In fact, this bioinformatic approach, followed by PCR amplification o f the identified 
repeat motif, has already been used by PFHBI team members. For example, February
(2002) screened the CTG repeat o f NUCB1. Furthermore, the GAG and GAT repeat
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motifs of HRC had already been described in the literature (Hofmann et al., 1991) and 
were therefore analysed by PCR-amplification for unusual expansions by de Meeus et al., 
(1995) and Christoffels (1997) (see the following section “Genes provisionally excluded 
in previous studies).
Position-dependent genes
The position-dependent candidate genes selected for mutation screening from the first 
three most prioritised groups were BAX, KCNA7, K1R2.4, LIN-7B, and GSY1 (table 3.13).
BAX, KCNA 7, KIR2.4, LIN-7B and GSY1
Mutation screening by direct sequencing of the exonic and flanking intronic sequences 
the selected genes revealed no disease-causing mutations (table 4.1). With the exception 
o f GSY1, these genes can only be provisionally excluded because the remaining intronic 
and UTR regions should also be investigated, for possible disease-causative mutations. 
For example, in dilated cardiomyopathy, mutations were found in the regulatory region 
and the coding regions of the human cardiotrophin gene (CTF1) (Erdmann et al., 2000).
Exclusion of previously identified candidates
As part of this study, genetic fine mapping o f the PFHBI locus has excluded four o f the 
seven candidates identified by Christoffels (2001), namely, KPTN, GLTSRC2, CGI-123 
and DKF2P761A179 (fig. 4.4). Another PFHBI team member screened and subsequently 
provisionally excluded NUCB1 as a PFHBI disease-causative gene (F. February, 2002).
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Figure 4.4 Positions o f  previously identified PFHBI candidate genes on the current PFHBI map. 
The genetic markers D19S902 and D19S866 flanking the PFHBI locus, cen, centomeric end; tel, telomeric 
end; a, KPTN; b, GLTSRC2; c, NUCBl; d, TEAD2; e, CD37; f, CGI-123; g, DKFZp761 A 179.
The remaining two candidates, TEAD2 and CD37, prioritised by Christoffels, map to the 
PFHBI locus and, as yet, have not been screened. The gene CD37 was also prioritised in 
the present study, and by Brink (1997), as a plausible PFHBI candidate gene (section
3.4.2).
Genes provisionally excluded in previous studies
As part of an M.Sc study, Christoffels (1997) investigated two triplet repeats GAG and 
GAT within exon 1 o f HRC which were o f interest, because of the anticipation reported 
by Van der Merwe et al., (1988). In the general Caucasian population the (GAT)n repeat 
motif comprises 12 to 15 repeats and is tetra-allelic, whereas the (GAG)„ repeat motif 
comprises 8 or 9 repeats and is biallelic (Christoffels, 1997). His investigation showed no 
expansions o f either of these triplets in PFHBI-affected individuals. Following the same 
rationale, De Meeus et al., (1995) screened the same two triplet repeats in the CCD- 
affected Lebanese kindred but again no abnormal repeat expansions were found. 
Subsequently, Dr Black sequenced HRC in its entirety but found no disease-causing
DI9S902 D19S866 tel
—r - |------------- 1--------1-----1------------- 1---- 1-----1--------------
b c d e f  g
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mutation (personal communication, Black). Based on all these investigations, HRC can 
now be excluded as PFHBI-causative.
Table 4.1 Excluded and provisionally excluded PFHBI genes
Genes 5’UTR 3’UTR Exons Introns Approach
screened screened screened used
Present study
PI 15-RhoGEF experimental
Cx experimental
CTG expansion RED analysis
BAX nd nd 1-6 nd sequencing
KCNA7 nd nd 1 & 2 nd sequencing
KIR2.4 nd nd 1-3 nd sequencing
L1N-7B nd nd 1-5 nd sequencing
GSY1 com nd 1-3 nd sequencing
6 to 10 nd sequencing
13-16 (B to D) nd sequencing
KPTN BLAST-search
GLTSRC2 BLAST-search
CGI-123 BLAST-search
DKF2P761A179 BLAST-search
Previous studies
8HRC com com 1-6 com sequencing
bNUCBl nd nd 1-13 nd sequencing
‘SNRP70 nd nd 1-10 nd sequencing &
PCR-SSCP
‘SR-A1 nd nd 6 nd sequencing
dGSYl nd nd 4 ,5 nd PCR-SSCP
11, 12 nd PCR-SSCP
BAX, BCL2-associated X protein; KCNA7, potassium voltage-gated channel shaker-related subfamily
member 7; KIR2.4, potassium inwardly-rectifying channel, subfamily J, member 14; LIN-7B, lin-7
homolog B (C. elegans); GSY1, glycogen synthase \;KPTN, actin-binding protein; GLTSRC2, unknown 
mRNA ; CGI-123, CGI prote\n;DKF2P761AI7, unknown mRNA; HRC, histidine-rich calcium binding 
protein; NUCB1, nucleobindin 1; SNRP70, small nuclear ribonucleoprotein 70kDa polypeptide (RNP 
antigen); SR-A1, serine arginine-rich pre-mRNA splicing factor SR-A1 ; nd, not done, com, completed; a, 
personal communications, Black; b, February, 2002; c, Du Plessis, 2004; d, Makubalo, 2000.
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Makubalo (2000) screened four exons of GSY1, which contained domains conserved 
across species, for mutations using PCR-SSCP (section 1.5.4). The rationale was that any 
sequence variation occurring in these conserved regions might have a deleterious effect 
on the function of the protein and possibly cause PFHBI. As part of the present study, the 
remaining exons and 5’UTR regions of GSY1 were screened (section 3.6.2). No PFHBI- 
causative mutations were found.
In a study by F. February (2002), NUCBl was screened for PFHBI-causative mutations 
and excluded. In a recent study by Du Plessis (2004), the role of mutations in genes 
implicated in cardiac development was investigated. The delicate control o f alternative 
splicing is thought to be pivotal in development (Lopez, 1998) and, therefore, any 
imbalance in this mechanism may be disease-causative. The gene SNRP70 and two SR- 
A7-encoding domains located in exon 6 of the SR-A1 gene were selected for mutation 
screening, since both genes map to the PFHBI locus, are splicing factors and are 
expressed in cardiac tissue. Furthermore the SR-A1-encoding domains play a role in the 
binding of the splicing machinery. PCR-SSCP mutation screening of the nine exons, the 
flanking intronic sequences o f SNRP70 and the two SR-A 1-encoding domains, namely, 
SR (serine, arginine) and the DR (aspartic acid, arginine) o f SR-A 1 did not reveal any 
disease-causative mutations, thus excluding SNRP70 and exon 6 of SR-A1 as PFHBI- 
causative.
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In summary, only one of nine genes investigated using direct sequencing, namely, HRC, 
can be excluded because the entire gene was investigated for disease-causative mutations. 
The remaining eight genes (table 4.1) are only provisionally excluded since regulatory 
and intronic and regions should be screened for disease-causative mutations. Even if the 
gene is completely excluded, in the case of more compelling candidates, further 
investigation at the mRNA and protein level might be warranted.
4.7 LIMITATIONS OF THE PRESENT STUDY AND FUTURE STUDIES
The occurrence of BB disorders similar to PFHBI is not restricted to South Africa and is 
reported globally (table 1.1, section 1.3.2.3). It is proposed that the discovery of the 
PFHBI gene and its causative mutation will assist in an understanding o f the genetic 
mechanisms underlying these cardiac conduction disorders. It is envisaged that combined 
knowledge will eventually translate into improved diagnosis and management of the 
disease.
Complete gene mutation screening
Many familial disorders have been associated with point mutations or deletions in exonic 
or in the flanking intronic sequences o f genes. For example, in ICCD a mutation occurs 
in exon 12 of SCN5A, resulting in a substitution o f cysteine 514 for glycine (G514C) in 
the channel protein (Tan et al., 2001). In PCCD, again it is a mutation in SCN5A that is 
responsible for the disease, but it occurs in the highly conserved donor splice site of
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intron 22, which results in an abnormal transcript and consequent in frame skipping of 
exon 22 (Schott et al., 1999). However, mutations can also occur in either the regulatory 
or intronic regions of a gene. For example, in dilated cardiomyopathy, mutations were 
found in the regulatory region and the coding regions of the human cardiotrophin gene 
(CTF1) (Erdmann et al., 2000). For this reason, one cannot exclude the possibility o f the 
PFHBI-causing mutation occurring in the non-coding or regulatory regions o f the 
responsible gene. Hence, in the present study, one of the limitations is that, with the 
exceptions of HRC in which the whole gene was sequenced, and GSY1 in which the 5’ 
UTR region was screened, only the exonic and the flanking intronic regions of the PFHBI 
candidate genes were screened for mutations.
Ascertainment bias
One question raised during this study is how real is the phenomenon of anticipation in 
PFHBI? The findings of Van der Merwe and colleagues (1988) in a South African family 
and De Meeus and colleagues (1995) in a Lebanese family both showed evidence of 
anticipation as a feature of the disorder. Since, in both cases, the families were known to 
the investigating clinicians, the family members had regular examinations and were 
closely monitored. Therefore, it can be argued that these studies might suffer from 
ascertainment bias.
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Com parative genomics
Since a number of predicted genes have been placed at the PFHBI locus, comparative 
genomics, i.e., comparing human sequences to sequences from other organisms, for 
example, M. musculus, D. rerio, and Takifugu, is a useful resource to support the 
existence of these genes and can help to annotate them (Nobregia and Pennacchio, 2004). 
For example, Du Plessis (2004) used murine sequences to find homologous genes in 
humans, which had not yet been mapped to the PFHBI locus but were on the syntenic 
region of mouse chromosome 7. Using this approach, he identified two novel genes at the 
PFHBI locus, which showed similarity to the genes encoding murine small ubiquitin- 
related modifier-1 (sumo-1) (Shao et al., 2004) and cytochrome oxidase VIC (cox6c) 
(Bachman et al., 1997) and on assessment, the former was considered a plausible 
candidate gene for PFHBI. Both these predicted genes have been placed 
bioinformatically on the integrated physical and genetic map (fig. 3.15). The first gene 
participates in the apoptotic pathway and is now known to tag proteins destined for 
degradation in the heart and brain (Shao et al., 2004), however, not enough information 
was available from the database to explore the human homolog. The second gene is 
involved in the electron transport chain which results in energy production and a 
mutation in this gene would have a multisystemic effect.
The mouse genome has already been particularly valuable in the search for homologous 
genes in the human genome, since 82%, or 45Mb, of chromosome 19 is orthologous to 
mouse chromosome 7 (Grimwood et al., 2004). For example, as part of this study, the
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coding sequence and the genomic organisation o f KCNA7 (AF315818) (fig. 3.21) 
(Bardien-Kruger et al., 2002) were determined using the alignment of a human BAC 
clone AC0008687 with published mouse cDNA sequence (AF032099) (Kalman et al., 
1998).
In addition, animal models of human disease, e.g., mouse and zebrafish (Sehnert and 
Stainier, 2002) also play an important role in the functional analysis of genes; 
understanding the manner in which specific mutations affect the heart in these organisms 
will help in an understanding of the functioning human orthologs and their possible role 
in cardiac conduction diseases, as discussed for DM (see section 1.2.3.1) (Mathe, 2002).
Gene density on chromosome 19
A number o f researchers working with this region of chromosome 19 appear to be 
experiencing difficulties in finding “their” disease-causative gene for disorders, for 
example, LGMD2 (Driss et al., 2000), CED (Ghadami et al., 2000) and DFNA4 (Chen et 
al., 1995) (section 1.4.4, fig. 1.14). This may largely be due to the nature of chromosome 
19 sequence (Grimwood et al., 2004), namely, the gene density, which results in the large 
number of plausible candidate genes present at different loci, e.g., the estimated number 
of annotated genes at the PFHBI locus is 63. Other factors hampering all gene searches 
on chromosome 19 are probably due to the high G+C content which interferes with 
sequencing. Additionally, numerous CpG islands and the density of repetitive DNA could
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cause problems when applying gene prediction programmes to sequence data from this 
area, which can result in a number of false positives (Mathe, 2002).
A comparison of the status of PFHBI with other gene searches
In most cases, gene searches are part of a team effort (section 1.6). The searches for 
FRDA and RP13 genes have been successful, whereas the searches for the PFHBI and 
the KWE genes, in the latter case as far as we know, are still ongoing. There are a 
number of similarities between the PFHBI and the KWE gene searches (section 1.6.2). At 
the start of each study, linkage analysis and fine mapping reduced the PFHBI (Brink et 
al., 1995) and the KWE (Starfield et al., 1997) loci to lOcM, subsequently these loci have 
been reduced, to a physical distance of 2.4Mb for PFHBI and 635,404bp for KWE 
(Appel et al., 2002). In addition, both groups generated a detailed physical and transcript 
map of each locus, e.g., with the PFHBI study, a computational method was used and 
with KWE, the BAC contig was sequenced and then bioinformatics were applied (Appel 
et al., 2002). Ideally, the reduction of the PFHBI locus to a region comparable in size to 
the KWE locus is desirable but, even then, identifying the disease-causing gene and the 
associated mutation may prove to be challenging, as it has been for KWE.
Mapping data obtained from more than one family, as was the case for the successful 
RP13 gene search, is useful, because the chances o f meiotic events are increased, thus 
increasing the chance of reduction of the disease-causing locus. For example, in the RP13 
gene search, three families were investigated, namely, a large SA family o f British
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ancestry, a family of British descent living in the USA and a British family based in 
Britain (section 1.6.1). In the PFHBI search, there was an initial collaboration with a 
French group from the Inserm laboratory, Paris, a collaboration which proved to be 
useful to both groups, the French group’s search locus was larger, 13cM in length (de 
Meeus, et al., 1995) compared to the PFHBI locus, which had already been reduced to 
7cM (fig. 1.9) (personal communication, De Jager, 1998). When the two groups met, 
based on combined data, the French group reduced their locus to 7cM. As part of the 
present study, the most centromeric marker o f the CCD locus i.e., D19S606, (fig. 1.9) 
was typed in the PFHBI families, which indeed reduced the locus to 4cM and confirmed 
the French group’s data excluding the proximal regions. The collaboration has 
subsequently lapsed and it has not been possible unable to establish what stage they has 
been in CCD gene search, since no further publication or communication has been 
forthcoming.
In addition to genomic sequencing, other experimental methodologies could be used to 
strengthen the candidature of attractive genes. Ideally, examining expression profiles of 
the genes in the conduction tissue by RT PCR or by raising antibodies to investigate the 
distribution o f the protein products would be valuable. However, a biopsy of human 
cardiac tissue presents challenges. An alternative approach may be to use the bovine 
heart, in which conduction tissue is visible as what is called the ox “false tendon” 
(Obbiassi et al., 1987).
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Thus it is hoped that, although there are apparently no other non-founder PFHBI families 
in South Africa or worldwide, recruitment of new members of the existing families will 
identify new meiotic recombination breakpoints which will further reduce the number of 
genes to be screened for disease-causing mutations. Database searches for new 
polymorphic markers will also be useful to further reduce the PFHBI locus.
As part of the ongoing research the suggested candidate genes, TEAD2 and CD37, should 
be screened for PFHBI disease-causative mutations. The predicted proteins placed at the 
PFHBI locus should be re-examined since a number o f these genes are either removed or 
replaced by annotated genes. As new genes are placed at the PFHBI locus, the genes 
listed for screening should be re-prioritised as PFHBI candidates. In addition, the 
integrated map of the PFHBI locus should be updated on a regular basis as new data are 
deposited into the databases.
Ultimately, when the region is small enough, sequencing across the critical region of an 
affected and an unaffected PFHBI individual should be pursued to find the disease- 
causative mutation.
It is envisaged that the identification o f PFHBI-causative gene and associated mutation 
will provide a platform for further studies to understand the pathophysiology, not only of 
PFHBI, but also of other more commonly occurring conduction disturbances.
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APPENDIX I
SOLUTIONS, BUFFERS AND METHODS
1. STOCK SOLUTIONS 
10x TBE BUFFER
ETHIDIUM BROMIDE (lOmg/ml)
Ethidium bromide (Sigma) 500mg
ddH20  50ml
Stir well on magnetic stirrer for 4 hours, store in a dark container at 4°C.
10% AMMONIUM PERSULPHATE
Ammonium persulphate (Merck) 5g
ddH20  50ml
Mix well and store at 4°C
2. DNA EXTRACTION 
CELL LYSIS BUFFER
Sucrose (Merck) 0.32M
Triton X-100 (Merck) 1%
MgCl2 (Merck) 5mM
Tris-HCl, pH 8.0 (Biorad) lOmM
ddH20  to 1 litre
Tris-OH (Merck) 
Boric acid (Merck) 
Na2EDTA (Merck)
0.89M, pH8.0 
0.89M
20mM, pH8.0
lOx TE BUFFER STOCK SOLUTIONS
Tris-HCL (Merck)
EDTA (Boehringer Mannheim)
0.1M, pH8.0 
0.01M, pH8.0
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3M NaAc
NaAc.3 H2 0  (Merck) 40.81g
Adjust to pH to 5.2 with glacial acetic acid (Merck) and adjust volume to 100ml with
ddH2 0.
Na-EDTA SOLUTION
NaCl (Merck)
EDTA (Merck)
Mix well.
PHENOL/CHLOROFORM
Mix phenol (Merck) (saturated with lxTE), chloroform (Merck) and 8 -hydroxyquinoline 
(Merck) in a ratio of 25:24:1. Store at 4°C.
CHLOROFORM/OCT ANOL
Mix chloroform (Merck) and octanol (Merck) in a ratio of 24:1. Store at 4°C.
3. BACTERIAL CELL GROWTH MEDIA
LURIA-BERTANI MEDIUM
NaCl (Merck)
Tryptone (Biolab)
Yeast extract (Oxoid) 
ddH20  to 1 litre
Adjust to pH7.2 with 5M NaOH and autoclave.
LURIA-BERTANI AGAR
NaCl 
Tryptone 
Yeast extract 
ddH20  to 1 litre
Dissolve in 700ml ddH20  and adjust to pH7.2 with 5M NaOH (Merck).
1 0 g
1 0 g
5g
1 0 g
1 0 g
5g
18.75ml of 4M stock solution 
250ml of lOOmM stock solution
Bacto-agar (Difco Laboratories) 
ddH20  to 1 litre and autoclave
15g
Stellenbosch University http://scholar.sun.ac.za/
4. COSMID DNA EXTRACTION
Using the QIAGEN* plasmid/cosmid purification kit buffers (Stratagene). (See section 
14).
5. PLASMID AND BAC DNA EXTRACTION
SOLUTION I (Resuspension buffer)
Glucose (BDH Chemicals)
Tris (pH8.0) (Merck)
EDTA (Boehringer Mannheim) 
ddH2 0  to 500ml and autoclave
SOLUTION II (Lysis buffer)
NaOH (Merck)
SDS (Sigma) 
ddH2 0  to 1 ml
SOLUTION III (Neutralising buffer)
Glacial acetic acid (Merk)
Potassium acetate (Merck) 
ddH2 0  to 1 0 0 ml
6. COLONY BLOT SOLUTIONS
DENATURING SOLUTIONS
NaCl (Merck)
NaOH (Merck) 
ddH2 0  to 1 litre
NEUTRALISING SOLUTION
NaCl (Merck)
Tris (pH 8.0) (Merck) 
ddH2 0  to 1 litre
50mM
25mM
0.5M
0.2M
1%
11.5%
3M
1.5M
0.5M
1.5M
0.5M
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PRE-WASH SOLUTION
SSC
SDS (Sigma)
EDTA (Boehringer Mannheim) 
ddH20  to 1 litre
7. HYBRIDISATION STOCK SOLUTIONS
20xSSC
NaCl (Merck)
Na citrate (BDH Chemicals)
100X DENHARDT’S SOLUTION
Ficoll 400 (Merck) 
Polyvinylpyrrolidine 
BSA fraction 
Store at -20°C.
20X SSPE
NaCl
Na2HP04 (BDH Chemicals) 
NaH2P 04 (BDH Chemicals) 
SDS (Sigma)
PEG8 0 0 0  (Pharmacia)
SOLUTIONS FOR MEMBRANE FILTERS
PRE-HYBRIDISATION SOLUTION
20x SSPE 
100X Denhardt’s 
10% SDS
Sonicated E. coli DNA (Sigma) 
ddH20  to 80ml
HYBRIDISATION WASH SOLUTION
SSC
SDS
5x
0.5%
ImM
0.15M
0.15M
0.025mM 
0.027mM 
2% (g/ml)
125mM
17mM
8mM
173mM
12.5mM
20ml
4ml
1.6ml
5mg/ml
2x
0.1%
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8. AGAROSE GEL SOLUTIONS
0.7% AGAROSE GEL
Agarose (Seakem) 0.35g
lOxTBE 5ml
H20  45ml
1% AGAROSE GEL
Agarose 0.5g
lOxTBE 5ml
H20  45ml
1,5% AGAROSE GEL
Agarose 0.75g
lOxTBE 5ml
H20  45ml
2% AGAROSE GEL
Agarose 1.0g
lOxTBE 5 ml
H20  45ml
Melt agarose (FMC) in a microwave oven on HIGH power, swirling occasionally until it 
is completely dissolved. Cool the solution to 50°C -60°C and add 5 pi ethidium bromide 
(lOmg/ml) prior to casting.
9. POLYACRYLAMIDE GEL SOLUTIONS
12% NON-DENATURING POLYACRYLAMIDE GEL SOLUTION
40% acrylamide stock solution 8ml
1 Ox TBE stock solution 2ml
ddH20  10ml
10% ammonium persulphate 160 pi
TEMED 60pl
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5% DENATURING POLYACRYLAMIDE GEL SOLUTION
40% acrylamide stock solution 10.8ml
1 Ox TBE stock solution 6ml
Urea 26.64g
ddH20  12.75ml
Stir well with a magnetic stirrer until all urea is dissolved, then add 
10% ammonium persulphate 500pi
TEMED 50(4.1
METHOD
CASTING OF SEQUENCING GELS
Glass plates were prepared by carefully and meticulously washing both plates with 
detergent. The plates were wiped with 70% ethanol, and were dried thoroughly to remove 
any traces of detergent. The notched plate was then silanised with Wynn’s C-thru 
windshield rain dispersant (Wynn Oil S.A. Pty Ltd, SA) so that this plate could be 
removed while the gel remained fixed to the large plate, and the notched plate was placed 
silanised side-down on top of the spacers. This assembly was sealed with the use of a 
rubber boot (S2 casting boot, Life M Technologies) and the gel poured with the glass 
assembly at a slight angle. The glass assembly was placed horizontally and the loading 
front was formed with a top spacer of identical thickness to the lengthwise spacers. The 
gel was allowed to set for 1-2 hours, whereupon the top spacer was removed and replaced 
with a sharkstooth comb to separate wells for loading of samples.
10. SSCP ANALYSIS GEL SOLUTIONS
0.35x MDE GEL SOLUTION
2x MDE™ stock solution (FMC) 28ml
1 Ox TBE stock solution 9.7ml
H20  122ml
10% ammonium persulphate 1.6ml
TEMED 160jnl
5% NON-DENATURING POLYACRYLAMIDE GEL SOLUTION WITH 
10% GLYCEROL
40% acrylamide stock solution (BDH Chemicals) 27ml
1 Ox TBE stock solution 8ml
Glycerol (Merck) 16ml
H20  108ml
10% ammonium persulphate 1.6ml
TEMED 160(0.1
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10% NON-DENATURING POLYACRYLAMIDE GEL SOLUTION WI 
10% GLYCEROL
40% acrylamide stock solution 54ml
1 Ox TBE stock solution 8ml
Glycerol 16ml
H20 81ml
10% ammonium persulphate 1.6ml
TEMED (Promega) 160 pi
8% MILDLY-DENATURING POLYACRYLAMIDE GEL SOLUTION
40% acrylamide stock solution 32.4ml
1 Ox TBE stock solution 8ml
Urea 24g
Glycerol 8ml
h 2o 91.8ml
10% ammonium persulphate 1.6ml
TEMED 160 pi
10% MILDLY-DENATURING POLYACRYLAMIDE GEL SOLUTIOI^
40% acrylamide stock solution 40.5ml
lOx TBE stock solution 8ml
Urea 24g
Glycerol 8ml
H20 84ml
10% ammonium persulphate 1.6ml
TEMED 160pl
METHOD
CASTING OF SSCP GELS
Glass plates were prepared by carefully and meticulously washing both plates with 
detergent. The plates were wiped with 70% ethanol, and were dried thoroughly to remove 
any traces of detergent. The notched plate was then silanised with Wynn’s C-thru 
windshield rain dispersant (Wynn Oil S.A. Pty Ltd, SA) to ease the separation of the gel 
from the un-notched plate upon dismantling after electrophoresis. More 70% ethanol was 
sprayed on to the inner surface of the large glass plate. A sheet of Gelbond™ (FMC 
Bioproducts, Rockland, Maine, USA), cut to the same size as the large glass plate, was 
placed, hydrophobic side down, on this plate, taking care not to remove the protective 
sheet of paper from the hydrophilic side of the nylon membrane. Air bubbles trapped 
between the Gelbond™ and the glass were removed by careful rubbing over the 
protective sheet of paper with a piece of paper towel. Subsequently, this sheet of paper 
was removed from the nylon membrane and spacers of 1mm (SSCP analysis gels)
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thickness placed lengthwise at the edges of the large glass plate. The notched plate was 
placed silanised side-down on top of these spacers. This assembly was subsequently 
sealed with the use of rubber boot (S2 rubber casting boot, Life™ Technologies) and the 
gel poured with the glass assembly slanted at a slight angle. The glass assembly was 
subsequently laid down horizontally and a square-tooth well-forming comb inserted. The 
gel was allowed to set for 1 -2 hours.
11. LOADING DYES
BROMOPHENOL BLUE LOADING DYE FOR AGAROSE AND 
POLYACRYLAMIDE GEL ELECTROPHORESIS
All the components were mixed. The blue colour intensity of the loading dye was 
decreased compared to the conventional loading dye, in order to prevent masking of 
small PCR amplified DNA fragments on agarose gels.
Bromphenol blue (BDH Chemicals) 
Glycerol (Merck)
Tris-Cl, pH8 (Merck)
0.1% (w/v) 
60% (v/v) 
lOmM
SSCP LOADING DYE
Bromophenol blue (BDH Chemicals)
Xylene cyanol (M & B Laboratory Chemicals) 
Formamide (Merck) 95%
lOmM
20mM
0.1% (w/v) 
0.1% (w/v)
NaOH
EDTA
Mix well. Aliquot and store at -20°C.
SEQUENCING STOP SOLUTION
Bromophenol blue (BDH Chemicals)
Xylene cyanol (M & B Laboratory Chemicals) 
Formamide (Merck)
0.1 % (w/v) 
0.1% (w/v) 
95% (v/v)
12. SILVER STAINING OF NON-DENATURING 
POLYACRYLAMIDE GELS
AgNOj SOLUTION (0.1%)
AgN0 3  (Merck) 
ddH20
lg
1 litre
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DEVELOPING SOLUTION
NaOH 15g
NaBH4 (Sigma) O.lg
Formaldehyde 4ml
ddH20  to 1 litre
Mix well on magnetic stirrer until all NaOH pellets are dissolved.
METHOD
SILVER STAINING OF POLYACRYLAMIDE GELS
The gel casting plates were dismantled and the polyacrylamide gel was gently immersed 
into a shallow receptacle containing freshly prepared AgN0 3  solution. The gel was 
agitated for 10 min, on a shaking platform. The AgN0 3  solution was poured off and the 
gel was thoroughly washed with ddH20 . Freshly prepared developing solution was added 
and the gel was agitated in the solution until DNA fragments become visible as bands on 
the gel. The developing solution was poured off, the gel rinsed in ddH20 , air-dried (SSCP 
gels) and photographed.
13. X-RAY FILM DEVELOPING 
DEVELOPING SOLUTION
Polycon A variable contrast X-ray developer polycon A
(Champion Photochemistry Pty Ltd, Midrand, SA) solution 1.98 litre
Polycon A variable contrast X-ray developer solution 2 18.1 ml
ddH20  9.9 litre
STOP SOLUTION
Glacial acetic acid 540ml
Make up to 9 litres with ddH20
FIXING SOLUTION
Perfix (Champion Photochemistry Pty Ltd, Midrand, SA) 1.8 litre
Hardener-S (Champion Photochemistry Pty Ltd, Midrand, SA) 225ml 
Make up to 9 litres with H20.
METHOD
The X-ray was clamped to a stainless steel frame under red light, and was immersed into 
the developing solution for 4 min, then into the stop solution for 30 sec and finally into
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the fixer solution for 2 min. The film was rinsed well with H2 O, and then allowed to air 
dry.
14. METHODS FOR THE IDENTIFICATION OF RECOMBINANT COSMIDS
CONTAINING (A^G)„ MOTIFS
Cosmid culture preparation and Colony blots
The recombinant Lawrist-16 cosmid cultures were prepared by dipping a sterile loop into 
a stab culture or by scraping the top of frozen glycerol stocks. The loop was then used to 
inoculate 2ml of Luria Bertani (LB) broth in 15ml tubes containing kanamycin (Kn) 
(50(j.g/ul). The tubes were incubated at 37°C overnight with vigorous shaking and 
subsequently 2ml of the culture were streaked onto a LB agar (LBA) plate containing 
50|ag/ml of Kn, which was incubated overnight, at 37°C. A single colony was picked 
from the incubated agar plate, inoculated into 250ml LB/Kn (50p.g/ml) medium and 
incubated at 37°C overnight with vigorous shaking.
Isolation and purification of cosmid DNA 
QIAGEN Method
The QIAGEN™ commercial DNA purification kit (QIAGEN, Germany) was used to 
isolate cosmid DNA from bacterial genomic DNA with slight modifications to the 
manufacturer’s protocol. Cells were harvested from 250ml overnight culture by 
centrifugation at 4°C for 10 min at 6000rpm in a Sorvall RC-5B (Du Pont, USA) 
centrifuge using a GSA rotor. The supernatant was discarded and the pellet carefully and 
completely resuspended in 50ml of buffer PI containing RNAse A (100|ag/ml). The cells 
were then lysed by adding 50ml of buffer P2 to the suspension, which was then gently 
mixed and incubated for 5 min at room temperature. Fifty millilitres of chilled buffer P3 
was added to the lysed cells and this was incubated on ice for 10 min. Bacterial DNA was 
precipitated from the insoluble cosmid DNA by centrifugation at 20000g (1 lOOOrpm) in a 
Sorvall RC-5B centrifuge with a GSA rotor for 30 min. The cosmid DNA-containing 
supernatant was transferred into a sterile GSA tube, re-centrifuged, for 15 min until the 
supernatant was clear. The supernatant was transferred into a clean tube. The next part of 
the purification involved gel filtration.
A QIAGEN-tip500 column was first equilibrated with 10ml of QBT buffer (QIAGEN, 
Germany) (Appendix I) before loading the cosmid containing supernatant. The next step 
involved washing the column twice with 30ml buffer QC to remove contaminants from 
the DNA. The DNA was released from the column by the addition of 15 ml of buffer QF 
and the eluant was collected in a SS34 tube. Cosmid DNA precipitation was performed 
by the addition of 10.5ml (0.7 volumes) of isopropanol at room temperature and 
centrifugation at 15000g (9500rpm) in a Sorvall RC-5B centrifuge using a SS34 rotor for 
30 min at 4°C. The supernatant was carefully removed and the DNA-containing pellet 
washed with 5ml ethanol (70%), followed by centrifugation at 15000x g in a Sorvall RC- 
5B centrifuge using a SS34 rotor, for 10 min at 4°C. Ethanol was decanted and the 
remnants blotted with a paper towel. The pellet was air-dried for 5 min and resuspended
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in 200|il lxTE buffer (pH8.0). Absorbance was read on a spectrophotometer at 260nm to 
determine the DNA concentration (fag/ml) using the formula: OD2 6 0  x 50 x Dilution 
factor (1OD2 6 0  = 50fxg). The DNA was analysed on a 0.7% agarose gel containing 0.01% 
EtBr and lxTBE to check its integrity (section 2.7.1). The cosmid DNA could now be 
utilised for the preparation of dot blots, Southern or sub-cloning
Preparation of Dot blots
Dot blots were used for the initial screening of cosmids to identify those cosmids 
containing (A3 G)n repeats and again later to verify the presence of (A3 G)n repeats in the 
inserts. The denaturation of the cosmid DNA was performed in the following steps: To 
each 200ng of cosmid DNA an equal volume of 0.4N NaOH was added and the mixture 
was incubated at room temperature for 5 min. The mixture was snap-cooled on ice for 2 
min and spotted onto the previously marked positions on a Hybond™ N+ filter 
(Amersham, UK), which had been placed on 3MM-chromatography paper (Whatman, 
England).Fifty nanograms of human genomic DNA were spotted onto the filter as a 
positive control and ddH20  as a negative control. The filter was air-dried for 15 min and 
thereafter baked for 2 hrs in an 80°C vacuum oven (Towson and Mecer Ltd, England). 
Subsequently, the filter was either re-hydrated in 2x SSC prior to the pre-hybridisation 
step of the screening process (section 2.10.1.6) or covered with clingfilm (GLADwrap™) 
and stored at 4°C until required.
Cosmid DNA digestion and Southern blot preparation
The digestion reaction, which contained 30fo.g cosmid DNA, 90U Sau3AI (Promega, 
USA), lOx buffer as specified by the manufacturer (Promega,US A), and ddH20 to 150(il, 
was incubated at 37°C for 3 hrs (see fig. 2.5A). The digestion was monitored by 
electrophoresis of a 2jal aliquot of the reaction mix on a 0.7% agarose gel (Appendix I). 
When digestion was considered to be complete, the digested fragments were separated on 
a 20 x 20cm 0.7% agarose gel containing 0.01% EtBr (Appendix I) by electrophoresis at 
35V overnight. In addition, X Pstl, (Promega, USA) was run alongside the digested 
cosmid inserts as a marker. The following day a luminescent ruler was placed alongside 
the gel on an UV-transilluminator (3UVM™ Transilluminator model, LMS-26E) and 
photographed using an ITC camera (Berkenhoff and Drebes, Germany) and a Sony video 
graphic printer (UP-860CE).
The gel containing the digested cosmid samples was prepared for Southern blotting in the 
following way. Immediately after the electrophoretic separation of the digested cosmid 
DNA fragments, the gel was depurinated by submersion and gentle agitation in 0.2M HC1 
for 10 min in a glass container. The HC1 was decanted, and the gel rinsed three times in 
ddH20 before placing it on a platform covered with 3MM Whatman paper for alkaline 
transfer of DNA fragments from the gel onto a Hybond™ N+ nucleic acid transfer 
membrane filter (Amersham, UK), following the manufacturer’s protocol for alkaline 
Southern blotting (Amersham, UK). The DNA was fixed by baking the filter for 2 hrs at
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80°C in a vacuum oven (Towson and Mercer Ltd, England). Thereafter, the Hybond™ N+ 
membrane was either re-hydrated in 2x SSC (Appendix I) in preparation for probing with 
a radioactively labeled oligonucleotide or stored at 4°C.
14.5 Labeling of (A3G)io oligonucleotides
In order to identify the (A3 G)n repeat containing fragments to be used for subcloning, the 
Hybond™ N+ membrane was probed with an end labeled y-32P[dATP]-(A3G)io 
oligonucleotide. The end-labeling reaction mixture contained 1 fa.1 of (A3 G)io 
oligonucleotide (50pmol), 10^1 y-32P[dATP] (Amersham, UK), 2^1 T4 polynucleotide 
kinase (20 units) (Promega, USA), 5p.l of 10xT4 polynucleotide kinase buffer (Promega, 
USA), and 32|il ddH20. The labeling mixture was incubated for 2 hrs at 37°C.
Gel filtration chromatography on Sephadex G-25 was used to separate the radio-labeled
'1 'y
probe from the unincorporated y- P[dATP]. The incorporated radioactivity in the 
labeled oligonucleotide had to be at least lx l0 6 cpm/ml of hybridisation solution before 
hybridisation was pursued.
14.6 Pre-hybridisation, hybridisation and post-hybridisation
The filters (Hybond™ N+ membranes, dot blots or the colony blots) were prehybridised 
in twenty millilitres of pre-warmed (42°C) pre-hybridisation liquid (Appendix I), in a 
heat-sealable plastic bag, in a Perspex container, in a shaking waterbath (Heto Lab 
equipment, Denmark) at 42°C for 6 hrs. Thereafter, one comer of the bag was cut open 
and the pre-hybridisation fluid discarded. Twenty millilitres of fresh hybridisation 
solution (Appendix I) containing the radioactivity labeled probe was added to the bag 
which was then re-sealed and incubated overnight at 42°C, in a shaking water-bath (Heto 
Lab equipment, Denmark). After incubation, the hybridisation solution was discarded 
appropriately, and the filters washed. This was done by submerging the labeled filters in a 
flat-bottomed plastic box containing 2x SSC with 0.1% SDS (Appendix I), after which 
the filters were incubated for 30 min at room temperature with gentle shaking. This 
washing step was repeated 4 times, with fresh 2x SSC with 0.1% SDS for each wash. 
During the washes the filters were checked with a Geiger counter during and after each 
wash, so that the washing step was stopped when the radioactivity dropped to 10 counts 
per sec since most of the background radioactivity would have been removed. The filters 
were dried at room temperature on a sheet of 3MM-chromatography paper (Whatman), 
sealed in a plastic bag. The filters were exposed to an X-ray film (Cronex-4, Protea 
Medical) for 48 hrs and were developed as described in section 2.7.4. In the case of 
filters, positive signals observed on the autoradiograph represented inserts containing 
(A3 G)n repeats. The method used to identify and isolate these inserts is described in 
section 14.7. The identified (A3 G)n repeat containing DNA was investigated further as 
described in section 2.10.2.
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14.7 Insert DNA preparation
Sa«3Al restriction enzyme digestion of pBluescript SK DNA
For the purposes of cloning, 30pg of cosmid DNA containing the (A3G)n repeat were 
digested with 90U of Sau3A\ (Amersham, UK) according to the manufacturer’s protocol 
for 3 hrs and electrophoresed on 0.7% agarose gel (20cm x 20cm x 3cm) (Appendix I) at 
30V overnight alongside X Pstl (Promega, USA). The following day, the gel was 
photographed and the fragments containing the (A3G)n repeat were identified by 
comparison of the positive signals from the autoradiograph (section 2.10.1.6) and the 
X Pstl size marker as a guide. These fragments were excised from the gel using a sterile 
blade and then the DNA was extracted from the gel slice using a Talent kit (Cleanmix, 
Italy) according to the manufacturer’s protocol (as described in section 2.6.3.1) and 
resuspended in 40pl ddl-bO.
Partial fill-in reactions for insert
In order to prevent self-ligation of the insert molecules and to render the ends compatible 
to the partially filled in vector, dGTP and dATP were added to the insert in the presence 
of the Klenow fragment of DNA polymerase (Promega, USA). This was then referred to 
as a partially filled-in insert. The fill-in reaction mixture consisted of 40jfl (lOng) of 
insert DNA, 0.5pl dGTP (lOmM), 0.5p.l dATP (lOmM), 2|al (10U) Klenow fragment of 
DNA polymerase (Promega, USA), 5jal lOx Klenow buffer (Promega, USA) and ddFLO 
made up to 50|fl. Incubation was carried out at 37°C for 2 hrs, after which l|al (0.5M) 
EDTA was added to terminate each reaction and the reaction tube was stored at 4°C.
14.8 Vector preparation
Sail restriction enzyme digestion of pBluescript SK DNA
Plasmid vector pBluescript SK (Stratagene, USA) (fig. 2.4) cultures were prepared in a 
similar manner to the cosmid, as described in section 2.10.1.1 except LB/ampicillin 
(Amp) (50pg/ml) selective medium was used. The plasmid vector, pBluescript SK, 
molecular weight 2.9kb, was linearised by digesting with Sal 1 restriction enzyme 
(Promega, USA). The digestion reaction mixture contained 10|ig vector DNA, 4|ol 
(lOOmM) spermidine, 200U Sail (Promega, USA), lOp.1 lOx buffer as specified by the 
manufacturer (Promega, USA) and ddFhO to a final volume of 1 OOjal. The reaction was 
incubated at 37°C for 3 hrs. To verify that the vector had been linearised, 5pl of digestion 
reaction mixture was analysed on a 0.7% agarose gel (section 2.7.1), with an equal 
volume of an uncut vector sample and X Pstl size marker in adjacent lanes. Thereafter, 
linearised vector DNA in the remaining sample was precipitated by the addition of250pl 
100% ethanol. The mixture was vortexed briefly and incubated for 30 min at -80°C, prior 
to centrifugation in a microfuge (model Microfuge® Lite, Beckmann Instruments, 
Germany) at 14000rpm for 15 min at room temperature. The resulting supernatant was 
carefully decanted and the pellet washed twice with 200(il 70% ethanol, followed by 
centrifugation in a microfuge (model Microfuge® Lite, Beckmann, Germany) at 
14000rpm for 10 min. The ethanol was decanted, and the pellet lyophilised in a Speedy-
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Vac concentrator (Savant Instruments, USA) for 5 min and then resuspended in 40(il 
ddH20. As the 5’-overhanging ends generated by Sal 1 digestion of plasmid vector and 
the Sau3A\ digestion of insert DNA were incompatible for ligation, partial fill-in 
reactions were first performed for both insert and vector DNA.
Partial fill-in of vector
The phospate group at the 5’-end of a linearised vector has a tendency to self ligate in the 
presence of T4 DNA ligase (Damak and Bullock 1993). For this reason, the ends of the 
vectors were rendered non-complementary by the addition of deoxy-thymidine 
triphosphate (dTTP) and deoxy-cytosine (dCTP) to the linearised vector in the presence 
of the Klenow fragment of DNA polymerase (Promega, USA) then referred to as a 
partially filled vector. The fill-in reaction mixture consisted of 40 j j .1 of vector DNA, 0.5 j j .1 
dTTP (lOmM), 0.5ju.l dCTP (lOmM), 2|il (10U) Klenow fragment of DNA polymerase 
(Promega, USA), 5|al lOx Klenow buffer and ddF^O to 50|j.l. Incubation was carried out 
at 37°C for 2 hrs, after which l|il (0.5M) EDTA was added to quench each reaction, 
which were stored at 4°C.
Self ligation of vector
The fill-in reaction of the vector may not be completely successful for all the vector 
molecules, with the result that a proportion of the vector will not yield transformants, 
which are non-recombinants. Therefore, to increase the efficiency of cloning, the partially 
filled-in vector was self-ligated and the resulting circularised vector was separated from 
the linearised vector by electrophoresis, based on their different migration distances in 
agarose. The self ligation reaction contained 5|il lOx ligation buffer (Appendix I), 5jj.1 of 
5mM ATP, 5pl lOmM of dithiothreitol (DTT), 34^1 partially filled-in vector and 5U T4 
ligase (Boehringer Mannheim, Germany) and incubation was performed overnight at 
room temperature or at 4°C. The following day, the ligation mixture was electrophoresed 
on a 0.7% agarose gel (Appendix I) next to X Pstl marker, 25ng of linearised vector and 
2pl uncut pBluescript SK (Stratagene, USA) to distinguish the linearised from the 
circularised vector and visualised under UV light. The linear vector was cut out with a 
sterile blade and placed in a sterile microfuge tube. The DNA was extracted using the 
Talent kit (Cleanmix, Italy) according to the manufacturer’s protocol and stored at 4°C.
14.9 Subcloning of (A3G)n repeat fragments
The cosmid vector is approximately 8kb in size and can house an insert of up to 42kb in 
size; since Taq polymerase can generate fragments for sequencing up to lkb in length, 
the insert was digested into smaller fragments of about lkb in size. These fragments were 
then subcloned into pBluescript SK (Stratagene, USA), from which sequencing was 
initiated by using standard vector primers.
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Organic extraction of filled insert and vector
For subcloning, the partially filled insert and vector were purified by organic extraction. 
The partial fill-in reactions of both vector and insert were purified by the same method. 
To each tube 50(4.1 TE, 1.5fxl 5M NaCl and 100p.l of phenol/chloroform (Appendix I) 
were added. The reagents were agitated by vortexing and centrifuged in a microfuge 
(model Microfuge® Lite, Beckmann, Germany) at MOOOrpm for 5 min. The DNA- 
containing (top) aqueous phase was transferred into a clean 1.5ml eppendorf tube and 
after a 100|al aliquot of chloroform/isoamylalcohol was added, the sample was vortexed 
for 15 sec and then centrifuged as before. The top layer was carefully transferred to a 
clean 1.5ml eppendorf tube without disturbing the interface, after which 300pl of 100% 
ethanol was added and the sample incubated at -70°C for 15 min to precipitate the DNA. 
The DNA was pelleted by centrifugation at MOOOrpm for 15 min at 4°C in a microfuge 
(model Microfuge® Lite, Beckmann, Germany). Both insert DNA and vector DNA- 
containing pellets were washed in 70% ethanol, lyophilised in a Speedy-Vac concentrator 
(Savant Instruments, USA) for 5 min and resuspended in 40jj.1 ddH20.
Ligation
The partial fill-in reactions created compatible cohesive termini for both insert and vector 
to facilitate the ligation process, which resulted in the formation of a chimeric molecule. 
In order to find the optimal vectoninsert ratios, l|il of insert at varying dilutions of 1/10, 
1/50 and 1/100 in H20  were used, while keeping the volume of vector constant (table 1, 
ligation numbers 1, 2, 3 and 4). The one control reaction, ligation number 5, excluded the 
use of insert DNA, in order to determine the number of false recombinants formed as a 
result of the vector re-ligating to itself, i.e. establishing the efficiency of the partial fill-in 
reaction. The second control was the exclusion of vector DNA, to assess the competency 
of the E. coli XL1 Blue strain (table 2.5, ligation number 6). The ligation reactions were 
incubated at 16°C overnight in an Endocal refrigerated circulating bath (Neslab, 
Massachusetts, USA) and thereafter, stored at 4°C until required for transformation.
Table 1 Ligation reactions of insert DNA to pBluescript vector.
Ligation
number
Vector
Ml
Insert
Ml
ATP
5mM
DTT
lOmM
Ligation
Buffer
Ml
T4
ligase
3U/jj.1
H20
Ml
1 1 1 1 1 1 1 4
2 1 1 (1/10) 1 1 1 1 4
3 1 1 (1/50) 1 1 1 1 4
4 1 1 (1/100) 1 1 1 1 4
5 1 0 1 1 1 1 5
6 0 0 1 1 1 1 6
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Transformation
E. coli XLl-blue competent cells (Stratagene, USA) were prepared using the calcium 
chloride protocol (Sambrook et al., 1989). Five microlitres of ligation mixture (table 1) 
were added to pre-chilled 15ml falcon tubes (Centrolab, Italy), followed by the addition 
of a 50ul aliquot of thawed competent cells and the resulting mixture was incubated on 
ice for 30 min. Meanwhile, in another tube, equal volumes (800(4.1) of 5-bromo-4-chloro- 
3-indoyl-P-D-galactopyranoside (X-gal) (20mg/ml) and isopropyl-P-D-thio- 
galactopyranoside (IPTG) (20mg/ml) were mixed together, of which 80(j.l were spread 
onto a LBA plate containing Amp (50pg/ml) and Tetracycline (Tet) (15|j.g/ml). After 
incubation, the chilled competent cells were heat-shocked by incubation in a water-bath 
at 42°C for 45 sec and were then placed on ice for 1 min, after which 500^1 of LB at 37°C 
was added to the transformed cells, which were then left in a shaking incubator at 37°C 
for 1 to 2 hrs. Subsequently, 200|ol of transformed cells were spread on the LBA plates 
containing IPTG and X-gal using 10-15 autoclaved beads (2-3mm in diameter) and the 
plates were incubated inverted at 37°C overnight. An aliquot of uncut pBR322 was added 
to the competent cells, to confirm the efficiency of transformation.
Colony lifts of recombinant of clones
Colony lifts were performed to identify recombinant clones containing the (A3 G)n repeat. 
Plates containing recombinant clones were placed at 4°C for at least 1 hr after overnight 
incubation at 37°C and prior to the colony procedure. For each master plate, two pieces of 
Hybond N+ (Amersham, UK) membrane were cut to the size of the petri plate and 
marked with a pencil as master or duplicate, for replica plating. Using forceps, the first or 
master filter, was carefully placed on the plate with colonies for 1 minute and holes keyed 
in with an 18 gauge needle, taking care not to make any lateral movements, to act as a 
reference for the orientation of the filter on the plate. The master filter was carefully 
removed and placed, colony side up, on a fresh LBA/Amp/Tc plate. A duplicate filter 
was made by carefully placing the second filter on top of the master filter with the holes 
keyed in the same position as the master filter. The fresh plate with sandwiched duplicate 
filters and the original plate were incubated for 5 hrs at 37°C, after which the original 
plate was covered with with clingfilm (GLADwrap™) and stored at 4°C stored until 
required.
Following incubation, the filter sandwich was removed from the plate with the two halves 
kept together. Thereafter, the filters were separated, each one placed colony side up and 
they were treated sequentially with 10% SDS (Sigma, USA) for 3 min, denaturing 
solution (Appendix I) for 5 min and then with neutralising solution (Appendix I) for 5 
min. This was performed in three separate containers layered with 3 MM blotting paper 
(Whatman, England), which had been previously soaked, but not submerged in these 
solutions. Each filter was then transferred to a container with 2x SSC-soaked (Appendix 
I) 3MM blotting paper (Whatman, England) for a 5 min wash, before being air-dried for 
30 min on dry 3MM blotting paper (Whatman, England). The filters were baked for 2 hrs 
in an 80°C vacuum oven (Towson and Mercer Ltd, England). Thereafter, the filters were
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either covered with clingfilm (GLADwrap™) and stored at 4°C, or re-hydrated in 2x SSC 
for 5 min in preparation for probing with radioactively labeled oligonucleotide (section 
2.10.1.5). The filters were finally washed and exposed to X-ray film overnight at room 
temperature. After development of the film, duplicate positive colonies were identified 
and selected from the original plate for sequencing.
Identification and characterisation of (A3G),, repeat motif
To verify that the positive colonies picked from the plates contained cloned insert, 
recombinant plasmid DNA was extracted (section 2.10.1.2) and digested with Kpnl and 
feci at the vector restriction enzyme sites on either side of the multiple cloning site 
(MCS) (fig. 2.6). This digestion reaction contained 5(j.l plasmid DNA, 3-5U Kpnl 
(Promega, USA), 3-5U SacI (Promega, USA), 1 jj.1 lOx buffer according to the 
manufacturer’s (Promega, USA) specifications and ddF^O to 10(_il. The reaction mixture 
was incubated at 37°C for 2 hrs. Thereafter, 5(0.1 of sample was withdrawn and 2jj.1 
loading dye added to it, after which the sample was loaded onto a 0.7% agarose gel 
(section 2.7.1) for analysis of digest reaction products. The DNA size marker A, Pstl was 
electrophoresed alongside the sample, as well as an undigested recombinant plasmid. 
Following the verification of the presence of an insert, the corresponding recombinant 
plasmid clones were sequenced (section 2.6.3) using vector primers T3 and T7 (fig. 2.4).
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APPENDIX II
WEBSITES
Database/Programme Description and electronic address
BCM searchlauncher
CLUSTALW 1.81
Ensembl
An integrated website which allows access to a number of 
bioinformatics tools, Baylor College of Medicine, Houston, 
Texas,US A
http://www.hgsc.bcm.tcm.edu
Multiple DNA sequence alignment programme distributed 
by the European Bioinformatics Institute (EBI) at 
Cambrige, UK
http ://www. ebi. ac.uk/clustalw
Ensembl is a joint project between European Molecular 
Biology Laboratories (EMBL), EBI and the Sanger 
Institute, which develop a software system producing and 
maintaining automatic annotation on metazoan genomes 
and is funded by the Wellcome Trust. 
http://www.ensemb.org/
EST2GENOME
Genbank
DNA alignment programme 
http://ftp.sanger.ac.uk/pub/EMBOSS
DNA and protein sequence databases distributed by the 
USA National Centre for Biotechnology (NCBI), NIH 
http://www.ncbi.nlm.nih.gov
BLAST A Basic Local Alignment Search Tool (BLAST) for gene 
and protein similarity searches 
http://www.ncbi.nlm.nih.gov/BLAST
BLASTp A Basic Local Alignment Search Tool (BLAST) for gene 
and protein similarity searches 
http://www.ncbi.nlm.nih.gov/BLAST
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EST
htgs
human genome 
nr
nucleotide
SNP
STS
Genemap99
OMIM
Locuslink
UNIGENE
Genomescan
Genoscope
JGI
Collection of expressed sequence tags (ESTs) 
http://www.ncbi.nlm.nih.gov/dbEST
High throughput genomic sequence database 
http://www.ncbi.nlm.gov/htgs
Human genome DNA sequence database 
http://www.ncbi.nlm.nih.gov/human genome
Nonredundant DNA sequence database 
http://www.ncbi.nlm.gov/nr
collection of nucleotide sequences 
(http://www.ncbi.nlm.nih/nucleotide).
Collection of single nucleotide polymorphisms (SNPs) 
http://www.ncbi.nih.gov/SNP
Collection of sequence tag sites (STSs) 
http://www.ncbi.nih.nlm.gov/STS
Mapping information of human genomes 
http:// www.ncbi. nlm. nih.gov/Genemap99
Online Mendelian Inheritance in Man (OMIM) contains 
information on human genes and genetic disorders 
http://www.ncbi.nih.gov/OMIM
Provides descriptive information about genetic loci 
http://ncbi.nih.nlm.gov/LOCUSLINK
Short gene transcript clustering programme 
(htpp://www.ncbi.nlm.nih.gov/UNIGENE).
Identifies the functional domains of proteins. 
http://genomescan.gov were used to identify
The French National Sequencing Center facility, which has 
a database of human sequences 
http//www.genoscope.org
Joint Genome Institute, which houses chromosomal 
sequence data and was formed by the merging of Los 
Alamos National Laboratory and the Lawrence Berkeley 
National Laboratory
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LLNL
Primer
Repeatmasker
Stanford Human Genome 
Centre
STACKpack
SWISS-PROT
Tandem Repeatfinder
http://www.jgi.doe.gov
JGI ftp site collaborative containing chromosome 19 
sequence
(ftp ://sawdoff. 1 lnl. go v/pub/JGIdata/Human/Ch 19)
A US Department of Energy national laboratory operated 
by the University of California involved in the 
establishment of the human chromosome 19 sequencing 
database
http//: www-bio. llnl. gov/genome/
PCR primer design programme 
http://eatworms.swmed.edu/~tim/primerfinder
Programme used to remove E. coli sequences from human 
draft sequence
(http://ftp.genome.washington.edu/cgi-bin/RepeatMasker
Completion of the sequencing of chromosome 19 
http://www-shgc.stanford.edu
Gene transcript clustering programme. Developed at South 
African National Institute of Bioinformatics (SANBI), SA. 
http://www.sanbi.ac.za/STACK
Protein database. Maintained at University of Geneva 
Access via NCBI and EBI
htpp://www.ncbi.nlm.nih.gov/ or http://www.ebi.ac.uk
A programme designed to detect long stretches of tandem 
repeats
(http://c3biomath.mssm.edu/trf.basic.submit.html)
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APPENDIX m
THE CLUSTAL ALIGNMENTS OF SCREENED CANDIDATE 
GENESFOR MUTATIONS (SEE SECTION 3.5 OF RESULTS)
The arrangement of the clustal alignment o f sequences o f DNA samples was presented as 
follows: Sample 1 is the database sequence o f the different exons with the flanking 
intronic sequence. The exonic sequence is indicated in red and the flanking intronic 
sequence is indicated in black. Sample 2 is the sequence from the coding strand from an 
unaffected individual that does not have the disease-associated haplotype. Sample 3 is 
the reverse complement o f the reverse sequence o f sample 2. Sample 4 is the sequence 
from the coding strand from an affected PFHBI individual of pedigree 1, carrying the 
disease-associated haplotype. Sample 5 is the reverse complement o f the reverse 
sequence o f sample 4. Sample 6 is the sequence from the coding strand from an affected 
PFHBI individual o f pedigree 2, carrying the disease-associated haplotype. Sample 7 is 
the reverse complement o f the reverse sequence o f sample 6. Sample 8 is the sequence 
from the coding strand from an affected PFHBI individual o f pedigree 5, carrying the 
disease-associated haplotype. Sample 9 is the reverse complement o f the reverse 
sequence o f sample 8. The alignment results for each exon with its flanking sequence of 
K1R2.4 (tables 1-6), LIN-7B (tables 7-11), BAX (tables 12-16) and GSY1 (tables 17-33) 
are presented.
A summary o f exons in which sequence changes were detected is presented in table 3.14. 
and the legends in the following tables are shown in bold.
The sequencing data o f KCNA7 is not presented in this section but can be found in 
section 3.6.1.3 o f results.
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1  GAAGATCATCACCCCCTTTCACAGTTGGGGAACAGGCTCAGGGAACG 4 7
2  GAAGATCATCACCCCCTTTCACAGTTGGGGAACAGGCTCAGGGAACG
4 GAAGATCATCACCCCCTTTCACAGTTGGGGAACAGGCTCAGGGAACG
5  GAAGATCATCACCCCCTTTCACAGTTGGGGAACAGGCTCAGGGAACG
6 GAAGATCATCACCCCCTTTCACAGTTGGGGAACAGGCTCAGGGAACG
7 GAAGATCATCACCCCCTTTCACAGTTGGGGAACAGGCTCAGGGAACG 
9 GAAGATCATCACCCCCTTTCACAGTTGGGGAACAGGCTCAGGGAACG
KIR2. 4
Table 1 CLUSTALW 1.81 alignment: of exon 1 of KIR2.4
1  CCATGAGCTGGCCAGGCCCCCGCAGTGCCAGGGGGAATGCTGGTTGGGTCCTAAGCCTTT 1 0 7
2  CCATGAGCTGGCCAGGCCCCCGCAGTGCCAGGGGGAATGCTGGTTGGGTCCTAAGCCTTT
4 CCATGAGCTGGCCAGGCCCCCGCAGTGCCAGGGGGAATGCTGGTTGGGTCCTAAGCCTTT
5  CCATGAGCTGGCCAGGCCCCCGCAGTGCCAGGGGGAATGCTGGTTGGGTCCTAAGCCTTT
6 CCATGAGCTGGCCAGGCCCCCGCAGTGCCAGGGGGAATGCTGGTTGGGTCCTAAGCCTTT
7 CCATGAGCTGGCCAGGCCCCCGCAGTGCCAGGGGGAATGCTGGTTGGGTCCTAAGCCTTT 
9  CCATGAGCTGGCCAGGCCCCCGCAGTGCCAGGGGGAATGCTGGTTGGGTCCTAAGCCTTT
************************************************************
1 CTTTCCTTCCCAGAGTTCTGCCCTCGAAATCCTCCAGTCCCACCTCAGCCCCGTGAGGCA 1 6 7
4 CTTTCCTTCCCAGAGTTCTGCCCTCGAAATCCTCCAGTCCCACCTCAGCCCCGTGAGGCA
5 CTTTCCTTCCCAGAGTTCTGCCCTCGAAATCCTCCAGTCCCACCTCAGCCCCGTGAGGCA
6 CTTTCCTTCCCAGAGTTCTGCCCTCGAAATCCTCCAGTCCCACCTCAGCCCCGTGAGGCA
7 CTTTCCTTCCCAGAGTTCTGCCCTCGAAATCCTCCAGTCCCACCTCAGCCCCGTGAGGCA
9 CTTTCCTTCCCAGAGTTCTGCCCTCGAAATCCTCCAGTCCCACCTCAGCCCCGTGAGGCA 2
1  GACCCGTTGTCTACTTCCCAAAGCCAACGGGAACCTTCACCAGGGGGCCATCTGCGGCCA 2 2 7
2 GACCCGTTGTCTACTTCCCAAAGCCAACGGGAACCTTCACCAGGGGGCCATCTGCGGCCA
4 GACCCGTTGTCTACTTCCCAAAGCCAACGGGAACCTTCACCAGGGGGCCATCTGCGGCCA
5  GACCCGTTGTCTACTTCCCAAAGCCAACGGGAACCTTCACCAGGGGGCCATCTGCGGCCA
6 GACCCGTTGTCTACTTCCCAAAGCCAACGGGAACCTTCACCAGGGGGCCATCTGCGGCCA
7 GACCCGTTGTCTACTTCCCAAAGCCAACGGGAACCTTCACCAGGGGGCCATCTGCGGCCA 
9  GACCCGTTGTCTACTTCCCAAAGCCAACGGGAACCTTCACCAGGGGGCCATCTGCGGCCA
1 ACATGGCCCAGCTCCCAGGCTGGCTGCGACTCAGGCTCAGGGCACCCCCCTCCCCTAGCA 2 8 7
2 ACATGGCCCAGCTCCCAGGCTGGCTGCGACTCAGGCTCAGGGCACCCCCCTCCCCTAGCA
4 ACATGGCCCAGCTCCCAGGCTGGCTGCGACTCAGGCTCAGGGCACCCCCCTCCCCTAGCA
5  ACATGGCCCAGCTCCCAGGCTGGCTGCGACTCAGGCTCAGGGCACCCCCCTCCCCTAGCA
6 ACATGGCCCAGCTCCCAGGCTGGCTGCGACTCAGGCTCAGGGCACCCCCCTCCCCTAGCA
7 ACATGGCCCAGCTCCCAGGCTGGCTGCGACTCAGGCTCAGGGCACCCCCCTCCCCTAGCA 
9 ACATGGCCCAGCTCCCAGGCTGGCTGCGACTCAGGCTCAGGGCACCCCCCTCCCCTAGCA
1 .  AAAGCAGGGCGGGAGGGAAAGGGAT 3 1 2
2 AAAGCAGGGCGGGAGGGAAAGGGAT
4 AAAGCAGGGCGGGAGGGAAAGGGAT
5  AAAGCAGGGCGGGAGGGAAAGGGAT
6 AAAGCAGGGCGGGAGGGAAAGGGAT
7 AAAGCAGGGC GGGAGGGAAAGGGAT 
9 AAAGCAGGGCGGGAGGGAAAGGGAT
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Exonic sequence of the database sequence is shown in red (from position 25 to 172) and 
is 148bp in size. The size of the PCR product analysed is 312bp, which includes the 
exonic and the flanking intronic sequence.
1 = sequence of the exon from the database (http://www.ncbi.nhn.nih/nucleotide)
2 = forward sequence
3 = reverse complement sequence of the reverse
4 = forward sequence
5 = reverse complement sequence of the reverse
6 = forward sequence
7 = reverse complement sequence of the reverse
8 = forward sequence
9 = reverse complement sequence of the reverse
J -  an unaffected individual 
\  affected individual from pedigree 1
3 ” affected individual from pedigree 2
1 - affected individual from pedigree 5
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CACGGAAGTCCCGCCTCTCCTCCCGG 2 8
CACGGAAGTCCCGCCTCTCCTCCCGG
CACGGAAGTCCCGCCTCTCCTCCCGG
CACGGAAGTCCCGCCTCTCCTCCCGG
CACGGAAGTCCCGCCTCTCCTCCCGG
CACGGAAGTCCCGCCTCTCCTCCCGG
CACGGAAGTCCCGCCTCTCCTCCCGG
CACGGAAGTCCCGCCTCTCCTCCCGG
CACGGAAGTCCCGCCTCTCCTCCCGG
CLUSTALW 1.81 alignment of exon 2A of KCNJ14
GCGCACCTGCAGCAGCTGGGCACGCACGTGGGCCTCGACCAGGTGGCTGCGGCGCAGGTT 8 8
GCGCACCTGCAGCAGCTGGGCACGCACGTGGGCCTCGACCAGGTGGCTGCGGCGCAGGTT
GCGCACCTGCAGCAGCTGGGCACGCACGTGGGCCTCGACCAGGTGGCTGCGGCGCAGGTT
GCGCACCTGCAGCAGCTGGGCACGCACGTGGGCCTCGACCAGGTGGCTGCGGCGCAGGTT
GCGCACCTGCAGCAGCTGGGCACGCACGTGGGCCTCGACCAGGTGGCTGCGGCGCAGGTT
GCGCACCTGCAGCAGCTGGGCACGCACGTGGGCCTCGACCAGGTGGCTGCGGCGCAGGTT
GCGCACCTGCAGCAGCTGGGCACGCACGTGGGCCTCGACCAGGTGGCTGCGGCGCAGGTT
GCGCACCTGCAGCAGCTGGGCACGCACGTGGGCCTCGACCAGGTGGCTGCGGCGCAGGTT
GCGCACCTGCAGCAGCTGGGCACGCACGTGGGCCTCGACCAGGTGGCTGCGGCGCAGGTT
GCCGACGCGCCACATGAGGCAGAGGCGGTGGTCGCGCAGCGCCACGACGGCGTTCTCGCT 1 4 8
GCCGACGCGCCACATGAGGCAGAGGCGGTGGTCGCGCAGCGCCACGACGGCGTTCTCGCT
GCCGACGCGCCACATGAGGCAGAGGCGGTGGTCGCGCAGCGCCACGACGGCGTTCTCGCT
GCCGACGCGCCACATGAGGCAGAGGCGGTGGTCGCGCAGCGCCACGACGGCGTTCTCGCT
GCCGACGCGCCACATGAGGCAGAGGCGGTGGTCGCGCAGCGCCACGACGGCGTTCTCGCT
GCCGACGCGCCACATGAGGCAGAGGCGGTGGTCGCGCAGCGCCACGACGGCGTTCTCGCT
GCCGACGCGCCACATGAGGCAGAGGCGGTGGTCGCGCAGCGCCACGACGGCGTTCTCGCT
GCCGACGCGCCACATGAGGCAGAGGCGGTGGTCGCGCAGCGCCACGACGGCGTTCTCGCT
GCCGACGCGCCACATGAGGCAGAGGCGGTGGTCGCGCAGCGCCACGACGGCGTTCTCGCT
GAAGACCAGCGTCTCGTTGCGCTTCTTGGGTTTGGCCATCTTGGCCATGACAGCACCCAC 2 0 8
GAAGACCAGCGTCTCGTTGCGCTTCTTGGGTTTGGCCATCTTGGCCATGACAGCACCCAC
GAAGACCAGCGTCTCGTTGCGCTTCTTGGGTTTGGCCATCTTGGCCATGACAGCACCCAC
GAAGACCAGCGTCTCGTTGCGCTTCTTGGGTTTGGCCATCTTGGCCATGACAGCACCCAC
GAAGACCAGCGTCTCGTTGCGCTTCTTGGGTTTGGCCATCTTGGCCATGACAGCACCCAC
GAAGACCAGCGTCTCGTTGCGCTTCTTGGGTTTGGCCATCTTGGCCATGACAGCACCCAC
GAAGACCAGCGTCTCGTTGCGCTTCTTGGGTTTGGCCATCTTGGCCATGACAGCACCCAC
GAAGACCAGCGTCTCGTTGCGCTTCTTGGGTTTGGCCATCTTGGCCATGACAGCACCCAC
GAAGACCAGCGTCTCGTTGCGCTTCTTGGGTTTGGCCATCTTGGCCATGACAGCACCCAC
GACGAAGGCGTCGAGCACGCAGCCGGCAATGCACTGCAGCACCACGGCGGCCACAGCGGC 2 6 8
GACGAAGGCGTCGAGCACGCAGCCGGCAATGCACTGCAGCACCACGGCGGCCACAGCGGC
GACGAAGGCGTCGAGCACGCAGCCGGCAATGCACTGCAGCACCACGGCGGCCACAGCGGC
GACGAAGGCGTCGAGCACGCAGCCGGCAATGCACTGCAGCACCACGGCGGCCACAGCGGC
GACGAAGGCGTCGAGCACGCAGCCGGCAATGCACTGCAGCACCACGGCGGCCACAGCGGC
GACGAAGGCGTCGAGCACGCAGCCGGCAATGCACTGCAGCACCACGGCGGCCACAGCGGC
GACGAAGGCGTCGAGCACGCAGCCGGCAATGCACTGCAGCACCACGGCGGCCACAGCGGC
GACGAAGGCGTCGAGCACGCAGCCGGCAATGCACTGCAGCACCACGGCGGCCACAGCGGC
GACGAAGGCGTCGAGCACGCAGCCGGCAATGCACTGCAGCACCACGGCGGCCACAGCGGC
Stellenbosch University http://scholar.sun.ac.za/
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1  CGGGCACTCCTCGGTGACGCTGCGCACGCCGTAGCCGATGGACGTCTGCGTCTCCAGCGC 3 2 8
2  CGGGCACTCCTCGGTGACGCTGCGCACGCCGTAGCCGATGGACGTCTGCGTCTCCAGCGC
3  CGGGCACTCCTCGGTGACGCTGCGCACGCCGTAGCCGATGGACGTCTGCGTCTCCAGCGC
4 CGGGCACTCCTCGGTGACGCTGCGCACGCCGTAGCCGATGGACGTCTGCGTCTCCAGCGC
5  CGGGCACTCCTCGGTGACGCTGCGCACGCCGTAGCCGATGGACGTCTGCGTCTCCAGCGC
6  CGGGCACTCCTCGGTGACGCTGCGCACGCCGTAGCCGATGGACGTCTGCGTCTCCAGCGC
7  CGGGCACTCCTCGGTGACGCTGCGCACGCCGTAGCCGATGGACGTCTGCGTCTCCAGCGC
8  CGGGCACTCCTCGGTGACGCTGCGCACGCCGTAGCCGATGGACGTCTGCGTCTCCAGCGC
9  CGGGCACTCCTCGGTGACGCTGCGCACGCCGTAGCCGATGGACGTCTGCGTCTCCAGCGC
1 GAAGAGGAAGGCGGCCAGGAAGCTGGCCACGTGTGAGAAGCAGGGCGCGGGCGGTGGCGG 3 6 8
2  GAAGAGGAAGGCGGCCAGGAAGCTGGCCACGTGTGAGAAGCAGGGCGCGGGCGGTGGCGG
3  GAAGAGGAAGGCGGCCAGGAAGCTGGCCACGTGTGAGAAGCAGGGCGCGGGCGGTGGCGG
4  GAAGAGGAAGGCGGCCAGGAAGCTGGCCACGTGTGAGAAGCAGGGCGCGGGCGGTGGCGG
5  GAAGAGGAAGGCGGCCAGGAAGCTGGCCACGTGTGAGAAGCAGGGCGCGGGCGGTGGCGG
6  GAAGAGGAAGGCGGCCAGGAAGCTGGCCACGTGTGAGAAGCAGGGCGCGGGCGGTGGCGG
7 GAAGAGGAAGGCGGCCAGGAAGCTGGCCACGTGTGAGAAGCAGGGCGCGGGCGGTGGCGG
8 GAAGAGGAAGGCGGCCAGGAAGCTGGCCACGTGTGAGAAGCAGGGCGCGGGCGGTGGCGG
9  GAAGAGGAAGGCGGCCAGGAAGCTGGCCACGTGTGAGAAGCAGGGCGCGGGCGGTGGCGG
1  GGCGGCCAGGT 3 7 9
2  GGCGGCCAGGT
3  GGCGGCCAGGT
4 GGCGGCCAGGT
5  GGCGGCCAGTT
6  GGCGGCCAGGT
7  GGCGGCCAGGT
8  GGCGGCCAGGT
9  GGCGGCCAGGT
Exon 2 (740bp) was subdivided into two parts, namely exon 2A (3 71 bp) and 2B 
(369bp). The database exonic sequence o f 2A (from position 9 to 379) is shown in red. 
The overlapping exonic sequence o f 2A with 2B is underlined. The size o f the PCR 
product analysed is shown (379bp), which includes the flanking intronic sequence, 
exonic sequence o f 2A and the flanking exonic sequence o f 2B.
1 = sequence o f the exon from the database (http://www.ncbi.nlm.nih/nucleotide)
2 - forward sequence
3 = reverse complement sequence o f  the reverse
4 = forward sequence
5 = reverse complement sequence o f  the reverse
6 = forward sequence
7= reverse complement sequence o f the reverse
8 = forward sequence '
9 = reverse complement sequence o f  the reverse J
}
}
}
an unaffected individual 
affected individual from pedigree 1 
affected individual from pedigree 2 
affected individual from pedigree 5
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GGCGGGGCGGCCAGGTC 3 8 0
GGCGGGGCGGCCAGGTC
GGCGGGGCGGCCAGGTC
GGCGGGGCGGCCAGGTC
GGCGGGGCGGCCAGGTC
GGCGGGGCGGCCAGGTC
GGCGGGGCGGCCAGGTC
GGCGGGGCGGCCAGGTC
GGCGGGGCGGCCAGGTC
3 CLUSTALW 1.81 alignment of exon 2B of Kir2.4
GCCGTGCAGCGAGGCAATGAGCCAGAAGGCCAGGCCGAAGAGCAGCCAGGAGGCGAGGAA 4 4 0
GCCGTGCAGCGAGGCAATGAGCCAGAAGGCCAGGCCGAAGAGCAGCCAGGAGGCGAGGAA
GCCGTGCAGCGAGGCAATGAGCCAGAAGGCCAGGCCGAAGAGCAGCCAGGAGGCGAGGAA
GCCGTGCAGCGAGGCAATGAGCCAGAAGGCCAGGCCGAAGAGCAGCCAGGAGGCGAGGAA
GCCGTGCAGCGAGGCAATGAGCCAGAAGGCCAGGCCGAAGAGCAGCCAGGAGGCGAGGAA
GCCGTGCAGCGAGGCAATGAGCCAGAAGGCCAGGCCGAAGAGCAGCCAGGAGGCGAGGAA
GCCGTGCAGCGAGGCAATGAGCCAGAAGGCCAGGCCGAAGAGCAGCCAGGAGGCGAGGAA
GCCGTGCAGCGAGGCAATGAGCCAGAAGGCCAGGCCGAAGAGCAGCCAGGAGGCGAGGAA
GCCGTGCAGCGAGGCAATGAGCCAGAAGGCCAGGCCGAAGAGCAGCCAGGAGGCGAGGAA
GGAGCAGGAGAAGAGCAGGCACATCCAGCGCCAGCGCACGTCCACGCATGTGGTGAACAG 5 0 0
GGAGCAGGAGAAGAGCAGGCACATCCAGCGCCAGCGCACGTCCACGCATGTGGTGAACAG
GGAGCAGGAGAAGAGCAGGCACATCCAGCGCCAGCGCACGTCCACGCATGTGGTGAACAG
GGAGCAGGAGAAGAGCAGGCACATCCAGCGCCAGCGCACGTCCACGCATGTGGTGAACAG
GGAGCAGGAGAAGAGCAGGCACATCCAGCGCCAGCGCACGTCCACGCATGTGGTGAACAG
GGAGCAGGAGAAGAGCAGGCACATCCAGCGCCAGCGCACGTCCACGCATGTGGTGAACAG
GGAGCAGGAGAAGAGCAGGCACATCCAGCGCCAGCGCACGTCCACGCATGTGGTGAACAG
GGAGCAGGAGAAGAGCAGGCACATCCAGCGCCAGCGCACGTCCACGCATGTGGTGAACAG
GGAGCAGGAGAAGAGCAGGCACATCCAGCGCCAGCGCACGTCCACGCATGTGGTGAACAG
GTCGCTCAGGTAGCGCGCGCCCTGGCCACCCAGGTTTACGAAACGCACGTTGCAGTGCCC 5 6 0
GTCGCTCAGGTAGCGCGCGCCCTGGCCACCCAGGTTTACGAAACGCACGTTGCAGTGCCC
GTCGCTCAGGTAGCGCGCGCCCTGGCCACCCAGGTTTACGAAACGCACGTTGCAGTGCCC
GTCGCTCAGGTAGCGCGCGCCCTGGCCACCCAGGTTTACGAAACGCACGTTGCAGTGCCC
GTCGCTCAGGTAGCGCGCGCCCTGGCCACCCAGGTTTACGAAACGCACGTTGCAGTGCCC
GTCGCTCAGGTAGCGCGCGCCCTGGCCACCCAGGTTTACGAAACGCACGTTGCAGTGCCC
GTCGCTCAGGTAGCGCGCGCCCTGGCCACCCAGGTTTACGAAACGCACGTTGCAGTGCCC
GTCGCTCAGGTAGCGCGCGCCCTGGCCACCCAGGTTTACGAAACGCACGTTGCAGTGCCC
GTCGCTCAGGTAGCGCGCGCCCTGGCCACCCAGGTTTACGAAACGCACGTTGCAGTGCCC
GTCTTTCTTGACGAAGCGACCGCGGCGCCGGCCCACGGGTGACTGCACCGGTGCCGGCGC 6 2 0
GTCTTTCTTGACGAAGCGACCGCGGCGCCGGCCCACGGGTGACTGCACCGGTGCCGGCGC
GTCTTTCTTGACGAAGCGACCGCGGCGCCGGCCCACGGGTGACTGCACCGGTGCCGGCGC
GTCTTTCTTGACGAAGCGACCGCGGCGCCGGCCCACGGGTGACTGCACCGGTGCCGGCGC
GTCTTTCTTGACGAAGCGACCGCGGCGCCGGCCCACGGGTGACTGCACCGGTGCCGGCGC
GTCTTTCTTGACGAAGCGACCGCGGCGCCGGCCCACGGGTGACTGCACCGGTGCCGGCGC
GTCTTTCTTGACGAAGCGACCGCGGCGCCGGCCCACGGGTGACTGCACCGGTGCCGGCGC
GTCTTTCTTGACGAAGCGACCGCGGCGCCGGCCCACGGGTGACTGCACCGGTGCCGGCGC
GTCTTTCTTGACGAAGCGACCGCGGCGCCGGCCCACGGGTGACTGCACCGGTGCCGGCGC
Stellenbosch University http://scholar.sun.ac.za/
314
1  CCACCCGTTGCGGCACAACCCGGGCCCGGCCTCCTCTTCATCGCCCGCCCGGCTGTCTCC 6 8 0
2  CCACCCGTTGCGGCACAACCCGGGCCCGGCCTCCTCTTCATCGCCCGCCCGGCTGTCTCC
3  CCACCCGTTGCGGCACAACCCGGGCCCGGCCTCCTCTTCATCGCCCGCCCGGCTGTCTCC
5  CCACCCGTTGCGGCACAACCCGGGCCCGGCCTCCTCTTCATCGCCCGCCCGGCTGTCTCC
6  CCACCCGTTGCGGCACAACCCGGGCCCGGCCTCCTCTTCATCGCCCGCCCGGCTGTCTCC
7  CCACCCGTTGCGGCACAACCCGGGCCCGGCCTCCTCTTCATCGCCCGCCCGGCTGTCTCC
8  CCACCCGTTGCGGCACAACCCGGGCCCGGCCTCCTCTTCATCGCCCGCCCGGCTGTCTCC
9  CCACCCGTTGCGGCACAACCCGGGCCCGGCCTCCTCTTCATCGCCCGCCCGGCTGTCTCC
1  CGAATCCAGGGCGCCGCTGAGGCGGCGTAGGGCCCTGGCCAGGCCCATTGGACGGAGGGA 7 4 0
2  CGAATCCAGGGCGCCGCTGAGGCGGCGTAGGGCCCTGGCCAGGCCCATTGGACGGAGGGA
3  CGAATCCAGGGCGCCGCTGAGGCGGCGTAGGGCCCTGGCCAGGCCCATTGGACGGAGGGA
4  CGAATCCAGGGCGCCGCTGAGGCGGCGTAGGGCCCTGGCCAGGCCCATTGGACGGAGGGA
5  CGAATCCAGGGCGCCGCTGAGGCGGCGTAGGGCCCTGGCCAGGCCCATTGGACGGAGGGA
6  CGAATCCAGGGCGCCGCTGAGGCGGCGTAGGGCCCTGGCCAGGCCCATTGGACGGAGGGA
7  CGAATCCAGGGCGCCGCTGAGGCGGCGTAGGGCCCTGGCCAGGCCCATTGGACGGAGGGA
8  CGAATCCAGGGCGCCGCTGAGGCGGCGTAGGGCCCTGGCCAGGCCCATTGGACGGAGGGA
9  CGAATCCAGGGCGCCGCTGAGGCGGCGTAGGGCCCTGGCCAGGCCCATTGGACGGAGGGA
1 CCCCCTCCACTTGGCCTAGTGGGGGGCAGGCGCCCCCAAC 8 0 0
2  CCCCCTCCACTTGGCCTAGTGGGGGGCAGGCGCCCCCAAC
3  CCCCCTCCACTTGGCCTAGTGGGGGGCAGGCGCCCCCAAC
4 CCCCCTCCACTTGGCCTAGTGGGGGGCAGGCGCCCCCAAC
5  CCCCCTCCACTTGGCCTAGTGGGGGGCAGGCGCCCCCAAC
6  CCCCCTCCACTTGGCCTAGTGGGGGGCAGGCGCCCCCAAC
7 CCCCCTCCACTTGGCCTAGTGGGGGGCAGGCGCCCCCAAC
8 CCCCCTCCACTTGGCCTAGTGGGGGGCAGGCGCCCCCAAC
9  CCCCCTCCACTTGGCCTAGTGGGGGGCAGGCGCCCCCAAC
The database exonic sequence is shown in red (from position 364 to 758bp). The size of 
the PCR product analysed is shown (438bp), which includes the flanking exonic 
sequence from 2A, exonic sequence o f 2B and the flanking intronic sequence. The 
overlapping exonic sequence 2A with 2B is underlined.
1 = sequence o f the exon from the database (http://www.ncbi.nlm.nih/nucleotide)
2 = forward sequence
3 = reverse complement sequence o f the reverse
4 = forward sequence
5 = reverse complement sequence o f  the reverse
6 = forward sequence
7 = reverse complement sequence o f the reverse
8 = forward sequence
9 = reverse complement sequence o f the reverse
}
}
}
}
an unaffected individual 
affected individual from pedigree 1 
affected individual from pedigree 2 
affected individual from pedigree 5
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CAGCCCTGGGCCTCC 1 5  
CAGCCCTGGGCCTCC 
CAGCCCTGGGCCTCC 
CAGCCCTGGGCCTCC 
CAGCCCTGGGCCTCC 
CAGCCCTGGGCCTCC 
CAGCCCTGGGCCTCC 
CAGCCCTGGGCCTCC 
***************
CCCTTCCCTTGTCCACTAATTAGCCCTGTGCCCTACAGGGTCTCACCTTCACCTTCAC 7  5
CCCTTCCCTTGTCCACTAATTAGCCCTGTGCCCTACAGGGTCTCACCTTCACCTTCAC
CCCTTCCCTTGTCCACTAATTAGCCCTGTGCCCTACAGGGTCTCACCTTCACCTTCAC
CCCTTCCCTTGTCCACTAATTAGCCCTGTGCCCTACAGGGTCTCACCTTCACCTTCAC
CCCTTCCCTTGTCCACTAATTAGCCCTGTGCCCTACAGGGTCTCACCTTCACCTTCAC
CCCTTCCCTTGTCCACTAATTAGCCCTGTGCCCTACAGGGTCTCACCTTCACCTTCAC
CCCTTCCCTTGTCCACTAATTAGCCCTGTGCCCTACAGGGTCTCACCTTCACCTTCAC
CCCTTCCCTTGTCCACTAATTAGCCCTGTGCCCTACAGGGTCTCACCTTCACCTTCAC
4 CLUSTALW 1.81 alignment of exon 3A of KIR2.4
CTTCCAGGTCAGGCCAGAAATGTTGCTTCTGAAGTCCTGAGTCCACCTCCTAGCACTGCC 1 3 5
CTTCCAGGTCAGGCCAGAAATGTTGCTTCTGAAGTCCTGAGTCCACCTCCTAGCACTGCC
CTTCCAGGTCAGGCCAGAAATGTTGCTTCTGAAGTCCTGAGTCCACCTCCTAGCACTGCC
CTTCCAGGTCAGGCCAGAAATGTTGCTTCTGAAGTCCTGAGTCCACCTCCTAGCACTGCC
CTTCCAGGTCAGGCCAGAAATGTTGCTTCTGAAGTCCTGAGTCCACCTCCTAGCACTGCC
CTTCCAGGTCAGGCCAGAAATGTTGCTTCTGAAGTCCTGAGTCCACCTCCTAGCACTGCC
CTTCCAGGTCAGGCCAGAAATGTTGCTTCTGAAGTCCTGAGTCCACCTCCTAGCACTGCC
CTTCCAGGTCAGGCCAGAAATGTTGCTTCTGAAGTCCTGAGTCCACCTCCTAGCACTGCC
AAGCAGTCCACCTGGAGGTGATGAGAACTTCCAGGCTTTGGTAATGGACAACTCTGTATC 1 9 5
AAGCAGTCCACCTGGAGGTGATGAGAACTTCCAGGCTTTGGTAATGGACAACTCTGTATC
AAGCAGTCCACCTGGAGGTGATGAGAACTTCCAGGCTTTGGTAATGGACAACTCTGTATC
AAGCAGTCCACCTGGAGGTGATGAGAACTTCCAGGCTTTGGTAATGGACAACTCTGTATC
AAGCAGTCCACCTGGAGGTGATGAGAACTTCCAGGCTTTGGTAATGGACAACTCTGTATC
AAGCAGTCCACCTGGAGGTGATGAGAACTTCCAGGCTTTGGTAATGGACAACTCTGTATC
AAGCAGTCCACCTGGAGGTGATGAGAACTTCCAGGCTTTGGTAATGGACAACTCTGTATC
AAGCAGTCCACCTGGAGGTGATGAGAACTTCCAGGCTTTGGTAATGGACAACTCTGTATC
CCTGGAGCCTTCATTCCTTTTGGCATTACAGAACCACAAGAAGTCATCTAGAATCATTGA 2 5 5
CCTGGAGCCTTCATTCCTTTTGGCATTACAGAACCACAAGAAGTCATCTAGAATCATTGA
CCTGGAGCCTTCATTCCTTTTGGCATTACAGAACCACAAGAAGTCATCTAGAATCATTGA
CCTGGAGCCTTCATTCCTTTTGGCATTACAGAACCACAAGAAGTCATCTAGAATCATTGA
CCTGGAGCCTTCATTCCTTTTGGCATTACAGAACCACAAGAAGTCATCTAGAATCATTGA
CCTGGAGCCTTCATTCCTTTTGGCATTACAGAACCACAAGAAGTCATCTAGAATCATTGA
CCTGGAGCCTTCATTCCTTTTGGCATTACAGAACCACAAGAAGTCATCTAGAATCATTGA
CCTGGAGCCTTCATTCCTTTTGGCATTACAGAACCACAAGAAGTCATCTAGAATCATTGA
GATTCTCAACTCCATTGGGCAAACTGGAACCAGCAAAATCTCAGATATCTAGAATTGCCA 3 1 5
GATTCTCAACTCCATTGGGCAAACTGGAACCAGCAAAATCTCAGATATCTAGAATTGCCA
GATTCTCAACTCCATTGGGCAAACTGGAACCAGCAAAATCTCAGATATCTAGAATTGCCA
GATTCTCAACTCCATTGGGCAAACTGGAACCAGCAAAATCTCAGATATCTAGAATTGCCA
GATTCTCAACTCCATTGGGCAAACTGGAACCAGCAAAATCTCAGATATCTAGAATTGCCA
GATTCTCAACTCCATTGGGCAAACTGGAACCAGCAAAATCTCAGATATCTAGAATTGCCA
GATTCTCAACTCCATTGGGCAAACTGGAACCAGCAAAATCTCAGATATCTAGAATTGCCA
GATTCTCAACTCCATTGGGCAAACTGGAACCAGCAAAATCTCAGATATCTAGAATTGCCA
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CTGCTTCCTTGACTCTGTGATCAGTCTACAGCCACAGAATCCTGATTCCCTTTGGACATT 3 7 5
CTGCTTCCTTGACTCTGTGATCAGTCTACAGCCACAGAATCCTGATTCCCTTTGGACATT
CTGCTTCCTTGACTCTGTGATCAGTCTACAGCCACAGAATCCTGATTCCCTTTGGACATT
CTGCTTCCTTGACTCTGTGATCAGTCTACAGCCACAGAATCCTGATTCCCTTTGGACATT
CTGCTTCCTTGACTCTGTGATCAGTCTACAGCCACAGAATCCTGATTCCCTTTGGACATT
CTGCTTCCTTGACTCTGTGATCAGTCTACAGCCACAGAATCCTGATTCCCTTTGGACATT
CTGCTTCCTTGACTCTGTGATCAGTCTACAGCCACAGAATCCTGATTCCCTTTGGACATT
CTGCTTCCTTGACTCTGTGATCAGTCTACAGCCACAGAATCCTGATTCCCTTTGGACATT
CTAGAATGGCACTTTAAAAAAAAACAACCCACCCAGTGGATCCTTTCAAAGCACTGCTTA 4 3 5
CTAGAATGGCACTTTAAAAAAAAACAACCCACCCAGTGGATCCTTTCAAAGCACTGCTTA
CTAGAATGGCACTTTAAAAAAAAACAACCCACCCAGTGGATCCTTTCAAAGCACTGCTTA
CTAGAATGGCACTTTAAAAAAAAACAACCCACCCAGTGGATCCTTTCAAAGCACTGCTTA
CTAGAATGGCACTTTAAAAAAAAACAACCCACCCAGTGGATCCTTTCAAAGCACTGCTTA
CTAGAATGGCACTTTAAAAAAAAACAACCCACCCAGTGGATCCTTTCAAAGCACTGCTTA
CTAGAATGGCACTTTAAAAAAAAACAACCCACCCAGTGGATCCTTTCAAAGCACTGCTTA
CTAGAATGGCACTTTAAAAAAAAACAACCCACCCAGTGGATCCTTTCAAAGCACTGCTTA
TTCTCTTGGCTGGGTGCTCTACAGCCAGAAGTTGGAGTTATCTAATATCAAGAACTCTTA 4 9 5
TTCTCTTGGCTGGGTGCTCTACAGCCAGAAGTTGGAGTTATCTAATATCAAGAACTCTTA
TTCTCTTGGCTGGGTGCTCTACAGCCAGAAGTTGGAGTTATCTAATATCAAGAACTCTTA
TTCTCTTGGCTGGGTGCTCTACAGCCAGAAGTTGGAGTTATCTAATATCAAGAACTCTTA
TTCTCTTGGCTGGGTGCTCTACAGCCAGAAGTTGGAGTTATCTAATATCAAGAACTCTTA
TTCTCTTGGCTGGGTGCTCTACAGCCAGAAGTTGGAGTTATCTAATATCAAGAACTCTTA
TTCTCTTGGCTGGGTGCTCTACAGCCAGAAGTTGGAGTTATCTAATATCAAGAACTCTTA
TTCTCTTGGCTGGGTGCTCTACAGCCAGAAGTTGGAGTTATCTAATATCAAGAACTCTTA
ATCTGTCACTTCAGTCTTTCTAAACCCACAGACTAACAATGTTTTGTGCATTCTAGAAAC 5 5 5
ATCTGTCACTTCAGTCTTTCTAAACCCACAGACTAACAATGTTTTGTGCATTCTAGAAAC
ATCTGTCACTTCAGTCTTTCTAAACCCACAGACTAACAATGTTTTGTGCATTCTAGAAAC
ATCTGTCACTTCAGTCTTTCTAAACCCACAGACTAACAATGTTTTGTGCATTCTAGAAAC
ATCTGTCACTTCAGTCTTTCTAAACCCACAGACTAACAATGTTTTGTGCATTCTAGAAAC
ATCTGTCACTTCAGTCTTTCTAAACCCACAGACTAACAATGTTTTGTGCATTCTAGAAAC
ATCTGTCACTTCAGTCTTTCTAAACCCACAGACTAACAATGTTTTGTGCATTCTAGAAAC
ATCTGTCACTTCAGTCTTTCTAAACCCACAGACTAACAATGTTTTGTGCATTCTAGAAAC
ATTACTCTTTAGTTTCTGGAGTAGTTCAACTCTCCACGTAAAATCTGTCCTAGACTCACC 6 1 5
ATTACTCTTTAGTTTCTGGAGTAGTTCAACTCTCCACGTAAAATCTGTCCTAGACTCACC
ATTACTCTTTAGTTTCTGGAGTAGTTCAACTCTCCACGTAAAATCTGTCCTAGACTCACC
ATTACTCTTTAGTTTCTGGAGTAGTTCAACTCTCCACGTAAAATCTGTCCTAGACTCACC
ATTACTCTTTAGTTTCTGGAGTAGTTCAACTCTCCACGTAAAATCTGTCCTAGACTCACC
ATTACTCTTTAGTTTCTGGAGTAGTTCAACTCTCCACGTAAAATCTGTCCTAGACTCACC
ATTACTCTTTAGTTTCTGGAGTAGTTCAACTCTCCACGTAAAATCTGTCCTAGACTCACC
ATTACTCTTTAGTTTCTGGAGTAGTTCAACTCTCCACGTAAAATCTGTCCTAGACTCACC
AGTGCTTGCCTCTGTGGT 6 3 3
AGTGCTTGCCTCTGTGGT
AGTGCTTGCCTCTGTGGT
AGTGCTTGCCTCTGTGGT
AGTGCTTGCCTCTGTGGT
AGTGCTTGCCTCTGTGGT
AGTGCTTGCCTCTGTGGT
AGTGCTTGCCTCTGTGGT
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Exon 3 was subdivided into exons 3A, 3B and 3C (1789bp in size). The database exonic 
sequence 3A is shown in red (from position 4 to 633) and is 630bp in size. The size of 
the PCR product analysed is 633bp, which includes the flanking intronic sequence, exon 
3 A and part of exon 3B. The overlapping exonic sequence o f 3A and 3B is underlined.
1 = sequence o f  the exon from the database (http://www.ncbi.nlm.nih/nucleotide)
- an unaffected individual
affected individual from pedigree 1
2 =  forward sequence
3 =  reverse complement sequence o f  the reverse _
4 =  forward sequence
5 =  reverse complement sequence o f  the reverse
6 =  forward sequence T
7 =  reverse complement sequence o f  the reverse J  affected individual from pedigree 2
8 = forward sequence -i
9 =  reverse complement sequence o f  the reverse j  affected individual from pedigree 5
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GGTCTTTGGTCAATCAAGATGATCTTGAATACTTGGGGCATTCCATAACCTTCCCTCCTT 6 9 0
GGTCTTTGGTCAATCAAGATGATCTTGAATACTTGGGGCATTCCATAACCTTCCCTCCTT
GGTCTTTGGTCAATCAAGATGATCTTGAATACTTGGGGCATTCCATAACCTTCCCTCCTT
GGTCTTTGGTCAATCAAGATGATCTTGAATACTTGGGGCATTCCATAAjCCTTCCCTCCTT
GGTCTTTGGTCAATCAAGATGATCTTGAATACTTGGGGCATTCCATAACCTTCCCTCCTT
GGTCTTTGGTCAATCAAGATGATCTTGAATACTTGGGGCATTCCATAACCTTCCCTCCTT
GGTCTTTGGTCAATCAAGATGATCTTGAATACTTGGGGCATTCCATAACCTTCCCTCCTT
GGTCTTTGGTCAATCAAGATGATCTTGAATACTTGGGGCATTCCATAACCTTCCCTCCTT
GGTCTTTGGTCAATCAAGATGATCTTGAATACTTGGGGCATTCCATAACCTTCCCTCCTT
CLUSTALW 1.81 alignment of exon 3B of KIR2.4
AGGTGGTCTAGAACAAATGATTTGCTACTCAGTTGGCTGAGTT6AGAAGCAACACTCCCT 7 5 0
AGGTGGTCTAGAACAAATGATTTGCTACTCAGTTGGCTGAGTTGAGAAGCAACACTCCCT
AGGTGGTCTAGAAGAAATGATTTGCTACTCAGTTGGCTGAGTTGAGAAGCAACACTCCCT
AGGTGGTCTAGAACAAATGATTTGCTACTCAGTTGGCTGAGTTGAGAAGCAACACTCCCT
AGGTGGTCTAGAACAAATGATTTGCTACTCAGTTGGCTGAGTTGAGAAGCAACACTCCCT
AGGTGGTCTAGAACAAATGATTTGCTACTCAGTTGGCTGAGTTGAGAAGCAACACTCCCT
AGGTGGTCTAGAACAAATGATTTGCTACTCAGTTGGCTGAGTTGAGAAGCAACACTCCCT
AGGTGGTCTAGAACAAATGATTTGCTACTCAGTTGGCTGAGTTGAGAAGCAACACTCCCT
AGGTGGTCTAGAACAAATGATTTGCTACTCAGTTGGCTGAGTTGAGAAGCAACACTCCCT
TGAATCTTAGGTGAATCCAGACCTACAAACTCTTGATATCTGATGCTGTTCAAGAACTGC 8 1 0
TGAATCTTAGGTGAATCCAGACCTACAAACTCTTGATATCTGATGCTGTTCAAGAACTGC
TGAATCTTAGGTGAATCCAGACCTACAAACTCTTGATATCTGATGCTGTTCAAGAACTGC
TGAATCTTAGGTGAATCCAGACCTACAAACTCTTGATATCTGATGCTGTTCAAGAACTGC
TGAATCTTAGGTGAATCCAGACCTACAAACTCTTGATATCTGATGCTGTTCAAGAACTGC
TGAATCTTAGGTGAATCCAGACCTACAAACTCTTGATATCTGATGCTGTTCAAGAACTGC
TGAATCTTAGGTGAATCCAGACCTACAAACTCTTGATATCTGATGCTGTTCAAGAACTGC
TGAATCTTAGGTGAATCCAGACCTACAAACTCTTGATATCTGATGCTGTTCAAGAACTGC
t g a a t c t t a g g t g a a t c c a g a c c t a c a a a c t c t t g a t a t c t g a t g c t g t t c a a g a a c t g c
CAACTTGCTTCCCCAGAGGCAGTCTATACCATTGGCTTCTCACCCTGGTCAACAATCCAG 8 7 0
CAACTTGCTTCCCCAGAGGCAGTCTATACCATTGGCTTCTCACCCTGGTCAACAATCCAG
CAACTTGCTTCCCCAGAGGCAGTCTATACCATTGGCTTCTCACCCTGGTCAACAATCCAG
CAACTTGCTTCCCCAGAGGCAGTCTATACCATTGGCTTCTCACCCTGGTCAACAATCCAG
CAACTTGCTTCCCCAGAGGCAGTCTATACCATTGGCTTCTCACCCTGGTCAACAATCCAG
CAACTTGCTTCCCCAGAGGCAGTCTATACCATTGGCTTCTCACCCTGGTCAACAATCCAG
CAACTTGCTTCCCCAGAGGCAGTCTATACCATTGGCTTCTCACCCTGGTCAACAATCCAG
CAACTTGCTTCCCCAGAGGCAGTCTATACCATTGGCTTCTCACCCTGGTCAACAATCCAG
CAACTTGCTTCCCCAGAGGCAGTCTATACCATTGGCTTCTCACCCTGGTCAACAATCCAG
GTCTCCCCATATAGAGGAATCTAGAACTGCCAGTCTTTTCCTCTTGGGTGATCCAGAATT 9 3 0
GTCTCCCCATATAGAGGAATCTAGAACTGCCAGTCTTTTCCTCTTGGGTGATCCAGAATT
GTCTCCCCATATAGAGGAATCTAGAACTGCCAGTCTTTTCCTCTTGGGTGATCCAGAATT
GTCTCCCCATATAGAGGAATCTAGAACTGCCAGTCTTTTCCTCTTGGGTGATCCAGAATT
GTCTCCCCATATAGAGGAATCTAGAACTGCCAGTCTTTTCCTCTTGGGTGATCCAGAATT
GTCTCCCCATATAGAGGAATCTAGAACTGCCAGTCTTTTCCTCTTGGGTGATCCAGAATT
GTCTCCCCATATAGAGGAATCTAGAACTGCCAGTCTTTTCCTCTTGGGTGATCCAGAATT
GTCTCCCCATATAGAGGAATCTAGAACTGCCAGTCTTTTCCTCTTGGGTGATCCAGAATT
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CTGGTGAGACTGAGGAATCAGGCTCATAAAGGGTTCTCAGGAGGGAGCACAGAAGCAGAG
CTGGTGAGACTGAGGAATCAGGCTCATAAAGGGTTCTCAGGAGGGAGCACAGAAGCAGAG
CTGGTGAGACTGAGGAATCAGGCTCATAAAGGGTTCTCAGGAGGGAGCACAGAAGCAGAG
CTGGTGAGACTGAGGAATCAGGCTCATAAAGGGTTCTCAGGAGGGAGCACAGAAGCAGAG
CTGGTGAGACTGAGGAATCAGGCTCATAAAGGGTTCTCAGGAGGGAGCACAGAAGCAGAG
CTGGTGAGACTGAGGAATCAGGCTCATAAAGGGTTCTCAGGAGGGAGCACAGAAGCAGAG
CTGGTGAGACTGAGGAATCAGGCTCATAAAGGGTTCTCAGGAGGGAGCACAGAAGCAGAG
CTGGTGAGACTGAGGAATCAGGCTCATAAAGGGTTCTCAGGAGGGAGCACAGAAGCAGAG
CTGGTGAGACTGAGGAATCAGGCTCATAAAGGGTTCTCAGGAGGGAGCACAGAAGCAGAG
GAATTAAGGTCCAGTATGTCCATGGTGGGTCACCAGGCATGGCAGAACCTTACCACCTAG
GAATTAAGGTCCAGTATGTCCATGGTGGGTCACCAGGCATGGCAGAACCTTACCACCTAG
GAATTAAGGTCCAGTATGTCCATGGTGGGTCACCAGGCATGGCAGAACCTTACCACCTAG
GAATTAAGGTCCAGTATGTCCATGGTGGGTCACCAGGCATGGCAGAACCTTACCACCTAG
GAATTAAGGTCCAGTATGTCCATGGTGGGTCACCAGGCATGGCAGAACCTTACCACCTAG
GAATTAAGGTCCAGTATGTCCATGGTGGGTCACCAGGCATGGCAGAACCTTACCACCTAG
GAATTAAGGTCCAGTATGTCCATGGTGGGTCACCAGGCATGGCAGAACCTTACCACCTAG
GAATTAAGGTCCAGTATGTCCATGGTGGGTCACCAGGCATGGCAGAACCTTACCACCTAG
GAATTAAGGTCCAGTATGTCCATGGTGGGTCACCAGGCATGGCAGAACCTTACCACCTAG
TCATTTACCCAGCAGGCCTGTCGGTATTCAGGAACACCTGCCCCCATCCCAGGAGAGAGC
TCATTTACCCAGCAGGCCTGTCGGTATTCAGGAACACCTGCCCCCATCCCAGGAGAGAGC
TCATTTACCCAGCAGGCCTGTCGGTATTCAGGAACACCTGCCCCCATCCCAGGAGAGAGC
TCATTTACCCAGCAGGCCTGTCGGTATTCAGGAACACCTGCCCCCATCCCAGGAGAGAGC
TCATTTACCCAGCAGGCCTGTCGGTATTCAGGAACACCTGCCCCCATCCCAGGAGAGAGC
TCATTTACCCAGCAGGCCTGTCGGTATTCAGGAACACCTGCCCCCATCCCAGGAGAGAGC
TCATTTACCCAGCAGGCCTGTCGGTATTCAGGAACACCTGCCCCCATCCCAGGAGAGAGC
TCATTTACCCAGCAGGCCTGTCGGTATTCAGGAACACCTGCCCCCATCCCAGGAGAGAGC
TCATTTACCCAGCAGGCCTGTCGGTATTCAGGRACACCTGCCCCCATCCCAGGAGAGAGC
CCCATCCCTCCATC 1 1 6 8  
CCCATCCCTCCATC 
CCCATCCCTCCATC 
CCCATCCCTCCATC 
CCCATCCCTCCATC 
CCCATCCCTCCATC 
CCCATCCCTCCATC 
CCCATCCCTCCATC 
CCCATCCCTCCATC 
**************
9 9 0
1 0 5 0
1110
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The database exonic sequence o f 3B is shown in red (from position 630 to 1168) and is 
539bp in size. The size of the PCR product is 539bp, which includes part o f the exonic 
sequence from 3A, exon 3B and part o f exon 3C. The overlapping exonic sequence of 
exon 3A and 3C is underlined.
1 = sequence o f  the exon from the database (http://www.ncbi.nlm.nih/nucleotide)
an unaffected individual 
affected individual from pedigree 1 
affected individual from pedigree 2 
affected individual from pedigree 5
2 = forward sequence
3 = reverse complement sequence o f the reverse „
4 = forward sequence
5 = reverse complement sequence o f the reverse
6 = forward sequence ~l
7 = reverse complement sequence o f the reverse J
8 - forward sequence
9 = reverse complement sequence o f  the reverse j
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TCGCCTCCTGCTGCAGCCCCGTGTGA 1 1 9 2
t c g c c t c c t g c t g c a g c c c c g t g t g a
TCGCCTCCTGCTGCAGCCCCGTGTGA
TCGCCTCCTGCTGCAGCCCCGTGTGA
TCCCCTCCTGGTGCAACCCCGGGTGA
TCGCCTCCTGCTGCAACCCCGTGTGA
TCGCCTCCTGCTGCAGCCCCGTGTGA
TCGCCTCCTGCTGCAGCCCCGTGTGA
TCGCCTCCTGCTGCAGCCCCGTGTGA
6 CLUSTALW 1.81 alignment of exon 3C of KTR2.4
CCCCAGAGGGTGAGTACATCCCGCTGGACCACCAGGATGTGGATGTGGGCTTTGATGGAG 1 2  5 2
CCCCAGAAGGTGAGTACATCCCGCTGGACCACCAGGATGTGGATGTGGGCTTTGATGGAG
CCCCAGAGGGTGAGTACATCCCGCTGGACCACCAGGATGTGGATGTGGGCTTTGATGGAG
CCCCAGAGGGTGAGTACATCCCGCTGGACCACCAGGATGTGGATGTGGGCTTTGATGGAG
CCCCAGAGGGTGAGTACATCCCGCTGGACCACCAAGATGTGAATGTGGGCTTTGATGGAG
CCCCAGAGGGTGAGTACATCCCGCTGGACCACCAGGATGTGGATGTGGGCTTTGATGGAG
CCCCAGAGGGTGAGTACATCCCGCTGGACCACCAGGATGTGGATGTGGGCTTTGATGGAG
CCCCAGAGGGTGAGTACATCCCGCTGGACCACCAGGATGTGGATGTGGGCTTTGATGGAG
CCCCAGAGGGTGAGTACATCCCGCTGGACCACCAGGATGTGGATGTGGGCTTTGATGGAG
GCACCGATCGTATCTTCCTCGTGTCCCCCATCACCATCGTCCATGAGATCGACTCTGCCA 1 3 1 2
GCACCGATCGTATCTTCCTCGTGTCCCCCATCACCATCGTCCATGAGATCGACTCTGCCA
GCACCGATCGTATCTTCCTCGTGTCCCCCATCACCATCGTCCATGAGATCGACTCTGCCA
GCACCGATCGTATCTTCCTCGTGTCCCCCATCACCATCGTCCATGAGATCGACTCTGCCA
GCACCGATCGTATCTTCCTCGTGTCCCCCATCACCATCGTCCATGAGATCGACTCTGCCA
GCACCGATCGTATCTTCCTCGTGTCCCCCATCACCATCGTCCATGAGATCGACTCTGCCA
GCACCGATCGTATCTTCCTCGTGTCCCCCATCACCATCGTCCATGAGATCGACTCTGCCA
GCACCGATCGTATCTTCCTCGTGTCCCCCATCACCATCGTCCATGAGATCGACTCTGCCA
GCACCGATCGTATCTTCCTCGTGTCCCCCATCACCATCGTCCATGAGATCGACTCTGCCA
GTCCTCTGTATGAGCTAGGACGTGCCGAGCTGGCCAGGGCTGACTTTGAGCTGGTGGTC 1 3 7 2
GTCCTCTGTATGAGCTAGGACGTGCCGAGCTGGCCAGGGCTGACTTTGAGCTGGTGGTC
GTCCTCTGTATGAGCTAGGACGTGCCGAGCTGGCCAGGGCTGACTTTGAGCTGGTGGTC
GTCCTCTGTATGAGCTAGGACGTGCCGAGCTGGCCAGGGCTGACTTTGAGCTGGTGGTC
GTCCTCTGTATGAGCTAGGACGTGCCGAGCTGGCCAGGGCTGACTTTGAGCTGGTGGTC
GTCCTCTGTATGAGCTAGGACGTGCCGAGCTGGCCAGGGCTGACTTTGAGCTGGTGGTC
GTCCTCTGTATGAGCTAGGACGTGCCGAGCTGGCCAGGGCTGACTTTGAGCTGGTGGTC
g t c c t c t g t a t g a g c t a g g a c g t g c c g a g c t g g c c a g g g c t g a c t t t g a g c t g g t g g t c
GTCCTCTGTATGAGCTAGGACGTGCCGAGCTGGCCAGGGCTGACTTTGAGCTGGTGGTC
ATTCTCGAGGGGATGGTTGAGGCCACAGCCATGACCACACAGTGTCGCTCGTCCTACCTC 1 4 3 2
ATTCTCGAGGGGATGGTTGAGGCCACAGCCATGACCACACAGTGTCGCTCGTCCTACCTC
ATTCTCGAGGGGATGGTTGAGGCCACAGCCATGACCACACAGTGTCGCTCGTCCTACCTC
ATTCTCGAGGGGATGGTTGAGGCCACAGCCATGACCACACAGTGTCGCTCGTCCTACCTC
ATTCTCGAGGGGATGGTTGAGGCCACAGCCATGACCACACAGTGTCGCTCGTCCTACCTC
ATTCTCGAGGGGATGGTTGAGGCCACAGCCATGACCACACAGTGTCGCTCGTCCTACCTC
ATTCTCGAGGGGATGGTTGAGGCCACAGCCATGACCACACAGTGTCGCTCGTCCTACCTC
ATTCTCGAGGGGATGGTTGAGGCCACAGCCATGACCACACAGTGTCGCTCGTCCTACCTC
ATTCTCGAGGGGATGGTTGAGGCCACAGCCATGACCACACAGTGTCGCTCGTCCTACCTC
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CCTGGTGAACTGCTCTGGGGCCATCGTTTTGAGCCAGTTCTCTTCCAGCGTGGCTCCCAG
CCTGGTGAACTGCTCTGGGGCCATCGTTTTGAGCCAGTTCTCTTCCAGCGTGGCTCCCAG
CCTGGTGAACTGCTCTGGGGCCATCGTTTTGAGCCAGTTCTCTTCCAGCGTGGCTCCCAG
CCTGGTGAACTGCTCTGGGGCCATCGTTTTGAGCCAGTTCTCTTCCAGCGTGGCTCCCAG
CCTGGTGAACTGCTCTGGGGCCATCGTTTTGAGCCAGTTCTCTTCCAGCGTGGCTCCCAG
CCTGGTGAACTGCTCTGGGGCCATCGTTTTGAGCCAGTTCTCTTCCAGCGTGGCTCCCAG
CCTGGTGAACTGCTCTGGGGCCATCGTTTTGAGCCAGTTCTCTTCCAGCGTGGCTCCCAG
TATGAGGTCGACTATCGCCACTTCCATCGCACTTATGAGGTCCCAGGGACACCGGTC
TATGAGGTCGACTATCGCCACTTCCATCGCACTTATGAGGTCCCAGGGACACCGGTC
TATGAGGTCGACTATCGCCACTTCCATCGCACTTATGAGGTCCCAGGGACACCGGTC
TATGAGGTCGACTATCGCCACTTCCATCGCACTTATGAGGTCCCAGGGACACCGGTC
TATGAGGTCGACTATCGCCACTTCCATCGCACTTATGAGGTCCCAGGGACACCGGTC
TATGAGGTCGACTATCGCCACTTCCATCGCACTTATGAGGTCCCAGGGACACCGGTC
TATGAGGTCGACTATCGCCACTTCCATCGCACTTATGAGGTCCCAGGGACACCGGTC
TATGAGGTCGACTATCGCCACTTCCATCGCACTTATGAGGTCCCAGGGACACCGGTC
TATGAGGTCGACTATCGCCACTTCCATCGCACTTATGAGGTCCCAGGGACACCGGTC
TGCAGTGCTAAGGAGCTGGATGAACGGGCAGAGCAGGCTTCCCACAGCCTCAAGTCTAGT
TGCAGTGCTAAGGAGCTGGATGAACGGGCAGAGCAGGCTTCCCACAGCCTCAAGTCTAGT
TGCAGTGCTAAGGAGCTGGATGAACGGGCAGAGCAGGCTTCCCACAGCCTCAAGTCTAGT
TGCAGTGCTAAGGAGCTGGATGAACGGGCAGAGCAGGCTTCCCACAGCCTCAAGTCTAGT
TGCAGTGTTAAGGAGCTGGATGAACGGGCAGAGCAGGCTTCCCACAGCCTCAAGTCTAGT
TGCAGTGCTAAGGAGCTGGATGAACGGGCAGAGCAGGCTTCCCACAGCCTCAAGTCTAGT
TGCAGTGCTAAGGAGCTGGATGAACGGGCAGAGCAGGCTTCCCACAGCCTCAAGTCTAGT
TGCAGTGCTAAGGAGCTGGATGAACGGGCAGAGCAGGCTTCCCACAGCCTCAAGTCTAGT
TGCAGTGCTAAGGAGCTGGATGAACGGGCAGAGCAGGCTTCCCACAGCCTCAAGTCTAGT
TTCCCCGGCTCTCTGACTGCATTTTGTTATGAGAATGAACTTGCTCTGAGCTGCTGCCAG
TTCCCCGGCTCTCTGACTGCATTTTGTTATGAGAATGAACTTGCTCTGAGCTGCTGCCAG
TTCCCCGGCTCTCTGACTGCATTTTGTTATGAGAATGAACTTGCTCTGAGCTGCTGCCAG
TTCCCCGGCTCTCTGACTGCATTTTGTTATGAGAATGAACTTGCTCTGAGCTGCTGCCAG
TTCCCCGGCTCTCTGACTGCATTTTGTTATGAGAATGAACTTGCTCTGAGCTGCTGCCAG
TTCCCCGGCTCTCTGACTGCATTTTGTTATGAGAATGAACTTGCTCTGAGCTGCTGCCAG
TTCCCCGGCTCTCTGACTGCATTTTGTTATGAGAATGAACTTGCTCTGAGCTGCTGCCAG
TTCCCCGGCTCTCTGACTGCATTTTGTTATGAGAATGAACTTGCTCTGAGCTGCTGCCAG
TTCCCCGGCTCTCTGACTGCATTTTGTTATGAGAATGAACTTGCTCTGAGCTGCTGCCAG
GAGGAAGATGAGGACGATGAGACTGAGGAAGGGAATGGGGTGGAAACAGAAGATGGGGCT
GAGGAAGATGAGGACGATGAGACTGAGGAAGGGAATGGGGTGGAAACAGAAGATGGGGCT
GAGGAAGATGAGGACGATGAGACTGAGGAAGGGAATGGGGTGGAAACAGAAGATGGGGCT
GAGGAAGATGAGGACGATGAGACTGAGGAAGGGAATGGGGTGGAAACAGAAGATGGGGCT
GAGGAAGATGAGGACGATGAGACTGAGGAAGGGAATGGGGTGGAAACAGAAGATGGGGCT
GAGGAAGATGAGGACGATGAGACTGAGGAAGGGAATGGGGTGGAAACAGAAGATGGGGCT
GAGGAAGATGAGGACGATGAGACTGAGGAAGGGAATGGGGTGGAAACAGAAGATGGGGCT
GAGGAAGATGAGGACGATGAGACTGAGGAAGGGAATGGGGTGGAAACAGAAGATGGGGCT
GAGGAAGATGAGGACGATGAGACTGAGGAAGGGAATGGGGTGGAAACAGAAGATGGGGCT
1 4 9 2
1 5 4 9
1 6 0 9
1 6 6 9
1729
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1  GCTAGCCCCCGAGTTCTCACACCAACCCTGGCGCTGACCCTGCCTCCATGATGCAAACT 1 7 8 9
2  GCTAGCCCCCGAGTTCTCACACCAACCCTGGCGCTGACCCTGCCTCCATGATGCAAACT
3  GCTAGCCCCCGAGTTCTCACACCAACCCTGGCGCTGACCCTGCCTCCATGATGCAAACT
4 GCTAGCCCCCGAGTTCTCACACCAACCCTGGCGCTGACCCTGCCTCCATGATGCAAACT
5  GCTAGCCCCCGAGTTCTCACACCAACCCTGGCGCTGACCCTGCCTCCATGATGCAAACT
6 GCTAGCCCCCGAGTTCTCACACCAACCCTGGCGCTGACCCTGCCTCCATGATGCAAACT
7  GCTAGCCCCCGAGTTCTCACACCAACCCTGGCGCTGACCCTGCCTCCATGATGCAAACT
8 GCTAGCCCCCGAGTTCTCACACCAACCCTGGCGCTGACCCTGCCTCCATGATGCAAACT
9  GCTAGCCCCCGAGTTCTCACACCAACCCTGGCGCTGACCCTGCCTCCATGATGCAAACT
The database exonic sequence o f 3C is shown in red (from position 1166 to 1741). The 
size o f the PCR product is 624bp, which includes the overlapping exonic sequence of 
exon 3B with 3C, entire sequence o f exon 3A and flanking the intronic sequence. The 
overlapping sequence is underlined.
1 = sequence o f the exon from the database (http://www.ncbi.nlm.nih/nucleotide)
2 = forward sequence
3 = reverse complement sequence o f the reverse
4 - forward sequence
5 = reverse complement sequence o f  the reverse
6 = forward sequence
7 = reverse complement sequence o f the reverse
8 = forward sequence
9 = reverse complement sequence o f the reverse U
}
}
}
an unaffected individual 
affected individual from pedigree 1 
affected individual from pedigree 2 
affected individual from pedigree 5
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L IN -7 B
Table 7 CLUSTALW 1.81 alignments of exon 1 of L IN -7 B
1  CGCCAGGGCAGGCGGGCGGCTGGCAGCTGTGGCGCCGACATGGCTGCGCTGGTGGAGC 5 8
3  CGCCAGGGCAGGCGGGCGGCTGGCAGCTGTGGCGCCGACATGGCTGCGCTGGTGGAGC
5  CGCCAGGGCAGGCGGGCGGCTGGCAGCTGTGGCGCCGACATGGCTGCGCTGGTGGAGC
6 CGCCAGGGCAGGCGGGCGGCTGGCAGCTGTGGCGCCGACATGGCTGCGCTGGTGGAGC
7  CGCCAGGGCAGGCGGGCGGCTGGCAGCTGTGGCGCCGACATGGCTGCGCTGGTGGAGC
1  C GC TGGGGC T GGAGC GGGGTAAGCGTGCGCC 8 9
2  CGCTGGGGCTGGAGCGGGGTAAGCGTGCGCC
3  CGCTGGGGCTGGAGCGGGGTAAGCGTGCGCC
5  CGCTGGGGCTGGAGCGGGGTAAGCGTGCGCC
6  CGCTGGGGCTGGAGCGGGGTAAGCGTGCGCC
7  CGCTGGGGCTGGAGCGGGGTAAGCGTGCGCC
The database exonic sequence is shown in red (from position 40 to 82) and is 43 bp in 
size. The PCR product is 89bp in size, which includes the flanking intronic sequence and 
the entire exonic sequence.
1 = sequence o f the exon from the database (http://www
2 = forward sequence
3 = reverse complement sequence o f the reverse
4 = forward sequence
5 = reverse complement sequence o f the reverse
6 = forward sequence
7 = reverse complement sequence o f  the reverse
8 = forward sequence
9 = reverse complement sequence o f the reverse
.ncbi.nlm.nih/nucleotide)
>
}
>
}
an unaffected individual 
affected individual from pedigree 1 
affected individual from pedigree 2 
affected individual from pedigree 5
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1  GGTTTCTGCGCCCCGCCCCCGCCCCGCAGAC G TG T C C C GGGC GGT T  GAGC T C  5 2
2  GGTTTCTGCGCCCCGCCCCCGCCCCGCAGACGTGTCCCGGGCGGTTGAGCTC
3  GGTTTCTGCGCCCCGCCCCCGCCCCGCAGACGTGTCCCGGGCGGTTGAGCTC
4 GGTTTCTGCGCCCCGCCCCCGCCCCGCAGACGTGTCCCGGGCGGTTGAGCTC
5  GGTTTCTGCGCCCCGCCCCCGCCCCGCAGACGTGTCCCGGGCGGTTGAGCTC
8  GGTTTCTGCGCCCCGCCCCCGCCCCGCAGACGTGTCCCGGGCGGTTGAGCTC
9  GGTTTCTGCGCCCCGCCCCCGCCCCGCAGACGTGTCCCGGGCGGTTGAGCTC
Table 8 CLUSTALW 1.81 alignments of exon 2 of LIN- TB
1 CTCGAGCGGCTCCAGCGCAGCGGGGAGCTGCCGCCGCAGAAGCTGCAGGCCCTCCAGCGA 112
2 CTCGAGCGGCTCCAGCGCAGCGGGGAGCTGCCGCCGCAGAAGCTGCAGGCCCTCCAGCGA
3  CTCGAGCGGCTCCAGCGCAGCGGGGAGCTGCCGCCGCAGAAGCTGCAGGCCCTCCAGCGA
4 CTCGAGCGGCTCCAGCGCAGCGGGGAGCTGCCGCCGCAGAAGCTGCAGGCCCTCCAGCGA
5  CTCGAGCGGCTCCAGCGCAGCGGGGAGCTGCCGCCGCAGAAGCTGCAGGCCCTCCAGCGA
8  CTCGAGCGGCTCCAGCGCAGCGGGGAGCTGCCGCCGCAGAAGCTGCAGGCCCTCCAGCGA
9 CTCGAGCGGCTCCAGCGCAGCGGGGAGCTGCCGCCGCAGAAGCTGCAGGCCCTCCAGCGA
1 GTTCTGCAGAGCCGCTTCTGCTCCGCTATCCGAGAGGTGAGGGGCGCGCGGCGCAGGGGC 172
2 GTTCTGCAGAGCCGCTTCTGCTCCGCTATCCGAGAGGTGAGGGGCGCGCGGCGCAGGGGC
3  GTTCTGCAGAGCCGCTTCTGCTCCGCTATCCGAGAGGTGAGGGGCGCGCGGCGCAGGGGC
4 GTTCTGCAGAGCCGCTTCTGCTCCGCTATCCGAGAGGTGAGGGGCGCGCGGCGCAGGGGC
5  GTTCTGCAGAGCCGCTTCTGCTCCGCTATCCGAGAGGTGAGGGGCGCGCGGCGCAGGGGC
8 GTTCTGCAGAGCCGCTTCTGCTCCGCTATCCGAGAGGTGAGGGGCGCGCGGCGCAGGGGC
9 GTTCTGCAGAGCCGCTTCTGCTCCGCTATCCGAGAGGTGAGGGGCGCGCGGCGCAGGGGC
The database exonic sequence is shown in red (from position 30 to 148) and is 119bp in 
size. The size o f the PCR product is 172bp, which includes the flanking intronic 
sequence and the entire exonic sequence.
1 = sequence o f the exon from the database (http://www.ncbi.nlm.nih/nucleotide)
} an unaffected individual2 = forward sequence3 = reverse complement sequence o f the reverse
4 - forward sequence ->
5 = reverse complement sequence o f  the reverse \  affected d iv id u a l &om pedigree 1
6 = forward sequence
7 = reverse complement sequence o f  the reverse ~L affected individual from pedigree 2
8 = forward sequence
9 = reverse complement sequence o f  the reverse ~j_ affected individual from pedigree 5
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CGGGGGCGGGGCGGATCCTTGCGTG 2 5
CGGGGGCGGGGCGGATCCTTGCGTG
CGGGGGCGGGGCGGATCCTTGCGTG
CGGGGGCGGGGCGGATCCTTGCGTG
CGGGGGCGGGGCGGATCCTTGCGTG
CGGGGGCGGGGCGGATCCTTGCGTG
CGGGGGCGGGGCGGATCCTTGCGTG
CGGGGGCGGGGCGGATCCTTGCGTG
9 CLUSTALW 1.81 alignments of exon 3 of LIN-7B
GTAGCGGGAGAGGGTCTAGAGGCCTGAACTCCTGCGTCTAGGGCTGGAGGAGCTGGCGA 8 4
GTAGCGGGAGAGGGTCTAGAGGCCTGAACTCCTGCGTCTAGGGCTGGAGGAGCTGGCGA
GTAGCGGGAGAGGGTCTAGAGGCCTGAACTCCTGCGTCTAGGGCTGGAGGAGCTGGCGA
GTAGCGGGAGAGGGTCTAGAGGCCTGAACTCCTGCGTCTAGGGCTGGAGGAGCTGGCGA
GTAGCGGGAGAGGGTCTAGAGGCCTGAACTCCTGCGTCTAGGGCTGGAGGAGCTGGCGA
GTAGCGGGAGAGGGTCTAGAGGCCTGAACTCCTGCGTCTAGGGCTGGAGGAGCTGGCGA
GTAGCGGGAGAGGGTCTAGAGGCCTGAACTCCTGCGTCTAGGGCTGGAGGAGCTGGCGA
GTAGCGGGAGAGGGTCTAGAGGCCTGAACTCCTGCGTCTAGGGCTGGAGGAGCTGGCGA
CTCCCTGATGCCGCTGCCTCCTCACCCAGGTGTATGAGCAGCTTTATGACACGCTGGACA 1 4 4
CTCCCTGATGCCGCTGCCTCCTCACCCAGGTGTATGAGCAGCTTTATGACACGCTGGACA
CTCCCTGATGCCGCTGCCTCCTCACCCAGGTGTATGAGCAGCTTTATGACACGCTGGACA
CTCCCTGATGCCGCTGCCTCCTCACCCAGGTGTATGAGCAGCTTTATGACACGCTGGACA
CTCCCTGATGCCGCTGCCTCCTCACCCAGGTGTATGAGCAGCTTTATGACACGCTGGACA
CTCCCTGATGCCGCTGCCTCCTCACCCAGGTGTATGAGCAGCTTTATGACACGCTGGACA
CTCCCTGATGCCGCTGCCTCCTCACCCAGGTGTATGAGCAGCTTTATGACACGCTGGACA
CTCCCTGATGCCGCTGCCTCCTCACCCAGGTGTATGAGCAGCTTTATGACACGCTGGACA
TCACCGGCAGCGCCGAGATCCGAGCCCATGCCACAGCCAAGGTGGGCCCCGCACCCCATT 2 0 4
TCACCGGCAGCGCCGAGATCCGAGCCCATGCCACAGCCAAGGTGGGCCCCGCACCCCATT
TCACCGGCAGCGCCGAGATCCGAGCCCATGCCACAGCCAAGGTGGGCCCCGCACCCCATT
TCACCGGCAGCGCCGAGATCCGAGCCCATGCCACAGCCAAGGTGGGCCCCGCACCCCATT
TCACCGGCAGCGCCGAGATCCGAGCCCATGCCACAGCCAAGGTGGGCCCCGCACCCCATT
TCACCGGCAGCGCCGAGATCCGAGCCCATGCCACAGCCAAGGTGGGCCCCGCACCCCATT
TCACCGGCAGCGCCGAGATCCGAGCCCATGCCACAGCCAAGGTGGGCCCCGCACCCCATT
TCACCGGCAGCGCCGAGATCCGAGCCCATGCCACAGCCAAGGTGGGCCCCGCACCCCATT
GCTCCTGGTGTCTATTTAACTGCCTAGTCGAACTCAATAT 2 4 4
GCTCCTGGTGTCTATTTAACTGCCTAGTCGAACTCAATAT
GCTCCTGGTGTCTATTTAACTGCCTAGTCGAACTCAATAT
GCTCCTGGTGTCTATTTAACTGCCTAGTCGAACTCAATAT
GCTCCTGGTGTCTATTTAACTGCCTAGTCGAACTCAATAT
g c t c c t g g t g t c t a t t t a a c t g c c t a g t c g a a c t c a a t a t
GCTCCTGGTGTCTATTTAACTGCCTAGTCGAACTCAATAT
GCTCCTGGTGTCTATTTAACTGCCTAGTCGAACTCAATAT
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The database exonic sequence is shown in red (from position 30 to 230) and is 201bp in 
size. The size o f the PCR product is 244bp, which includes the flanking intronic 
sequence and the entire exonic sequence.
1 = sequence o f the exon from the database (http://www.ncbi.nlm.nih/nucleotide)
2 = forward sequence
3 = reverse complemei
4 = forward sequence
5 = reverse complemei
6 = forward sequence
7 = reverse complemei
8 = forward sequence
sequence o f the reverse J" an unaffected individual
sequence o f the reverse affected individual from pedigree 1
sequence o f the reverse affected individual from pedigree 2
sequence of the reverse affected individual from pedigree 5
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ATCCCCCACCCCAGCTTTCATGCCTACCTGGAAGGGGCCCTCATCTTCAGTCGC 5 4
ATCCCCCACCCCAGCTTTCATGCCTACCTGGAAGGGGCCCTCATCTTCAGTCGC
ATCCCCCACCCCAGCTTTCATGCCTACCTGGAAGGGGCCCTCATCrrCAGTCGC
ATCCCCCACCCCAGCTTTCATGCCTACCTGGAAGGGGCCCTCATCTTCASTCGC
ATCCCCCACCCCAGCTTTCATGCCTACCTGGAAGGGGCCCTCATCTTCAGTCGC
a t c c c c c a c c c c a g c t t t c a t g c c t a c c t g g a a g g g g c c c t c a t c t t c a g t c g c
ATCCCCCACCCCAGCTTTCATGCCTACCTGGAAGGGGCCCTCATCTTCAGTCGC
ATCCCCCACCCCAGCTTTCATGCCTACCTGGAAGGGGCCCTCATCTTCAGTCGC
ATCCCCCACCCCAGCTTTCATGCCTACCTGGAAGGGGCCCTCATCTTCAGTCGC
10 CLUSTALW 1.81 alignments of exon 4 of LIN- TB
TTTCTCTCTCCCAGGCCACAGTGGCTGCCTTCACAGCCAGCGAGGGCCACGCACATCCCA 1 1 4
TTTCTCTCTCCCAGGCCACAGTGGCTGCCTTCACAGCCAGCGAGGGCCACGCACATCCCA
TTTCTCTCTCCCAGGCCACAGTGGCTGCCTTCACAGCCAGCGAGGGCCACGCACATCCCA
CTTCTCTCTCCCAGGCCACAGTGGCTGCCTTCACAGCCAGCGAGGGCCACGCACATCCCA
TTTCTCTCTCCCAGGCCACAGTGGCTGCCTTCACAGCCAGCGAGGGCCACGCACATCCCA
TTTCTCTCTCCCAGGCCACAGTGGCTGCCTTCACAGCCAGCGAGGGCCACGCACATCCCA
t t t c t c t c t c c c a g g c c a c a g t g g c t g c c t t c a c a g c c a g c g a g g g c c a c g c a c a t c c c a
TTTCTCTCTCCCAGGCCACAGTGGCTGCCTTCACAGCCAGCGAGGGCCACGCACATCCCA
GGGTAGTGGAGCTACCCAAGACGGATGAGGGCCTAGGCTTCAACATCATGGGTGGCAAAG 1 7 4
GGGTAGTGGAGCTACCCAAGACGGATGAGGGCCTAGGCTTCAACATCATGGGTGGCAAAG
GGGTAGTGGAGCTACCCAAGACGGATGAGGGCCTAGGCTTCAACATCATGGGTGGCAAAG
GGGTAGTGGAGCTACCCAAGACGGATGAGGGCCTAGGCTTCAACATCATGGGTGGCAAAG
GGGTAGTGGAGCTACCCAAGACGGATGAGGGCCTAGGCTTCAACATCATGGGTGGCAAAG
GGGTAGTGGAGCTACCCAAGACGGATGAGGGCCTAGGCTTCAACATCATGGGTGGCAAAG
GGGTAGTGGAGCTACCCAAGACGGATGAGGGCCTAGGCTTCAACATCATGGGTGGCAAAG
GGGTAGTGGAGCTACCCAAGACGGATGAGGGCCTAGGCTTCAACATCATGGGTGGCAAAG
GGGTAGTGGAGCTACCCAAGACGGATGAGGGCCTAGGCTTCAACATCATGGGTGGCAAAG
AGCAAAACTCGCCCATCTACATCTCCCGGGTCATCCCAGGGGGTGTGGCTGACCGCCATG 2 3 4
AGCAAAACTCGCCCATCTACATCTCCCGGGTCATCCCAGGGGGTGTGGCTGACCGCCATG
AGCAAAACTCGCCCATCTACATCTCCCGGGTCATCCCAGGGGGTGTGGCTGACCGCCATG
AGCAAAACTCGCCCATCTACATCTCCCGGGTCATCCCAGGGGGTGTGGCTGACCGCCATG
AGCAAAACTCGCCCATCTACATCTCCCGGGTCATCCCAGGGGGTGTGGCTGACCGCCATG
AGCAAAACTCGCCCATCTACATCTCCCGGGTCATCCCAGGGGGTGTGGCTGACCGCCATG
AGCAAAACTCGCCCATCTACATCTCCCGGGTCATCCCAGGGGGTGTGGCTGACCGCCATG
AGCAAAACTCGCCCATCTACATCTCCCGGGTCATCCCAGGGGGTGTGGCTGACCGCCATG
AGCAAAACTCGCCCATCTACATCTCCCGGGTCATCCCAGGGGGTGTGGCTGACCGCCATG
GAGGCCTCAAGCGTGGGGATCAACTGTTGTCGGTGAACGGTGTGGTGAGTGGAGGGCT 2  9 2
GAGGCCTCAAGCGTGGGGATCAACTGTTGTCGGTGAACGGTGTGGTGAGTGGAGGGCT
GAGGCCTCAAGCGTGGGGATCAACTGTTGTCGGTGAACGGTGTGGTGAGTGGAGGGCT
GAGGCCTCAAGCGTGGGGATCAACTGTTGTCGGTGAACGGTGTGGTGAGTGGAGGGCT
GAGGCCTCAAGCGTGGGGATCAACTGTTGTCGGTGAACGGTGTGGTGAGTGGAGGGCT
GAGGCCTCAAGCGTGGGGATCAACTGTTGTCGGTGAACGGTGTGGTGAGTGGAGGGCT
GAGGCCTCAAGCGTGGGGATCAACTGTTGTCGGTGAACGGTGTGGTGAGTGGAGGGCT
GAGGCCTCAAGCGTGGGGATCAACTGTTGTCGGTGAACGGTGTGGTGAGTGGAGGGCT
GAGGCCTCAAGCGTGGGGATCAACTGTTGTCGGTGAACGGTGTGGTGAGTGGAGGGCT
Stellenbosch University http://scholar.sun.ac.za/
1  AGGCAGGACTGGGGGA 3 0 9
2  GAGGCAGGACTGGGGGA
3  GAGGCAGGACTGGGGGA
4  GAGGCAGGACTGGGGGA
5  GAGGCAGGACTGGGGGA
6 GAGGCAGGACTGGGGGA
7  GAGGCAGGACTGGGGGA
8  GAGGCAGGACTGGGGGA
9  GAGGCAGGACTGGGGGA
The database exonic sequence is shown in red (from position 15 to 293) and is 279bp in 
size. The size of the PCR product is 309bp, which includes the flanking intronic 
sequence and the entire exonic sequence.
1 = sequence o f the exon from the database (http
2 = forward sequence
3 = reverse complement sequence o f the reverse
4 = forward sequence
5 = reverse complement sequence o f  the reverse
6 = forward sequence
7 = reverse complement sequence o f the reverse
8 = forward sequence
9 = reverse complement sequence o f the reverse
://www.ncbi.nlm.nih/nucleotide)
3" an unaffected individual 
"J- affected individual from pedigree 1 
affected individual from pedigree 2 
affected individual from pedigree 5
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AGTGGG 6
AGTGGG
AGTGGG
AGTGGG
AGTGGG
AGTGGG
AGTGGG
AGTGGG
AGTGGG
11 CLUSTALW 1.81 alignments of exon 5 of LIN-7B
GGCTGGACGAGGGCAGCGGGCCCCAGGCTCAGCTGTCTGTGTTGGGCCCTGCAGAGCGTT 6 6
GGCTGGAGGAGGGCAGCGGGCCCCAGGCTCAGCTGTCTGTGTTGGGCCCTGCAGAGCGTT
GGCTGGACGAGGGCAGCGGGCCCCAGGCTCAGCTGTCTGTGTTGGGCCCTGCAGAGCGTT
GGCTGGACGAGGGCAGCGGGCCCCAGGCTCAGCTGTCTGTGTTGGGCCCTGCAGAGCGTT
GGCTGGACGAGGGCAGCGGGCCCCAGGCTCAGCTGTCTGTGTTGGGCCCTGCAGAGCGTT
GGCTGGACGAGGGCAGCGGGCCCCAGGCTCAGCTGTCTGTGTTGGGCCCTGCAGAGCGTT
GGCTGGACGAGGGCAGCGGGCCCCAGGCTCAGCTGTCTGTGTTGGGCCCTGCAGAGCGTT
GGCTGGACGAGGGCAGCGGGCCCCAGGCTCAGCTGTCTGTGTTGGGCCCTGCAGAGCGTT
GGCTGGACGAGGGCAGCGGGCCCCAGGCTCAGCTGTCTGTGTTGGGCCCTGCAGAGCGTT
GAGGGTGAGCAGCATGAGAAGGCGGTGGAGCTGCTGAAGGCGGCCCAGGGCTCGGTGAAG 1 2 6
GAGGGTGAGCAGCATGAGAAGGCGGTGGAGCTGCTGAAGGCGGCCCAGGGCTCGGTGAAG
GAGGGTGAGCAGCATGAGAAGGCGGTGGAGCTGCTGAAGGCGGCCCAGGGCTCGGTGAAG
GAGGGTGAGCAGCATGAGAAGGCGGTGGAGCTGCTGAAGGCGGCCCAGGGCTCGGTGAAG
GAGGGTGAGCAGCATGAGAAGGCGGTGGAGCTGCTGAAGGCGGCCCAGGGCTCGGTGAAG
GAGGGTGAGCAGCATGAGAAGGCGGTGGAGCTGCTGAAGGCGGCCCAGGGCTCGGTGAAG
GAGGGTGAGCAGCATGAGAAGGCGGTGGAGCTGCTGAAGGCGGCCCAGGGCTCGGTGAAG
GAGGGTGAGCAGCATGAGAAGGCGGTGGAGCTGCTGAAGGCGGCCCAGGGCTCGGTGAAG
GAGGGTGAGCAGCATGAGAAGGCGGTGGAGCTGCTGAAGGCGGCCCAGGGCTCGGTGAAG
CTGGTTGTCCGTTACACACCGCGAGTGCTGGAGGAGATGGAGGCCCGGTTCGAGAAGATG 1 8 6
CTGGTTGTCCGTTACACACCGCGAGTGCTGGAGGAGATGGAGGCCCGGTTCGAGAAGATG
CTGGTTGTCCGTTACACACCGCGAGTGCTGGAGGAGATGGAGGCCCGGTTCGAGAAGATG
CTGGTTGTCCGTTACACACCGCGAGTGCTGGAGGAGATGGAGGCCCGGTTCGAGAAGATG
CTGGTTGTCCGTTACACACCGCGAGTGCTGGAGGAGATGGAGGCCCGGTTCGAGAAGATG
CTGGTTGTCCGTTACACACCGCGAGTGCTGGAGGAGATGGAGGCCCGGTTCGAGAAGATG
CTGGTTGTCCGTTACACACCGCGAGTGCTGGAGGAGATGGAGGCCCGGTTCGAGAAGATG
CTGGTTGTCCGTTACACACCGCGAGTGCTGGAGGAGATGGAGGCCCGGTTCGAGAAGATG
CTGGTTGTCCGTTACACACCGCGAGTGCTGGAGGAGATGGAGGCCCGGTTCGAGAAGATG
CGCTCTGCCCGCCGGCGCCAACAGCATCAGAGCTACTCGTGAGCCCCTGGGTCACCACA 2 4 6
c g c t c t g c c c g c c g g c g c c a a c a g c a t c a g a g c t a c t c g t g a g c c c c t g g g t c a c c a c a
CGCTCTGCCCGCCGGCGCCAACAGCATCAGAGCTACTCGTGAGCCCCTGGGTCACCACA
CGCTCTGCCCGCCGGCGCCAACAGCATCAGAGCTACTCGTGAGCCCCTGGGTCACCACA
CGCTCTGCCCGCCGGCGCCAACAGCATCAGAGCTACTCGTGAGCCCCTGGGTCACCACA
CGCTCTGCCCGCCGGCGCCAACAGCATCAGAGCTACTCGTGAGCCCCTGGGTCACCACA
CGCTCTGCCCGCCGGCGCCAACAGCATCAGAGCTACTCGTGAGCCCCTGGGTCACCACA
CGCTCTGCCCGCCGGCGCCAACAGCATCAGAGCTACTCGTGAGCCCCTGGGTCACCACA
CGCTCTGCCCGCCGGCGCCAACAGCATCAGAGCTACTCGTGAGCCCCTGGGTCACCACA
Stellenbosch University http://scholar.sun.ac.za/
1  CCCCTGGGGCCTCCACGGGCTCCCTTTAACCCCAGG 2 8 2
2  CCCCTGGGGCCTCCACGGGCTCCCTTTAACCCCAGG
3  CCCCTGGGGCCTCCACGGGCTCCCTTTAACCCCAGG
4  CCCCTGGGGCCTCCACGGGCTCCCTTTAACCCCAGG
5  CCCCTGGGGCCTCCACGGGCTCCCTTTAACCCCAGG
6  CCCCTGGGGCCTCCACGGGCTCCCTTTAACCCCAGG
7  CCCCTGGGGCCTCCACGGGCTCCCTTTAACCCCAGG
8 CCCCTGGGGCCTCCACGGGCTCCCTTTAACCCCAGG
9 CCCCTGGGGCCTCCACGGGCTCCCTTTAACCCCAGG
The database exonic sequence is shown in red (from position 61 to 224) and is 164bp in 
size. The size o f the PCR product is 282bp, which includes the flanking intronic 
sequence and the entire exonic sequence.
1 = sequence o f  the exon from the database (http://www.ncbi.nlm.nih/nucleotide)
2 = forward sequence
3 = reverse complement sequence o f the reverse
4 = forward sequence
5 = reverse complement sequence o f the reverse
6 = forward sequence
7 = reverse complement sequence o f the reverse
8 = forward sequence
9 = reverse complement sequence o f  the reverse
an unaffected individual 
affected individual from pedigree 1 
affected individual from pedigree 2 
affected individual from pedigree 5
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BAX
Table 12 CLUSTALW 1.81 analysis of exon 1 of BAX
1  GGGCGCGCTGCGGCTCGCCCGCGCGG 2 6
2  GGGCGCGCTGCGGCTCGCCCGCGCGG
3  GGGCGCGCTGCGGCTCGCCCGCGCGG
4 GGGCGCGCTGCGGCTCGCCCGCGCGG
5  GGGCGCGCTGCGGCTCGCCCGCGCGG
6  GGGCGCGCTGCGGCTCGCCCGCGCGG
7 GGGCGCGCTGCGGCTCGCCCGCGCGG
8 GGGCGCGCTGCGGCTCGCCCGCGCGG
9 GGGCGCGCTGCGGCTCGCCCGCGCGG
**************************
1  ACCCGGCGAGAGGCGGCGGCGGGAGCGGCGGTGTAT GGAC GGGT C C GGGGAGCAGC CCA  8 5
2  ACCCGGCGAGAGGCGGCGGCGGGAGCGGCGGTGTATGGACGGGTCCGGGGAGCAGCCCA
3  ACCCGGCGAGAGGCGGCGGCGGGAGCGGCGGTGTATGGACGGGTCCGGGGAGCAGCCCA
4  ACCCGGCGAGAGGCGGCGGCGGGAGCGGCGGTGTATGGACGGGTCCGGGGAGCAGCCCA
5  ACCCGGCGAGAGGCGGCGGCGGGAGCGGCGGTGTATGGACGGGTCCGGGGAGCAGCCCA
6  ACCCGGCGAGAGGCGGCGGCGGGAGCGGCGGTGTATGGACGGGTCCGGGGAGCAGCCCA
7  ACCCGGCGAGAGGCGGCGGCGGGAGCGGCGGTGTATGGACGGGTCCGGGGAGCAGCCCA
8 ACCCGGCGAGAGGCGGCGGCGGGAGCGGCGGTGTATGGACGGGTCCGGGGAGCAGCCCA
9  ACCCGGCGAGAGGCGGCGGCGGGAGCGGCGGTGTATGGACGGGTCCGGGGAGCAGCCCA
1  GAGGCGGGGGTGAGGCGGGAGGCAGACGGG 1 1 5
2  GAAGCGGGGGTGAGGCGGGAGGCAGACGGG
3  GAGGCGGGGGTGAGGCGGGAGGCAGACGGG
4  GAGGCGGGGGTGAGGCGGGAGGCCGACGGG
5  GAGGCGGGGGTGAGGCGGGAGGCAGACGGG
6  GANGCGAGGGTGAGGCGGGAGGCAGACGGG
7  GAGGCGGGGGTGAGGCGGGAGGCAGACGGG
8 GAGGCGGGGGTGAGGCGGGAGGCAGACGGG
9  GAGGCGGGGGTGAGGCGGGAGGCAGACGGG
The database exonic sequence is shown in red (from position 61 to 94) and is 34bp in 
size. The size o f the PCR product is 115bp, which includes the flanking intronic 
sequence and the entire exonic sequence.
1 = sequence o f  the exon from the database (http://www.ncbi.nlm.nih/nucleotide)
2 = forward sequence
3 = reverse complement sequence o f  the reverse
4 = forward sequence
5 = reverse complement sequence o f the reverse
6 = forward sequence
7 = reverse complement sequence o f the reverse
8 = forward sequence
9 = reverse complement sequence o f the reverse
}
}
an unaffected individual 
affected individual from pedigree 1 
affected individual from pedigree 2 
affected individual from pedigree 5
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TTCCCTTCCTTTCTCCTCTAGGGCCCAC 2 8
TTCCCTTCCTTTCTCCTCTAGGGCCCAC
TTCCCTTCCTTTCTCCTCTAGGGCCCAC
TTCCCTTCCTTTCTCCTCTAGGGCCCAC
TTCCCTTCCTTTCTCCTCTAGGGCCCAC
TTCCCTTCCTTTCTCCTCTAGGGCCCAC
TTCCCTTCCTTTCTCCTCTAGGGCCCAC
TTCCCTTCCTTTCTCCTCTAGGGCCCAC
13 CLUSTALW 1.81 analysis of exon 2 and 3 of SAX.
CAGCTCTGAGCAGATCATGAAGACAGGGGCCCTTTTGCTTCAGGGGTGAGTTTGAGG 8 5  
CAGCTCTGAGCAGATCATGAAGACAGGGGCCCTTTTGCTTCAGGGGTGAGTTTGAGG
CAGCTCTGAGCAGATCATGAAGACAGGGGCCCTTTTGCTTCAGGGGTGAGTTTGAGG
CAGCTCTGAGCAGATCATGAAGACAGGGGCCCTTTTGCTTCAGGGGTGAGTTTGAGG
CAGCTCTGAGCAGATCATGAAGACAGGGGCCCTTTTGCTTCAGGGGTGAGTTTGAGG
CAGCTCTGAGCAGATCATGAAGACAGGGGCCCTTTTGCTTCAGGGGTGAGTTTGAGG
CAGCTCTGAGCAGATCATGAAGACAGGGGCCCTTTTGCTTCAGGGGTGAGTTTGAGG
TCTGATTATTGTGGCACAGATTTGAGAGAGTGACACCCCGTTCTGATTCTGCACCCTCAC 1 4 5
TCTGATTATTGTGGCACAGATTTGAGAGAGTGACACCCCGTTCTGATTCTGCACCCTCAC
TCTGATTATTGTGGCACAGATTTGAGAGAGTGACACCCCGTTCTGATTCTGCACCCTCAC
TCTGATTATTGTGGCACAGATTTGAGAGAGTGACACCCCGTTCTGATTCTGCACCCTCAC
TCTGATTATTGTGGCACAGATTTGAGAGAGTGACACCCCGTTCTGATTCTGCACCCTCAC
TCTGATTATTGTGGCACAGATTTGAGAGAGTGACACCCCGTTCTGATTCTGCACCCTCAC
TCTGATTATTGTGGCACAGATTTGAGAGAGTGACACCCCGTTCTGATTCTGCACCCTCAC
TCTGATTATTGTGGCACAGATTTGAGAGAGTGACACCCCGTTCTGATTCTGCACCCTCAC
TCCATCCCCACTCTAGTTTCATCCAGGATCGAGCAGGGCGAATGGGGGGGGAGGCACCCG 2 0 5
TCCATCCCCACTCTAGTTTCATCCAGGATCGAGCAGGGCGAATGGGGGGGGAGGCACCCG
TCCATCCCCACTCTAGTTTCATCCAGGATCGAGCAGGGCGAATGGGGGGGGAGGCACCCG
TCCATCCCCACTCTAGTTTCATCCAGGATCGAGCAGGGCGAATGGGGGGGGAGGCACCCG
TCCATCCCCACTCTAGTTTCATCCAGGATCGAGCAGGGCGAATGGGGGGGGAGGCACCCG
TCCATCCCCACTCTAGTTTCATCCAGGATCGAGCAGGGCGAATGGGGGGGGAGGCACCCG
TCCATCCCCACTCTAGTTTCATCCAGGATCGAGCAGGGCGAATGGGGGGGGAGGCACCCG
TCCATCCCCACTCTAGTTTCATCCAGGATCGAGCAGGGCGAATGGGGGGGGAGGCACCCG
AGCTGGCCCTGGACCCGGTGCCTCAGGATGCGTCCACCAAGAAGCTGAGCGAGTGTCT 2 6 3  
AGCTGGCCCTGGACCCGGTGCCTCAGGATGCGTCCACCAAGAAGCTGAGCGAGTGTCT 
AGCTGGCCCTGGACCCGGTGCCTCAGGATGCGTCCACCAAGAAGCTGAGCGAGTGTCT 
AGCTGGCCCTGGACCCGGTGCCTCAGGATGCGTCCACCAAGAAGCTGAGCGAGTGTCT
a g c t g g c c c t g g a c c c g g t g c c t c a g g a t g c g t c c a c c a a g a a g c t g a g c g a g t g t c t
AGCTGGCCCTGGACCCGGTGCCTCAGGATGCGTCCACCAAGAAGCTGAGCGAGTGTCT
a g c t g g c c c t g g a c c c g g t g c c t c a g g a t g c g t c c a c c a a g a a g c t g a g c g a g t g t c t
AGCTGGCCCTGGACCCGGTGCCTCAGGATGCGTCCACCAAGAAGCTGAGCGAGTGTCT
CAAGCGCATCGGGGACGAACTGGACAGTAACATGGAGCTGCAGAGGTGTGGGCCCCTGGG 3 2 3
CAAGCGCATCGGGGACGAACTGGACAGTAACATGGAGCTGCAGAGGTGTGGGCCCCTGGG
CAAGCGCATCGGGGACGAACTGGACAGTAACATGGAGCTGCAGAGGTGTGGGCCCCTGGG
CAAGCGCATCGGGGACGAACTGGACAGTAACATGGAGCTGCAGAGGTGTGGGCCCCTGGG
CAAGCGCATCGGGGACGAACTGGACAGTAACATGGAGCTGCAGAGGTGTGGGCCCCTGGG
CAAGCGCATCGGGGACGAACTGGACAGTAACATGGAGCTGCAGAGGTGTGGGCCCCTGGG
CAAGCGCATCGGGGACGAACTGGACAGTAACATGGAGCTGCAGAGGTGTGGGCCCCTGGG
CAAGCGCATCGGGGACGAACTGGACAGTAACATGGAGCTGCAGAGGTGTGGGCCCCTGGG
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The exonic sequence o f exon 2 (position 22-73, which is 52bp in size) and exon 3 
(position 162-310, which is 149bp in size) is shown in red. The size o f the PCR product 
containing both exons 2 and 3 is 323bp and is flanked by the intronic sequences.
1 = sequence o f  the exon from the database (http://www.ncbi.nhn.nih/nucleotide)
2 = forward sequence
3 = reverse complement sequence o f the reverse
4 = forward sequence
5 = reverse complement sequence o f the reverse
6 = forward sequence
7 = reverse complement sequence o f the reverse
8 = forward sequence
9 = reverse complement sequence o f  the reverse
}
}
}
}
an unaffected individual 
affected individual from pedigree 1 
affected individual from pedigree 2 
affected individual from pedigree 5
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ACTCC 5  
ACTCC 
ACTCC 
ACTCC 
ACTCC 
ACTCC 
ACTCC 
ACTCC 
ACTCC 
*****
CCCCGAGAGGTCTTTTTCCGAGTGGCAGCTGACATGTTTTCTGACGGCAACT 5 7
CCCCGAGAGGTCTTTTTC CGAGTGGCAGCTGACATGTTTTCTGACGGCAACT
CCCCGAGAGGTCTTTTTCCGAGTGGCAGCTGACATGTTTTCTGACGGCAACT
CCCCGAGAGGTCTTTTTCCGAGTGGCAGCTGACATGTTTTCTGACGGCAACT
CCCCGAGAGGTCTTTTTCCGAGTGGCAGCTGACATGTTTTCTGACGGCAACT
CCCCGAGAGGTCTTTTTCCGAGTGGCAGCTGACATGTTTTCTGACGGCAACT
CCCCGAGAGGTCTTTTTCCGAGTGGCAGCTGACATGTTTTCTGACGGCAACT
CCCCGAGAGGTCTTTTTCCGAGTGGCAGCTGACATGTTTTCTGACGGCAACT
CCCCGAGAGGTCTTTTTCCGAGTGGCAGCTGACATGTTTTCTGACGGCAACT
14 CLUSTALW 1.81 analysis of exon 4 of BAX.
TCAACTGGGGCCGGGTTGTCGCCCTTTTCTACTTTGCCAGCAAACTGGTGCTCAAGGT 1 1 5
TCAACTGGGGCCGGGTTGTCGCCCTTTTCTACTTTGCCAGCAAACTGGTGCTCAAGGT
TCAACTGGGGCCGGGTTGTCGCCCTTTTCTACTTTGCCAGCAAACTGGTGCTCAAGGT
TCAACTGGGGCCGGGTTGTCGCCCTTTTCTACTTTGCCAGCAAACTGGTGCTCAAGGT
TCAACTGGGGCCGGGTTGTCGCCCTTTTCTACTTTGCCAGCAAACTGGTGCTCAAGGT
TCAACTGGGGCCGGGTTGTCGCCCTTTTCTACTTTGCCAGCAAACTGGTGCTCAAGGT
TCAACTGGGGCCGGGTTGTCGCCCTTTTCTACTTTGCCAGCAAACTGGTGCTCAAGGT
TCAACTGGGGCCGGGTTGTCGCCCTTTTCTACTTTGCCAGCAAACTGGTGCTCAAGGT
TCAACTGGGGCCGGGTTGTCGCCCTTTTCTACTTTGCCAGCAAACTGGTGCTCAAGGT
GGGCAGC T GCAGGGCAGTGAGCCCAGGGATG 1 4 6
GGGCAGCTGCAGGGCAGTGAGCCCAGGGATG
GGGCAGCTGCAGGGCAGTGAGCCCAGGGATG
GGGCAGCTGCAGGGCAGTGAGCCCAGGGATG
GGGCAGCTGCAGGGCAGTGAGCCCAGGGATG
GGGCAGCTGCAGGGCAGTGAGCCCAGGGATG
GGGCAGCTGCAGGGCAGTGAGCCCAGGGATG
GGGCAGCTGCAGGGCAGTGAGCCCAGGGATG
GGGCAGCTGCAGGGCAGTGAGCCCAGGGATG
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The database exonic sequence is shown in red (from position 13 to 131) and is 119bp in 
size. The size o f the PCR product is 146bp, which includes the flanking intronic 
sequence and the entire exonic sequence.
1 = sequence o f the exon from the database (http://www.ncbi.nlm.nih/nucleotide)
2 = forward sequence
3 = reverse complement sequence o f the reverse
4 = forward sequence
5 = reverse complement sequence o f the reverse
6 = forward sequence
7 = reverse complement sequence o f  the reverse
8 = forward sequence
9 = reverse complement sequence o f the reverse
an unaffected individual 
affected individual from pedigree 1 
affected individual from pedigree 2 
affected individual from pedigree 5
Stellenbosch University http://scholar.sun.ac.za/
Table 15 CLUSTALW 1.81 analysis of exon 5 of BAX.
1  TAACGCCCACTCCACTCCCCACAGGC C C T 2 9
2  TAACGCCCACTCCACTCCCCACAGGCCCT
3  TAACGCCCACTCCACTCCCCACAGGCCCT
4  TAACGCCCACTCCACTCCCCACAGGCCCT
5  TAACGCCCACTCCACTCCCCACAGGCCCT
6  TAACGCCCACTCCACTCCCCACAGGCCCT
7  TAACGCCCACTCCACTCCCCACAGGCCCT
8  TAACGCCCACTCCACTCCCCACAGGCCCT
9  TAACGCCCACTCCACTCCCCACAGGCCCT
1  GTGCACCAAGGTGCCGGAACTGATCAGAACCATCATGGGCTGGACATTGGACTTCCTCC 8 8
2  GTGCACCAAGGTGCCGGAACTGATCAGAACCATCATGGGCTGGACATTGGACTTCCTCC
3  GTGCACCAAGGTGCCGGAACTGATCAGAACCATCATGGGCTGGACATTGGACTTCCTCC
4 GTGCACCAAGGTGCCGGAACTGATCAGAACCATCATGGGCTGGACATTGGACTTCCTCC
5  GTGCACCAAGGTGCCGGAACTGATCAGAACCATCATGGGCTGGACATTGGACTTCCTCC
6  GTGCACCAAGGTGCCGGAACTGATCAGAACCATCATGGGCTGGACATTGGACTTCCTCC
7  GTGCACCAAGGTGCCGGAACTGATCAGAACCATCATGGGCTGGACATTGGACTTCCTCC
8 GTGCACCAAGGTGCCGGAACTGATCAGAACCATCATGGGCTGGACATTGGACTTCCTCC
9 GTGCACCAAGGTGCCGGAACTGATCAGAACCATCATGGGCTGGACATTGGACTTCCTCC
1  GGGAGCGGCTGTTGGGCTGGATCCAAGACCAGGGTGGTTGGGTGAGA 1 2 5
2  GGGAGCGGCTGTTGGGCTGGATCCAAGACCAGGGTGGTTGGGTGAGA
3  GGGAGCGGCTGTTGGGCTGGATCCAAGACCAGGGTGGTTGGGTGAGA
4  GGGAGCGGCTGTTGGGCTGGATCCAAGACCAGGGTGGTTGGGTGAGA
5  GGGAGCGGCTGTTGGGCTGGATCCAAGACCAGGGTGGTTGGGTGAGA
6  GGGAGCGGCTGTTGGGCTGGATCCAAGACCAGGGTGGTTGGGTGAGA
7  GGGAGCGGCTGTTGGGCTGGATCCCAGACCAGGGTGGTTGGGTGAGA
8  GGGAGCGGCTGTTGGGCTGGATCCAAGACCAGGGTGGTTGGGTGAGA
9  GGGAGCGGCTGTTGGGCTGGATCCAAGACCAGGGTGGTTGGGTGAGA
The database exonic sequence is shown in red (from position 24 to 98) and is 75 bp in 
size. The size o f the PCR product is 126bp, which includes the flanking intronic 
sequence and the entire exonic sequence
1 = sequence of the exon from the database (http://www.ncbi.nlm.nih/nucleotide)
2 = forward sequence
3 = reverse complement sequence of the reverse
4 = forward sequence
5 = reverse complement sequence of the reverse
6 = forward sequence
7 = reverse complement sequence of the reverse
8 = forward sequence
9 = reverse complement sequence of the reverse
}
}
an unaffected individual 
affected individual from pedigree 1 
affected individual from pedigree 2 
affected individual from pedigree 5
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16 CLUSTALW 1.81 analysis of exon 6 of BAX.
CCCTGTCTCCAGGACGGCCTCCTCTC
CCCTGTCTCCAGGACGGCCTCCTCTC
CCCTGTCTCCAGGACGGCCTCCTCTC
CCCTGTCTCCAGGACGGCCTCCTCTC
CCCTGTCTCCAGGACGGCCTCCTCTC
CCCTGTCTCCAGGACGGCCTCCTCTC
CCCTGTCTCCAGGACGGCCTCCTCTC
CTACTTTGGGACGCCCACGTGGCAGACCGTGACCATCTTTGTGGCGGGAGTGCTCACCGC 8 6
CTACTTTGGGACGCCCACGTGGCAGACCGTGACCATCTTTGTGGCGGGAGTGCTCACCGC
CTACTTTGGGACGCCCACGTGGCAGACCGTGACCATCTTTGTGGCGGGAGTGCTCACCGC
CTACTTTGGGACGCCCACGTGGCAGACCGTGACCATCTTTGTGGCGGGAGTGCTCACCGC
CTACTTTGGGACGCCCACGTGGCAGACCGTGACCATCTTTGTGGCGGGAGTGCTCACCGC
CTACTTTGGGACGCCCACGTGGCAGACCGTGACCATCTTTGTGGCGGGAGTGCTCACCGC
CTACTTTGGGACGCCCACGTGGCAGACCGTGACCATCTTTGTGGCGGGAGTGCTCACCGC
CTACTTTGGGACGCCCACGTGGCAGACCGTGACCATCTTTGTGGCGGGAGTGCTCACCGC
CTCGCTCACCATCTGGAAGAAGATGGGCTGAGGCCCCCAGCTGCCTTGGACTGTGTT 1 4 3
CTCACTCACCATCTGGAAGAAGATGGGCTGAGGCCCCCAGCTGCCTTGGACTGTGTT
CTCACTCACCATCTGGAAGAAGATGGGCTGAGGCCCCCAGCTGCCTTGGACTGTGTT
CTCACTCACCATCTGGAAGAAGATGGGCTGAGGCCCCCAGCTGCCTTGGACTGTGTT
CTCACTCACCATCTGGAAGAAGATGGGCTGAGGCCCCCAGCTGCCTTGGACTGTGTT
CTCACTCACCATCTGGAAGAAGATGGGCTGAGGCCCCCAGCTGCCTTGGACTGTGTT
CTCACTCACCATCTGGAAGAAGATGGGCTGAGGCCCCCAGCTGCCTTGGACTGTGTT
CTCACTCACCATCTGGAAGAAGATGGGCTGAGGCCCCCAGCTGCCTTGGACTGTGTT
TTTCCTCCATAAATTATGGCATT 1 6 6
TTTCCTCCATAAATTATGGCATT
TTTCCTCCATAAATTATGGCATT
TTTCCTCCATAAATTATGGCATT
TTTCCTCCATAAATTATGGCATT
TTTCCTCCATAAATTATGGCATT
TTTCCTCCATAAATTATGGCATT
TTTTCTCCATAAATTATGGCATT
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The database exonic sequence is shown in red (from position 13 to 138) and is 126bp in 
size. The size o f the PCR product is 166bp, which includes the flanking intronic 
sequence and the entire exonic sequence.
An error was found in the submitted database sequence of exon 6 (L22473) of BAX 
at base pair position 552 (base pair position 90 in table 16, shown in blue). The 
BLAST search results of exon 6 sequence against the human genome database 
indicated that the G at base pair position 1756471 on the NT_011109 contig should 
be replaced by an A (see table 16).
1 = sequence o f the exon from the database (http
2 = forward sequence
3 = reverse complement sequence o f  the reverse
4 = forward sequence
5 = reverse complement sequence o f  the reverse
6 = forward sequence
7 = reverse complement sequence o f  the reverse
8 = forward sequence
9 = reverse complement sequence o f the reverse
://www.ncbi.nlm.nih/nucleotide)
}
>
}
}
an unaffected individual 
affected individual from pedigree 1 
affected individual from pedigree 2 
affected individual from pedigree 5
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GLYCOGEN SYNTHASE ( GSY1)
Table 17 ClustalW 1.81 alignment of sequence of the UTR5A region 
of GSY1
1  CCCCCTTCTCCC 1 2
2  CCCCCTTCTCCC
3  CCCCCTTCTCCC
4 CCCCCCTCTCCC
5  CCCCCTTCTCCC
6  CCCCCTTCTCCC
7 CCCCCTTCTCCC
8  CCCCCTTCTCCC
9  CCCCCTTCTCCC
************
1  CCAGATCTGGGTGGCCGAGCTTCCTCCTCTTTCAGACCCAGGAGTCTGAACCCCCAG 6 9
2  CCAGATCTGGGTGGCCGAGCTTCCTCCTCTTTCAGACCCAGGAGTCTGAACCCCCAG
3  CCAGATCTGGGTGGCCGAGCTTCCTCCTCTTTCAGACCCAGGAGTCTGAACCCCCAG
4  CCAGATCTGGGTGGCCGAGCTTCCTCCTCTTTCAGACCCAGGGAGTCTGAACCCCCA
5  CCAGATCTGGGTGGCCGAGCTTCCTCCTCTTTCAGACCCAGGAGTCTGAACCCCCAG
6  CCAGATCTGGGTGGCCGAGCTTCCTCCTCTTTCAGACCCAGGAGTCTGAACCCCCAG
7  CCAGATCTGGGTGGCCGAGCTTCCTCCTCTTTCAGACCCAGGAGTCTGAACCCCCAG
8  CCAGATCTGGGTGGCCGAGCTTCCTCCTCTTTCAGACCCAGGAGTCTGAACCCCCAG
9 CCAGATCTGGGTGGCCGAGCTTCCTCCTCTTTCAGACCCAGGAGTCTGAACCCCCAG
1  ATCCCCCCTCCCTCAGACCCACAGTCAGGGCCTCCAGCATCCTCCTCTCTCAAACTCG 1 2 8
2  ATCCCCCCTCCCTCAGACCCAGGASTCAGGGCCTCCAGCATCCTCCTCTCTCAAACTCG
3  ATCCCCCCTCCCTCAGACCCAGGAGTCAGGGCCTCCAGCATCCTCCTCTCTCAAACTCG
4 ATCCCCCCTCCCTCAGACCCAGGAGTCAGGGCCTCCAGCATCCTCCTCTCTCAAACTCG
5  ATCCCCCCTCCCTCAGACCCAGGAGTCAGGGCCTCCAGCATCCTCCTCTCTCAAACTCG
6  ATCCCCCCTCCCTCAGACCCAGGAGTCAGGGCCTCCAGCATCCTCCTCTCTCAAACTCG
7 ATCCCCCCTCCCTCAGACCCAGGAGTCAGGGCCTCCAGCATCCTCCTCTCTCAAACTCG
8  ATCCCCCCTCCCTCAGACCCAGGAGTCAGGGCCTCCAGCATCCTCCTCTCTCAAACTCG
9  ATCCCCCCTCCCTCAGACCCAGGAGTCAGGGCCTCCAGCATCCTCCTCTCTCAAACTCG
1 AGACTGCTAGCTCGCTCCTCACCCTCCATGCACCCACACTTACAACGGTTGCCATGATGC 1 8 8
2  AGACTGCTAGCTCGCTCCTCACCCTCCATGCACCCACACTTACAACGGTTGCCATGATGC
3  AGACTGCTAGCTCGCTCCTCACCCTCCATGCACCCACACTTACAACGGTTGCCATGATGC
4  AGACTGCTAGCTCGCTCCTCACCCTCCATGCACCCACACTTACAACGGTTGCCATGATGC
5  AGACTGCTAGCTCGCTCCTCACCCTCCATGCACCCACACTTACAACGGTTGCCATGATGC
6  AGACTGCTAGCTCGCTCCTCACCCTCCATGCACCCACACTTACAACGGTTGCCATGATGC
7  AGACTGCTAGCTCGCTCCTCACCCTCCATGCACCCACACTTACAACGGTTGCCATGATGC
8  AGACTGCTAGCTCGCTCCTCACCCTCCATGCACCCACACTTACAACGGTTGCCATGATGC
9 AGACTGCTAGCTCGCTCCTCACCCTCCATGCACCCACACTTACAACGGTTGCCATGATGC
1  TCACCAACTGCCAGAGTCCTAGCGGAAACGGAAACGCGCGAGGAGCGAGATGTTCTGG 2 4 6
2  TCACCAACTGCCAGAGTCCTAGCGGAAACGGAAACGCGCGAGGAGCGAGATCTTCTGG
3  TCACCAACTGCCAGAGTCCTAGCGGAAACGGAAACGCGCGAGGAGCGAGATCTTCTGG
4  TCACCAACTGCCAGAGTCCTAGCGGAAACGGAAACGCGCGAGGAGCGAGATCTTCTGG
5  TCACCAACTGCCAGAGTCCTAGCGGAAACGGAAACGCGCGAGGAGCGAGATCTTCTGG
6  TCACCAACTGCCAGAGTCCTAGCGGAAACGGAAACGCGCGAGGAGCGAGATCTTCTGG
7  TCACCAACTGCCAGAGTCCTAGCGGAAACGGAAACGCGCGAGGAGXGAGATCTTCTGG
8 TCACCAACTGCCAGAGTCCTAGCGGAAACGGAAACGCGCGAGGAGCGAGATCTTCTGG
9  TCACCAACTGCCAGAGTCCTAGCGGAAACGGAAACGCGCGAGGAGCGAGATCTTCTGG
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UTR5 region of GSY1 was subdivided into the UTR5A, UTR5B and UTR5C regions. 
The UTR5A region extends from 1 to 246bp. The overlapping sequence o f the UTR5A 
region with the UTR5B region is underlined.
In the case of GSYly it was also found that some other interesting results emerged, 
namely the database sequence of UTR5A (acc no. S79190) at position 139 and 140 
was incorrect. The nucleotide CC (shown in red) should be replaced with a GG 
(table 17 in Appendix III, base pair position 91 and 92). This result was verified by 
a BLAST homology search of the UTR5A The database sequence against the 
Human genome database (http://www.ncbi.nlm.nih.gov/human genome).
1 = sequence o f  the exon from the database (http://www.ncbi.nlm.nih/nucleotide)
2 = forward sequence
3 = reverse complement sequence o f the reverse
4 = forward sequence
5 = reverse complement sequence o f the reverse
6 = forward sequence
7 = reverse complement sequence o f the reverse
8 = forward sequence
9 = reverse complement sequence o f  the reverse
}
}
an unaffected individual 
affected individual from pedigree 1 
affected individual from pedigree 2 
affected individual from pedigree 5
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ClustalWl.81 alignment of sequence of the UTR5B region
TGGTTCCTCATAAATATGTAAATATTGTGGGGGCGT 2 7 9
TGGTTCCTCATAAATGTGTAAATATTGTGGGGGCGT
TGGTTCCTCATAAATATGTAAATATTGTGGGGGCGT
TGGTTCCTCATAAATATGTAAATATTGTGGGGGCGT
TGGTTCCTCATAAATATGTAAATATTGTGGGGGCGT
TGGTTCCTCATAAATATGTAAATATTGTGGGGGCGT
TGGTTCCTCATAAATATGTAAATATTGTGGGGGCGT
TGGTTCCTCATAAATATGTAAATATTGTGGGGGCGT
GGCGGGACTTTATGCCCCGCCCTCCCACCGAGGCTGCGCTGGAAGACGGGCGTCCGG 3 6 3
GGCGGGACTTTATGCCCCGCCCTCCCACCGAGGCTGCGCTGGAAGACGGGCGTCCGG
GGCGGGACTTTATGCCCCGCCCTCCCACCGAGGCTGCGCTGGAAGACGGGCGTCCGG
GGCGGGACTTTATGCCCCGCCCTCCCACCGAGGCTGCGCTGGAAGACGGGCGTCCGG
GGCGGGACTTTATGCCCCGCCCTCCCACCGAGGCTGCGCTGGAAGACGGGCGTCCGG
GGCGGGACTTTATGCCCCGCCCTCCCACCGAGGCTGCGCTGGAAGACGGGCGTCCGG
GGCGGGACTTTATGCCCCGCCCTCCCACCGAGGCTGCGCTGGAAGACGGGCGTCCGG
GGCGGGACTTTATGCCCCGCCCTCCCACCGAGGCTGCGCTGGAAGACGGGCGTCCGG
AACTCCTGGGTCCATTCCCAATGTCTCCTGGCTCCTCCTCCTTTTGCTCAGCCCCACCA 4 2 2
A ACTCCTGGGTCCATTCCCAATGTCTCCTGGCTCCTCCTCCTTTTGCTCAGCCCCACCA
AACTCCTGGGTCCATTCCCAATGTCTCCTGGCTCCTCCTCCTTTTGCTCAGCCCCACCA
AACTCCTGG GTCCATTCCCAATGTCTCCTGGCTCCTCCTCCTTTTGCTCAGCCCCACCA
AACTCCTGGGTCCATTCCCAATGTCTCCTGGCTCCTCCTCCTTTTGCTCAGCCCCACCA
AACTCCTGGGTCCATTCCCAATGTCTCCTGGCTCCTCCTCCTTTTGCTCAGCCCCACCA
AACTCCTGGGTCCATTCCCAATGTCTCCTGGCTCCTCCTCCTTTTGCTCAGCCCCACCA
AACTCCTGGGTCCATTCCCAATGTCTCCTGGCTCCTCCTCCTTTTGCTCAGCCCCACCA
CCGCCCCGCTCAGGCCGATTGCAAAATTCTTAGCTGTTCTTTGAGTAACCACACGTCCTC 4 8 2  
CCGCCCCGCTCAGGCCGATTGCAAAATTCTTAGCTGTTCTTTGAGTAACCACACGTCCTC 
CCGCCCCGCTCAGGCCGATTGCAAAATTCTTAGCTGTTCTTTGAGTAACCACACGTCCTC 
CCGCCCCGCTCAGGCCGATTGCAAAATTCTTAGCTGTTCTTTGAGTAACCACACGTCCTC
CCGCCCCGCTCAGGCCGATTGCAAAATTCTTAGCTGTTCTTTGAGTAACCACACGTCCTC
CCGCCCCGCTCAGGCCGATTGCAAAATTCTTAGCTGTTCTTTGAGTAACCACACGTCCTC
CCGCCCCGCTCAGGCCGATTGCAAAATTCTTAGCTGTTCTTTGAGTAACCACACGTCCTC
CACGCTCCTTTCCTCTTTATCCCACCCTCCTCCTCCTCCCCACTTTGAG GCCTCCA 5 3 8
CA CG CTCCTTTCCTCTTTATCCCACCCTCCTCCTCCTCCCCACTTTGAG GCCTCCA
CA CG CTCCTTTCCTCTTTATCCCACCCTCCTCCTCTTCCCCACTTTG AAGCCTCCA
CA CG CTCCTTTCCTCTTTATCCCACCCTCCTCCTCCTCCCCACTTTGAG GCCTCCA
CA CG CTCCTTTCCTCTTTATCCCACCCTCCTCCTCCTCCCCACTTTGAG GCCTCCA
CA CG CTCCTTTCCTCTTTATCCCACCCTCCTCCTCCTCCCCACTTTGAG GCCTCCA
CA CG CTCCTTTCCTCTTTATCCCACCCTCCTCCTCCTCCCCACTTTGAG GCCTCCA
CACGCTCCTTTCCTCTTTATCCCACCCTCCTCCTG CTCCCCACTTTGAGGCCTCCA
GCTCCAGATTGACAGAGCTGAAGGCC 5 6 4
GCTCCAGATTGACAGAGCTGAAGGCC
GCTCCAGATTGACAGAGCTGAAGGCC
GCTCCAGATTGACAGAGCTGAAGGCC
GCTCCAGATTGACAGAGCTGAAGGCC
GCTCCAGATTGACAGAGCTGAAGGCC
GCTCCAGATTGACAGAGCTGAAGGCC
GCTCCAGATTGACAGAGCTGAAGGCC
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The UTR5B region analysed extends from position 243 to 564. The PCR product is 
322bp in size and the overlapping sequences of UTR5B with UTR5A and UTR5C are 
underlined.
1 = sequence o f the exon from the database (http://www.ncbi.nlm.nih/nucleotide)
2 = forward sequence
3 = reverse complement sequence o f the reverse
4 = forward sequence
5 = reverse complement sequence o f  the reverse
6 = forward sequence
7 = reverse complement sequence o f the reverse
8 = forward sequence
9 = reverse complement sequence o f  the reverse J -  affected individual from pedigree 5
}
>
}
an unaffected individual 
affected individual from pedigree 1
affected individual from pedigree 2
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ClustalW 1.81 alignment of sequence of the UTR5C region
GAAGGCCACTCGTTTCCGTAAAGCGCA 5 8 4
GAAGGCCACTCGTTTCCGTAAAGCGCA
GAAGGCCACTCGTTTCCGTAAAGCGCA
GAAGGCCACTCGTTTCCGTAAAGCGCA
GAAGGCCACTAGTTTCCGTAAAGCGCA
GAAGGCCACTAGTTTCCGTAAAGCGCA
GAAGGCCACTCGTTTCCGTAAAGCGCA
GAAGGCCACTCGTTTCCGTAAAGCGCA
GAAGGCCACTCGTTTCCGTAAAGCGCA
GCGGCAAGCTCCGCCCCCTGGAGGTCTCACGGCCGAGGCGGGGCCGGGACACAGCG 6 4 0
GCGGCAAGCTCCGCCCCCTGGAGGTCTCACGGCCGAGGCGGGGCCGGGACACAGCG
GCGGCAAGCTCCGCCCCCTGGAGGTCTCACGGCCGAGGCGGGGCCGGGACACAGCG
GCGGCAAGCTCCGCCCCCTGGAGGTCTCACGGCCGAGGCGGGGCCGGGACACAGCG
GCGGCAAGCTCCGCCCCCTGGAGGTCTCACGGCCGAGGCGGGGCCGGGACACAGCG
GCGGCAAGCTCCGCCCCCTGGAGGTCTCACGGCCGAGGCGGGGCCGGGACACAGCG
GCGGCAAGCTCCGCCCCCTGGAGGTCTCACGGCCGAGGCGGGGCCGGGACACAGCG
GCGGCAAGCTCCGCCCCCTGGAGGTCTCACGGCCGAGGCGGGGCCGGGACACAGCG
GCGGCAAGCTCCGCCCCCTGGAGGTCTCACGGCCGAGGCGGGGCCGGGACACAGCG
ACTCCAACCCGTTCCACCAATGAGGACACGCGGAAATCCCCGCCCCCGGGCGTGGGCCAA 7 0 0
ACTCCAACCCGTTCCACCAATGAGGACACGCGGAAATCCCCGCCCCCGGGCGTGGGCCAA
ACTCCAACCCGTTCCACCAATGAGGACACGCGGAAATCCCCGCCCCCGGGCGTGGGCCAA
ACTCCAACCCGTTCCACCAATGAGGACACGCGGAAATCCCCGCCCCCGGGCGTGGGCCAA
ACTCCAACCCGTTCCACCAATGAGGACACGCGGAAATCCCCGCCCCCGGGCGTGGGCCAA
ACTCCAACCCGTTCCACCAATGAGGACACGCGGAAATCCCCGCCCCCGGGCGTGGGCCAA
ACTCCAACCCGTTCCACCAATGAGGACACGCGGAAATCCCCGCCCCCGGGCGTGGGCCAA
ACTCCAACCCGTTCCACCAATGAGGACACGCGGAAATCCCCGCCCCCGGGCGTGGGCCAA
ACTCCAACCCGTTCCACCAATGAGGACACGCGGAAATCCCCGCCCCCGGGCGTGGGCCAA
TGGCGCTGGCTGGGGGGGGCGGCCACCGCCTCCTGGCGGCTGCGAGGTTTCACTGCAGG 7 6 0
TGGCGCTGGCTGGGGGGGGCGGCCACCGCCTCCTGGCGGCTGCGAGGTTTCACTGCAGG
TGGCGCTGGCTGGGGGGGGCGGCCACCGCCTCCTGGCGGCTGCGAGGTTTCACTGCAGG
TGGCGCTGGCTGGGGGGGGCGGCCACCGCCTCCTGGCGGCTGCGAGGTTTCACTGCAGG
TGGCGCTGGCTGGGGGGGGCGGCCACCGCCTCCTGGCGGCTGCGAGGTTTCACTGCAGG
TGGCGCTGGCTGGGGGGGGCGGCCACCGCCTCCTGGCGGCTGCGAGGTTTCACTGCAGG
TGGCGCTGGCTGGGGGGGGCGGCCACCGCCTCCTGGCGGCTGCGAGGTTTCACTGCAGG
TGGCGCTGGCTGGGGGGGGCGGCCACCGCCTCCTGGCGGCTGCGAGGTTTCACTGCAGG
TGGCGCTGGCTGGGGGGGGCGGCCACCGCCTCCTGGCGGCTGCGAGGTTTCACTGCAGG
GGCGCCAGTGGGCTCAGTGACGCTGCGGCCTCCTTCTGCCTAGGTCCCAACGCTTCGGGG 8 2 0
GGCGCCAGTGGGCTCAGTGACGCTGCGGCCTCCTTCTGCCTAGGTCCCAACGCTTCGGGG
GGCGCCAGTGGGCTCAGTGACGCTGCGGCCTCCTTCTGCCTAGGTCCCAACGCTTCGGGG
GGCGCCAGTGGGCTCAGTGACGCTGCGGCCTCCTTCTGCCTAGGTCCCAACGCTTCGGGG
GGCGCCAGTGGGCTCAGTGACGCTGCGGCCTCCTTCTGCCTAGGTCCCAACGCTTCGGGG
GGCGCCAGTGGGCTCAGTGACGCTGCGGCCTCCTTCTGCCTAGGTCCCAACGCTTCGGGG
GGCGCCAGTGGGCTCAGTGACGCTGCGGCCTCCTTCTGCCTAGGTCCCAACGCTTCGGGG
GGCGCCAGTGGGCTCAGTGACGCTGCGGCCTCCTTCTGCCTAGGTCCCAACGCTTCGGGG
GGCGCCAGTGGGCTCAGTGACGCTGCGGCCTCCTTCTGCCTAGGTCCCAACGCTTCGGGG
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1  CAGGGGTGCGGTCTTGCAATAGGAAGCCGAGCGTCTTGCAAGCTTCCCGTCGGGCACCA 8 7 9
2  CAGGGGTGCGGTCTTGCAATAGGAAGCCGAGCGTCTTGCAAGCTTCCCGTCGGGCACCA
3  CAGGGGTGCGGTCTTGCAATAGGAAGCCGAGCGTCTTGCAAGCTTCCCGTCGGGCACCA
4  CAGGGGTGCGGTCTTGCAATAGGAAGCCGAGCGTCTTGCAAGCTTCCCGTCGGGCACCA
5  CAGGGGTGCGGTCTTGCAATAGGAAGCCGAGCGTCTTGCAAGCTTCCCGTCGGGCACCA
6  CAGGGGTGCGGTCTTGCAATAGGAAGCCGAGCGTCTTGCAAGCTTCCCGTCGGGCACCA
7 CAGGGGTGCGGTCTTGCAATAGGAAGCCGAGCGTCTTGCAAGCTTCCCGTCGGGCACCA
8 CAGGGGTGCGGTCTTGCAATAGGAAGCCGAGCGTCTTGCAAGCTTCCCGTCGGGCACCA
9 CAGGGGTGCGGTCTTGCAATAGGAAGCCGAGCGTCTTGCAAGCTTCCCGTCGGGCACCA
The UTR5C region analysed extends from position 558 to 879 and the size o f the PCR 
product is 322bp. The overlapping sequences o f the UTR5B region with the UTR5C 
region are underlined.
1 = sequence o f  the exon from the database (http://www.ncbi.nlm.nih/nucleotide)
2 = forward sequence
3 = reverse complement sequence o f the reverse
4 = forward sequence
5 = reverse complement sequence o f the reverse
6 = forward sequence
7 = reverse complement sequence o f the reverse
8 = forward sequence -
9 = reverse complement sequence o f the reverse r
}
}
}
an unaffected individual 
affected individual from pedigree 1 
affected individual from pedigree 2 
affected individual from pedigree 5
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TGTCTTGCAATAGGAAGCCGAGCGTCTTGCAAGCTTCC 3 8
TGTCTTGCAATAGGAAGCCGAGCGTCTTGCAAGCTTCC
TGTCTTGCAATAGGAAGCCGAGCGTCTTGCAAGCTTCC
TGTCTTGCAATAGGAAGCCGAGCGTCTTGCAAGCTTCC
TGTCTTGCAATAGGAAGCCGAGCGTCTTGCAAGCTTCC
TGTCTTGCAATAGGAAGCCGAGCGTCTTGCAAGCTTCC
TGTCTTGCAATAGGAAGCCGAGCGTCTTGCAAGCTTCC
TGTCTTGCAATAGGAAGCCGAGCGTCTTGCAAGCTTCC
TGTCTTGCAATAGGAAGCCGAGCGTCTTGCAAGCTTCC
ClustalW 1.81 alignment of the exon 1 sequences of GSY1
CGTCGGGCACCAGCTACTCGGCCCCGCACCCTACCTGGTGCATTCCCTAGACAC 9 2
CGTCGGGCACCAGCTACTCGGCCCCGCACCCTACCTGGTGCATTCCCTAGACAC
CGTCGGGCACCAGCTACTCGGCCCCGCACCCTACCTGGTGCATTCCCTAGACAC
CGTCGGGCACCAGCTACTCGGCCCCGCACCCTACCTGGTGCATTCCCTAGACAC
CGTCGGGCACCAGCTACTCGGCCCCGCACCCTACCTGGTGCATTCCCTAGACAC
CGTCGGGCACCAGCTACTCGGCCCCGCACCCTACCTGGTGCATTCCCTAGACAC
CGTCGGGCACCAGCTACTCGGCCCCGCACCCTACCTGGTGCATTCCCTAGACAC
CGTGCGGCACCAGCTACTCGGCCCCGCACCCTACCTGGTGCATTCCCTAGACAC
CGTCGGGCACCAGCTACTCGGCCCCGCACCCTACCTGGTGCATTCCCTAGACAC
CTCCGGGGTCCCTACCTGGAGATCCCCGGAGCCCCCCTTCCTGCGCCAGCCATGCC 1 4 8
CTCCGGGGTCCCTACCTGGAGATCCCCGGAGCCCCCCTTCCTGCGCCAGCCATGCC
CTCCGGGGTCCCTACCTGGAGATCCCCGGAGCCCCCCTTCCTGCGCCAGCCATGCC
CTCCGGGGTCCCTACCTGGAGATCCCCGGAGCCCCCCTTCCTGCGCCAGCCATGCC
CTCCGGGGTCCCTACCTGGAGATCCCCGGAGCCCCCCTTCCTGCGCCAGCCATGCC
CTCCGGGGTCCCTACCTGGAGATCCCCGGAGCCCCCCTTCCTGCGCCAGCCATGCC
CTCCGGGGTCCCTACCTGGAGATCCCCGGAGCCCCCCTTCCTGCGCCAGCCATGCC
CTCCGGGGTCCCTACCTGGAGATCCCCGAAGCCCCCCTTCCTGCGCCAGCCATGCC
CTCCGGGGTCCCTACCTGGAGATCCCCGGAGCCCCCCTTCCTGCGCCAGCCATGCC
TTTAAACCGCACTTTGTCCATGTCCTCACTGCCAGGACTGGAGGACTGGGAGGATGAA 2 0 6
TTTAAACCGCACTTTGTCCATGTCCTCACTGCCAGGACTGGAGGACTGGGAGGATGAA
TTTAAACCGCACTTTGTCCATGTCCTCACTGCCAGGACTGGAGGACTGGGAGGATGAA
TTTAAACCGCACTTTGTCCATGTCCTCACTGCCAGGACTGGAGGACTGGGAGGATGAA
TTTAAACCGCACTTTGTCCATGTCCTCACTGCCAGGACTGGAGGACTGGGAGGATGAA
TTTAAACCGCACTTTGTCCATGTCCTCACTGCCAGGACTGGAGGACTGGGAGGATGAA
TTTAAACCGCACTTTGTCCATGTCCTCACTGCCAGGACTGGAGGACTGGGAGGATGAA
TTTAAACCGCACTTTGTCCATGTCCTCACTGCCAGGACTGGAGGACTGGGAGGATGAA
TTTAAACCGCACTTTGTCCATGTCCTCACTGCCAGGACTGGAGGACTGGGAGGATGAA
TTCGACCTGGAGAACGCAGTGCTCTTCGAAGTGGCCTGGGAGGTGGCTAACAAGGGT 2 6 3
TTCGACCTGGAGAACGCAGTGCTCTTCGAAGTGGCCTGGGAGGTGGCTAACAAGGGT
TTCGACCTGGAGAACGCAGTGCTCTTCGAAGTGGCCTGGGAGGTGGCTAACAAGGGT
TTCGACCTGGAGAACGCAGTGCTCTTCGAAGTGGCCTGGGAGGTGGCTAACAAGGGT
TTCGACCTGGAGAACGCAGTGCTCTTCGAAGTGGCCTGGGAGGTGGCTAACAAGGGT
TTCGACCTGGAGAACGCAGTGCTCTTCGAAGTGGCCTGGGAGGTGGCTAACAAGGGT
TTCGACCTGGAGAACGCAGTGCTCTTCGAAGTGGCCTGGGAGGTGGCTAACAAGGGT
TTCGACCTGGAGAACGCAGTGCTCTTCGAAGTGGCCTGGGAGGTGGCTAACAAGGGT
TTCGACCTGGAGAACGCAGTGCTCTTCGAAGTGGCCTGGGAGGTGGCTAACAAGGGT
Stellenbosch University http://scholar.sun.ac.za/
347
1  GAGCACGCCAGGCGT 2 7 8
2  GAGCACGCCAGGCGT 2 7 8
3  GAGCACGCCAGGCGT
4  GAGCACGCCAGGCGT
5  GAGCACGCCAGGCGT
6  GAGCACGCCAGGCGT
7 GAGCACGCCAGGCGT
8 GAGCACGCCAGGCGT
9 GAGCACGCCAGGCGT
The database exonic sequence is shown in red (position 18 to 236) and is 119bp in size. 
The size o f the PCR product is 278bp, which includes the exonic and the flanking 
intronic regions.
1 = sequence o f  the exon from the database (http://www.ncbi.nlm.nih/nucleotide)
2 = forward sequence
3 = reverse complement sequence o f  the reverse
4 = forward sequence
5 = reverse complement sequence o f the reverse
6 = forward sequence
7 = reverse complement sequence o f the reverse
8 = forward sequence
9 = reverse complement sequence o f  the reverse U
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}
an unaffected individual 
affected individual from pedigree 1 
affected individual from pedigree 2 
affected individual from pedigree 5
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CCTGCCCTCACACGCTTGGGCCCACAGTGGGTG 3 3
CCTGCCCTCACACGCTTGGGCCCACAGTGGGTG
CCTGCCCTCACACGCTTGGGCCCACAGTGGGTG
CCTGCCCTCACACGCTTGGGCCCACAGTGGGTG
CCTGCCCTCACACGCTTGGGCCCACAGTGGGTG
CCTGCCCTCACACGCTTGGGCCCACAGTGGGTG
CCTGCCCTCACACGCTTGGGCCCACAGTGGGTG
ClustalW 1.81 alignment of exon 2 sequences of GSY1
GCATCTACACGGTGCTGCAGACGAAGGCGAAGGTGACAGGGGACGAATGGGGCGACAACT 9 3
GCATCTACACGGTGCTGCAGACGAAGGCGAAGGTGACAGGGGACGAATGGGGCGACAACT
GCATCTACACGGTGCTGCAGACGAAGGCGAAGGTGACAGGGGACGAATGGGGCGACAACT
GCATCTACACGGTGCTGCAGACGAAGGCGAAGGTGACAGGGGACGAATGGGGCGACAACT
GCATCTACACGGTGCTGCAGACGAAGGCGAAGGTGACAGGGGACGAATGGGGCGACAACT
GCATCTACACGGTGCTGCAGACGAAGGCGAAGGTGACAGGGGACGAATGGGGCGACAACT
GCATCTACACGGTGCTGCAGACGAAGGCGAAGGTGACAGGGGACGAATGGGGCGACAACT
ACTTCCTGGTGGGGCCGTACACGGAGCAGGGCGTGAGGACCCAGGTGGAACTGCTGGAGG 1 5 3
ACTTCCTGGTGGGGCCGTACACGGAGCAGGGCGTGAGGACCCAGGTGGAACTGCTGGAGG
ACTTCCTGGTGGGGCCGTACACGGAGCAGGGCGTGAGGACCCAGGTGGAACTGCTGGAGG
ACTTCCTGGTGGGGCCGTACACGGAGCAGGGCGTGAGGACCCAGGTGGAACTGCTGGAGG
ACTTCCTGGTGGGGCCGTACACGGAGCAGGGCGTGAGGACCCAGGTGGAACTGCTGGAGG
ACTTCCTGGTGGGGCCGTACACGGAGCAGGGCGTGAGGACCCAGGTGGAACTGCTGGAGG
ACTTCCTGGTGGGGCCGTACACGGAGCAGGGCGTGAGGACCCAGGTGGAACTGCTGGAGG
CCCCCACCCCGGCCCTGAAGAGGACACTGGATTCCATGAACAGCAAGGGCTGCAAGGT 2 1 1
CCCCCACCCCGGCCCTGAAGAGGACACTGGATTCCATGAACAGCAAGGGCTGCAAGGT
CCCCCACCCCGGCCCTGAAGAGGACACTGGATTCCATGAACAGCAAGGGCTGCAAGGT
CCCCCACCCCGGCCCTGAAGAGGACACTGGATTCCATGAACAGCAAGGGCTGCAAGGT
CCCCCACCCCGGCCCTGAAGAGGACACTGGATTCCATGAACAGCAAGGGCTGCAAGGT
CCCCCACCCCGGCCCTGAAGAGGACACTGGATTCCATGAACAGCAAGGGCTGCAAGGT
CCCCCACCCCGGCCCTGAAGAGGACACTGGATTCCATGAACAGCAAGGGCTGCAAGGT
GGGACGTGGCCCAGCCCAGGGCAGAAGCGGGTGGACAGCCTGCA 2 5 5  
GGGACGTGGCCCAGCCCAGGGCAGAAGCGGGTGGACAGCCTGCA 
GGGACGTGGCCCAGCCCAGGGCAGAAGCGGGTGGACAGCCTGCA 
GGGACGTGGCCCAGCCCAGGGCAGAAGCGGGTGGACAGCCTGCA 
GGGACGTGGCCCAGCCCAGGGCAGAAGCGGGTGGACAGCCTGCA 
GGGACGTGGCCCAGCCCAGGGCAGAAGCGGGTGGACAGCCTGCA 
GGGACGTGGCCCAGCCCAGGGCAGAAGCGGGTGGACAGCCTGCA 
8*******************************************
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The database exonic sequence is shown in red (from position 28 to 209) and is 172bp in 
size. The size of the PCR product is 255bp, which includes the exonic and the flanking 
intronic regions.
1 = sequence o f  the exon from the database (http://www.ncbi.nlm.nih/nucleotide)
2 = forward sequence
3 = reverse complement sequence o f the reverse
4 = forward sequence
5 = reverse complement sequence o f the reverse
6 -  forward sequence
7 = reverse complement sequence o f the reverse
8 = forward sequence
9 = reverse complement sequence o f  the reverse
}
}
}
}
an unaffected individual 
affected individual from pedigree 1 
affected individual from pedigree 2 
affected individual from pedigree 5
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CAACCCCATCCCAGGTGTATTTCGGGCGCTGGCTGAT 3 7
CAACCCCATCCCAGGTGTATTTCGGGCGCTGGCTGAT
CAACCCCATCCCAGGTGTATTTCGGGCGCTGGCTGAT
CAACCCCATCCCAGGTGTATTTCGGGCGCTGGCTGAT
CAACCCCATCCCAGGTGTATTTCGGGCGCTGGCTGAT
CAACCCCATCCCAGGTGTATTTCGGGCGCTGGCTGAT
CAACCCCATCCCAGGTGTATTTCGGGCGCTGGCTGAT
CAACCCCATCCCAGGTGTATTTCGGGCGCTGGCTGAT
CAACCCCATCCCAGGTGTATTTCGGGCGCTGGCTGAT
ClustalW 1.81 alignment of the exon 3 sequences of GSYI
CGAGGGAGGCCCTCTGGTGGTGCTCCTGGACGTGGGTGCCTCAGCTTGGGCCCTGGAGC 9  6
CGAGGGAGGCCCTCTGGTGGTGCTCCTGGACGTGGGTGCCTCAGCTTGGGCCCTGGAGC
CGAGGGAGGCCCTCTGGTGGTGCTCCTGGACGTGGGTGCCTCAGCTTGGGCCCTGGAGC
CGAGGGAGGCCCTCTGGTGGTGCTCCTGGACGTGGGTGCCTCAGCTTGGGCCCTGGAGC
CGAGGGAGGCCCTCTGGTGGTGCTCCTGGACGTGGGTGCCTCAGCTTGGGCCCTGGAGC
CGAGGGAGGCCCTCTGGTGGTGCTCCTGGACGTGGGTGCCTCAGCTTGGGCCCTGGAGC
CGAGGGAGGCCCTCTGGTGGTGCTCCTGGACGTGGGTGCCTCAGCTTGGGCCCTGGAGC
CGAGGGAGGCCCTCTGGTGGTGCTCCTGGACGTGGGTGCCTCAGCTTGGGCCCTGGAGC
CGAGGGAGGCCCTCTGGTGGTGCTCCTGGACGTGGGTGCCTCAGCTTGGGCCCTGGAGC
GCTGGAAGGGAGAGCTCTGGGATACCTGCAACATCGGAGTGCCGTGGTACGACCGCGAGG X 5 6
GCTGGAAGGGAGAGCTCTGGGATACCTGCAACATCGGAGTGCCGTGGTACGACCGCGAGG
GCTGGAAGGGAGAGCTCTGGGATACCTGCAACATCGGAGTGCCGTGGTACGACCGCGAGG
GCTGGAAGGGAGAGCTCTGGGATACCTGCAACATCGGAGTGCCGTGGTACGACCGCGAGG
GCTGGAAGGGAGAGCTCTGGGATACCTGCAACATCGGAGTGCCGTGGTACGACCGCGAGG
GCTGGAAGGGAGAGCTCTGGGATACCTGCAACATCGGAGTGCCGTGGTACGACCGCGAGG
GCTGGAAGGGAGAGCTCTGGGATACCTGCAACATCGGAGTGCCGTGGTACGACCGCGAGG
GCTGGAAGGGAGAGCTCTGG ATACCTGCAACATCGGAGTGCCGTGGTACGACCGCGAGG
GCTGGAAGGGAGAGCTCTGGGATACCTGCAACATCGGAGTGCCGTGGTACGACCGCGAGG
CCAACGACGCTGTCCTCTTTGGCTTTCTGACCACCTGGTTCCTGGGTGAGGTAGGCCCCG 2 X 6
CCAACGACGCTGTCCTCTTTGGCTTTCTGACCACCTGGTTCCTGGGTGAGGTAGGCCCCG
CCAACGACGCTGTCCTCTTTGGCTTTCTGACCACCTGGTTCCTGGGTGAGGTAGGCCCCG
CCAACGACGCTGTCCTCTTTGGCTTTCTGACCACCTGGTTCCTGGGTGAGGTAGGCCCCG
CCAACGACGCTGTCCTCTTTGGCTTTCTGACCACCTGGTTCCTGGGTGAGGTAGGCCCCG
CCAACGACGCTGTCCTCTTTGGCTTTCTGACCACCTGGTTCCTGGGTGAGGTAGGCCCCG
CCAACGACGCTGTCCTCTTTGGCTTTCTGACCACCTGGTTCCTGGGTGAGGTAGGCCCCG
CCAACGACGCTGTCCTCTTTGGCTTTCTGACCACCTGGTTCCTGGGTGAGGTAGGCCCCG
Stellenbosch University http://scholar.sun.ac.za/
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The database exonic sequence is shown in red (from position 15 to 167) and is 153bp in 
size. The size of the PCR product is 216bp, which includes the exonic and the flanking 
intronic regions.
1 = sequence o f the exon from the database (http.//www.ncbi.nlm.nih/nucleotide)
2 -  forward sequence
3 = reverse complement sequence o f the reverse
4 = forward sequence
5 = reverse complement sequence o f  the reverse
6 = forward sequence
7 = reverse complement sequence o f the reverse
8 = forward sequence
9 = reverse complement sequence o f the reverse
}
}
}
}
an unaffected individual 
affected individual from pedigree 1 
affected individual from pedigree 2 
affected individual from pedigree 5
Stellenbosch University http://scholar.sun.ac.za/
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Table 23 ClustalW 1.81 alignment of the exon 6 sequences of GSY1
1  CATGGGACCCTCACCCCCAATCCCAGATATTGTGACCCCCAATGGGCTGAATGTG 5 5
2  CATGGGACCCTCACCCCCAATCCCAGATATTGTGACCCCCAATGGGCTGAATGTG
3  CATGGGACCCTCACCCCCAATCCCAGATATTGTGACCCCCAATGGGCTGAATGTG
4  CATGGGACCCTCACCCCCAATCCCAGATATTGTGACCCCCAATGGGCTGAATGTG
5  CATGGGACCCTCACCCCCAATCCCAGATATTGTGACCCCCAATGGGCTGAATGTG
6  CATGGGACCCTCACCCCCAATCCCAGATATTGTGACCCCCAATGGGCTGAATGTG
7  CATGGGACCCTCACCCCCAATCCCAGATATTGTGACCCCCAATGGGCTGAATGTG
8 CATGGGACCCTCACCCCCAATCCCAGATATTGTGACCCCCAATGGGCTGAATGTG
9  CATGGGACCCTCACCCCCAATCCCAGATATTGTGACCCCCAATGGGCTGAATGTG
1  AAGAAGTTTTCTGCCATGCATGAGTTCCAGAACCTCCATGCTCAGAGCAAGGCTCGAATC 1 1 5
2  AAGAAGTTTTCTGCCATGCATGAGTTCCAGAACCTCCATGCTCAGAGCAAGGCTCGAATC
3  AAGAAGTTTTCTGCCATGCATGAGTTCCAGAACCTCCATGCTCAGAGCAAGGCTCGAATC
4  AAGAAGTTTTCTGCCATGCATGAGTTCCAGAACCTCCATGCTCAGAGCAAGGCTCGAATC
5  AAGAAGTTTTCTGCCATGCATGAGTTCCAGAACCTCCATGCTCAGAGCAAGGCTCGAATC
6  AAGAAGTTTTCTGCCATGCATGAGTTCCAGAACCTCCATGCTCAGAGCAAGGCTCGAATC
7  AAGAAGTTTTCTGCCATGCATGAGTTCCAGAACCTCCATGCTCAGAGCAAGGCTCGAATC
8  AAGAAGTTTTCTGCCATGCATGAGTTCCAGAACCTCCATGCTCAGAGCAAGGCTCGAATC
9  AAGAAGTTTTCTGCCATGCATGAGTTCCAGAACCTCCATGCTCAGAGCAAGGCTCGAATC
1  CAGGAGTTTGTGCGGGGCCATTTTTATGGGTACGTGGGGCATAT 1 5 9
2  CAGGAGTTTGTGCGGGGCCATTTTTATGGGTACGTGGGGCATAT
3  CAGGAGTTTGTGC GGGGC CATTTTTATGGGTACGTGGGGCA.TAT
4  CAGGAGTTTGTGCGGGGCCATTTTTATGGGTACGTGGGGCATAT
5  CAGGAGTTTGTGCGGGGCCA TTTTTATGGGTACGTGGGGCATAT
6  CAGGAGTTTGTGCGGGGCCATTTTTATGGGTACGTGGGGCATAT
7  CAGGAGTTTGTGCGGGGCCATTTTTATGGGTAGGTGGGGCATAT
8  CAGGAGTTTGTGJCGGGGCCATTTTTATGGGTACGTGGGGCATAT
9  CAGGAGTTTGTGCGGGGCCATTTTTATGGGTACGTGGGGCATAT
The database exonic sequence is shown in red (from position 27 to 144) and is 118bp in 
size. The size of the PCR product is 159bp, which includes the exonic and the flanking 
intronic regions.
1 = sequence o f  the exon from the database (http
2 = forward sequence
3 = reverse complement sequence o f  the reverse
4 = forward sequence
5 = reverse complement sequence o f  the reverse
6 = forward sequence
7 = reverse complement sequence o f  the reverse
8 = forward sequence
9 = reverse complement sequence o f the reverse
://www.ncbi.nlm.nih/nucleotide) 
an unaffected individual 
affected individual from pedigree 1 
affected individual from pedigree 2 
^  affected individual from pedigree 5
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ClustalW 1.81 alignment of the exon 7 sequences of GSYI
GTTCTTTAGGCAT C 1 4
GTTCTTTAGCCATC
GTTCTTTAGGCATC
GTTCTTTAGGCATC
GTTCTTTAGGCATC
GTTCTTTAGGCATC
GTTCTTTAGGCATC
GTTCTTTAGGCATC
GTTCTTTAGGCATC
TGGACTTCAACTTGGACAAGACCTTATACTTCTTTATCGCCGGCCGCTATGAGTTCT 7 1
TGGACTTCAACTTGGACAAGACCTTATACTTCTTTATCGCCGGCCGCTATGAGTTCT
TGGACTTCAACTTGGACAAGACCTTATACTTCTTTATCGCCGGCCGCTATGAGTTCT
TGGACTTCAACTTGGACAAGACCTTATACTTCTTTATCGCCGGCCGCTATGAGTTCT
TGGACTTCAACTTGGACAAGACCTTATACTTCTTTATCGCCGGCCGCTATGAGTTCT
TGGACTTCAACTTGGACAAGACCTTATACTTCTTTATCGCCGGCCGCTATGAGTTCT
TGGACTTCAACTTGGACAAGACCTTATACTTCTTTATCGCCGGCCGCTATGAGTTCT
TGGACTTCAACTTGGACAAGACCTTATACTTCTTTATCGCCGGCCGCTATGAGTTCT
TGGACTTCAACTTGGACAAGACCTTATACTTCTTTATCGCCGGCCGCTATGAGTTCT
CCAACAAGGGTGCTGACGTCTTCCTGGAGGCATTGGCTCGGCTCAACTATCTGCTC 1 2 7  
CCAACAAGGGTGCTGACGTCTTYCTGGAGGCATTGGCTCGGCTCAACTATCTGCTC 
CCAACAAGGGTGCTGACGTCTT CTGGAGGCATTGGCTCGGCTCAACTATCTGCTC 
CCAACAAGGGTGCTGACGTCTTYCTGGAGGCATTGGCTCGGCTCAACTATCTGCTC 
CCAACAAGGGTGCTGACGTCTT CTGGAGGCATTGGCTCGGCTCAACTATCTGCTC 
CCAACAAGGGTGCTGACGTCTTCCTGGAGGCATTGGCTCGGCTCAACTATCTGCTC 
CCAACAAGGGTGCTGACGTCTTCCTGGAGGCATTGGCTCGGCTCAACTATCTGCTC 
CCAACAAGGGTGCTGACGTCTTCCTGGAGGCATTGGCTCGGCTCAACTATCTGCTC 
CCAACAAGGGTGCTGACGTCTTCCTGGAGGCATTGGCTCGGCTCAACTATCTGCTC
AGAGTGAGGCCTGGGCT 1 4 4
AGAGTGAGGCCTGGGCT
AGAGTGAGGCCTGGGCT
AGAGTGAGGCCTGGGCT
AGAGTGAGGCCTGGGCT
AGAGTGAGGCCTGGGCT
AGAGTGAGGCCTGGGCT
AGAGTGAGGCCTGGGCT
AGAGTGAGGCCTGGGCT
Stellenbosch University http://scholar.sun.ac.za/
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1 = sequence o f  the exon from the database (http://www.ncbi.nlm.nih/nucleotide)
2 = forward sequence
3 = reverse complement sequence o f  the reverse
4 = forward sequence
5 = reverse complement sequence o f the reverse
6 = forward sequence
7 = reverse complement sequence o f  the reverse
8 = forward sequence
9 = reverse complement sequence o f the reverse
The database exonic sequence is shown in red (from position 10 to 130) and is 121 bp in 
size. The size o f the PCR product is 144bp, which includes the exonic and the flanking 
intronic regions.
A reported SNP in exon 7 (rs5464) of GSY1 was found in the DNA of an unaffected 
and an affected individual from pedigree 1 (table 24 in appendix III, base pair 
position 94 and 95). The alleles observed were C/T in the nucleotide position 1186 of 
the Genbank nucleotide sequence accession number J04501.
}
}
an unaffected individual 
affected individual from pedigree 1
J -  affected individual from pedigree 2 
affected individual from pedigree 5
Stellenbosch University http://scholar.sun.ac.za/
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Table 25 ClustalW 1.81 alignment of the exon 8 sequences of GSY1
1 CTTTC TTTCTG C  1 2
2  C TTTC TTTCTG C
3  CTTTCTTTCTG C
4  C TTTC TTTCTG C
5  C TTTC TTTCTG C
6 C TTTC TTTC TG C
7  C TTTC TTTCTG C
8 C TTTC TTTC TG C
9  C TTTC TTTC TG C
***********
1  GCAGGTGAACGGCAGCGAGCAGACAGTGGTTGCCTTCTTCATCATGCCAGCGCGGACCAA 7 2
2  GCAGGTGAACGGCAGCGAGCAGACAGTGGTTGCCTTCTTCATCATGCCAGCGCGGACCAA
3  GCAGGTGAACGGCAGCGAGCAGACAGTGGTTGCCTTCTTCATCATGCCAGCGCGGACCAA
4  GCAGGTGAACGGCAGCGAGCAGACAGTGGTTGCCTTCTTCATCATGCCAGCGCGGACCAA
5  GCAGGTGAACGGCAGCGAGCAGACAGTGGTTGCCTTCTTCATCATGCCAGCGCGGACCAA
6  GCAGGTGAACGGCAGCGAGCAGACAGTGGTTGCCTTCTTCATCATGCCAGCGCGGACCAA
7  GCAGGTGAACGGCAGCGAGCAGACAGTGGTTGCCTTCTTCATCATGCCAGCGCGGACCAA
8  GCAGGTGAACGGCAGCGAGCAGACAGTGGTTGCCTTCTTCATCATGCCAGCGCGGACCAA
9  GCAGGTGAACGGCAGCGAGCAGACAGTGGTTGCCTTCTTCATCATGCCAGCGCGGACCAA
1  CAATTTCAACGTGGAAACCCTCAAAGGCCAAGCTGTGCGCAAACAGCTT 1 2 1
2  CAATTTCAACGTGGAAACCCTCAAAGGCCAAGCTGTGCGCAAACAGCTT
3  CAATTTCAACGTGGAAACCCTCAAAGGCCAAGCTGTGCGCAAACAGCTT
4 CAATTTCAACGTGGAAACCCTCAAAGGCCAAGCTGTGCGCAAACAGCTT
5  CAATTTCAACGTGGAAACCCTCAAAGGCCAAGCTGTGCGCAAACAGCTT
6  CAATTTCAACGTGGAAACCCTCAAAGGCCAAGCTGTGCGCAAACAGCTT
7 CAATTTCAACGTGGAAACCCTCAAAGGCCAAGCTGTGCGCAAACAGCTT
8 CAATTTCAACGTGGAAACCCTCAAAGGCCAAGCTGTGCGCAAACAGCTT
9 CAATTTCAACGTGGAAACCCTCAAAGGCCAAGCTGTGCGCAAACAGCTT
The database exonic sequence is shown in red (from position 17 to 106) and is 90bp in 
size. The size of the PCR product is 121 bp, which includes the exonic and the flanking 
intronic regions.
1 = sequence o f the exon from the database (http
2 = forward sequence
3 = reverse complement sequence o f  the reverse
4 = forward sequence
5 = reverse complement sequence o f  the reverse
6 = forward sequence
7 = reverse complement sequence o f  the reverse
8 = forward sequence
9 = reverse complement sequence o f the reverse
://www.ncbi.nlm.nih/nucleotide)
>
}
}
}
an unaffected individual 
affected individual from pedigree 1 
affected individual from pedigree 2 
affected individual from pedigree 5
Stellenbosch University http://scholar.sun.ac.za/
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Table 26 ClustalW 1.81 alignment of the exon 9 sequences of GSYI
1  TGCAGCTGGTGTG 1 3
2  TGCAGCTGGTGTG
3  TGCAGCTGGTGTG
5  TGCAGCTGGTGTG
6  TGCAGCTGGTGTG
7  TGCAGCTGGTGTG
8  TGCAGCTGGTGTG
9  TGCAGCTGGTGTG
1  TATGTGACCCTGTTGCTCTGCTTCCTCCAGGGACACGGCCAACACGGTGAAGGAAAAGT 7 2
2  TATGTGACCCTGTTGCTCTGCTTCCTCCAGGGACACGGCCAACACGGTGAAGGAAAAGT
3  TATGTGACCCTGTTGCTCTGCTTCCTCCAGGGACACGGCCAACACGGTGAAGGAAAAGT
5  TATGTGACCCTGTTGCTCTGCTTCCTCCAGGGACACGGCCAACACGGTGAAGGAAAAGT
6  TATGTGACCCTGTTGCTCTGCTTCTTCCAGGGACACGGCCAACACGGTGAAGGAAAAGT
7  TATGTGACCCTGTTGCTCTGCTTCCTCCAGGGACACGGCCAACACGGTGAAGGAAAAGT
8 TATGTGACCCTGTTCCTCTGCTTGCTCCAGGGACACGGCCAACACGGTGAAGGAAAAGT
9  TATGTGACCCTGTTGCTCTGCTTCCTCCAGGGACACGGCCAACACGGTGAAGGAAAAGT
1  TCGGGAGGAAGCTTTATGAATCCTTACTGGTGTGAGTGCCCCACCCTCAGCCCTGTGC 1 3 0
2  TCGGGAGGAAGCTTTATGAATCCTTACTGGTGTGAGTGCCCCACCCTCAGCCCTGTGC
3  TCGGGAGGAAGCTTTATGAATCCTTACTGGTGTGAGTGCCCCACCCTCAGCCCTGTGC
5  TCGGGAGGAAGCTTTATGAATCCTTACTGGTGTGAGTGCCCCACCCTCAGCCCTGTGC
6  TCGGGAGGAAGCTTTATGAATCCTTACTGGTGTGAGTGCCCCACCCTCAGCCCTGTGC
7  TCGGGAGGAAGCTTTATGAATCCTTACTGGTGTGAGTGCCCCACCCTCAGCCCTGTGC
8  TCGGGAGGAAGCTTTATGAATCCTTACTGGTGTGAGTGCCCCACCCTCAGCCCTGTGC
9  TCGGGAGGAAGCTTTATGAATCCTTACTGGTGTGAGTGCCCCACCCTCAGCCCTGTGC
1 CCTCCTAGGCCCT 1 4 3
2  CCTCCTAGGCCCT
3  CCTCCTAGGCCCT
5  CCTCCTAGGCCCT
6  CCTCCTAGGCCCT
7 CCTCCTAGGCCCT
8 CCTCCTAGGCCCT
9 CCTCCTAGGCCCT
The database exonic sequence is shown in red (from position 6 to 103) and is 98bp in 
size. The size o f the PCR product is 143bp, which includes the exonic and the flanking 
intronic regions.
1 = sequence o f  the exon from the database (http
2 = forward sequence
3 = reverse complement sequence o f the reverse
4 = forward sequence
5 = reverse complement sequence o f the reverse
6 = forward sequence
7 = reverse complement sequence o f  the reverse
8 = forward sequence
9 = reverse complement sequence o f  the reverse
://www.ncbi.nlm.nih/nucleotide)
}
}
}
}
an unaffected individual 
affected individual from pedigree 1 
affected individual from pedigree 2 
affected individual from pedigree 5
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Table 27 ClustalW 1.81 alignment of the exon 10 sequences of
GSY1
1  TGCCTTGCAGTGGGAGCCTT 2 0
2  TGCCTTGCAGTGGGAGCCTT
3  TGCCTTGCAGTGGGAGCCTT
4  TGCCTTGCAGTGGGAGCCTT
5  TGCCTTGCAGTGGGAGCCTT
6  TGCCTTGCAGTGGGAGCCTT
7  TGCCTTGCAGTGGGAGCCTT
8  TGCCTTGCAGTGGGAGCCTT
9  TGCCTTGCAGTGGGAGCCTT
1 CCCGACATGAACAAGATGCTGGATAAGGAAGACTTCACTATGATGAAGAGAGCC 7 4
2  CCCGACATGAACAAGATGCTGGATAAGGAAGACTTCACTATGATGAAGAGAGCC
3  CCCGACATGAACAAGATGCTGGATAAGGAAGACTTCACTATGATGAAGAGAGCC
4 CCCGACATGAACAAGATGCTGGATAAGGAAGACTTCACTATGATGAAGAGAGCC
5  CCCGACATGAACAAGATGCTGGATAAGGAAGACTTCACTATGATGAAGAGAGCC
6  CCCGACATGAACAAGATGCTGGATAAGGAAGACTTCACTATGATGAAGAGAGCC
7  CCCGACATGAACAAGATGCTGGATAAGGAAGACTTCACTATGATGAAGAGAGCC
8  CCCGACATGAACAAGATGCTGGATAAGGAAGACTTCACTATGATGAAGAGAGCC
9  CCCGACATGAACAAGATGCTGGATAAGGAAGACTTCACTATGATGAAGAGAGCC
1  ATCTTTGCAACGCAGGTATGGATTGGAC 1 0 2
2  ATCTTTGCAACGCAGGTATGGATTGGAC
3  ATCTTTGCAACGCAGGTATGGATTGGAC
4  ATCTTTGCAACGCAGGTATGGATTGGAC
5  ATCTTTGCAACGCAGGTATGGATTGGAC
6  ATCTTTGCAACGCAGGTATGGATTGGAC
7  ATCTTTGCAACGCAGGTATGGATTGGAC
8  ATCTTTGCAACGCAGGTATGGATTGGAC
9  ATCTTTGCAACGCAGGTATGGATTGGAC
The database exonic sequence is shown in red (from position 17 to 89) and is 73bp in 
size. The size o f the PCR product is 102bp, which includes the exonic and the flanking 
intronic regions.
1 = sequence o f  the exon from the database (http
2 = forward sequence
3 = reverse complement sequence o f  the reverse
4 = forward sequence
5 = reverse complement sequence o f  the reverse
6 = forward sequence
7 = reverse complement sequence o f  the reverse
8 - forward sequence
9 = reverse complement sequence o f  the reverse
://www.ncbi.nlm.nih/nucleotide)
>
}
}
}
an unaffected individual 
affected individual from pedigree 1 
affected individual from pedigree 2 
affected individual from pedigree 5
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Table 28 ClustalW 1.81 alignment of the exon 13 sequences of
GSY1
1  GGGTCTCTCTCCTGCCTTCCCGCAGCT 2 8
2  GGGTCTCTCTCCTGCCTTCCCGCAGCT
3  GGGTCTCTCTCCTGCCTTCCCGCAGCT
4  GGGTCTCTCTCCTGCCTTCCCGCAGCT
5  GGGTCTCTCTCCTGCCTTCCCGCAGCT
6  GGGTCTCTCTCCTGCCTTCCCGCAGCT
7  GGGTCTCTCTCCTGCCTTCCCGCAGCT
8  GGGTCTCTCTCCTGCCTTCCCGCAGCT
9  GGGTCTCTCTCCTGCCTTCCCGCAGCT
1  GAGTGCACGGTTATGGGAATCCCCAGTATCTCCACCAATCTCTCCGGCTTCGGCTGCTT 8 7
2  GAGTGCACGGTTATGGGAATCCCCAGTATCTCCACCAATCTCTCCGGCTTCGGCTGCTT
3  GAGTGCACGGTTATGGGAATCCCCAGTATCTCCACCAATCTCTCCGGCTTCGGCTGCTT
4  GAGTGCACGGTTATGGGAATCCCCAGTATCTCCACCAATCTCTCCGGCTTCGGCTGCTT
5  GAGTGCACGGTTATGGGAATCCCCAGTATCTCCACCAATCTCTCCGGCTTCGGCTGCTT
6  GAGTGCACGGTTATGGGAATCCCCAGTATCTCCACCAATCTCTCCGGCTTCGGCTGCTT
7 GAGTGCACGGTTATGGGAATCCCCAGTATCTCCACCAATCTCTCCGGCTTCGGCTGCTT
8 GAGTGCACGGTTATGGGAATCCCCAGTATCTCCACCAATCTCTCCGGCTTCGGCTGCTT
9  GAGTGCACGGTTATGGGAATCCCCAGTATCTCCACCAATCTCTCCGGCTTCGGCTGCTT
1  CATGGAGGAACACATCGCAGACCCCTCAGCTTACGGTCAGCGCCCAGGCCCCTGAGGAT 1 4 6
2  CATGGAGGAACACATCGCAGACCCCTCAGCTTACGGTCAGCGCCCAGGCCCCTGAGGAT
3  CATGGAGGAACACATCGCAGACCCCTCAGCTTACGGTCAGCGCCCAGGCCCCTGAGGAT
4  CATGGAGGAACACATCGCAGACCCCTCAGCTTACGGTCAGCGCCCAGGCCCCTGAGGAT
5  CATGGAGGAACACATCGCAGACCCCTCAGCTTACGGTCAGCGCCCAGGCCCCTGAGGAT
6  CATGGAGGAACACATCGCAGACCCCTCAGCTTACGGTCAGCGCCCAGGCCCCTGAGGAT
7  CATGGAGGAACACATCGCAGACCCCTCAGCTTACGGTCAGCGCCCAGGCCCCTGAGGAT
8  CATGGAGGAACACATCGCAGACCCCTCAGCTTACGGTCAGCGCCCAGGCCCCTGAGGAT
9  CATGGAGGAACACATCGCAGACCCCTCAGCTTACGGTCAGCGCCCAGGCCCCTGAGGAT
The database exonic sequence is shown in red (from position 26 to 122) and is 97bp in 
size. The size o f the PCR product is 146bp, which includes the exonic and the flanking 
intronic regions.
1 = sequence o f  the exon from the database (http
2 = forward sequence
3 = reverse complement sequence o f the reverse
4 = forward sequence
5 = reverse complement sequence o f the reverse
6 = forward sequence
7 = reverse complement sequence o f  the reverse
8 = forward sequence
9 = reverse complement sequence o f the reverse
://www.ncbi.nlm.nih/nucleotide)
>
}
}
}
an unaffected individual 
affected individual from pedigree 1 
affected individual from pedigree 2 
affected individual from pedigree 5
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29 ClustalW 1.81 alignment of the exon 14 sequences of
AGGATGTTTTCTGAAC 1 6
AGGATGTTTTCTGAAC
AGGATGTTTTCTGAAC
AGGATGTTTTCTGAAC
AGGATGTTTTCTGAAC
AGGATGTTTTCTGAAC
AGGATGTTTTCTGAAC
AGGATGTTTTCTGAAC
AGGATGTTTTCTGAAC
CTGGGTCCTGGCCTCCACAGGTATCTACATTCTTGACCGGCGGTTCCGCAGCCTGGATG 9 8
CTGGGTCCTGGCCTCCACAGGTATCTACATTCTTGACCGGCGGTTCCGCAGCCTGGATG
CTGGGTCCTGGCCTCCACAGGTATCTACATTCTTGACCGGCGGTTCCGCAGCCTGGATG
CTGGGTCCTGGCCTCCACAGGTATCTACATTCTTGACCGGCGGTTCCGCAGCCTGGATG
CTGGGTCCTGGCCTCCACAGGTATCTACATTCTTGACCGGCGGTTCCGCAGCCTGGATG
CTGGGTCCTGGCCTCCACAGGTATCTACATTCTTGACCGGCGGTTCCGCAGCCTGGATG
CTGGGTCCTGGCCTCCACAGGTATCTACATTCTTGACCGGCGGTTCCGCAGCCTGGATG
CTGGGTCCTGGCCTCCACAGGTATCTACATTCTTGACCGGCGGTTCCGCAGCCTGGATG
CTGGGTCCTGGCCTCCACAGGTATCTACATTCTTGACCGGCGGTTCCGCAGCCTGGATG
ATTCCTGCTCGCAGCTCACCTCCTTCCTCTACAGTTTCTGTCAGCAGAGCCGGCGGCAG 1 5 7
ATTCCTGCTCGCAGCTCACCTCCTTCCTCTACAGTTTCTGTCAGCAGAGCCGGCGGCAG
ATTCCTGCTCGCAGCTCACCTCCTTCCTCTACAGTTTCTGTCAGCAGAGCCGGCGGCAG
ATTCCTGCTCGCAGCTCACCTCCTTCCTCTACAGTTTCTGTCAGCAGAGCCGGCGGCAG
ATTCCTGCTCGCAGCTCACCTCCTTCCTCTACAGTTTCTGTCAGCAGAGCCGGCGGCAG
ATTCCTGCTCGCAGCTCACCTCCTTCCTCTACAGTTTCTGTCAGCAGAGCCGGCGGCAG
ATTCCTGCTCGCAGCTCACCTCCTTCCTCTACAGTTTCTGTCAGCAGAGCCGGCGGCAG
ATTCCTGCTCGCAGCTCACCTCCTTCCTCTACAGTTTCTGTCAGCAGAGCCGGCGGCAG
ATTCCTGCTCGCAGCTCACCTCCTTCCTCTACAGTTTCTGTCAGCAGAGCCGGCGGCAG
CGTATCATCCAGCGGAACCGCACGGAGCGCCTCTCCGACCTTCTGGACTGGAAATAC 2 1 4
CGTATCATCCAGCGGAACCGCACGGAGCGCCTCTCCGACCTTCTGGACTGGAAATAC
CGTATCATCCAGCGGAACCGCACGGAGCGCCTCTCCGACCTTCTGGACTGGAAATAC
CGTATCATCCAGCGGAACCGCACGGAGCGCCTTTCCGACCTTCTGGACTGGAAATAC
CGTATCATCCAGCGGAACCGCACGGAGCGCCTCTCCGACCTTCTGGACTGGAAATAC
CGTATCATCCAGCGGAACCGCACGGAGCGCCTCTCCGACCTTCTGGACTGGAAATAC
CGTATCATCCAGCGGAACCGCACGGAGCGCCTCTCCGACCTTCTGGACTGGAAATAC
CGTATCATCCAGCGGAACCGCACGGAGCGCCTCTCCGACCTTCTGGACTGGAAATAC
CGTATCATCCAGCGGAACCGCACGGAGCGCCTCTCCGACCTTCTGGACTGGAAATAC
CTAGGCCGGGTAGGACCCCC 2 3 4  
CTAGGCCGGGTAGGACCCCC 
CTAGGCCGGGTAGGACCCCC 
CTAGGCCGGGTAGGACCCCC 
CTAGGCCGGGTAGGACCCCC 
CTAGGCCGGGTAGGACCCCC 
CTAGGCCGGGTAGGACCCCC 
CTAGGCCGGGTAGGACCCCC 
CTAGGCCGGGTAGGACCCCC 
********************
Stellenbosch University http://scholar.sun.ac.za/
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The database exonic sequence is shown in red (from position 37 to 223) and is 187bp in 
size. The size of the PCR product is 234bp, which includes the exonic and the flanking 
intronic regions.
1 = sequence o f  the exon from the database (http://www.ncbi.nlm.nih/nucleotide)
2 = forward sequence
3 = reverse complement sequence o f  the reverse
4 = forward sequence
5 = reverse complement sequence o f  the reverse
6 = forward sequence
7 = reverse complement sequence o f  the reverse
8 = forward sequence
9 = reverse complement sequence o f the reverse
}
}
}
}
an unaffected individual 
affected individual from pedigree 1 
affected individual from pedigree 2 
affected individual from pedigree 5
Stellenbosch University http://scholar.sun.ac.za/
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Table 30 ClustalW 1.81 alignment of the exon 15 sequences of 
GSYI
1  CCTTTCCCCTA6TACTATATGTCTGCGCG 2 9
2  CCTTTCCCCTAGTACTATATGTCTGCGCG
3  CCTTTCCCCTAGTACTATATGTCTGCGCG
4 CCTTTCCCCTAGTACTATATGTCTGCGCG
5  CCTTTCCCCTAGTACTATATGTCTGCGCG
6  CCTTTCCCCTAGTACTATATGTCTGCGCG
7  CCTTTCCCCTAGTACTATATGTCTGCGCG
8  CCTTTCCCCTAGTACTATATGTCTGCGCG
9  CCTTTCCCCTAGTACTATATGTCTGCGCG
1  CCACATGGCGCTGTCCAAGGCCTTTCCAGAGCACTTCACCTACGAGCCCAACGAGGCGG 8 8
2  CCACATGGCGCTGTCCAAGGCCTTTCCAGAGCACTTCACCTACGAGCCCAACGAGGCGG
3  CCACATGGCGCTGTCCAAGGCCTTTCCAGAGCACTTCACCTACGAGCCCAACGAGGCGG
4 CCACATGGCGCTGTCCAAGGCCTTTCCAGAGCACTTCACCTACGAGCCCAACGAGGCGG
5  CCACATGGCGCTGTCCAAGGCCTTTCCAGAGCACTTCACCTACGAGCCCAACGAGGCGG
6  CCACATGGCGCTGTCCAAGGCCTTTCCAGAGCACTTCACCTACGAGCCCAACGAGGCGG
7  CCACATGGCGCTGTCCAAGGCCTTTCCAGAGCACTTCACCTACGAGCCCAACGAGGCGG
8 CCACATGGCGCTGTCCAAGGCCTTTCCAGAGCACTTCACCTACGAGCCCAACGAGGCGG
9 CCACATGGCGCTGTCCAAGGCCTTTCCAGAGCACTTCACCTACGAGCCCAACGAGGCGG
1  ATGCGGTGAGTGGACCCTGG 1 0 8
2  ATGCGGTGAGTGGACCCTGG
3  ATGCGGTGAGTGGACCCTGG
4 ATGCGGTGAGTGGACCCTGG
5  ATGCGGTGAGTGGACCCTGG
6  ATGCGGTGAGTGGACCCTGG
7  ATGCGGTGAGTGGACCCTGG
8 ATGCGGTGAGTGGACCCTGG
9  ATGCGGTGAGTGGACCCTGG
The database exonic sequence is shown in red (from position 13 to 93) and is 81bp in 
size. The size o f the PCR product is 108bp, which includes the exonic and the flanking 
intronic regions.
1 = sequence o f the exon from the database O1ttp://www.ncbi.nlm.nih/nucleotide)
2 =  forward sequence
3 = reverse complement sequence o f the reverse
4 = forward sequence
5 = reverse complement sequence o f the reverse
6 = forward sequence
7 = reverse complement sequence o f  the reverse
8 = forward sequence
9 = reverse complement sequence o f  the reverse
}
}
}
}
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affected individual from pedigree 2 
affected individual from pedigree 5
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31 ClustalW 1.81 alignment of the exon 16B sequences of
TCCGCCCCACCACACTCCCCGCCTGTCCTGCCTCTCTGCTCCAGAGAGAGGATGCAGAGG 6 0
TCCGCCCCACCACACTCCCCGCCTGTCCTGCCTCTCTGCTCCAGAGAGAGGATGCAGAGG
TCCGCCCCACCACACTCCCCGCCTGTCCTGCCTCTCTGCTCCAGAGAGAGGATGCAGAGG
TCCGCCCCACCACACTCCCCGCCTGTCCTGCCTCTCTGCTCCAGAGAGAGGATGCAGAGG
TCCGCCCCACCACACTCCCCGCCTGTCCTGCCTCTCTGCTCCAGAGAGAGGATGCAGAGG
TCCGCCCCACCACACTCCCCGCCTGTCCTGCCTCTCTGCTCCAGAGAGAGGATGCAGAGG
TCCGCCCCACCACACTCCCCGCCTGTCCTGCCTCTCTGCTCCAGAGAGAGGATGCAGAGG
TCCGCCCCACCACACTCCCCGCCTGTCCTGCCTCTCTGCTCCAGAGAGAGGATGCAGAGG
TCCGCCCCACCACACTCCCCGCCTGTCCTGCCTCTCTGCTCCAGAGAGAGGATGCAGAGG
GGTGCTGCTCCTAAACCCCCGCTCCAGATCTGCACTGGGTGTGGCCCCGCAGTGCCCCCA 1 2 0
GGTGCTGCTCCTAAACCCCCGCTCCAGATCTGCACTGGGTGTGGCCCCGCAGTGCCCCCA
GGTGCTGCTCCTAAACCCCCGCTCCAGATCTGCACTGGGTGTGGCCCCGCAGTGCCCCCA
GGTGCTGCTCCTAAACCCCCGCTCCAGATCTGCACTGGGTGTGGCCCCGCAGTGCCCCCA
GGTGCTGCTCCTAAACCCCCGCTCCAGATCTGCACTGGGTGTGGCCCCGCAGTGCCCCCA
GGTGCTGCTCCTAAACCCCCGCTCCAGATCTGCACTGGGTGTGGCCCCGCAGTGCCCCCA
GGTGCTGCTCCTAAACCCCCGCTCCAGATCTGCACTGGGTGTGGCCCCGCAGTGCCCCCA
GGTGCTGCTCCTAAACCCCCGCTCCAGATCTGCACTGGGTGTGGCCCCGCAGTGCCCCCA
GGTGCTGCTCCTAAACCCCCGCTCCAGATCTGCACTGGGTGTGGCCCCGCAGTGCCCCCA
CCCAGTCCGCCAAACACTCCACCCCCTCCAGCTCCAGTTTCCAAGTTCCTGCACTCCAGA. 1 8 0
CCCAGTCCGCCAAACACTCCACCCCCTCCAGCTCCAGTTTCCAAGTTCCTGCACTCCAGA
CCCAGTCCGCCAAACACTCCACCCCCTCCAGCTCCAGTTTCCAAGTTCCTGCACTCCAGA
CCCAGTCCGCCAAACACTCCACCCCCTCCAGCTCCAGTTTCCAAGTTCCTGCACTCCAGA
CCCAGTCCGCCAAACACTCCACCCCCTCCAGCTCCAGTTTCCAAGTTCCTGCACTCCAGA
CCCAGTCCGCCAAACACTCCACCCCCTCCAGCTCCAGTTTCCAAGTTCCTGCACTCCAGA
CCCAGTCCGCCAAACACTCCACCCCCTCCAGCTCCAGTTTCCAAGTTCCTGCACTCCAGA
CCCAGTCCGCCAAACACTCCACCCCCTCCAGCTCCAGTTTCCAAGTTCCTGCACTCCAGA
CCCAGTCCGCCAAACACTCCACCCCCTCCAGCTCCAGTTTCCAAGTTCCTGCACTCCAGA
ATCCACAAAGCCGTGCCTTTCTCTGGCTCCAGAATATGCATAATCAGCGCCCTGGAGTCC 2 4 0
ATCCACAAAGCCGTGCCTTTCTCTGGCTCCAGAATATGCATAATCAGCGCCCTGGAGTCC
ATCCACAAAGCCGTGCCTTTCTCTGGCTCCAGAATATGCATAATCAGCGCCCTGGAGTCC
ATCCACAAAGCCGTGCCTTTCTCTGGCTCCAGAATATGCATAATCAGCGCCCTGGAGTCC
ATCCACAAAGCCGTGCCTTTCTCTGGCTCCAGAATATGCATAATCAGCGCCCTGGAGTCC
ATCCACAAAGCCGTGCCTTTCTCTGGCTCCAGAATATGCATAATCAGCGCCCTGGAGTCC
ATCCACAAAGCCGTGCCTTTCTCTGGCTCCAGAATATGCATAATCAGCGCCCTGGAGTCC
ATCCACAAAGCCGTGCCTTTCTCTGGCTCCAGAATATGCATAATCAGCGCCCTGGAGTCC
ATCCACAAAGCCGTGCCTTTCTCTGGCTCCAGAATATGCATAATCAGCGCCCTGGAGTCC
CCTGGGCCTGGACCGCTTCCCAGAGGCCAGGAATCTGCCATTACTCTGCGGTGGTGCCAG 3 0 0
CCTGGGCCTGGACCGCTTCCCAGAGGCCAGGAATCTGCCATTACTCTGCGGTGGTGCCAG
CCTGGGCCTGGACCGCTTCCCAGAGGCCAGGAATCTGCCATTACTCTGCGGTGGTGCCAG
CCTGGGCCTGGACCGCTTCCCAGAGGCCAGGAATCTGCCATTACTCTGCGGTGGTGCCAG
CCTGGGCCTGGACCGCTTCCCAGAGGCCAGGAATCTGCCATTACTCTGCGGTGGTGCCAG
CCTGGGCCTGGACCGCTTCCCAGAGGCCAGGAATCTGCCATTACTCTGCGGTGGTGCCAG
CCTGGGCCTGGACCGCTTCCCAGAGGCCAGGAATCTGCCATTACTCTGCGGTGGTGCCAG
CCTGGGCCTGGACCGCTTCCCAGAGGCCAGGAATCTGCCATTACTCTGCGGTGGTGCCAG
CCTGGGCCTGGACCGCTTCCCAGAGGCCAGGAATCTGCCATTACTCTGCGGTGGTGCCAG
Stellenbosch University http://scholar.sun.ac.za/
363
1 AGGTTTTAGGAAACCTGGCATGGTGCTTTCAGGTCTGGGGCTTTTAGAGCCCCCCGTGTG 3 6 0
2  AGGTTTTAGGAAACCTGGCATGGTGCTTTCAGGTCTGGGGCTTTTAGAGCCCCCCGTGTG
3  AGGTTTTAGGAAACCTGGCATGGTGCTTTCAGGTCTGGGGCTTTTAGAGCCCCCCGTGTG
4  AGGTTTTAGGAAACCTGGCATGGTGCTTTCAGGTCTGGGGCTTTTAGAGCCCCCCGTGTG
5  AGGTTTTAGGAAACCTGGCATGGTGCTTTCAGGTCTGGGGCTTTTAGAGCCCCCCGTGTG
6  AGGTTTTAGGAAACCTGGCATGGTGCTTTCAGGTCTGGGGCTTTTAGAGCCCCCCGTGTG
7  AGGTTTTAGGAAACCTGGCATGGTGCTTTCAGGTCTGGGGCTTTTAGAGCCCCCCGTGTG
8 AGGTTTTAGGAAACCTGGCATGGTGCTTTCAGGTCTGGGGCTTTTAGAGCCCCCCGTGTG
9  AGGTTTTAGGAAACCTGGCATGGTGCTTTCAGGTCTGGGGCTTTTAGAGCCCCCCGTGTG
1 GCTTACAAATTCTACAGCATACAGAGCAGGCCACGCTCAGGCCCGGCATGCGGGCCACCA 4 2 0
2  GCTTACAAATTCTACAGCATACAGAGCAGGCCACGCTCAGGCCCGGCATGCGGGCCACCA
3  GCTTACAAATTCTACAGCATACAGAGCAGGCCACGCTCAGGCCCGGCATGCGGGCCACCA
4  GCTTACAAATTCTACAGCATACAGAGCAGGCCACGCTCAGGCCCGGCATGCGGGCCACCA
5  GCTTACAAATTCTACAGCATACAGAGCAGGCCACGCTCAGGCCCGGCATGCGGGCCACCA
6  GCTTACAAATTCTACAGCATACAGAGCAGGCCACGCTCAGGCCCGGCATGCGGGCCACCA
7 GCTTACAAATTCTACAGCATACAGAGCAGGCCACGCTCAGGCCCGGCATGCGGGCCACCA
8 GCTTACAAATTCTACAGCATACAGAGCAGGCCACGCTCAGGCCCGGCATGCGGGCCACCA
9 GCTTACAAATTCTACAGCATACAGAGCAGGCCACGCTCAGGCCCGGCATGCGGGCCACCA
1 AGTTCTGGAAACCACGTGGTGT 4 4 2
2  AGTTCTGGAAACCACGTGGTGT
3  AGTTCTGGAAACCACGTGGTGT
4 AGTTCTGGAAACCACGTGGTGT
5  AGTTCTGGAAACCACGTGGTGT
6  AGTTCTGGAAACCACGTGGTGT
7  AGTTCTGGAAACCACGTGGTGT
8  AGTTCTGGAAACCACGTGGTGT
9 AGTTCTGGAAACCACGTGGTGT
Exon 16 is subdivided into exons 16A, 16B, 16C and 16D. Exon 16A was screened in a 
previous study (Makubalo, 2000). The database exonic sequence o f 16B, 16C and 16D is 
shown in red (from position 1 to 1110). Exonic sequence 16B (position 1 to 442bp) and 
is 442bp in size. The overlapping sequence o f exon 16B with exon 16C is underlined.
1 = sequence o f  the exon from the database (http
2 = forward sequence
3 = reverse complement sequence o f the reverse
4 = forward sequence
5 = reverse complement sequence o f  the reverse
6 = forward sequence
7 = reverse complement sequence o f  the reverse
8 = forward sequence
9 = reverse complement sequence o f  the reverse
://www.ncbi.nlm.nih/nucleotide)
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}
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32 ClustalW 1.81 alignment of the exon 16C sequences of
GGTGTCCCTGCGAATGGGGCGATCAAGTCCAGAGCCGGGGCACTTTCAGAGTTTG 4  9 2
GGTGTCCCTGCGAATGGGGCGATCAAGTCCAGAGCCGGGGCACTTTCAGAGTTTG
GGTGTCCCTGCGAATGGGGCGATCAAGTCCAGAGCCGGGGCACTTTCAGAGTTTG
GGTGTCCCTGCGAATGGGGCGATCAAGTCCAGAGCCGGGGCACTTTCAGAGTTTG
GGTGTCCCTGCGAATGGGGCGATCAAGTCCAGAGCCGGGGCACTTTCAGAGTTTG
GGTGTCCCTGCGAATGGGGCGATCAAGTCCAGAGCCGGGGCACTTTCAGAGTTTG
GGTGTCCCTGCGAATGGGGCGATCAAGTCCAGAGCCGGGGCACTTTCAGAGTTTG
GGTGTCCCTGCGAATGGGGCGATCAAGTCCAGAGCCGGGGCACTTTCAGAGTTTG
GGTGTCCCTGCGAATGGGGCGATCAAGTCCAGAGCCGGGGCACTTTCAGAGTTTG
AAGGTAACTGAGAGCAGATGGTCCTCCATTTCAACTCCAGAAGTGGGGCTCTGGGA 5 4 8
AAGGTAACTGAGAGCAGATGGTCCTCCATTTCAACTCCAGAAGTGGGGCTCTGGGA
AAGGTAACTGAGAGCAGATGGTCCTCCATTTCAACTCCAGAAGTGGGGCTCTGGGA
AAGGTAACTGAGAGCAGATGGTCCTCCATTTCAACTCCAGAAGTGGGGCTCTGGGA
AAGGTAACTGAGAGCAGATGGTCCTCCATTTCAACTCCAGAAGTGGGGCTCTGGGA
AAGGTAACTGAGAGCAGATGGTCCTCCATTTCAACTCCAGAAGTGGGGCTCTGGGA
AAGGTAACTGAGAGCAGATGGTCCTCCATTTCAACTCCAGAAGTGGGGCTCTGGGA
AAGGTAACTGAGAGCAGATGGTCCTCCATTTCAACTCCAGAAGTGGGGCTCTGGGA
AAGGTAACTGAGAGCAGATGGTCCTCCATTTCAACTCCAGAAGTGGGGCTCTGGGA
GGGATGTTCTAGCCCTCCCTGGCATGTCAGAGCCAGGCTCTGCCTGGAGGATCCCTCCA 6 0 7
GGGATGTTCTAGCCCTCCCTGGCATGTCAGAGCCAGGCTCTGCCTGGAGGATCCCTCCA
GGGATGTTCTAGCCCTCCCTGGCATGTCAGAGCCAGGCTCTGCCTGGAGGATCCCTCCA
GGGATGTTCTAGCCCTCCCTGGCATGTCAGAGCCAGGCTCTGCCTGGAGGATCCCTCCA
GGGATGTTCTAGCCCTCCCTGGCATGTCAGAGCCAGGCTCTGCCTGGAGGATCCCTCCA
GGGATGTTCTAGCCCTCCCTGGCATGTCAGAGCCAGGCTCTGCCTGGAGGATCCCTCCA
GGGATGTTCTAGCCCTCCCTGGCATGTCAGAGCCAGGCTCTGCCTGGAGGATCCCTCCA
GGGATGTTCTAGCCCTCCCTGGCATGTCAGAGCCAGGCTCTGCCTGGAGGATCCCTCCA
GGGATGTTCTAGCCCTCCCTGGCATGTCAGAGCCAGGCTCTGCCTGGAGGATCCCTCCA
TCCGGCTCCTGTCATCCCCTACACTTTGGCCAAGCAAGAGGTGGTAGAACCACTTGGCTG 6 6 7
TCCGGCTCCTGTCATCCCCTACACTTTGGCCAAGCAAGAGGTGGTAGAACCACTTGGCTG
TCCGGCTCCTGTCATCCCCTACACTTTGGCCAAGCAAGAGGTGGTAGAACCACTTGGCTG
TCCGGCTCCTGTCATCCCCTACACTTTGGCCAAGCAAGAGGTGGTAGAACCACTTGGCTG
TCCGGCTCCTGTCATCCCCTACACTTTGGCCAAGCAAGAGGTGGTAGAACCACTTGGCTG
TCCGGCTCCTGTCATCCCCTACACTTTGGCCAAGCAAGAGGTGGTAGAACCACTTGGCTG
TCCGGCTCCTGTCATCCCCTACACTTTGGCCAAGCAAGAGGTGGTAGAACCACTTGGCTG
TCCGGCTCCTGTCATCCCCTACACTTTGGCCAAGCAAGAGGTGGTAGAACCACTTGGCTG
TCCGGCTCCTGTCATCCCCTACACTTTGGCCAAGCAAGAGGTGGTAGAACCACTTGGCTG
CTCATTCCTTCTGGAGGACACACAGTCTCAGTCCAGATGCCTTCCTGTCTTTCTGGCC 7 2 5  
CTCATTCCTTCTGGAGGACACACAGTCTCAGTCCAGATGCCTTCCTGTCTTTCTGGCC 
CTCATTCCTTCTGGAGGACACACAGTCTCAGTCCAGATGCCTTCCTGTCTTTCTGGCC 
CTCATTCCTTCTGGAGGACACACAGTCTCAGTCCAGATGCCTTCCTGTCTTTCTGGCC
CTCATTCCTTCTGGAGGACACACAGTCTCAGTCGAGATGCCTTCCTGTCTTTCTGGCC
CTCATTCCTTCTGGAGGACACACAGTCTCAGTCCAGATGCCTTCCTGTCTTTCTGGCC
CTCATTCCTTCTGGAGGACACACAGTCTCAGTCCAGATGCCTTCCTGTCTTTCTGGCC
CTCATTCCTTCTGGAGGACACACAGTCTCAGTCCAGATGCCTTCCTGTCTTTCTGGCC
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1  CTTTCTGGACCAGATCCTACTCTTCCTTTCTAAATCTGAGATCTCCCTCCAGG 7 7 8
3  CTTTCTGGACCAGATCCTACTCTTCCTTTCTAAATCTGAGATCCTCCTCCAGG
4 CTTTCTGGACCAGATCCTACTCTTCCTTTCTAAATCTGAGATCTCCCTCCAGG
5  CTTTCTGGACCAGATCCTACTCTTCCTTTCTAAATCTGAGATCTCCCTCCAGG
6  CTTTCTGGACCAGATCCTACTCTTCCTTTCTAAATCTGAGATCTCCCTCCAGG
7 CTTTCTGGACCAGATCCTACTCTTCCTTTCTAAATCTGAGATCTCCCTCCAGG
8 CTTTCTGGACCAGATCCTACTCTTCCTTTCTAAATCTGAGATCTCCCTCCAGG
9 CTTTCTGGACCAGATCCTACTCTTCCTTTCTAAATCTGAGATCTCCTTCCAGG
1  GAATCCGCCTGCAGAGGACAGAGCTGGCTGTCTTCCCCCACCCC 8 2 2
2  GAATCCGCCTGCAGAGGACAGAGCTGGCTGTCTTCCCCCACCCC
3  GAATCCGCCTGCAGAGGACAGAGCTGGCTGTCTTCCCCCACCCC
5  GAATCCGCCTGCAGAGGACAGAGCTGGCTGTCTTCCCCCACCCC
7 GAATCCGCCTGCAGAGGACAGAGCTGGCTGTCCTCGCCCACCCC
8 GAATCCGCCTGCAGAGGACAGAGCTGGCTGTCTTCCCCCACCCC
The database exonic sequence is shown in red. Exonic sequence 16C (position 437 to 
822bp) and is 386bp in size. The overlapping sequence of exon 16B with exon 16C and 
exon 16C with exon 16D is underlined.
1 = sequence o f the exon from the database (http://www.ncbi.nlm.nih/nucleotide)
2 = forward sequence
3 = reverse complement sequence o f  the reverse
4 = forward sequence
5 = reverse complement sequence o f  the reverse
6 = forward sequence
7 = reverse complement sequence o f  the reverse
8 = forward sequence
9 = reverse complement sequence o f the reverse
}
}
>
}
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affected individual from pedigree 2 
affected individual from pedigree 5
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33 ClustalW 1.81 alignment of the exon 16D sequences of
CTTCCCCCACCCCTAACCTGGCTTATTCCCAACTGCT 8 4 4
CTTCCCCCACCCCTAACCTGGCTTATTCCCAACTGCT
CTTCCCCCACCCCTAACCTGGCTTATTCCCAACTGCT
CTTCCCCCACCCCTAACCTGGCTTATTCCCAACTGCT
CTTCCCCCACCCCTAACCTGGCTTATTCCCAACTGCT
CTTCCCCCACCCCTAACCTGGCTTATTCCCAACTGCT
CTTCCCCCACCCCTAACCTGGCTTATTCCCAACTGCT
CTTCCCCCACCCCTAACCTGGCTTATTCCCAACTGCT
CTTCCCCCACCCCTAACCTGGCTTATTCCCAACTGCT
CTGCCCACTGTGAAACCACTAGGTTCTAGGTCCTGGCTTCTAGATCTGGAACCTTACCA 9 0 3
CTGCCCACTGTGAAACCACTAGGTTCTAGGTCCTGGCTTCTAGATCTGGAACCTTACCA
CTGCCCACTGTGAAACCACTAGGTTCTAGGTCCTGGCTTCTAGATCTGGAACCTTACCA
CTGCCCACTGTGAAACCACTAGGTTCTAGGTCCTGGCTTCTAGATCTGGAACCTTACCA
CTGCCCACTGTGAAACCACTAGGTTCTAGGTCCTGGCTTCTAGATCTGGAACCTTACCA
CTGCCCACTGTGAAACCACTAGGTTCTAGGTCCTGGCTTCTAGATCTGGAACCTTACCA
CTGCCCACTGTGAAACCACTAGGTTCTAGGTCCTGGCTTCTAGATCTGGAACCTTACCA
CTGCCCACTGTGAAACCACTAGGTTCTAGGTCCTGGCTTCTAGATCTGGAACCTTACCA
CTGCCCACTGTGAAACCACTAGGTTCTAGGTCCTGGCTTCTAGATCTGGAACCTTACCA
CGTTACTGCATACTGATCCCTTTCCCATGATCCAGAACTGAGGTCACTGGGTTCTAGAAC 9 6 3
CGTTACTGCATACTGATCCCTTTCCCATGATCCAGAACTGAGGTCACTGGGTTCTAGAAC
CGTTACTGCATACTGATCCCTTTCCCATGATCCAGAACTGAGGTCACTGGGTTCTAGAAC
CGTTACTGCATACTGATCCCTTTCCCATGATCCAGAACTGAGGTCACTGGGTTCTAGAAC
CGTTACTGCATACTGATCCCTTTCCCATGATCCAGAACTGAGGTCACTGGGTTCTAGAAC
CGTTACTGCATACTGATCCCTTTCCCATGATCCAGAACTGAGGTCACTGGGTTCTAGAAC
CGTTACTGCATACTGATCCCTTTCCCATGATCCAGAACTGAGGTCACTGGGTTCTAGAAC
CGTTACTGCATACTGATCCCTTTCCCATGATCCAGAACTGAGGTCACTGGGTTCTAGAAC
CGTTACTGCATACTGATCCCTTTCCCATGATCCAGAACTGAGGTCACTGGGTTCTAGAAC
CCCCACATTTACCTCGAGGCTCTTCCATCCCCAAACTGTGCCCTGCCTTCAGCTTTGGTG 1 0 2 3
CCCCACATTTACCTCGAGGCTCTTCCATCCCCAAACTGTGCCCTGCCTTCAGCTTTGGTG
CCCCACATTTACCTCGAGGCTCTTCCATCCCCAAACTGTGCCCTGCCTTCAGCTTTGGTG
CCCCACATTTACCTCGAGGCTCTTCCATCCCCAAACTGTGCCCTGCCTTCAGCTTTGGTG
CCCCACATTTACCTCGAGGCTCTTCCATCCCCAAACTGTGCCCTGCCTTCAGCTTTGGTG
CCCCACATTTACCTCGAGGCTCTTCCATCCCCAAACTGTGCCCTGCCTTCAGCTTTGGTG
CCCCACATTTACCTCGAGGCTCTTCCATCCCCAAACTGTGCCCTGCCTTCAGCTTTGGTG
CCCCACATTTACCTCGAGGCTCTTCCATCCCCAAACTGTGCCCTGCCTTCAGCTTTGGTG
CCCCACATTTACCTCGAGGCTCTTCCATCCCCAAACTGTGCCCTGCCTTCAGCTTTGGTG
AAAGGGAGGGCCCCTCATGTGTGCTGTGCTGTGTCTGCACCGCTTGGTTTGCAGTTGAGA 1 0 8 3
AAAGGGAGGGCCCCTCATGTGTGCTGTGCTGTGTCTGCACCGCTTGGTTTGCAGTTGAGA
AAAGGGAGGGCCCCTCATGTGTGCTGTGCTGTGTCTGCACCGCTTGGTTTGCAGTTGAGA
AAAGGGAGGGCCCCTCATGTGTGCTGTGCTGTGTCTGCACCGCTTGGTTTGCAGTTGAGA
AAAGGGAGGGCCCCTCATGTGTGCTGTGCTGTGTCTGCACCGCTTGGTTTGCAGTTGAGA
AAAGGGAGGGCCCCTCATGTGTGCTGTGCTGTGTCTGCACCGCTTGGTTTGCAGTTGAGA
AAAGGGAGGGCCCCTCATGTGTGCTGTGCTGTGTCTGCACCGCTTGGTTTGCAGTTGAGA
AAAGGGAGGGCCCCTCATGTGTGCTGTGCTGTGTCTGCACCGCTTGGTTTGCAGTTGAGA
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1  GGGGAGGGCAGGAGGGGTGTGATTGGA 1 1 1 0
2  GGGGAGGGCAGGAGGGGTGTGATTGGA.
3  GGGGAGGGCAGGAGGGGTGTGATGGGA
4  GGGGAGGGCAGGAGGGGTGTGATTGGA
5  GGGGAGGGCAGGAGGGGTGTGATTGGA
6  GGGGAGGGCAGGAGGGGTGTGATTGGA
7  GGGGAGGGCAGGAGGGGTGTGATTGGA
8  GGGGAGGGCAGGAGGGGTGTGATTGGA
9  GGGGAGGGCAGGAGGGGTGTGATTGGA
The database exonic sequence is shown in red. Exonic sequence 16D (position 807 to 
l llObp) is 304bp in size. The overlapping sequence o f exon 16C with exon 16D is 
underlined.
1 = sequence o f the exon from the database (http
2 = forward sequence
3 = reverse complement sequence o f  the reverse
4 = forward sequence
5 = reverse complement sequence o f the reverse
6 = forward sequence
7 = reverse complement sequence o f the reverse
8 = forward sequence
9 = reverse complement sequence o f the reverse
://www.ncbi.nlm.nih/nucleotide)
}
}
}
}
an unaffected individual 
affected individual from pedigree 1 
affected individual from pedigree 2 
affected individual from pedigree 5
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Karolinska Institute, Sweden  
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M olecular Cardiology Laboratory 
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Department o f  M edicine 
Cornell University Medical College  
N ew  York, USA  
ctbasson@ m ail.m ed.com ell.edu
4. Prof B Black 
Cardiovascular Research Institute 
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University o f  California
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5. ProfG C handy
Department o f  Physiology and Biophysics
University o f  California Irvine
Irvine
California 92697  
USA
gchandy@ uci.edu
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